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II. Abstract 
Breast cancer is a deadly disease that accounts for a third of all female cancer-
related deaths globally. Although recent advances in early diagnosis and targeted 
therapy using prognostic markers have reduced deaths, more than 50% of newly 
diagnosed cases have already developed metastatic disease at diagnosis. Furthermore, 
the remaining cases still have a high risk of secondary disease and relapse. Breast 
cancer metastasis is the leading cause of breast cancer related mortality, it is incurable 
and current treatments aim to prolong life alongside pain management. Thus, there is a 
need for treatment for this disease.  
The epithelial-mesenchymal transition (EMT) is one of the processes by which 
cancer cells acquire the ability to invade and eventually metastasise. Therefore, 
understanding the regulation of breast cancer cell metastasis is essential for identifying 
methods for management of metastatic disease either by prevention or treatment. The 
first aim of this study was to develop an in vitro tissue culture model that can be used to 
assess breast cancer cell lines, that belong to several molecular subtypes, to undergo an 
EMT-like transition.  
Results showed that there were EMT-like changes seen in breast cancer cell lines 
and that the activation of these pathways is not restricted to, nor governed by, molecular 
subtypes of breast cancer. Also, an intermediate phenotype, where the cells showed 
mixed epithelial and mesenchymal morphology was observed in the basal-like breast 
cancer cells lines. This phenotype is observed for the first time in a tissue culture model 
of breast cancer cell lines and further identification of the criteria of these intermediate 
phenotype cells is required to draw further conclusions. These cells could represent the 
hybrid epithelial/mesenchymal cells that have increased metastatic ability. Thus, this 
model was utilised to study the role of Hedgehog (Hh) signalling pathway in the 
regulation of EMT in breast cancers.  
Data from a breast cancer cohort of patients samples showed that there was 
increased expression of Hh proteins (Gli1, Gli2 and Gli3) at the invasive front. This is 
the first study to assess subcellular localisation of the Gli proteins in breast cancer 
human patient samples. Also, the data suggested that breast cancer cells gain the ability 
to activate Hh signalling by autocrine rather than by paracrine signalling. These 
findings encouraged further investigation to understand the effect of inhibiting the Hh 
signalling using cyclopamine or LDE225 in vitro. 
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Inhibition with cyclopamine or LDE225 resulted in a reduction of cell yield and 
viability with increased cellular apoptosis. There was an observed alteration of Hh 
pathway proteins expression and subcellular localisation. Also, assessment of the 
catenin-related transcription, the outputs of canonical Wnt signalling, showed that 
inhibiting Hh signalling using cyclopamine and LDE225 resulted in reduction of Wnt 
signalling activity in MCF7 and MDA-MB-231 cell lines. Also, there was a reduction 
in E-cadherin expression in a dose dependent manner with a reduction in cell motility 
and invasion. 
Findings showed that Hh signalling was involved in the regulation of EMT in 
breast cancer cell lines and also showed that there was crosstalk between Hh and Wnt in 
breast cancer cells. Assessment of the co-expression of Hh pathway proteins in breast 
cancer samples provides potential prognostic markers for identifying breast cancer 
patients who could benefit from Hh-targeted therapy. 
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General Introduction 
1.1 Mammary gland development is a multistage process that involves 
epithelial and mesenchymal interaction 
The mammary gland is characterised by dynamic cellular plasticity that is 
responsible for hormonal responsive tissue remodelling in puberty (Javed and Lteif, 
2013). This remodelling is continuous throughout life and involves complex 
interactions between epithelial and mesenchymal tissue, which makes the mammary 
gland tissue prone to carcinogenesis (Kratochwil, 1986; Robinson et al., 1999; 
Gusterson and Stein, 2012; Javed and Lteif, 2013). Moreover, it was found that the 
process of epithelial-mesenchymal transition (EMT) is essential for the morphogenesis 
of mammary gland (Watson and Khaled, 2008; Chakrabarti et al., 2012). Understanding 
the anatomy and histology during stages of the mammary gland development, and the 
molecular pathways that regulate them provides insight into the deregulated processes 
during carcinogenesis (Hassiotou and Geddes, 2013). 
Significant remodelling of both the parenchyma and the stroma of the mammary 
gland occurs at the various phases of the postnatal stage, and several studies indicated 
that these changes correlate to the breast cancer subtypes and patient prognosis 
(Patsialou et al., 2009; McCready et al., 2010). 
1.1.1 The phases of mammary gland development require interactions and 
between epithelial and mesenchymal components 
The human mammary gland is an apocrine gland consisting of parenchymal 
(ductal, lobular epithelial and myoepithelial) and stromal elements (adipocytes, 
fibroblasts, blood vessels, and immune cells) (Van Keymeulen et al., 2011; Javed and 
Lteif, 2013). The ductal epithelial tissue is composed of two types of cells, inner 
luminal epithelial cells separated from basement membrane by myoepithelial cells 
(Figure 0-1-G) (Deugnier et al., 1995; Howard and Gusterson, 2000). Some of the 
luminal epithelial cells are in contact with basement membrane in the area of acini 
between the processes of myoepithelial cells (Figure 0-1-H) (Hamperl, 1970; Howard 
and Gusterson, 2000). 
Luminal cells that form the alveoli produce nutrients and secrete water while 
myoepithelial cells contract to guide the milk out of the breast ducts (Deugnier et al., 
2002; Van Keymeulen et al., 2011; Van Keymeulen et al., 2017). The ductal elements 
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are embedded in fibrous stromal tissue (Figure 0-1-E) (Hassiotou and Geddes, 2013). 
The mesenchymal cues control branching patterns of mammary gland regardless of 
epithelial origin (Sternlicht, 2006). 
 
 
 
Figure 0-1, The structure of mammary gland. 
Summary of mammary gland structure. (A) The mammary gland is a localised pectoral region between 
the second and sixth ribs (Vorherr, 1974; Geddes, 2007). (B) The nipple is infiltrated by nipple ducts 
(Cooper, 1840; Hassiotou and Geddes, 2013). The ductal system is composed of small ductules draining 
alveoli and combine into main ducts that dilate slightly to form the lactiferous sinus. The glandular 
structure at puberty is composed of lobes. The lobules are separated from each other by interlobular 
stroma consisting of dense fibrous tissue embedded in adipose tissue (Cooper, 1840; Hassiotou and 
Geddes, 2013). (C) Acini develop at the end of terminal branches (D) the terminal duct lobular unit, the 
functional unit of mammary gland (Sternlicht, 2006; Javed and Lteif, 2013). (D) The smaller lobules in 
terminal ductal lobular unit contain 10-100 alveoli (Cooper, 1840; Hassiotou and Geddes, 2013). (G) The 
myoepithelial cells on basement membrane of ducts are cuboidal whereas (H) myoepithelial cells in acini 
showed flattened morphology (Deugnier et al., 1995; Howard and Gusterson, 2000). The figure was 
drawn by the author from the mentioned references. 
 
Myoepithelial cells have a crucial role in the establishment of the polarised 
mammary epithelial bilayer and control the level of stromal invasion (Deugnier et al., 
2002; Gudjonsson et al., 2002). A significant function of myoepithelial cells is the 
production of basement membrane (Warburton et al., 1981; Kedeshian et al., 1998; 
Gudjonsson et al., 2002). Studies found that the interaction between luminal epithelial 
cells and extracellular matrix is mediated by myoepithelial cells (Deugnier et al., 2002). 
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Barsky and Karlin (2006) found that myoepithelial cells have anti-angiogenic properties 
and an anti-invasive function. 
1.2 Breast cancer  
1.2.1 Epidemiology and aetiology of breast cancer 
1.2.1.1 Breast cancer statistics show that it is an international burden 
According to the World Health Organisation WHO (2008), breast cancer is the 
most common type of cancer in females in both developed and the less developed 
countries. Incidence rate is increasing with a low survival rate of breast cancer 
particularly in less developed countries, due to diagnosis at late stages (Coleman et al., 
2008). In the UK, breast cancer remains the most common cancer in the UK since 1997 
with a 2% increase expected between 2014 and 2035 according to CRUK (2017). The 
ten year survival rate for breast cancer in the UK is 78%, which was doubled over the 
last 40 years (CRUK, 2017).  
1.2.1.2 Age is the most significant risk factor for breast cancer 
One of the most well-documented risk factors for breast cancer and many other 
cancers is age (Singletary, 2003). The risk of breast cancer increases in females 
significantly after the age of 30 until it reaches a plateau at 80 years old (Schlange et 
al., 2007).  
Lifestyle factors that cause an increased risk of breast cancer include alcohol 
consumption (Harvey et al., 1987; Schatzkin et al., 1987) and increased body weight 
(Tretli, 1989; Singletary, 2003). Duration of use of hormone replacement therapy 
(Colditz et al., 1990; Steinberg et al., 1991; Lancet, 1997), exposure to radiation (Land 
et al., 1980; Boice et al., 1991), early onset of the menstrual cycle (Brinton et al., 
1988), and smoking (Conway et al., 2002) have also been implicated. Furthermore, late 
full-term pregnancy and lactation (after the age of 30) (Brinton et al., 1983a; Brinton et 
al., 1983b), and a prior history of breast cancer (Hankey et al., 1983; Rosen et al., 
1989a) increase disease risk. Moreover, 5% of breast cancer cases are due to germline 
mutation (Easton et al., 1995). 
1.2.2 Challenges in identifying patients with poor prognosis via clinical diagnosis, 
histological classification and molecular classification 
The National Cancer Control Program (NCCP (2002) recommend the early 
diagnosis of the high-risk group (females over the age of 50); they concluded that use of 
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mammography is the most effective diagnostic method for early detection (NCCP, 
2002; Bevers et al., 2009). 
Symptoms of breast cancer include increased breast pain and tenderness (Barton 
et al., 1999; Millet and Dirbas, 2002), palpable mass detection (Pruthi, 2001), and 
nipple discharge (Meisner et al., 2008). Clinical breast examination recommended by 
the NCCN guidelines (Gradishar et al., 2017) includes inspection of breast positioning 
and examination of the breast parameters (van Dam et al., 1988; Pruthi, 2001). This is 
then followed by ultrasound, and fine needle aspiration and clinical confirmation 
procedures by core needle biopsy (Pruthi, 2001; Gradishar et al., 2017). Sections of 
fixed total tumour resection is the diagnostic procedure for confirmation of suspected 
malignancy by pathological examination (Meisner et al., 2008). 
The standard staging system for breast cancer following the guidelines of the 
American Joint Committee on Cancer (Edge and Compton, 2010) is based on the 
evaluation of the primary tumour size (T), lymph node involvement (N), and detected 
metastasis (M). Breast cancer is also categorised into five stages (I-V) depending on the 
TNM criteria and types (Woodward et al., 2003; Edge and Compton, 2010). 
Following the staging of the breast cancer, histological examination of the 
excised tumour is needed for evaluation of the subtype of breast cancer to determine the 
appropriate treatment (Gradishar et al., 2017). 
1.2.2.1 Histological classification of breast cancer was limited to the skill of the 
pathologist and was not successful in determining prognosis 
Breast cancer is a heterogeneous disease that has several distinctive histological 
and biological subtypes (Malhotra et al., 2010; Weigelt et al., 2010). Histologically, 
breast cancer is categorised into ductal and lobular types which are further divided into 
in situ and invasive carcinomas that were first described by Wellings and Jensen 
(1973); Wellings et al. (1975) and reviewed by Malhotra et al. (2010); Weigelt et al. 
(2010); Kaufman et al. (1984). 
Ductal carcinoma in situ is further categorised into Comedo, Cribriform, 
Micropapillary, Papillary and Solid-based on the architectural features of the tumours 
(Malhotra et al., 2010). The invasive tumours also include infiltrating ductal, invasive 
lobular, mixed ductal/lobular, mucinous (colloid), tubular, medullary and papillary 
carcinomas (Malhotra et al., 2010). 
The ductal and lobular classification of breast cancer does not reflect their 
origin, but they are designated according to morphology, architecture, and 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
5 
 
  
immunohistochemical properties (Malhotra et al., 2010; Weigelt et al., 2010). Invasive 
ductal carcinoma is the most common type (80%), and lobular is least frequent (8-
24.7%) of all the invasive adenocarcinomas of the breast (Martinez and Azzopardi, 
1979; Dixon et al., 1982; Dixon et al., 1991). 
There were limitations to the histological classification and staging of breast 
cancer depending on the skill of the pathologist, and subclassifying rare and poorly-
differentiated cases can be difficult. Therefore, several methods were conducted to find 
new approaches for subclassifying this heterogeneous disease and identify cases that 
require additional intervention. Breast cancers are extremely diverse both 
morphologically and genetically which results in differing responses to treatment 
(Perou et al., 2000), however, histological classification of breast cancer subtypes alone 
was not successful in identifying patients with the worst prognosis (Sims et al., 2007). 
1.2.2.2 Molecular classification of breast cancer from the discovery of the 
importance of hormone receptors to the development of targeted therapies 
Molecular classification of breast cancer commenced with the utilisation of 
receptors status, including oestrogen receptor (ER), progesterone receptor (PR) and the 
overexpression/amplification of human epidermal growth factor receptor two (HER2) 
as recommended by the World Health Organisation (WHO, 2008). Additionally, the 
cell proliferation marker (Ki67) is used to determine the prognosis of breast cancer 
patients (Sims et al., 2007). 
Determination of the status of these receptors identified patients likely to 
respond to targeted therapies (Rakha et al., 2010b). For example, tamoxifen and 
aromatase inhibitors (for ER or PR) (Cole et al., 1971; Giudici et al., 1988) or 
trastuzumab or lapatinib (for HER2) (Slamon et al., 1987; Press et al., 2008). However, 
the use of molecular profiling alone was not successful in predicting responses without 
the clinicopathological diagnosis (Rouzier et al., 2005). 
The molecular expression profiles were used to classify breast cancer according 
to poor prognosis (van 't Veer et al., 2002), relapse predictors (Paik et al., 2004), and 
genes associated with an increased risk of metastasis (Wang et al., 2005). The 
molecular classes provided unbiased hierarchical groups that displayed a significant 
difference in prediction of patient’s overall survival (Malhotra et al., 2010). Perou et al. 
(2000) identified several clusters of molecular classes of breast cancer including; basal-
like, HER2+ve, normal-like, luminal A and luminal B (Table 0-1) (Sorlie et al., 2001; 
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Sorlie et al., 2003). Rouzier et al. (2005) later found that breast cancer cases that belong 
to these clusters responded differently to chemotherapy treatment.  
Genetic profiling studies were able to identify molecular subtypes with poor 
prognosis including triple-negative (TNBC) (subtypes that are negative for the three 
prognostic receptors) and basal-like breast cancers (BLBC) comprise around 15% of all 
breast cancer cases with 90% of these cases showing poor differentiation at diagnosis, 
and 70% expressing basal markers (Rakha et al., 2009; Rakha and Chan, 2011). The 
basal-like breast cancers are also characterised by high-grade, increased mitotic activity 
and high nuclear atypia with pushing boundaries and spindle-shaped cells (Chao et al., 
2010; Seal and Chia, 2010). 
TNBC and BLBC subtypes have peak recurrence in the first three years after 
diagnosis that drops significantly after that, with decreased survival rate after detection 
of metastasis (Rakha et al., 2008; Rakha et al., 2009; Badve et al., 2011). Therefore, 
there is a pressing need for the identification of new prognostic markers, and their 
utilisation for the development of novel targeted therapies, see Table 0-1 (Sorlie et al., 
2001; de Ruijter et al., 2011; Arnedos et al., 2012). 
 
Table 0-1: Molecular classification of breast cancer, percentage prevalence, 
hormone receptor expression, HER2 status, cytokeratin expression and genetic 
characteristics. 
The table shows the subclassification of breast cancer according to the molecular clusters. The table also 
lists the markers associated with these subtypes (Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003; 
Herschkowitz et al., 2007; Prat et al., 2010; Rakha et al., 2010a). 
 
Molecular 
subclassification 
% 
prevalence 
 
Hormone 
receptors HER2 Cytokeratin Genetic characteristics  
ER PR 
Normal-like Unknown - - - - Adipose tissue gene signature 
Luminal A 19-39% + +/- - CKs 8/18 - 
Luminal B 10-23% + +/- + CKs 8/18 Proliferation markers 
HER2+ 4-10% - +/- + CKs 8/18 - 
Basal-like 16-37% - - - CKs 5/6, CK14, and CK17 EGFR 
Claudin-low 12-14% - +/- - - Claudin3/4/7 low. Vimentin, E-cadherin low, Zeb1 
 
Additional breast cancer molecular subtypes were discovered including the 
apocrine tumours, identified by Farmer et al. (2005), which are HER2+ve and androgen 
receptor (AR) positive. This subtype comprises the majority of the HER2+ve tumours 
and form the third major group after luminal and basal subtypes (Farmer et al., 2005; 
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Sims et al., 2007). The claudin-low subtype was identified based on the intrinsic 
genetic expression profile and low patient survival (Table 0-1) (Herschkowitz et al., 
2007; Prat et al., 2010). 
1.2.3 Treatment options for breast cancer 
Three types of treatment are available for breast cancer, the selection of 
treatment depends on the histological, clinicopathological features, and molecular type. 
The choices for treatment include surgical resection, radiation and systemic therapies 
used singly or in combination. Systemic therapy includes the use of targeted therapies 
(e.g. endocrine treatments) and chemotherapies. 
1.2.3.1 Surgery 
The first option for breast cancer treatment was the Halsted radical mastectomy 
that includes complete resection of the mammary gland, skin, breast tissue, underlying 
pectoralis major and minor muscles with the axillary lymph nodes (Halsted, 1907). This 
approach resulted in the reduction of local recurrence that ranged from 6% to 80%, 
however, with side effects of: sensory abnormalities, deformity, and lymphedema 
(Halsted, 1907). Fisher et al. (1989) developed a less radical surgical approach with 
preservation of most of the necessary breast tissue. This approach was developed 
further to the surgical approach used currently involving resection of primary tumour 
and the involved lymph nodes (Akram and Siddiqui, 2012). 
Neoadjuvant chemotherapy was utilised as the first approach to reduce the bulk 
of the tumour for locally invading tumours, followed by resection or total breast 
mastectomy depending on the clinical situation (Akram and Siddiqui, 2012). Still, 
surgery alone was not successful in treating breast cancer, nor in reducing recurrence 
and increasing survival. 
1.2.3.2 Radiotherapy 
Pfahler (1932) was the first to record the use of radiation therapy for the 
treatment of breast cancer. This technique increased the survival rate of early stage 
breast cancer patients by 80% (Pfahler, 1932). Radiation therapy showed the same 
efficacy as radical breast surgery (Atkins et al., 1972; Fisher et al., 1985; Fisher et al., 
1989). Later, studies found that the use of adjuvant radiation therapy resulted in the 
reduction, but not eradication, of local and regional metastasis and improved overall 
survival (Overgaard et al., 1997; Ragaz et al., 1997; Overgaard, 1999), thus, supporting 
the use of radiation therapy as a standard treatment in breast cancer. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
8 
 
  
1.2.3.3 Systemic therapy 
The initial chemotherapy treatment was using a single agent such as 
cyclophosphamide, and later combination of chemotherapeutic agents was tested with a 
varied response rate (Bonadonna et al., 1976; Brambilla et al., 1976). In the 1970s, 
Cyclophosphamide-Methotrexate-5-Fluorouracil (CMF) regimen was the gold standard 
for treating breast cancer cases as well as other solid cancers (Bonadonna et al., 1976). 
In the 1990s, CMF became the primary treatment regimen used as adjuvant 
chemotherapy for early breast cancers (Akram and Siddiqui, 2012). It was later found 
that it reduced breast cancer mortality by 20% (Early Breast Cancer Trialists' 
Collaborative, 2005). Other regimens were developed and tested including Docetaxel, 
Doxorubicin and Cyclophosphamide (TAC) and 5-Fluorouracil, Doxorubicin and 
Cyclophosphamide and found to be beneficial for early-stage breast cancer (Martin et 
al., 2005). 
Currently, chemotherapeutics are used as neoadjuvant, adjuvant and in 
metastatic breast cancer treatment (Akram and Siddiqui, 2012). The use of 
chemotherapy is not preferred because of the cytotoxic and genotoxic side effects 
(Evrard et al., 1999; Sodergren et al., 2016). Therefore, there has been a massive effort 
in the medical community to develop more advanced treatments with fewer side-
effects. 
Targeted therapy consists of blockers (e.g. Tamoxifen) and small molecules 
(aromatase inhibitors) (Malhotra et al., 2010; Rakha et al., 2010b; Liedtke and Kiesel, 
2012), which block peripheral synthesis of oestrogen (Giudici et al., 1988). The most 
recent targeted therapy is against the oncogene HER2 with either targeted antibodies 
(Trastuzumab) or small molecule inhibitors (lapatinib) (Slamon et al., 2001). 
1.2.4 Relapse, metastasis, and lack of targeted therapy persist in treating breast 
cancer 
Even with the advances in targeted treatments, there are three difficulties to 
overcome for the effective treatment of breast cancer. A significant number of patients 
with luminal/hormone-positive breast cancer and HER2-overexpressing breast cancers 
develop resistance to targeted therapy, followed by relapse and metastasis (Early Breast 
Cancer Trialists' Collaborative, 2005; Coates et al., 2007; Group et al., 2009; Cuzick et 
al., 2010). Another challenge is the management of disease already metastatic at 
presentation (Akram and Siddiqui, 2012). 
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Also, according to the recommended regimen of chemotherapy more than 80% 
breast cancer patients receive adjuvant chemotherapy (Eifel et al., 2001; NCCP, 2002). 
It is estimated that only 40% of those cases develop relapse and die eventually. Thus, 
indicating that more than half of those patients were over-treated with chemotherapy 
that has toxic side-effects (Eifel et al., 2001; O'Shaughnessy, 2005; Weigelt et al., 
2005). 
Another problem is the lack of targeted therapy for triple-negative breast 
cancers (hormone and HER2 receptor negative) (Rakha et al., 2009; Peddi et al., 2012). 
Moreover, triple-negative breast cancer has a high risk of distal recurrence, with 
increased cancer-related deaths after relapse, compared to the other subtypes of breast 
cancer (Dent et al., 2007; Tang et al., 2016). 
1.2.5 Breast cancer metastasis 
Almost 90% of all breast cancer-related deaths are caused by metastasis (Wang 
and Zhou, 2013). Detection of cancer metastasis is the worst prognostic factor and 
correlates with a poor survival rate (Rosen et al., 1989a; Kowalski et al., 2003; Weigelt 
et al., 2005). It is estimated that around 15% of breast cancer cases develop metastasis 
within five years of initial diagnosis (Weigelt et al., 2005; WHO, 2008; CRUK, 2017). 
Cancer metastasis commences with the invasion of tumour cells into the 
surrounding stroma followed by migration in the lymphatic system or bloodstream 
(Clark and Vignjevic, 2015), which is one of the hallmarks of cancer (Hanahan and 
Weinberg, 2011). Cancer cells achieve this through changing their cellular structure and 
alteration of their interaction with surrounding cells and extracellular matrix (Hanahan 
and Weinberg, 2011). 
1.2.5.1 Challenges associated with the management and treatment of breast cancer 
metastasis 
Breast cancer metastasis has a heterogeneous nature, making it difficult to 
identify risk factors and to develop effective treatments for this condition (Weigelt et 
al., 2005). The established prognostic indications that are currently used in clinical 
diagnosis are histological and clinicopathological factors used in the staging and 
grading of breast cancer (lymph node involvement, primary tumour size and loss of 
differentiation) (Koscielny et al., 1984; Carter et al., 1989; Elston and Ellis, 1991). 
Rosen et al. (1989b) found that about third of breast cancer cases that did not 
show signs of lymph node involvement went on to developed metastases. In addition, a 
third of breast cancer cases that did showed lymph node involvement also went on to 
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develop metastasise. They found that a third of breast cancer cases showing lymph node 
involvement did not develop metastasis in ten years following local therapy (Rosen et 
al., 1989b; McGuire and Clark, 1992). Similarly, Weiss et al. (1983) argued that there 
was no relationship between the tumour size and the metastatic potential of a tumour. 
Gene expression studies assisted in isolating signatures for metastatic traits and 
helped in identifying new therapeutic targets (Weigelt et al., 2005). Several studies 
identified molecular signatures that were associated with metastasis and poor survival 
(van 't Veer et al., 2002; van de Vijver et al., 2002; Ramaswamy et al., 2003). 
However, it was hypothesised that a rare subpopulation of cells acquires metastatic 
potential, which makes the genetic detection of such a rare population difficult (Fidler 
and Kripke, 1977). 
According to Weigelt et al. (2005), the challenges of managing breast cancer 
metastasis includes a lack of prognostic markers to identify patients with the worst 
prognosis, improving targeted treatments, and availability of model systems to study the 
process of breast cancer metastasis. Therefore, it is important to find new molecular 
markers that can be exploited in either the early identification of cases with a poor 
prognosis, or in the development of targeted therapy. 
The modes and the dynamics of cancer cell migration were previously described 
by Clark and Vignjevic (2015). Human cancer cells migrate in one of three ways; either 
as single-cells, multicellular streaming, or in collective migration (Clark and Vignjevic, 
2015). In all modes of metastasis, cells lose cell-cell contact and display a more 
mesenchymal phenotype (Clark and Vignjevic, 2015). It was observed that in epithelial 
tumours, including breast cancer, cancer cells metastasised collectively (Caussinus et 
al., 2008). Cancer cells formed strands and cords of tumour cells that invaded the 
adjacent stroma at the invasive front of a tumour (Caussinus et al., 2008; Clark and 
Vignjevic, 2015). 
As mentioned previously, the morphology of the cells at the invasive front of 
primary breast tumours have a spindle-shaped morphology (Chao et al., 2010; Seal and 
Chia, 2010). The process of EMT is linked prominently to the cellular alterations that 
take place to facilitate metastasis (Klymkowsky and Savagner, 2009; Thiery et al., 
2009). 
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1.3 EMT is essential for mammary gland development, and disturbance of 
EMT is an essential event in breast cancer progression and metastasis 
EMT is the phenotypic switching in shapes of cells that provides a flexibility of 
cellular function that is essential during normal embryogenesis and in other 
physiological stresses such as wound healing (Micalizzi et al., 2010). 
EMT involves a series of events that commence with loss of epithelial cell 
polarity with the disassembly of tight junctions (Micalizzi et al., 2010), followed by the 
loss of cell-cell contact and degradation of the basement membrane (Peinado et al., 
2004; Micalizzi et al., 2010). Epithelial membrane proteins such as E-cadherin and 
integrins are replaced by other types of cadherins and integrins with transient adhesive 
properties (Peinado et al., 2004). Also, vast changes in the arrangement of the 
cytoskeletal proteins take place, such as the replacement of the actin cytokeratin with 
stress fibres and, replacement of intermediate filaments with vimentin. Together, these 
cellular changes result in a phenotypic conversion of cuboidal epithelial cells to 
spindle/mesenchymal-like cells (Micalizzi et al., 2010). 
Kalluri and Weinberg (2009) classified EMT into three types, depending on 
clear functional consequence, but the molecular regulation of each subtype is not fully 
understood. EMT types I and II are involved in normal physiological processes 
including; embryogenesis and organogenesis (type I) and in the process of wound 
healing, tissue regeneration, inflammation and fibrosis (type II), (Kalluri and Weinberg, 
2009; Zeisberg and Neilson, 2009; Wang and Zhou, 2011). On the other hand, type III 
is involved in cancer metastasis and include misappropriation of the EMT signalling 
pathways (Kalluri and Weinberg, 2009; Zeisberg and Neilson, 2009; Wang and Zhou, 
2011). 
Complete EMT occurs during single cell migration, which is the mechanism 
that immune cells use to migrate to the site of inflammation (Halin et al., 2005). 
Complete EMT is not the only method by which epithelial cells gain the ability to 
migrate during development. Partial EMT results in collective movement in sheets of 
cells (Rorth, 2009). This form of cellular migration is also essential in human 
development as it helps in maintaining the cellular structure of the tissue while 
remodelling. It also allows immobile cells to be moved with the mobile cells, ensuring 
appropriate cellular distribution (Rorth, 2009). 
Collective cell movement is seen during normal tissue remodelling such as in 
intestinal turnover (Batlle et al., 2002; Barker et al., 2008) and in mammary gland 
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remodelling (Pearson and Hunter, 2007; Ewald et al., 2008). In collective migration, the 
cells display cellular alterations associated with EMT such as loss of polarity, 
modification of the extracellular matrix, and acquisition of mesenchymal phenotype 
while, at the same time, the cells maintain cell-cell junctions (Rorth, 2009). Therefore, 
due to the similarities between collective cellular migration and EMT, it was suggested 
that the epithelial and mesenchymal phenotypic conversion does not reflect an absolute 
status but rather a spectrum of epithelial and mesenchymal properties (Rorth, 2009; 
Micalizzi et al., 2010). There is evidence that the process of EMT is involved in the 
regulation of mammary gland development. In fact, EMT is involved in the regulation 
of the development of all the human body organs and this process is type I EMT (Wang 
and Zhou, 2011). Expansion of tissue occurs with infiltration of epithelial tissue 
through the mesenchyme to form the primary ducts (Tobon and Salazar, 1974; 
Sakakura et al., 1987; Hens and Wysolmerski, 2005). 
1.3.1 The EMT process is regulated by several signalling pathways that implies 
the possibility of crosstalk and is triggered by cellular status and 
stimulation from the microenvironment 
Several pathways are involved in the regulation of EMT in human tissue 
including Hedgehog, TGF-b, Notch, Wnt/b-catenin, TNF-a, integrins and receptor 
tyrosine kinase pathways (Garg, 2013) (Figure 0-2). Upon activation of the receptors 
with ligands, a signalling cascade is triggered inside the cells and initiates the process of 
EMT. 
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Figure 0-2, Pathways involved in the regulation of the process of EMT. 
The signalling pathways involved in regulating EMT. (A) Transforming growth factor b (TGFb) 
signalling is induced by binding of ligands to receptor. TGFb receptor activation by phosphorylation 
results in recruitment of SMAD transcription factors that translocate to nucleus and binds to DNA (Xu et 
al., 2000; Gonzalez and Medici, 2014). (B) Integrins are heterodimeric transmembrane proteins. Integrin 
interact with TGFb and activate the pathway (Mamuya and Duncan, 2012) also, integrins interacts with 
components of extracellular matrix (Yen et al., 2014). (C) Receptor tyrosine kinases (RTKs) are activated 
by binding to growth factors including epidermal growth factor (EGF), fibroblast growth factor (FGF), 
hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF). The binding results in 
dimerisation of receptors and eventually activation of signalling cascade (Lemmon and Schlessinger, 
2010; Gonzalez and Medici, 2014). (D) Wnt signalling is transduced by Wnt binding to Frizzled receptor 
or low-density lipoprotein receptor-related protein (LRP) receptors. Wnt activation releases b-catenin 
which translocates to nucleus and binds to T-cell factor/lymphoid enhancer binding factor-1 (TCF/LEF-
1) (Gonzalez and Medici, 2014; Nusse and Clevers, 2017). (E) Notch receptor is composed of 
extracellular and intracellular domain. Upon binding g-secretase cleaves intracellular domain of Notch 
(NICD) that translocates to nucleus (Kopan, 2002; Miele et al., 2006; Gonzalez and Medici, 2014). (F) 
Ligands of Hedgehog signalling pathway include Sonic hedgehog (Shh), Indian hedgehog (Ihh), and 
Desert hedgehog (Dhh) that bind to patched homolog 1 (Ptch1) and Ptch2, which release inhibition on 
Smoothened (Smo) (Gallet and Therond, 2005; Gonzalez and Medici, 2014). (G) The inflammatory 
stimuli activate TNFa and IL-6 which activate transcription factor signal transducer and activator of 
transcription 3 (STAT3), that activates Snail expression. (H) Hypoxia influence EMT by activation of 
Twist expression after activation of hypoxia-inducible factor 1a (HIF1a) (Yang et al., 2008a). The figure 
was drawn by the author from the mentioned references. 
 
Several layers of crosstalk between the EMT pathways have been identified. 
This crosstalk is due to the diverse range of processes involving EMT (Gonzalez and 
Medici, 2014). The context of cross-interaction between these signalling cascades also 
depends on interactions with the surrounding microenvironment and the cell state 
(Gonzalez and Medici, 2014). 
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The cellular statuses that result in triggering the EMT process include hypoxia 
(Lundgren et al., 2009; Daly et al., 2017); activation TGFb and other growth factors 
(Daniel et al., 1996; Cheng et al., 2012); autocrine feedback loops (Schlange et al., 
2007); and extracellular matrix remodelling (Silberstein et al., 1992; Gonzalez and 
Medici, 2014). 
Zeisberg and Neilson (2009) categorised the biomarkers that identify the various 
types of EMT into five groups; cell surface markers (E-cadherin), cytoskeletal markers 
(vimentin), extracellular matrix proteins (collagen and fibronectin), transcription factors 
(Snail, Slug, and Twist), and micro-RNAs (Figure 0-3). 
 
 
 
Figure 0-3, Markers of EMT. 
The types of markers that are affected by EMT with few examples. (A) Changes in cell surface markers 
including attenuated expression of E-cadherin and change of N-cadherin level. (B) Changes in 
cytoskeletal markers such as attenuated expression of cytokeratin; changes in localisation of b-catenin; 
changes of mesenchymal markers level such as vimentin and a-smooth muscle actin. (C) Changes of 
extracellular matrix proteins such as collagen and fibronectin. (D) Changes of EMT transcription factors 
expression such as; Snail 1 (Snail), Snail 2 (Slug), ZEB 1, Twist and LEF-1. (E) Changes of microRNAs 
expression. The figure was drawn by the author and details adapted from (Zeisberg and Neilson, 2009; 
Wang and Zhou, 2013). 
 
The most important hallmark of EMT commences with the loss of E-cadherin 
which directly affects the Wnt/b-catenin pathway. Also, increased expression of the 
mesenchymal markers (such as vimentin), with changes in the level and localisation of 
E-cadherin, status of Wnt/b-catenin signalling provides further confirmation of the 
mesenchymal change. 
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1.3.1.1 Constant E-cadherin expression and localisation to the cell membrane are 
the principal determinant of the epithelial status of cells 
Cell-cell contact organises the structure of mammary epithelial cells which is 
mediated by E-cadherin and other membrane proteins (Claudin and Occludin) (Morrow 
et al., 2010; Chen et al., 2014). E-cadherin facilitates several cellular functionalities 
including cell-cell contact, cellular polarity, differentiation, stem cell properties, cell 
motility, migration, proliferation and survival. These functions are mediated through 
interaction with b-catenin and cytoskeletal protein (Figure 0-4-B) (Nagafuchi and 
Takeichi, 1989; Nieman et al., 1999; Junxia et al., 2010; Chen et al., 2014). 
 
 
 
Figure 0-4, E-cadherin structure and the cell-cell adhesion structure formed by E-
cadherin. 
The figure shows the structure of E-cadherin protein and the cell-cell adhesion that is formed by E-
cadherin protein. A- E-cadherin multidomain glycoprotein structure (van Roy and Berx, 2008). B- The 
cell-cell calcium-dependent adhesions formed by E-cadherin assembly to the actin cytoskeleton through 
catenin proteins. It is linked to the cytoskeletal filaments via interaction with cytoplasmic proteins 
including (a-catenin and b-catenin) (Yoshida and Takeichi, 1982; Peyrieras et al., 1983). The key below 
explains the different components of the cell-cell adhesion. The figure was drawn by the author from the 
mentioned references. 
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E-cadherin is known as the caretaker of the epithelial phenotype (Thiery, 2002; 
Oloumi et al., 2004). E-cadherin functions to maintain the epithelial morphology via 
interaction of extracellular domains, and by intracellular domain binding to catenins 
(Takeichi, 1991; Tian et al., 2011). Of the components that interact with the 
intracellular domain of the of E-cadherin, b-catenin is also a crucial regulator of the 
Wnt signalling pathway (Clevers and Nusse, 2012). Cell contact is a critical 
determinant of the EMT status of cells, as loss of E-cadherin eventually leads to 
increasing the free b-catenin pool and, therefore, activation of the EMT process (Hay 
and Zuk, 1995). Therefore, the loss of cell-cell contact that is mediated by E-
cadherin/b-catenin triggers EMT in normal physiological processes as well as in 
diseases such as cancer (Tian et al., 2011). 
In epithelial cells, E-cadherin clusters to the cell membrane and interacts with 
the E-cadherin of neighbouring cells (Adams and Nelson, 1998; Thiery, 2002). This 
localisation of the protein to the cell membrane is critical for the maintenance of stable 
adherens junctions, and disturbance of E-cadherin is known to induce a mesenchymal 
change (Imhof et al., 1983; Thiery, 2002). In addition, there is a direct correlation 
between the increase in mesenchymal phenotype and reduction in E-cadherin 
production (Behrens et al., 1989; Thiery, 2002). 
E-cadherin expression in normal mammary gland tissue is strong and localised at 
the cell boundaries of epithelial cells, forming a cobblestone appearance of epithelial 
tissue (Wheelock et al., 2001; Kowalski et al., 2003). All non-epithelial tissue in the 
mammary gland does not express E-cadherin (Kowalski et al., 2003). 
Loss of E-cadherin protein or its function as result of mutation is a very rare 
event in breast cancer (Graff et al., 2000). It was reported previously that the CDH1 (E-
cadherin gene) tumour suppressor was lost in ductal carcinoma (Li and Mattingly, 
2008; Chen et al., 2014). Graff et al. (2000) concluded that E-cadherin epigenetically 
silenced was transient and heterogeneous depending on cancer cells microenvironment. 
They also concluded that loss of E-cadherin expression by methylation in primary 
breast tumours is an early event (Graff et al., 2000). 
E-cadherin is involved in several essential pathways necessary for breast cancer 
progression. Vutskits et al. (2006) found that E-cadherin has a role in controlling the 
molecular pathway that regulates the cell cycle. Moreover, disturbance of cell-cell 
contacts and the cytoplasmic localisation of cadherins stimulate anoikis resistance in 
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breast cancer cells (Ribeiro et al., 2013). Therefore, loss of E-cadherin is considered as 
one of the most critical hallmarks of cancer metastasis. 
The loss of E-cadherin protein is a hallmark for EMT activation in 
embryogenesis and cancer progression (Hazan et al., 2000; Huber et al., 2005; Yang 
and Weinberg, 2008; Polyak and Weinberg, 2009; Thiery et al., 2009; Yuki et al., 
2014). Onder et al. (2008) found that complete loss of E-cadherin was essential for 
cancer progression and induction of EMT in breast cancer. Derksen et al. (2006) 
confirmed that E-cadherin loss was responsible for anoikis-resistance and increased 
angiogenesis associated with metastasis in breast cancer, therefore suggested that E-
cadherin is essential for tumour initiation and progression. Onder et al. (2008) also 
found that a truncated form of E-cadherin, lacking external domain of the protein, was 
sufficient to induce EMT in mammary epithelial cells. These findings were similar to 
Liu et al. (2006b), in which they noticed two distinct regulatory functions of E-
cadherin; mediating an increase in proliferation at low density and inhibiting 
proliferation at higher densities. 
In breast cancer, partial or total loss of E-cadherin is linked to increased 
invasiveness (Siitonen et al., 1996), metastasis (Oka et al., 1993; Hunt et al., 1997) and 
poor prognosis (Heimann et al., 2000). Qureshi et al. (2006) found that loss of E-
cadherin expression correlated with prognosis and inversely with increased risk of 
metastasis in invasive ductal carcinoma. Rakha et al. (2005) suggested that loss of E-
cadherin in non-lobular breast cancers assists in identifying patients with the worst 
prognosis. Similarly, Mahler-Araujo et al. (2008) found that poor prognosis non-lobular 
breast carcinomas that have triple-negative and metaplastic characteristics were 
associated with reduced E-cadherin expression. 
Emerging evidence in the literature suggests that E-cadherin expression is 
essential in subsequent steps in EMT and cancer metastasis, but E-cadherin loss alone 
was not sufficient to start the invasion cascade in breast cancer cells (Onder et al., 
2008). Knocking down the expression of E-cadherin in normal-like breast cancer cell 
line MCF10A was insufficient to activate EMT nor increased the aggressiveness of this 
cell line (Chen et al., 2014). Likewise, restoring E-cadherin expression in the E-
cadherin knocked down cells did not restore the full epithelial morphology of MCF10A 
showing that E-cadherin expression alone was not enough to reverse mesenchymal 
transition (Li and Mattingly, 2008). Thus, loss of E-cadherin alone does not initiate 
invasion, even if it resulted in mesenchymal phenotypic change. Similarly, the 
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restoration of E-cadherin alone did not reverse the mesenchymal morphology of cells. 
Therefore, suggesting that the loss of E-cadherin is transient and can be reversed.  
Re-expression of E-cadherin is essential and parenchyma-tumour cell-cell 
contact is necessary to induce MET to establish metastases in distant site. Thus, the loss 
of E-cadherin is transient, and re-expression of the protein occurs by mesenchymal-
epithelial transition (MET) after establishing metastasis. Increased E-cadherin 
expression in metastatic ovarian cancer and high-grade glioma was associated with an 
increase in tumour invasiveness and poorer prognosis (Sundfeldt, 2003; Reddy et al., 
2005; Lewis-Tuffin et al., 2010). Furthermore, Chao et al. (2010) found that E-cadherin 
expression increased at the metastatic site in 60% of cases of breast cancer compared to 
the original tumour. Also, the MDA-MB-231 (TN and basal-like) breast cancer cell line 
re-expresses E-cadherin when co-cultured with liver cells and when injected into mouse 
tail. Therefore, they concluded that E-cadherin expression was essential to complete 
tumour metastasis and that loss of E-cadherin in tumour cells is reversible (Chao et al., 
2010). Normal parenchymal cells from normal breast tissue was able to restore E-
cadherin in the MDA-MB-231 cell line, however, culturing the same cells in the normal 
extracellular matrix or normal parenchyma-conditioned medium was not sufficient to 
change the mesenchymal phenotype to an epithelial one (Chao et al., 2010).  
In conclusion, loss of E-cadherin is the first step of EMT, yet this loss was not 
permanent, and re-expression was essential to promote secondary tumour establishment 
in breast cancer. Furthermore, acquisition of additional invasive properties is necessary 
for breast cancer progression in addition to the loss of E-cadherin (Onder et al., 2008; 
Kumar et al., 2011). It was suggested that breast cancer cell metastasis requires a 
reduction of E-cadherin and increased expression of other EMT-associated proteins 
(Nieman et al., 1999; Hazan et al., 2000). Therefore, assessing the expression of E-
cadherin alone does not reflect the status of EMT or invasiveness of breast cancer 
because the loss or changes in expression is not a permanent situation. So, it is essential 
to include additional markers in the confirmation of the EMT status in the assessment 
of the changes of this process in breast cancer. 
1.3.1.2 Increased expression of mesenchymal markers is associated with metastasis 
and increased cellular motility 
Vimentin is a type III intermediate filament that is expressed in normal cells of 
mesenchymal origin (Gilles et al., 2003; Herrmann and Aebi, 2004; Liu et al., 2015). It 
is an essential filament during the developmental stages of the mammary gland and for 
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maintenance of tissue integrity (Liu et al., 2015). It is highly organised and is involved 
in dynamic cellular processes. It is also associated with intracellular organelles and cell 
adhesion molecules (Kokkinos et al., 2007). Thus, vimentin protein maintains cellular 
structure and function (Kokkinos et al., 2007). Increased expression of this marker has 
been documented in several physiological processes including migration of epithelial 
cells in embryogenesis and organogenesis, and also during wound healing (Gilles et al., 
2003; Kokkinos et al., 2007; Lundgren et al., 2009). 
In the human breast, myoepithelial cells express vimentin (Qu et al., 2015). It is 
also expressed in fibroblasts, stromal cells, leukocytes, and it is low in epithelial cells 
(Kokkinos et al., 2007). The vimentin promoter is targeted by the b-catenin/TCF 
transcription factor in mammary cells (Gilles et al., 2003). Thus, the activation of EMT 
by the Wnt/b-catenin pathway results in increased mammary epithelial cell migration, 
caused by physiological and pathological processes (Gilles et al., 2003; Kokkinos et al., 
2007). 
Derksen et al. (2006) found that most adenocarcinomas and solid carcinomas that 
express an epithelial phenotype lacked expression of vimentin. Meanwhile carcinomas 
of metaplastic and biphasic histology express a high level of vimentin and lack 
expression of E-cadherin. 
Increased expression of vimentin was associated with increased EMT and linked 
to increased metastatic potential in breast cancer. Cell lines that show increased 
vimentin expression had increased fibroblastic morphology, with increased motility and 
migration through a Matrigel® matrix; whereas cells that have low expression of 
vimentin, had more epithelial-like morphology and decreased motility (Sommers et al., 
1991). Loss of epithelial cytokeratin alongside an increase in vimentin expression was 
associated with lymph node metastasis, high tumour grade, poor prognosis and reduced 
disease-free survival (Chen et al., 2008; Vora et al., 2009). Hemalatha et al. (2013) 
found that increased expression of vimentin was associated with higher breast cancer 
tumour grade and with increased proliferative marker expression. 
Association of this marker with the different subtypes of breast cancer has been 
reported. Increased expression of vimentin is associated with high-grade ductal 
carcinomas, but not with lobular carcinoma (Hemalatha et al., 2013; Liu et al., 2015). 
The expression of vimentin was also associated with low ER and PR breast cancers, as 
well as with increased invasiveness of the basement membrane (Kokkinos et al., 2007; 
Sarrio et al., 2008; Hemalatha et al., 2013; Liu et al., 2015). Moreover, it was reported 
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that vimentin overexpression is associated with TNBC and BLBC (Sarrio et al., 2008; 
Kasper et al., 2009; Ricardo et al., 2011). Studies also concluded that increased 
vimentin expression is associated with HER2 positivity, metastasis and advanced 
disease stage (Ribeiro et al., 2013; Tanaka et al., 2016). (Hemalatha et al., 2013). 
Furthermore, it was reported in several studies that loss of E-cadherin expression in 
highly invasive breast cancer cell lines is associated with increased expression of 
vimentin (Gilles et al., 2003; Chen et al., 2008). 
Increased vimentin expression was seen at the invasive front of breast cancer 
along with increased b-catenin expression in the cytoplasm and nucleus and the loss of 
E-cadherin localisation at cell-cell adhesions (Gilles et al., 2003; Sarrio et al., 2008). 
Several studies reported that b-catenin functions in EMT by regulating the expression 
level of vimentin (Mestdagt et al., 2006; Wang et al., 2015). Liu et al. (2015) found that 
vimentin increases the aggressiveness of cancer cells by increasing their tolerance to 
extracellular stress by maintaining mechanical homeostasis and reorganising the 
cellular cytoskeleton. 
High expression of vimentin has been seen in circulating tumour cells of patients 
with breast cancer, indicating that it was associated with increased early metastasis 
(Kallergi et al., 2011). Dwedar et al. (2016) found that hypomethylation of the vimentin 
gene was frequently associated with TN breast cancer. Yamashita et al. (2013) also 
found that vimentin expression was associated with poorer prognosis in TN breast 
cancer cases and suggested its use as a prognostic marker. 
However, no association was found between vimentin expression and tumour 
size, lymph node involvement and patient survival (Hemalatha et al., 2013). One of the 
reasons for this apparent contradiction in reporting is vimentin expression within the 
stem cells of the breast. It was concluded that the expression of vimentin in breast tissue 
is associated with cells that have bilinear origin or differentiation potential (epithelial 
and myoepithelial) and that it was not associated with the process of EMT (Hemalatha 
et al., 2013). Many studies indicated that vimentin expression is associated with stem 
cell-like properties in breast cancer cells (Manuel Iglesias et al., 2013; Liu et al., 2014; 
Qu et al., 2015). 
In conclusion, the assessment of more than one marker is essential for the 
estimation of the epithelial/mesenchymal status of breast cancer cells. Furthermore, 
expression scoring, and subcellular localisation of the markers must also be considered. 
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In addition to the decrease in E-cadherin and increase of the free pool of b-
catenin, increased vimentin expression is indicative for active EMT in human cancer 
(Gilles et al., 2003; Sarrio et al., 2008). Increased expression of vimentin was 
associated with several pathological conditions including human tumours (Conacci-
Sorrell et al., 2003; Ha et al., 2013). 
1.4 The critical role of Wnt/b-catenin pathway in the regulation of EMT 
during mammary gland development and breast cancer metastasis 
b-catenin protein is the intermediate protein that facilitates the interaction 
between a-catenin and E-cadherin, and it is typically localised to the cell membrane 
(Nagafuchi and Takeichi, 1989). At multiple stages during human development, b-
catenin is found in the cytoplasm and can facilitate the Wnt pathway. Upon activation 
of the pathway, b-catenin translocates to the nucleus and associates with the T-cell 
factor/lymphoid enhancer (TCF/LEF) transcription factors (Figure 0-4) (Korinek et al., 
1997; Morin et al., 1997; Porfiri et al., 1997). 
Expression of b-catenin in normal breast tissue, or normal-adjacent tissue, was 
seen localised at inter-cellular borders of epithelial cells with no localisation at the basal 
or luminal surface of the epithelial cells (Karayiannakis et al., 2001; Jiang et al., 2009). 
Weak punctate staining was observed in the cytoplasm of myoepithelial cells, with no 
localisation at the basal surface and no staining found in parenchymal cells of 
mammary gland (Karayiannakis et al., 2001). 
1.4.1 The Wnt/b-catenin pathway is essential for the regulation of EMT 
The localisation of b-catenin to areas of the cell-cell contact area is facilitated 
by binding to the E-cadherin intracellular domain and interaction with the actin 
cytoskeletal proteins essential for maintaining the epithelial phenotype (Chen et al., 
1999; Jeanes et al., 2008). Without activation of Wnt signalling (Figure 0-5-1), the 
cytoplasmic level of the b-catenin protein pool is controlled by adenomatous polyposis 
coli (APC). The APC protein targets the b-catenin protein for phosphorylation, 
resulting in ubiquitination and rapidly targeting for proteasomal degradation (Aberle et 
al., 1997; Bienz, 1999; Nusse and Clevers, 2017). 
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Figure 0-5, the Wnt signalling activation. 
The Wnt pathway. 1- Deactivated or resting Wnt signalling pathway. (A) b-catenin protein in normal 
cells is sequestered to cell membrane (Nagafuchi and Takeichi, 1989; Nusse and Clevers, 2017). (B) Free 
b-catenin is rapidly targeted by the tumour suppressor adenomatous polyposis coli (APC) complex that 
phosphorylates b-catenin (Pronobis et al., 2015; Nusse and Clevers, 2017). (C) Phosphorylated b-catenin 
is ubiquitinated. (D) Phosphorylated b-catenin rapid degradation by the proteasome (Aberle et al., 1997; 
Clevers and Nusse, 2012). 2- Wnt signalling activation. (A) Wnt signalling is activated by binding of 
ligand (Wnt) to Frizzled receptor (Janda et al., 2012; Nusse and Clevers, 2017). (B) Activation of Wnt 
releases of b-catenin protein from E-cadherin/b-catenin complex (Hulsken et al., 1994; Tian et al., 2011; 
Nusse and Clevers, 2017). (C) Active Wnt signalling inhibits of APC complex and disassembly of actin 
filaments from the E-cadherin/b-catenin complex (Hulsken et al., 1994; Bienz, 1999). (D) Increase b-
catenin free pool in cytoplasm as a result of Wnt activation. D- Free b-catenin protein translocates to 
nucleus (Bienz, 1999; Nusse and Clevers, 2017). (E) In nucleus, b-catenin binds to TCF/LEF and (F) and 
activates transcription of targeted genes (Korinek et al., 1998; Bienz, 1999; Clevers and Nusse, 2012). 
The figure was drawn by the author from the mentioned references. 
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Loss of E-cadherin alone does not result in nuclear localisation of b-catenin due 
to constant activation of the APC degradation pathway (Hulsken et al., 1994; Bienz, 
1999). Activated Wnt signalling inhibits APC and results in reduced b-catenin 
degradation and accumulation of the protein in the cytoplasm (Aberle et al., 1997; 
Clevers and Nusse, 2012). Free b-catenin then translocates to the nucleus and functions 
as a transcriptional co-regulator with a TCF/LEF transcription factor (Korinek et al., 
1998; Nusse and Clevers, 2017). The Wnt/b-catenin pathway is essential in embryonic 
development and implicated in many other physiological processes (Korinek et al., 
1998; Chu et al., 2004; Nusse and Clevers, 2017).  
1.4.2 The Wnt/b-catenin signalling is essential during the development of the 
mammary gland 
The Wnt/b-catenin pathway is involved in several aspects of mammary gland 
development (both prenatal and postnatal) and is also crucial for mammary stem cell 
maintenance (van Amerongen et al., 2012). Also, it has been found that Wnt/b-catenin 
is involved in determining the fate of mammary gland stem and progenitor cells (van 
Amerongen et al., 2012). 
There is an agreement in the literature that the lymphoid enhancer binding factor 
1 gene (Lef1) is involved early in mammary gland development (van Genderen et al., 
1994; Hennighausen and Robinson, 2001). Members of the Wnt family (Wnt6, Wnt3 
and Wnt10B) are involved in the initiation, primitive bud formation and branching of 
the mammary gland (Mailleux et al., 2002; Chu et al., 2004; Eblaghie et al., 2004; 
Veltmaat et al., 2004). Additionally, the Tcf1 and Tcf4 transcription factors are also 
active in the mammary epithelial cells during early mammary gland development 
(Wodarz and Nusse, 1998; Roose et al., 1999). 
Another essential mediator in prenatal mammary gland development is Slug, 
which is a member of the Snail family of zinc-finger transcriptional repressors (Phillips 
et al., 2014). It is also implicated in many cellular and developmental processes 
including EMT, cellular migration and differentiation (Guo et al., 2012; Phillips and 
Kuperwasser, 2014). Proia et al. (2011) found that Slug controls luminal epithelial cell 
differentiation. 
During the postnatal stage of mammary gland development, the branching of the 
ducts is controlled by sex hormones (oestrogen and progesterone) (Brisken et al., 2000). 
In particular, Brisken et al. (2000) found that sex hormones caused side-branching by 
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influencing Wnt4 during early pregnancy. They also found that Wnt4 expression was 
localised in the luminal cells of the ductal epithelium and that it is controlled by 
progesterone (Brisken et al., 2000). 
1.4.3 The involvement of Wnt/b-catenin pathway in the activation of EMT 
process in breast cancer metastasis 
EMT is activated stably or transiently during cancer invasion and metastasis 
(Hanahan and Weinberg, 2011). Several studies linked the EMT process to the 
metastasis of human cancers including colon cancer (Conacci-Sorrell et al., 2003), 
cervical cancer (Ha et al., 2013), prostate cancer (Tsai and Yang, 2013), and breast 
cancer (Sarrio et al., 2008). 
Wnt activation drives tumour-associated gene expression in colorectal and other 
cancers (Korinek et al., 1997; Nusse and Clevers, 2017). The release of b-catenin from 
E-cadherin results in nuclear accumulation and activation of Wnt-related transcription 
via binding to the TCF/Lef complex and that lead to the onset of tumour-promoting 
activity (Figure 0-5) (Rijsewijk et al., 1987; Khramtsov et al., 2010; Nusse and Clevers, 
2017). Continuous activation of this pathway is associated with many human cancers 
(Conacci-Sorrell et al., 2003; Rosa et al., 2015; Wang et al., 2015). In colon cancer, 
there is a cumulative effect that starts with the loss of E-cadherin and release of b-
catenin which localises to the nucleus and activates slug, which further represses E-
cadherin production (Conacci-Sorrell et al., 2003). Dey et al. (2013) found that 
increased activity of Wnt/b-catenin signalling associated with high-grade breast 
tumours, poor prognosis and metastasis to lung and brain, but not to bone marrow. 
The same signalling pathways involved in regulating EMT during mammary 
gland development have been implicated in breast cancer metastasis (Wang and Zhou, 
2011). It was also concluded that EMT provides the breast cancer cells with the ability 
to tolerate physiological stress and could provide an opportunity to develop novel 
treatments (Trimboli et al., 2008). 
Several studies considered abnormalities in b-catenin protein expression in breast 
cancer as a predictive marker of poor prognosis, including nuclear accumulation and 
loss of membrane localisation (Lin et al., 2000; Geyer et al., 2011; He et al., 2014; 
Wang et al., 2015). In breast cancer, altered availability of b-catenin was reported to 
result from the suppression or loss of E-cadherin expression (Onder et al., 2008). 
Bukholm et al. (1998) found that disrupting components of adherens junctions, 
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including E-cadherin, a-catenin and g-catenin, resulted in an increased availability of b-
catenin, and thereby, increasing the risk of metastasis in breast cancer patients.  
The free pool of b-catenin can translocate to the nucleus and regulate 
transcription of EMT-related proteins (Figure 0-5). The transcriptional targets of b-
catenin (with TCF/Lef) are known regulators of EMT (Figure 0-5). Onder et al. (2008) 
concluded that CRT (catenin related transcription) was responsible for regulating a 
number of target genes known to induce and facilitate changes associated with EMT. b-
catenin, on its own, was not sufficient to induce EMT. 
1.4.3.1 Dysfunction of Wnt/b-catenin is associated with breast cancer 
Many studies have indicated that there were dysfunctions of the Wnt/b-catenin 
pathway in breast cancers (Geyer et al., 2011; Li and Zhou, 2011). In fact, this pathway 
was reported to be active at the earliest stages of tumour development in both ductal 
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), (Karayiannakis et al., 
2001; Geyer et al., 2011; He et al., 2014). The dysfunction of Wnt/b-catenin signalling 
was also reported in advanced stage breast cancer (Bukholm et al., 1998; Geyer et al., 
2011). Dey et al. (2013) found that there was increased Wnt/b-catenin pathway 
activation in TNBC, and that this increase correlated with tumour grade, poor prognosis 
and development of metastasis. 
1.4.3.2 Mutation of b-catenin gene is not common in breast cancers 
No genetic mutations have been detected in b-catenin in breast cancer, and it is 
thought that the changes in the function of this protein are due to post-transcriptional 
modifications, such as phosphorylation (Karayiannakis et al., 2001; Nakopoulou et al., 
2006; He et al., 2014). Schlosshauer et al. (2000) conducted a genetic analysis of b-
catenin protein and concluded that there were no mutations of b-catenin found in the 
most common breast cancer cell lines including MCF7, MDA-MB-361, BT20, MDA-
MB-231, and MDA-MB-453. 
Similarly, mutations in APC were rare in breast cancer (Lin et al., 2000; 
Nakopoulou et al., 2006; Rosa et al., 2015). Also, Schlosshauer et al. (2000) found that 
only one in 27 breast cancers had a truncating mutation in the APC gene, therefore, 
concluding that APC mutations are rare in breast cancer. 
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1.4.3.3 Abnormalities of b-catenin expression is associated with breast cancer 
Several studies have reported that abnormalities in b-catenin expression are seen 
in all stages of breast cancer. Overexpression of b-catenin correlates with tumour size, 
grade, lymph node involvement and metastasis in breast cancer (Bukholm et al., 1998; 
Geyer et al., 2011). There is also a significant correlation between increased b-catenin 
expression and lack or loss of E-cadherin expression in grade three lobular and non-
lobular breast carcinomas (Geyer et al., 2011). Also, loss of b-catenin expression was 
reported by Jiang et al. (2009) in TNBC infiltrating ductal carcinoma of high-grade. 
In contrast, Karayiannakis et al. (2001) concluded that there was no association 
between b-catenin staining pattern and tumour grade. They also reported that there was 
no significant correlation between b-catenin expression and features including tumour 
size, lymph node involvement, metastasis-free survival and hormonal status 
(Karayiannakis et al., 2001). The variation in the findings of these studies could be due 
to variation in sample size, antibody clone, used scoring criteria, variation in the 
method of statistical analysis. 
Geyer et al. (2011) attributed the contradiction in the literature around b-catenin 
expression in breast cancer subtypes to variations in the interpretation of histological 
localisation of the protein in human samples. Rosa et al. (2015) also mentioned that the 
assessment and analysis of b-catenin protein in human samples could be challenging, 
and that confirmation of b-catenin activation should be assessed by more than one 
method of analysis. Moreover, Rosa et al. (2015) related this issue to b-catenin 
antibody cross-reactivity with other catenin types that was not addressed and confirmed 
in published research. 
Assessing the localisation of b-catenin protein is equally important. Several 
studies recorded the pattern of distribution in breast cancer samples. Paredes et al. 
(2008), reported that there were alterations in the localisation and level of expression of 
all catenins in breast cancer samples. 
b-catenin in particular showed a reduction in localisation at cell-cell contact sites 
and increased cytoplasmic localisation in 70% of cases in that study (Paredes et al., 
2008). Membranous localisation of b-catenin require E-cadherin (Li and Mattingly, 
2008; Paredes et al., 2008; Wang et al., 2015). Karayiannakis et al. (2001) found that 
there was heterogeneous b-catenin staining in around 60% and loss of expression of b-
catenin in around 50% of lobular breast carcinomas compared to heterogeneous staining 
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of b-catenin in 80% and cytoplasmic or nuclear staining in less than 15% of lobular 
carcinomas. 
Jiang et al. (2009) found that in benign breast tumours b-catenin was localised in 
the nucleus of myoepithelial and luminal epithelial cells with moderate cytoplasmic 
staining in non-tumorous ducts. In addition, either complete loss or increase of nuclear 
localisation was associated with TNBC, BLBC and poor clinical outcomes (Geyer et 
al., 2011; Rosa et al., 2015). Cytoplasmic localisation of b-catenin significantly 
correlated with increased tumour size, and therefore associated with increased breast 
cancer stage (Paredes et al., 2008). 
The reports of alteration in b-catenin patterns associated with increased tumour 
stage in breast cancer samples led the researchers to conclude that this pathway could 
be utilised to develop a targeted therapy. Wu et al. (2012) found in their study that 
resistance to targeted therapy in HER2+ve cancers was associated with partial EMT as a 
result of activation of Wnt/b-catenin pathway. They also attributed the resistance to 
targeted therapy itself to the activation of Wnt/b-catenin pathway (Wu et al., 2012). 
Conversely, Zhu et al. (2010) found that Herceptin treatment resulted in a reduction of 
the b-catenin pool by increasing phosphorylation of the protein. Therefore, many 
studies suggested the use of Wnt/b-catenin pathway as a therapeutic target in breast 
cancer for prevention of therapy resistance and treatment of breast cancer metastasis 
(Lin et al., 2000; Geyer et al., 2011). 
1.5 A vital role for Hedgehog (Hh) signalling pathway in the regulation of 
EMT during mammary gland development and breast cancer 
metastasis 
The Hedgehog signalling (Hh) pathway was discovered in 1980 in a study 
aimed to understand the segmentation of the body (Nusslein-Volhard and Wieschaus, 
1980) and mediates epithelial-mesenchymal interaction during human embryonic 
development and organogenesis (Ingham and McMahon, 2001; McMahon et al., 2003). 
This pathway can be activated by interaction between the Hh receptor and its ligand 
(canonical) and also via an alternate pathway through interaction with other signalling 
cascades (non-canonical) (Jenkins, 2009; Brennan et al., 2012; Flemban and 
Qualtrough, 2015). 
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1.5.1 Components of the Hedgehog signalling pathway 
The components of the Hh signalling pathway include the secreted 
glycoproteins; Sonic (Shh), Desert (Dhh) and Indian (Ihh) (Ingham and McMahon, 
2001; Pasca di Magliano and Hebrok, 2003). These ligands bind to one of the receptors 
including; Hedgehog-interacting protein 1 (Hip1), Patched1 (Ptch1) and Patched2 
(Ptch2) (Marigo et al., 1996; Chuang and McMahon, 1999). The receptors then release 
the blocking effect on another transmembrane protein called Smoothened, Smo (Figure 
0-6-B, and Figure 0-7-C)(Pasca di Magliano and Hebrok, 2003; Flemban and 
Qualtrough, 2015). As a consequence of this, Smo activates intracellular signalling via 
the Glioma-associated oncogene (Gli1, Gli2, and Gli3) transcription factors (Figure 
0-7-D) (Ruiz i Altaba et al., 2002; Pasca di Magliano and Hebrok, 2003). These 
transcription factors are sequestered in the cytoplasm through connection to the cellular 
cytoskeleton by interaction with multiprotein complex Fused (Fu) and suppressor of 
Fused (SuFu) (Figure 0-6-D) (Murone et al., 2000; Pasca di Magliano and Hebrok, 
2003). 
 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
29 
 
  
 
 
Figure 0-6, The resting status of the Hh signalling pathway. 
The resting (inactivated) hedgehog (Hh) signalling pathway. (A) In the absence of Hh ligand, Patched 
(Ptch) protein form an inactive complex with downstream receptor Smoothened (Smo) (Corbit et al., 
2005). It works as inhibitor of Smo protein expression (Denef et al., 2000) and a suppressor of Smo (B) 
(Ding and Wang, 2017). (C) Several Hh pathway components transduce the signal intracellularly 
including suppressor of Fused (SUFU) protein that function to inhibit the Gli transcription factors by 
sequestering them to cytoplasm in absence of Hh signalling (Nozawa et al., 2013). Thus, blocking Hh 
target genes by localisation of repressor form of Gli (Gli3) in nucleus of inactive cells (Rubin and de 
Sauvage, 2006). The figure was drawn by the author from the mentioned references. 
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Figure 0-7, The active status of the Hh signalling pathway. 
The active status of Hedgehog (Hh) signalling. (A) Hh ligands are synthesised as precursor proteins in 
the Golgi apparatus (Huangfu et al., 2003; Ramsbottom and Pownall, 2016) that is cleaved in 
endoplasmic reticulum before secretion (Ramsbottom and Pownall, 2016). The ligand presence and 
binding to Ptch receptor results in release of inhibiting function of Ptch on the expression (B) and 
function of Smo receptor (C) (Ramsbottom and Pownall, 2016), which leads to the activation of pathway 
(D). This result in induction of activated form of Gli that translocate to nucleus and act as a transcription 
factor and result in transcription of Hh target genes (F) (Rubin and de Sauvage, 2006; Ramsbottom and 
Pownall, 2016). The figure was drawn by the author from the mentioned references. 
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The Gli proteins are large zinc-finger transcription factors that are composed of 
more than a thousand amino acids (Ruiz i Altaba et al., 2002; Ruiz i Altaba et al., 
2007). There are three Gli proteins in humans, and they have a context-dependent 
transcriptional regulation function (Stecca and Ruiz, 2010). These Gli proteins have 
both activator and repressor forms (Figure 0-8) which is referred to as the Gli code 
(Ruiz i Altaba et al., 2007; Aberger and Ruiz, 2014). 
 
 
 
Figure 0-8, The gli code. 
The repressor and activator forms of Gli proteins. During resting status of Hh signalling, Gli1 protein is 
not expressed while Gli2 and Gli3 are expressed in full-length form that is cleaved into repressor forms 
(Ruiz i Altaba, 1998; Stamataki et al., 2005). With activation of Hh signalling, Gli1 is transcribed as an 
active form (full-length) while cleavage of both Gli2 and Gli3 halts. Thus, Gli2 remain in full-length 
activator form, and Gli3 is no longer active (full-length) (Stamataki et al., 2005; Ruiz i Altaba et al., 
2007). The figure was drawn by the author from the mentioned references. 
 
The nuclear localisation of these Gli transcription factors is essential for protein 
function (Ruiz i Altaba et al., 2007). Negative modulators of the Hh signalling pathway 
(including Ptch) sequester Gli1 in cytoplasm of cells (Ruiz i Altaba et al., 2007). Thus, 
studying of localisation of Gli transcription factors is essential for the determination of 
the activation status of the pathway. 
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Other factors can activate Hh signalling in a non-canonical way including 
dysregulation of the signalling pathway and activation by other signalling cascades such 
as Wnt signalling. Several mechanisms were indicated to dysregulate Hh signalling 
including both ligand-independent and ligand-dependent mechanisms (Hui et al., 2013). 
The ligand-dependent mechanisms are a result of increased expression of SMO and 
Gli1 or inactivation of PTCH (Hui et al., 2013). 
1.5.1.1 Crosstalk between the hedgehog signalling and Wnt signalling pathways 
One of the pathways that can activate the Hh signalling pathway non-
canonically is the Wnt pathway (Figure 0-9 and Figure 0-10) (Ding and Wang, 2017). 
In fact, interaction between the Wnt and Hh signalling pathway is seen during 
embryogenesis and cellular differentiation (Price, 2006; Moussaif and Sze, 2009; Ding 
and Wang, 2017). 
Several studies showed that there was cross reaction between the two signalling 
pathways. The integration between Hh and Wnt signalling was revealed by 
pharmacological studies using inhibitory drugs. Singh et al. (2012) found that the Hh 
signalling inhibits the activation of Wnt signalling during embryogenesis (Figure 0-9-
A). Additionally, Wnt activation rescues the suppression of the Hh signalling. Kim et 
al. (2010a) found that increased Gli1 expression resulted in a decreased level of nuclear 
b-catenin localisation (Figure 0-9-B). The Wnt/b-catenin signalling inhibits Hh activity 
via transcriptional regulation of Gli3 (Figure 0-10-A) (Alvarez-Medina et al., 2008). 
Gli3 expression was directly regulated by the b-catenin/TCF/LEF complex (Figure 
0-10-B) (Alvarez-Medina et al., 2008). 
The overlap between these signalling pathways is not well understood, but the 
regulation of both signalling pathways is disturbed in human cancer. Co-activation of 
both Wnt and Hh pathways has been observed in several types of human cancers (Yang 
et al., 2008b). Qualtrough et al. (2015) found that inhibition of Hh signalling using 
cyclopamine resulted in a reduction in b-catenin-related transcription (CRT) in 
colorectal cancer cell lines that was rescued by addition of Shh protein. Furthermore, a 
significant association between the nuclear expression of Gli1 and nuclear expression of 
b-catenin was observed in human breast cancer samples (Arnold et al., 2017). Thus, 
indicating that the crosstalk between the Hh and Wnt signalling pathways in breast 
cancer is context-dependent and requires further study. 
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Figure 0-9, Hh signalling mediated inhibition of the Wnt signalling pathway. 
The inhibitory effect of Hh signalling on the Wnt signalling pathway. (A) Active Gli1 expression directly 
inhibit Wnt receptor Frizzled. (B) Gli1 protein directly inhibits localisation of b-catenin in nucleus of 
cells. The figure was drawn by the author from the mentioned references (Ding and Wang, 2017). 
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Figure 0-10, Wnt signalling mediated inhibition on the Hh signalling pathway. 
The inhibitory effect of the Wnt pathway on Hh signalling. (A) APC protein directly regulates expression 
of Gli3 protein. B- b-catenin/TCF/LEF complex control expression of Gli3 protein which inhibit Gli1. 
The figure was drawn by the author from (Ding and Wang, 2017). 
 
1.5.2 The Hedgehog signalling pathway is essential for mammary gland 
development and breast cancer progression and metastasis 
The activation of the Hh signalling pathway during the development of the 
mammary gland first occurs during early embryogenesis (Michno et al., 2003; Lee et 
al., 2013). Lewis (2001) reported involvement of hedgehog signalling in mouse 
mammary gland development. Hh signalling was active in the terminal end bud during 
early adulthood and was continuously activated in the stromal components around the 
ducts in all phases of postnatal development except for the early stage of involution 
after weaning (Lewis, 2001). Hh signalling activation was seen in ducts and alveoli of 
the mammary gland during early and late pregnancy, and lactation (Lewis, 2001) 
All members of the Hh signalling pathway are found expressed in the 
components of the mammary gland during different stages of its development (prenatal 
and postnatal). They are also thought to have a function in the differentiation and 
maintenance of the normal structure of the mammary gland (Flemban and Qualtrough, 
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2015). Epithelial expression of the ligands Shh and Ihh was found to be essential in 
early mammary bud formation (Hens and Wysolmerski, 2005). Lewis et al. (1999) 
found that Ihh expression increased during pregnancy and lactation. 
The expression of Ptch1 was also shown to be essential in both the epithelial 
and mesenchymal compartments during prenatal mammary gland development (Lewis 
et al., 1999). Later, during postnatal phase a lack of Ptch1 in mice resulted in both 
hyperplasia and dysplasia in the ductal compartment during puberty and adulthood 
(Lewis et al., 1999; Flemban and Qualtrough, 2015). 
Michno et al. (2003) found that mesenchymal Gli2 was essential for mammary 
gland development during embryogenesis. Hatsell and Cowin (2006) found that Gli3 
had an essential role in repressing Hh signalling during embryogenesis and both Gli3 
and Gli2 were expressed in the prenatal phase of mammary gland development. In the 
postnatal stages, Gli3 was expressed in the luminal cells and both Gli2 and Gli3 were 
expressed in the stromal and myoepithelial cells (Hatsell and Cowin, 2006). It was 
found that Gli2 protein was expressed in the mesenchymal cells during puberty near the 
terminal buds and the expression increased in the alveolar epithelial cells during the 
later phases of pregnancy (Michno et al., 2003; Flemban and Qualtrough, 2015). 
1.5.3 The Hedgehog signalling pathway is involved in cancer progression and 
metastasis 
Inappropriate activation of Hh signalling is apparent in 25% of all tumours, 
therefore, highlighting the importance of dysregulation of this pathway in human 
tumour progression (Briscoe and Therond, 2005; Flemban and Qualtrough, 2015). Loss 
of balance of Hh signalling was implicated in many human tumours including; sporadic 
basal-cell carcinoma (Xie et al., 1998), tumours of the central nervous system 
(Reifenberger et al., 1998), lung cancer (Watkins et al., 2003), tumours of the 
gastrointestinal tract (Berman et al., 2003), pancreatic cancer (Thayer et al., 2003), and 
prostate cancer (Karhadkar et al., 2004). Other studies showed that the inhibition of Hh 
signalling resulted in similar effects in other human cancers as summarised Table 0-2. 
The first inhibitor of the Hh signalling pathway to be discovered was the plant 
alkaloid cyclopamine (Bryden et al., 1971). The mechanism of action was discovered 
later, and it was found that this inhibitor binds to and inactivates Smo (Cooper et al., 
1998). Several other small molecule inhibitors such as LDE225 have since been 
synthesised and found to have a more potent effect when compared with cyclopamine 
(Gupta et al., 2010). 
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Table 0-2: Inhibition of Hh signalling in human cancers has been investigated. 
This table provide examples of the studies that investigated the effect of inhibiting the Hh signalling in 
human cancers and their main findings. 
 
Cancer type Inhibitor Finding Reference 
Medulloblastoma Cyclopamine  Growth inhibition. (Berman et al., 2002) 
Small cell lung 
carcinoma  Cyclopamine  Inhibit the Shh-dependent growth. (Watkins et al., 2003) 
Prostate cancer Cyclopamine Inhibition of proliferation and evidence of autocrine signalling. (Sanchez et al., 2004) 
Colon cancer Cyclopamine Induced apoptosis. (Qualtrough et al., 2004) 
Colon cancer GANT61 Cell death caused by increased DNA damage. (Mazumdar et al., 2011) 
Colon cancer GANT61 DNA damage followed by cell death. (Agyeman et al., 2012) 
Colon cancer Cyclopamine and GANT61 
Hh signalling controls tissue inflammation 
and antagonise apoptosis. (Yoshimoto et al., 2012) 
Colon cancer GANT61 
Inhibition of Gli1 DNA interaction and 
reduction of transcription of Hh signalling 
output genes. 
(Agyeman et al., 2014) 
Lung squamous 
cell carcinoma Vismodegib 
Suppressed migration and up-regulated E-
cadherin. (Yue et al., 2014) 
Renal cell 
carcinoma LDE225 
Reduction of tumour growth and metastatic 
spread. (D'Amato et al., 2014) 
Colon cancer Cyclopamine  
Reduction of expression of EMT 
transcription factors and reduction in 
invasiveness. 
(Qualtrough et al., 2015) 
Gastric 
carcinoma  Cyclopamine 
Reduction of viability in concentration 
dependent manner and decrease invasion 
and metastasis. 
(Gao et al., 2015) 
 
1.5.3.1 The Hedgehog signalling is involved in the regulation of EMT in breast 
cancer 
 Mutations of Hh signalling are rare events in breast cancer (Wicking et al., 
1998; Hui et al., 2013). Other epigenetic and post-transcriptional events were found to 
cause improper activation of Hh signalling in mammary tumours. These include 
dysregulation of alternative splicing that causes inappropriate expression of the active 
Gli isoforms (Cao et al., 2012) and methylation of the PTCH promoter (Wolf et al., 
2007). These studies led to the notion that Hh signalling activation is context-dependent 
and affected by cellular contact, polarity and other factors that can manipulate post-
transcriptional modification of the Gli proteins (Aberger and Ruiz, 2014; Gonnissen et 
al., 2015). 
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Moraes et al. (2007) reported that Ptch1 expression was reduced in about half of 
the cases of DCIS and invasive breast cancer. They also found that Smo was ectopically 
expressed in 70% of DCIS and 30% of invasive breast cancers (Moraes et al., 2007). 
They concluded that altered Hh signalling causes increased proliferation of cells that 
were capable of anchorage-independent growth (Moraes et al., 2007). Cui et al. (2010) 
observed that there was significant upregulation of Shh in breast carcinoma and 
concluded that this was an essential event for breast carcinogenesis. 
Several studies inhibited this pathway in breast cancer cell lines in vitro and 
found that the inhibition of Hh signalling with cyclopamine resulted in a decrease in 
TNBC cell line proliferation and reduced invasive ability (Kameda et al., 2009). Also, 
Che et al. (2013) found that cyclopamine treatment resulted in reduced cell proliferation 
in the ER+ve cell line MCF7 and suggested the utilisation of this pathway as a 
therapeutic target for breast cancer. Nonetheless, the correlation between reduction in 
the migration, proliferation and the changes in the expression of key EMT markers was 
not the focus of many of previous studies. Similarly, the expression of the hedgehog 
signalling components and changes in localisation of the Gli proteins or b-catenin 
following inhibition of the Hh signalling was not conducted in previous studies.  
Changes in the Gli proteins expression was studied in clinical breast tissue 
sections in several studies and intensity and proportion of expression correlated with the 
clinicopathological criteria only. Overexpression of the Gli1 transcription factor in 
breast tumours was associated with unfavourable overall survival, high tumour stage, 
and increased lymph node metastasis (ten Haaf et al., 2009). Jeng et al. (2013) 
suggested that high expression of Shh, PTCH1, GLI1, and Smo correlated with 
increased breast cancer invasiveness. Also, few of the previous studies focused on 
assessing subcellular localisation of the Gli proteins. One study reported that the 
nuclear translocation of Gli1 was involved in micro-invasion and suggested that this 
pathway is involved in the progression of a non-invasive phenotype towards invasive 
behaviour (Souzaki et al., 2010). Kubo et al. (2004) found that high intensity of Gli1 
was associated with malignancy and that nuclear expression of this marker was 
associated with ER expression. Co-activation of the Hh and Wnt signalling was not 
explored in detail in breast cancer. In fact, a single study explored both pathways in 
breast cancer clinical samples and it was concluded that co-activation of Wnt and Hh 
signalling in TNBC and is associated with an increased risk of disease recurrence and 
decreased overall survival (Arnold et al., 2017). 
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1.6 Challenges in studying EMT in human cancer particularly in breast 
cancer  
1.6.1 Lack of direct clinical evidence of EMT in breast cancer and partial EMT 
theory 
The involvement of the EMT process in breast cancer progression and metastasis 
is not ascertained due to a lack of direct clinical evidence (Tarin et al., 2005; Savagner, 
2010). Also, dedifferentiated carcinomas with a poor prognosis are described clinically 
as “EMT-like morphology” rather than in terms of an EMT transition and full transition 
is a rare event and occur only in high grade carcinomas. In addition, both EMT and 
differentiation processes are controlled by mutual pathways (Klymkowsky and 
Savagner, 2009; Savagner, 2010). The only direct clinical evidence for EMT in breast 
cancer cases is seen in metaplastic carcinomas, which is very rare subclass of breast 
cancers. In this type, the epithelial cancer cells undergo complete mesenchymal 
transition and the only way to distinguish the epithelial and mesenchymal 
compartments is by staining for cytokeratins and vimentin (Zhuang et al., 1997; 
Saegusa et al., 2009; Savagner, 2010). 
It was suggested previously by Savagner (2010) that the involvement of EMT in 
breast cancer varied due to tumour heterogeneity and variations in molecular signatures, 
however, no further investigation was carried to explore this hypothesis. Several studies 
reported evidence of EMT activation in basal-like breast cancers (Sarrio et al., 2008; 
Chen et al., 2014). One aspect that remains missing in previous studies is the 
comparison of the expression and activation of EMT in various breast cancer cell lines 
that belong to various molecular subclassification of breast cancer. Exploring this 
hypothesis could show if the status of EMT differ according to the molecular subclass 
and could lead to exploring the causes of this variation.  
Aleskandarany et al. (2014) reported that lack of E-cadherin, a hallmark for EMT, 
was associated with lobular breast cancers. Other studies found that the lack of E-
cadherin in lobular breast cancers is due to genetic or epigenetic silencing mechanisms 
(Moll et al., 1993; Berx et al., 1996). Lack of E-cadherin expression in these subtypes 
did not result in full EMT. In fact, several studies proposed the “term partial EMT” to 
describe the ability of cells to detach and undertake a mode of invasion similar to the 
ameboid described previously by Clark and Vignjevic (2015) and Yang et al. (2004).  
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Hase et al. (1993) described partial EMT in cells at the invasive front of 
colorectal cancer. These cells had disorganised structure and showed a uniformed 
phenotype irrespective of the differentiation status of the original tumours (Hase et al., 
1993). In breast cancer, co-expression of both epithelial and mesenchymal markers 
occurs in those single detached cells in multiple breast cancer cell lines (Grosse-Wilde 
et al., 2015; Hong et al., 2015). Tran et al. (2014) found that the same EMT inducing 
transcription factors can increase tumour-initiating (stem-cell-like) potential in the 
“partial EMT” cells that was identified in breast cancer metastasis by Sarrio et al. 
(2008). Pastushenko et al. (2018) was able to identify multiple subpopulations of cells 
within a tumour associated with different stages of EMT. These cells showed 
differences in plasticity, invasiveness and metastatic potential that regulate the EMT 
transcription states (Pastushenko et al., 2018). 
Previous studies showed that EMT is not an absolute state, but rather a spectrum 
of changes regulated by intracellular and extracellular components. The identification 
of EMT in clinical breast cancer samples is elusive and we hypothesis that the 
mesenchymal status of breast cancer cells could be transient and perhaps not 
synchronised across the whole tumour cell population in vitro which contribute to 
challenges in identifying EMT in clinical samples. Also, our study hypothesised that 
breast cancer luminal and basal subtypes present various states in the spectrum of EMT 
with molecular subtypes that present the end of the epithelial and mesenchymal 
spectrum. Comparison of the changes in expression and activation of EMT proteins 
would provide additional understanding of breast cancer metastasis through EMT 
regulation and status variation according to molecular subclass of breast cancer. 
1.6.2 Lack of in vitro cell line model for the investigation of EMT in breast 
cancer 
One of the challenges in studying EMT in breast cancer is the lack of a well-
defined in vitro model to investigate this process. Researchers in the field have taken a 
variety of approaches for studying EMT. These include using mouse xenograft models 
(Han et al., 2015), 3D cultures in Matrigel® or mammospheres (Manuel Iglesias et al., 
2013; Liu et al., 2014; Qu et al., 2015). There are drawbacks to using these models 
including the expense of growing the mouse models. The 3D models using 
mammospheres or Matrigel® are known to enrich the cancer stem cell population in the 
cell lines (Manuel Iglesias et al., 2013; Liu et al., 2014; Qu et al., 2015) therefore, 
adding variables and further complexity. These models can be successfully utilised for 
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understanding how cancer stem cells could initiate the mesenchymal transition leading 
to cancer invasion. Currently, most of the in vitro work using breast cancer cell lines on 
the topic of EMT focuses on the expression of the adhesion molecules, metastasis, and 
invasion markers at a single density (Chekhun et al., 2013; Manuel Iglesias et al., 
2013; Liu et al., 2014).  
Some studies used varying seeding densities approach to study changes in 
morphology and cell-cell contact in breast cancer. Using this seeding density model, 
Zhang et al. (2006) found that the expression and function of anchorage-dependent 
proteins reduced with decreasing density of breast cancer cells (Zhang et al., 2006). In 
Liu et al. (2006b) study, they also used a serial dilution of densities and their objective 
was to determine cellular spreading and the effect of cell-cell adhesion on proliferation. 
Although changes in seeding density of cells caused changes in cellular functions, this 
approach of in vitro investigation was not utilised with the focus on studying EMT 
using breast cancer cell lines.  
Changing specifications of in vitro tissue culture are known to influence 
changes in cell lines including changes in cellular contact, cellular spreading, 
morphology, proliferation, and differentiation. Watt (1988) noted that chondrocytes 
showed decreased cellular spreading and differentiation when seeded at low density. 
Also, by culturing chondrocytes at a higher density and enhanced differentiation. 
Recently, Yassin et al. (2015) found that seeding density was one of the essential 
factors for differentiation of bone and that optimisation of the seeding density was 
critical for new bone formation. Colon cancer cell line CaCo-2 differentiated in a 
density-dependent manner (Behrens et al., 2004).  
Beside differentiation effects, other studies found that the density of tissue 
culture affected the proliferation of cell lines. A study of hepatic cancer and smooth 
muscle cell lines showed that low-density culture reduced proliferation by transient 
gene silencing (Selli et al., 2016). The same cell lines showed phenotypic switching in 
association with the proliferative changes (Selli et al., 2016). It was also noted that 
prostate cancer cell lines showed reduced cellular proliferation due to lack of cell-cell 
contact when seeded at very low density (Liberio et al., 2014). The proliferative 
changes associated with changes in seeding density was also noted in many other cell 
lines derived from a range of tissue types (Haverty et al., 2016). Several studies used 
density alteration to evoke epithelial-mesenchymal transition-like (EMT-like) change in 
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cancer cells (Conacci-Sorrell et al., 2003; Nelson et al., 2008; Sarrio et al., 2008; 
Benton et al., 2009; Chen et al., 2014; Cichon et al., 2015). 
The seeding density model was adapted by Conacci-Sorrell et al. (2003) to 
study the effect of density on colon cancer cells. They found that by culturing two colon 
cancer cell lines at high density, the cells regained the phenotype of epithelial cells and 
that in sparse culture the same cells switched to fibroblastic morphology similar to cells 
seen at the tumour invasive front (Conacci-Sorrell et al., 2003). This study concluded 
that this phenotypic switch in cellular morphology was the result of high b-catenin 
expression in these colon cancer cells. At higher density, the b-catenin localises with E-
cadherin protein to form the adherens junction. As density decreased, adherens 
junctions decrease resulting in translocation of the highly expressed b-catenin protein to 
the nucleus, where it forms the b-catenin-TCF complex and initiates the EMT pathway 
(Conacci-Sorrell et al., 2003). 
Sarrio et al. (2008) used the seeding density approach to assess EMT in basal-
like breast cancer. They found that MCF10A cells (a normal-like and basal-like type B 
breast cancer cell lines) display EMT-like change in low density and reorganisation of 
cytoskeletal proteins. This study concluded that this phenotypic switch was associated 
with breast tumours that have a basal phenotype genetic context and that this subtype of 
breast cancer can undergo EMT under specific environmental conditions that were 
present with sparse density (Sarrio et al., 2008). However, they have not compared this 
with any other cell line that belongs to a different molecular subclassification. They 
compared epithelial and mesenchymal markers later in a human tissue cohort of several 
subclassification. Sarrio et al. (2008) proposed that the basal-like breast cancers have 
some of the mesenchymal criteria that made them vulnerable to change from epithelial 
to mesenchymal. This finding enforces the hypothesis that the basal molecular signature 
could make breast cancer belonging to this subtype more susceptible to EMT, which 
was not explored in detail in previous studies.  
Later Kim et al. (2011) used the seeding density approach and found that by 
simple manipulation of cell-cell adhesion they discovered a regulatory function of E-
cadherin protein that controls cellular proliferation in normal-like breast cell line 
MCF10A. They also found that by restoring E-cadherin in the MDA-MB-231 cell line 
(basal-like and triple-negative subtype) they were able to restore this cell-cell adhesion 
regulatory function (Kim et al., 2011). Cichon et al. (2015) found that upon reducing 
cellular contact of mouse breast cancer cells by decreasing seeding density, epithelial 
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differentiation-associated genes were reduced, and concluded that loss of cell contact is 
essential in the earliest stages of cancer development. 
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1.7 Aims 
1.7.1 Aims to 
The aim of the current study is to investigate the ability of breast cancer cell 
lines to undergo EMT-like change and to assess if this is affected by the molecular 
subtype of breast cancer. Also, this study aims to compare the potential role of 
Hedgehog signalling to regulate EMT-like change in the various subtypes of breast 
cancer. These investigations will include the potential crosstalk between Hh and Wnt 
signalling to drive the metastatic process and evaluate the therapeutic potential of Hh 
inhibitors in treating patients with advanced disease.  
1.7.2 Objectives 
• To develop an in vitro cell density-based model of EMT using breast cancer cell 
lines, allowing comparison of the different subtypes of breast cancer. Also, to 
compare changes in the expression (level and localisation) of three EMT 
markers (E-cadherin, b-catenin, and vimentin) in response to changes induced in 
response to varied levels of cell-cell contact using the seeding density model. 
• To assess the expression of several markers of EMT (E-cadherin, and b-catenin) 
and the hedgehog pathway (Gli1, Gli2 and Gli3) in a cohort of breast cancer 
samples and to correlate the expression of these markers with breast cancer 
subtypes and clinicopathological features. The expression of the Gli effector 
proteins will also be measures in a panel of cell lines representing the various 
molecular subtypes of breast cancers. Also, to assess the effect of inhibiting the 
Hh signalling pathway in breast cancer cell lines on several cellular parameters 
(viability, cell yield, cell death, motility and invasion). Also, to assess the effect 
of Hh signalling inhibition on the outputs of the Wnt/b-catenin and EMT 
process. 
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2. Materials and Methods 
All materials were obtained from SIGMA-ALDRICH (Dorset, UK) unless 
otherwise stated. 
2.1 Tissue culture 
2.1.1 Experimental cell lines 
A number of established breast cell lines were used to define the seeding density 
model characteristics (2.1.5) and in the rest of the experiments. Also, a number of other 
immortalised cell lines were used as positive controls in several experiments (Table 2-9 
and Table 2-11). Cell lines were obtained from the Health Protection Agency (ECACC, 
Salisbury, UK) unless otherwise stated. 
2.1.1.1 Breast cancer cell lines 
A number of human breast cancer cell lines were cultured in vitro in this study 
including one normal-like breast cancer cell line (Table 2-1). 
 
Table 2-1: The breast cancer cell lines selected for investigation. 
The breast cancer cell lines used in this study and a summary of breast cancer subtype they were 
originally from. The source of cell lines is also summarised with hormone receptors status. Intra-Ductal 
Carcinoma (IDC), Adenocarcinoma (AC), Fibrocystic disease (FD), Plural Effusion (PE), Primary breast 
(P.Br), Oestrogen Receptor (ER), Progesterone (PR), Human EGF Receptor 2 (HER2), and Receptor 
tyrosine-protein kinase erbB-2 gene (ERBB2). 
 
Cell line 
Breast 
cancer 
subtype 
Origin Source ER PR 
HER2 
Reference Amplification of 
ERBB2 
Overexpression 
of HER2 
MCF7 Luminal A IDC PE + + - - (Soule et al., 1973) 
MDA-MB-361 Luminal B AC P. Br + + + + (Cailleau et al., 1974) 
MDA-MB-453 Unclassified AC PE - - + - (Cailleau et al., 1978) 
BT20 Basal A IDC P. Br - - - - (Lasfargues and Ozzello, 1958) 
MDA-MB-231 Basal B AC PE - - - - (Cailleau et al., 1978) 
MCF10A Basal B FD P. Br - - - - (Soule et al., 1990) 
 
2.1.1.2 Non-breast cancer cell lines 
A number of established human cancer cell lines were cultured in vitro in this 
study to be used during initial screens and antibody validation experiments as 
established positive controls (Table 2-9 and Table 2-11). These were used for many of 
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the EMT process experiments and analysis of Hedgehog (Hh) pathway components 
(Table 2-2). 
 
Table 2-2: Control cell lines used for verification. 
A number of established non-breast cancer cell lines were used during initial screens and antibody 
validation experiments as established positive controls for many of the EMT process and Hedgehog 
pathway components. 
 
Cell line Origin Reference 
HT29 Human colorectal adenocarcinoma (Fogh et al., 1977) 
SW480 Human colorectal adenocarcinoma (Leibovitz et al., 1976) 
Hela Human cervical cancer (Scherer et al., 1953) 
SKOV3 Human ovarian cancer (Fogh et al., 1977) 
HepG2 Human hepatocellular carcinoma (Aden et al., 1979) 
K562 Human chronic myelogenous leukaemia (CML) (Lozzio and Lozzio, 1975) 
Jurkat Human acute T cell leukaemia (Schneider et al., 1977) 
DU145 Human prostate cancer (Mickey et al., 1977) 
PC3 Human prostate cancer (Kaighn et al., 1979) 
U251 Human glioma cell line (Westermark et al., 1973) 
 
The immortalised glioma cell line U251, MCF10A, DU145 and MDA-MB-231 
were obtained from The American Type Tissue Culture Collection (ATCC, USA). 
2.1.2 Standard tissue culture procedure 
For consistency and unless otherwise stated, all cell lines were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heat inactivated 
foetal bovine serum (FBS) (Life Technologies, UK) and 2mM L-glutamine (complete 
medium). 
MCF10A cells (Table 2-1) were cultured in 1:1 mixture of DMEM/Ham’s F12 
medium with 15mM HEPES supplemented with 5% heat inactivated horse serum, 2mM 
L-glutamine, and 0.5mg/ml hydrocortisone, 10μg/ml Insulin-Transferrin (Life 
Technologies, UK), 100ng/ml Cholera toxin and 20ng/ml EGF. After 24hours, the 
MCF10A full medium was replaced with a medium that does not contain EGF and 
incubated for additional 24hours before further analysis to reduce the effect of EGF on 
EMT. 
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Suspension cell line (K562 and Jurkat) (Table 2-2) was maintained by collection 
and centrifugation at 350xg for 10minutes. Cells were then resuspended in fresh culture 
medium. 
All other cell lines were cultured as adherent monolayers (Table 2-1 and Table 
2-2) in 75cm2 (T75) or 25cm2 (T25) tissue culture flasks (Corning Costar, UK) and 
maintained at 37ºC and 5% CO2 in a humidified atmosphere. The growth media was 
changed twice weekly and cells were passaged at 80–90% confluency. 
2.1.3 Sub-culturing of cells 
For passaging, cells were washed with phosphate buffered saline (PBS) before 
incubation at 37ºC in PBS containing 1000unit/ml trypsin and 0.5mM 
ethylenediaminetetraacetic acid (EDTA). Trypsinised cells were removed in normal 
growth medium, collected by centrifugation at 1000xg for 3minutes, resuspended in 
fresh growth medium and re-seeded accordingly. 
2.1.4 Seeding for experimental procedures 
For experiments, sub-confluent cells were trypsinised (2.1.3) and resuspended in 
a known volume of normal growth medium (2.1.2). Cell number was determined using 
of a Neubauer counting chamber (BDH, UK) and cells were centrifuged at 1000xg for 
3minutes, then resuspended in an appropriate volume of fresh growth medium. For 
routine tissue culture maintenance, cells were seeded at density equivalent to 4x104 
cells/cm2, unless otherwise stated, into tissue culture flasks (T25 or T75) (Corning 
Costar, UK). Control cell lines (Table 2-2), cells were seeded at a density equivalent to 
4x104 cells/cm2 (1x106 cells per T25 flask). 
2.1.5 Seeding density experiment 
Breast cancer cell lines were cultured as previously described. The seeding 
density method used by Conacci-Sorrell (2003) (based on colon cancer cell lines) and 
was adapted to be used for studying EMT in breast cancer cell lines. The initial 
procedure used is summarised in (Table 2-3). 
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Figure 2-1, Initial step in seeding density experiment. 
The figure illustrates the method used for determining the seeding densities used in the seeding density 
model. After the maximum seeding densities were determined, the cells were cultured at serial of dilution 
of cells in six well plate. The shape and morphology of the cells were then observed under the phase 
contrast microscope for selecting the seeding densities used in the model. 
 
2.1.5.1 Determining Seeding Densities used in the model 
Breast cancer cell lines were seeded in T75 flasks and maintained as described 
earlier (2.1.2). Subsequently, cells were detached from the flask using trypsin and cell 
number was determined using a haemocytometer and divided by 75 to estimate the 
number of cells that grow in 1 cm2 (Figure 2-1). This number was used to determine the 
total cells number that form a confluent layer in well of 6-well plate. The density of the 
confluent culture was seeded into the first well of a 24 well plate and then diluted in the 
following wells and cultured for 24hours in humidified condition at 37°C in 5% carbon 
dioxide. Afterward, cell morphology was observed under the light microscope at three 
densities (high, medium, and low) for further study. 
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Table 2-3: The number of cells required to produce 95% confluent tissue culture 
in 24 hours. 
Table list a summary of the numbers of cells seeded per cm2 to form 95 % confluent culture after 24 
hours 
 
Cell line Cells per cm2 
MCF7 2x104 
MDA-MB-361 4.8x104 
MDA-MB-453 2.8x104 
BT20 1x104 
MDA-MB-231 1.2x104 
MCF10A 1x104 
 
2.1.6 Cryopreservation of cells 
To ensure consistency between experiments, cell use was confined within a 
narrow range of passage numbers (less than 8) and replenished from stocks maintained 
in liquid nitrogen. For freezing, confluent cells were trypsinised, resuspended in growth 
medium and centrifuged at 1000xg for 3minutes. Cells were then resuspended in 
growth medium containing 10% (v/v) DMSO cryoprotectant and 20% FBS in complete 
culture medium (2.1.2). The cell suspension was dispensed as 1ml aliquots into 
cryovials. Cells were frozen slowly in a cryopreserving chamber (Mr. Frosty) 
containing fresh isopropanol and placed at -80ºC for 24hours before being transferred to 
liquid nitrogen. Cells were recovered by thawing at 37ºC and the DMSO/medium was 
removed by centrifugation and washing in complete medium. Cells were resuspended 
and seeded in normal growth medium and were allowed to recover for at least one 
passage before experimental use. 
2.1.7 Cell counts and viability 
Cell numbers were assessed manually using a haemocytometer, and automated 
using Luna-FL™ Automated Fluorescence Cell Counters (Labtech International Ltd, 
East Sussex, UK). Automated cell counts were compared to manual counts by 
measuring the number of cells from different cultures to minimise counting errors and 
ensure accurate live/dead cell counting. 
The viability of the cells was determined using trypan blue (TB), which is a cell 
membrane impermeable dye, with x2 dilution factor (10μl sample and 10μl stain). It is 
an exclusion assay based on the principle that live cells possess intact cell membranes 
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that exclude certain dyes (such as TB) whereas dead cells do not (Strober, 2001). In 
addition, acridine orange/propidium iodide (AO/PI) (Labtech, Sussex, UK) was used to 
measure cell viability with 1:10 dilution factor as recommended by the manufacturer 
(2μl sample and 18μl stains). AO/PI are nucleic acid binding dyes, where AO is cell 
permeable and stains nucleated cells generating a green fluorescence, while PI 
(~668Daltons) only enters cells with compromised membranes and therefore dying, 
dead, and necrotic nucleated cells stain with PI and generate a red fluorescence. When 
cells are stained with both AO and PI, live nucleated cells only fluoresce green and 
dead nucleated cells only fluoresce red. The AO/PI viability assay is a functionally 
linear rapid assay that is superior to conventional viability measurement by TB 
exclusion (Mascotti et al., 2000). 
2.1.8 Tissue culture treatment 
Treatments were prepared in reduced serum medium, 1:1 mixture of 
DMEM/Ham’s F12 medium with 15mM HEPES supplemented with 2% FBS, 2mM L-
Glutamine, 0.5mg/ml hydrocortisone, and 10µg/ml insulin/transferrin. Two inhibitors 
were selected (cyclopamine and LDE225) were used at three concentrations (1µM, 
5µM, and 10µM). The selected concentrations did not exceed 10µM to avoid non-
specific cytotoxicity and off-target effects. Also, vehicle controls were prepared by the 
addition of 0.1% (v/v) of 95% ethanol. The cells were incubated for 48hours in 37°C in 
humid atmosphere that contain 5% CO2 tissue culture incubator. 
Two cell lines were selected for assessing the effect of inhibiting Hh signalling 
in breast cancer (MCF7 and MDA-MB-231). MCF7 is a luminal cell line was shown to 
have low metastatic ability and MDA-MB-231 a triple-negative and basal-like cell line 
that have high metastatic ability (Rizwan et al., 2015). 
2.1.8.1 Cyclopamine 
Cyclopamine is a steroidal alkaloid isolated from the plant Veratrum 
californicum in the late 1960s and was identified for its teratogenic properties (Cooper 
et al., 1998). It was later discovered that it has strong potential to bind to the 
transmembrane domain of Smo and act as a potent inhibitor of the Hh signalling 
pathway (Binns et al., 1959; Keeler and Binns, 1964; Cooper et al., 1998; Ma et al., 
2013; Lee et al., 2014; Rimkus et al., 2016). 
Cyclopamine (obtained from Selleckchem, UK) was prepared as a 10mM stock 
solution in 95% Ethanol (v/v) and stored at -80º C. Cells were treated for 48 hours with 
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different concentrations of cyclopamine (1µM, 5µM and 10µM) or an equivalent 
volume of 95% ethanol (vehicle control) in serum reduced medium. 
2.1.8.2 Sonidegib (Erismodegib, NVP-LDE225) 
LDE225 is a Smo antagonist that belongs to the biphenyl carboxamides family 
and was first marketed by Novartis as Odomzo approved by the FDA in 2015 for 
treating basal-cell carcinoma. This drug interacts with the binding site of Smo and 
prevents the downstream activation of the hedgehog signalling pathway (Pan et al., 
2010; Skvara et al., 2011; Fu et al., 2013; D'Amato et al., 2014; Kish and Corry, 2016; 
Jain et al., 2017). 
LDE225 (obtained from Selleckchem, UK) was prepared as a 10mM stock 
solution in 95% Ethanol (v/v) and stored at -80ºC. cells were treated for 48hours with 
different concentrations of LDE225 (1µM, 5µM and 10µM) or an equivalent volume of 
95% ethanol (vehicle control) in reduced serum medium. 
2.1.9 Plasmid preparation 
A range of expression and reporter plasmids were used as described previously 
(Qualtrough et al., 2015) and contain the coding sequences or promoter regions of a 
number of different components (Table 2-4). 
2.1.9.1 Reporters used 
pTOPFLASH (experimental reporter used to detect the activity of b-CRT) and 
pFOPFLASH (containing mutated TCF binding sites as a negative control) were 
obtained from Upstate Biotechnology (NY) (Figure 2-2-A and B). pCMV-Renilla 
control plasmid that is intended for use as an internal control reporter and may be used 
in combination with any experimental reporter vector to co-transfect mammalian cells 
was obtained from Promega (Madison, WI, USA) (Figure 2-2-C). 
 
Table 2-4: Promotor reporter constructs. 
 
Construct Function Reference 
pCMV-Renilla Renilla control Promega 
pTOPFLASH LEF/TCF responsive reporter (Korinek et al., 1997) 
pFOPFLASH TOPFLASH control reporter (Korinek et al., 1997) 
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Figure 2-2, The maps for the reporter plasmid constructs. 
The maps for reporter plasmid constructs used. All plasmids consist of promoter, Luciferase and 
amplification sites. (A) pTOPFLASH reporter consisting of several TCF binding sites. (B) pFOPFLASH 
reporter consisting of mutated TCF binding site. (C) pCMV-Renilla contains the Cytomegalovirus (CMV) 
enhancer and immediate/early promoter elements to provide high-level expression of Renilla luciferase in 
co-transfected mammalian cells. This figure was drawn by the author. 
 
The activity of the pCMV-Renilla reporter provides an internal control that 
serves as the baseline response in transfected cells. Normalising the activity of the 
experimental reporter to the activity of the internal control minimises experimental 
variability caused by differences in cell viability or transfection efficiency. Other 
sources of variability, such as differences in pipetting volumes, cell lysis efficiency and 
assay efficiency, can be effectively eliminated. 
2.1.9.2 Plasmid preparation 
E.coli recipient strain DH5a was kindly provided by Dr. Tim Craig (UWE) and 
was used to make competent bacteria for transformation and plasmid production. DH5a 
were grown to log phase in 500ml of Maitland Lysogeny broth (LB) broth and used to 
produce glycerol stocks of Chemocompetent bacteria. These were maintained at -70°C 
until required for transformation. Chemocompetent E.coli were transformed by resting 
on ice for 30minutes in the presence of 5µl of plasmid DNA, then heat shocking for 
90seconds at 42°C and returning to ice for a further 15minutes. E.coli were plated out 
on nutrient agar plates (Maitland, UK) containing 20µg/ml-1 Ampicillin and incubated 
at 37°C overnight. A single colony was used to inoculate 10ml of LB broth containing 
50µg/ml-1 of Ampicillin and incubated with shaking at 37°C overnight. 5ml of the 
resultant inoculum was then spun down at 6000xg for 15minutes and plasmid purified 
using Qiagen miniprep kit (Qiagen, Germany). 
1ml of inoculum was used to inoculate 500ml of LB broth, which was incubated 
overnight at 37°C with shaking. The plasmids were extracted using Qiagen maxiprep 
kit (Qiagen, Germany) and resuspended in Tris-EDTA (TE) buffer (10mM Tris Base, 
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1mM EDTA solution, 1% Tween 20 (v/v), pH9.0). The final concentration and purity 
were determined by dsDNA analysis were determined in triplicate samples using the 
Nanodrop 1000 spectrophotometer (Thermo Scientific), where 2μl of dsDNA extract 
was measured. Purified plasmids in TE buffer were stored at 4°C. 
2.1.10 Transfection procedure 
2.1.10.1 Cell seeding 
For analysis of promotor activity, the various promotor reporter constructs 
(Table2-3) were transiently transfected into cells. In general, this was performed on 
cells grown in 24 well plates (Corning Costar, UK) at 8x104 cells/well (equivalent to 
1x106 cells in a T25 tissue culture flask). Cells were grown under standard growth 
conditions for 48hours in reduced serum medium or treatment medium (5.2.1). 
Experimental design is shown in Table 2-4 using two breast cancer cell lines (MCF7 
and MDA-MB-231). Transfection of the SW480 colorectal cancer cell line was carried 
out as a positive control for the transfection procedure (Qualtrough et al., 2015). 
 
Table 2-5: Transfection procedure for determining the effect of Hh inhibition by 
cyclopamine and LDE225 on CRT. 
This table is a layout for the experimental design followed to determine effect of Hh inhibition on the 
CRT. This experiment was conducted in triplicate with (n=3) for each cell line. 
 
Vehicle control (0.1% 
(v/v) of 95% ethanol 
Vehicle control 
pTOPFLASH 
pCMV-Renilla 
Vehicle control 
pFOPFLASH 
pCMV-Renilla 
1µM cyclopamine 
1µM cyclopamine 
pTOPFLASH 
pCMV-Renilla 
1µM cyclopamine 
pFOPFLASH 
pCMV-Renilla 
1µM LDE225 
1µM LDE225 
pTOPFLASH 
pCMV-Renilla 
1µM LDE225 
pFOPFLASH 
pCMV-Renilla 
 
2.1.10.2 Lipofectamine reagent protocol 
For reporter and expression construct co-transfection experiments (per triplicate 
wells), 0.72µg of each reporter constructs was mixed with 0.08µg Renilla construct in 
150µl of Optimem mix (Life Technologies, UK) (0.8µg DNA in total). 6µl of 
Lipofectamine 2000 reagent (Life Technologies, UK) was mixed in a separate 150µl of 
Optimem and incubated at room temperature for 5minutes. The two reaction mixtures 
were combined with 1200µl of Optimem and incubated for a further 20minutes. Cells 
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were washed with PBS, which was thoroughly removed to avoid dilution effects, and 
500µl of the reaction mixture was added to each well. After 6hours, the transfection 
mix was replaced with serum reduced-medium or treatment medium (according to the 
experiment) and the cells were maintained under standard conditions until harvested 
after 48 hours. 
2.1.10.3   Passive cell lysis and luminescent analysis 
After transfection, cells were lysed in 100µl/well of 1x Passive Lysis Buffer 
(PLB) (Promega, USA). After 15minutes, lysates were transferred to an Eppendorf tube 
for analysis and stored at -70°C. Cell lysates were assayed using Promega Dual 
Luciferase Reporter Assay System (Promega, USA) in 96 wells white plates (Corning 
Costar, UK) on a FluoStar luminometer. Samples were corrected for background 
emission against the average of five readings from an untransfected control. Firefly 
luciferase activity was determined from three separate experiments performed in 
triplicate. 
2.2 Western Blotting analysis 
2.2.1 Sample preparation from trypsinised cells 
In experiments where cells were harvested by trypsinisation and counted, 
aliquots were retained for analysis by Western blotting. Counted cells were transferred 
into 1.5ml Eppendorf tubes. Cells pellets were obtained by centrifugation at 1000xg for 
3minutes at 4°C and the PBS was aspirated. Cell pellets were lysed in 100µl of 
Radioimmunoprecipitation (RIPA) lysis buffer with protease inhibitor cocktail 
(prepared according to manufacturer’s instruction; Roche) for 30minutes on ice, by 
vortexing with 5minutes intervals for 30seconds. The lysate was then centrifuged for 
30minutes at maximum speed (17949.49xg) at 4°C. The supernatants were transferred 
to fresh 1.5ml Eppendorf tubes and the protein concentrations of supernatants 
determined with a Pierce Bicinchoninic acid assay (BCA) protein assay kit (Thermo 
Scientific) as instructed by the manufacturer. 
2.2.2 Whole cell protein extraction 
To avoid significant cleavage of cellular protein, cell samples were prepared by 
lysing the cells in situ using RIPA lysis buffer with protease inhibitor cocktail (prepared 
according to manufacturer’s instruction; Roche). The medium was aspirated, and cells 
were washed twice in ice cold PBS prior to an appropriate amount of lysis buffer being 
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added. Cells were incubated on ice for 15minutes before scraping and then transferred 
to a 1.5ml Eppendorf tube. Lysates were centrifuged for 30minutes at maximum speed 
(17949.49xg) at 4°C. The supernatants were transferred to fresh 1.5ml Eppendorf tubes 
and the protein concentrations of supernatants were determined with a Pierce BCA 
protein assay kit (Thermo Scientific) as explained by the manufacturer. 
2.2.3 Quantification of extracted protein 
Briefly, 25μl of each sample was incubated for 30minutes at 37°C with 200μl of 
working solution in a 96-well plate (Corning Costar, UK), in triplicate. Subsequently, 
the absorbance was measured by a FluoStar spectrophotometer at 562nm. Protein 
concentrations were calculated by using a standard curve of known albumin standards 
ranging from 0 to 1500μg/ml. Protein samples were stored at -70°C until analysed. 
2.2.4 SDS-PAGE technique 
2.2.4.1   Acrylamide gel preparation 
The components for the solutions used in the Sodium Dodecyl Sulphate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) technique are listed in (Table 2-6). 
Proteins from cell lysates were separated by protein size using SDS-PAGE. The mini-
Protean 3 electrophoresis system (Bio-Rad, USA) was used to cast 8-12% acrylamide 
resolving gels (1.5mm thick). In this study, different concentrations of acrylamide gels 
were prepared depending on the size of the protein investigated, 10% for E-cadherin 
and β-catenin, and 12% for smaller sized proteins ( 
Table 2-7). Gels were allowed to set for at least 30minutes before loading and 
running. Then a stacking gel was made on top of the resolving gel at 5% concentration 
(Table2-7). 
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Table 2-6: Western blotting buffers used in this study. 
Buffers used in western blotting and their components and concentrations. 
 
Solution components 
10% SDS 10xElectrode buffer 
10g Sodium Dodecyl Sulphate 
(SDS) 30.3g Tris base 
100ml H2O 144g Glycine 
1.5M Tris-HCl/ SDS pH8.8 1L H2O 
45.41g Tris Running buffer 
0.4% SDS (10ml of the 10% stock) 0.1% SDS (10ml of 10% stock) 
200ml H2O 1xTris Glycine (100ml of 10xelectrode buffer) 
pH to 8.8 with 1M HCl Make up to 1L with H2O 
Make to 250ml with H2O Transfer Buffer 
1M Tris-HCl/SDS pH6.8 100ml Methanol 
6.06g Tris 1XTris Glycine (50ml of 10xelectrode buffer) 
0.4% SDS (4ml of 10% stock) Make up to 500ml with H2O 
90ml H2O 0.1% Ponceau S Red 
pH to 6.8 with 1M HCl 0.1mg  
Make to 100ml 1L 1% Acetic acid 
 
Table 2-7: A list of the concentration of resolving SDS/PAGE gels used in this 
study. 
Component volumes (mL) per gel mould volume of 10ml. 
 
Solution components 
Components volumes (ml) per gel 
volume of 15ml 
Gel concentration 8% 10% 12% 
H2O 6.9 5.9 4.9 
30% Acrylamide mix 4 5 6 
1.5M Tris (pH8.8) 3.8 3.8 3.8 
10% SDS (SLS, UK) 0.15 0.15 0.15 
10% ammonium 
persulfate 
0.15 0.15 0.15 
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TEMED 0.018 0.016 0.012 
Table 2-8: List of the solutions used in the preparation of 5% stacking SDS/PAGE. 
Components of solution used to prepare 5% stacking gel. Components volumes (ml) per gel mould 
volume of 4mL. 
 
Solution components 
Components volumes 
(ml) per gel mould 
volume of 4ml 
H2O 2.7 
30% Acrylamide mix 0.67 
1.5M Tris (pH6.8) 0.5 
10% SDS (SLS, UK) 0.04 
10% ammonium persulfate 0.04 
TEMED 0.008 
 
100µg of protein (unless otherwise stated) was loaded into each lane. 10µl of 
Amersham ECL Plex Fluorescent Rainbow Marker (GE Healthcare Life Sciences, 
USA) was loaded into a spare well and sample was electrophoresed until stain front 
remained visible. 
2.2.4.2 Sample preparation 
Equal amounts of protein were loaded from each lysate that were diluted in 1x 
NuPAGE LDS sample buffer (Novex, Life Technologies, USA) or Laemmli sample 
buffer (Bio-Rad, USA) containing 5% Beta-Mercaptoethanol. Samples were then heated 
in a preheated heat block at 100°C for 5minutes. The samples are cooled briefly in ice 
prior to loading into the gel. 
2.2.4.3 Gel electrophoresis conditions 
Gels were run at constant voltage (125v) for 90minutes in room temperature in 
1x running buffer (Table 2-6). 
2.2.4.4 Protein transfer 
The proteins were then transferred onto polyvinylidene difluoride (PVDF) 
membrane (GE Healthcare Life Sciences, USA) using the Mini Trans-Blot 
Electrophoretic Transfer Cell (Bio-Rad, USA). PVDF membrane is activated by 
incubation in 100% methanol for 15minutes. Then proteins were transferred from gel to 
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PVDF in methanol containing transfer buffer (Table 2-6) at constant voltage (25V) for 
90minutes. To confirm successful protein transfer, both the gel and the membrane were 
stained by a reversible stain with 0.1% Ponceau S (w/v) in 1% acetic acid (v/v), 
subsequently removed by washing with distilled water, without affecting the proteins in 
the blots. 
2.2.5 Probing for proteins of interest 
2.2.5.1 Blocking, washing and antibody preparation 
Membranes were blocked in 5% low fat milk prepared in PBS containing 0.1% 
Tween 20 (PBS/T) overnight at -4°C with continuous agitation. Membranes were 
washed in PBS/T three times for 3minutes between incubations. Antibody dilutions 
(Table 2-9) were prepared in blocking buffer. Loading accuracy was subsequently 
assessed by analysis using a primary antibody raised against α-Tubulin. 
 
Table 2-9: List of primary antibodies used for probing the membranes. 
The primary antibodies used in this study and their origin. Also, dilations and incubation period used in 
this study. 
 
Antibody Clone Isotype Company Concentration Band size Control 
E-cadherin 34/E-cadherin 
Mouse 
monoclonal 
IgG2b 
Becton, 
Dickinson (BD) 
Transduction 
laboratoriesTM 
1:100 120kDa HT29, and MCF7 
b-catenin 14/Beta-catenin 
Mouse 
monoclonal IgG1 
BD Transduction 
laboratoriesTM 1:150 92kDa 
SW480, and 
HT29 
Vimentin RV202 Mouse monoclonal IgG1 
BD Transduction 
laboratoriesTM 1:50 57kDa 
MDA-MB-
231, and 
Hela 
Gli1 H-300 Rabbit poly clonal IgG 
Santa Cruz 
Biotechnology 1:100 
114-
173kDa 
K562, and 
PC3 
Gli2 C-10 Mouse monoclonal IgG1 
Santa Cruz 
Biotechnology 1:100 
86-
168kDa 
K562, and 
PC3 
Gli3 B-4 
Mouse 
monoclonal 
IgG2b kappa light 
chain 
Santa Cruz 
Biotechnology 1:100 190kDa 
K562, and 
Jurkat 
Smoothened E-5 
Mouse 
monoclonal IgG2a 
kappa light chain 
Santa Cruz 
Biotechnology 1:100 85kDa 
K562, and 
Hela 
Patched 3B3 
Mouse 
monoclonal IgG2a 
kappa light chain 
Santa Cruz 
Biotechnology 1:100 140kDa PC3 
Sonic Hedgehog 
(Shh) E-1 
Mouse 
monoclonal IgG1 
kappa light chain 
Santa Cruz 
Biotechnology 1:100 19-45kDa Hela 
Indian Hedgehog 
(Ihh) H-12 
Mouse 
monoclonal IgG1 
kappa light chain 
Santa Cruz 
Biotechnology 1:100 45kDa 
Hela, and 
HepG2 
a-Tubulin DM1A Mouse monoclonal IgG1 
SIGMA-
ALDRICH 1:1000 50kDa - 
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Table 2-10: List of secondary antibodies used for visualisation of blot and their 
origin. 
Table include a summary of dilation and incubation periods of antibodies. 
 
Antibody Host Reactivity Company Concentration 
IRDye® 800CW anti-Mouse IgG (H+L) Donkey Mouse Li-Cor® 1:15000 
IRDye® 680RD anti-Rabbit IgG (H+L) Donkey Rabbit Li-Cor® 1:15000 
 
2.2.5.2 Visualisation and imaging of proteins bands 
Protein bands were detected using the Enhanced Chemiluminescence (ECL) 
method by adding 2mL of the chemiluminescent substrate to the membrane (Millipore 
Forte) for 2minutes in continuous rotation, followed by developing the ECL film 
(Amersham, GE Healthcare, USA) in the dark room after 30second, 1minute and 
3minutes exposure. The Li-Cor Odyssey® FC system was used for detection of 
secondary antibodies labelled by the near-infrared fluorescence. Images were captured 
at appropriate exposure time using the appropriate detector filter using the Image 
StudioTM software. 
2.2.5.3 Densitometric analysis 
In order to quantify differences in protein expression observed by Western 
blotting analysis, the films were scanned (600dpi) using Photoshop software (Adobe) 
and densitometric analysis was performed using ImageJ software (NIH, USA). All 
densitometric analysis was normalised to a common band on each film and for protein 
screening experiments, averages are representative of data from three separate 
experiments. 
2.3 Immunocytochemistry  
2.3.1 Seeding cells on coverslips 
Cells were cultured on 19-22mm diameter rounded glass coverslips (VWR, 
International) pre-coated with Poly-L-Lysine (PLL) according to manufacturer’s 
instructions. In brief, coverslips were sterilised in 100 % ethanol for 30minutes then 
coated with 0.01% PLL (v/v) for 5minutes, drained and air dried. Coverslips were 
stored in sterile plates until needed. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
59 
 
  
2.3.2 Sample preparation 
Cells were seeded onto sterile coated 19-22mm glass coverslips (VWR, 
international) at the appropriate density/well in 12 well plates (Corning Costar, UK). 
For treatment IC, cells were seeded at medium density (Table 3-1). Cells were grown 
under standard growth conditions for 24hours prior to changing to treatment medium. 
2.3.3 Cell fixation and permeabilisation 
Cells on coverslips were washed once with sterile PBS before being fixed and 
permeabilised by 4% (w/v) paraformaldehyde (PFA) containing 0.1% (v/v) Triton X-
100 (BDH, UK) for 15minutes at room temperature inside the tissue culture hood. 
Subsequently, they were washed three time with sterile PBS and stored in PBS at -2°C 
until further analysis. 
2.3.4 Immunocytochemistry procedure 
Cells were washed once with PBS and then blocked for 60minutes in PBS 
containing 2% (w/v) Bovine Serum Albumin (BSA), 5% FBS (v/v) (Life Technologies, 
UK), and 0.1% Gelatine from cold fish skin. Coverslips were then incubated for 1hour 
in primary antibody prepared in the blocking buffer at the appropriate concentration at 
room temperature (Table 2-11). After this, coverslips were washed three times for 
5minutes each in PBS, cells were then incubated in the dark with the appropriate 
secondary antibody at the recommended concentration, at room temperature (Table 2-
11). Following antibody adhesion, cells were washed a further three times and then 
incubated for 5minutes in (1:10,000) 4’,6-Diamidino-2-phenylindole (DAPI) nuclear 
counterstain. Cells were then washed with PBS a further three times for 5minutes and 
then the coverslips were mounted in aqueous mounting medium containing DAPI 
(Vector Labs, UK). Cells were visualised using the fluorescence microscope (Leica, 
Germany) or using the inverted Leica UltraView spinning disc confocal laser scanning 
microscopy and images acquired/compiled using Leica Confocal Software (Leica, 
Germany). 
Controls were prepared for each set of experiments, including control cell lines 
positive for the protein of interest (Table 2-11). A negative control of each cell line was 
also included by incubating the cells in blocking buffer instead of primary antibody 
step. This step was necessary to ensure proper quality control measures in all 
experiments. 
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Table 2-11: List of the primary antibodies used for IC. 
These were the primary antibodies used in this study and their origin. Also, listed are the dilutions and 
the incubation period used in this study. 
 
Antibody Clone Isotype Company Concentration Control 
E-cadherin 34/E-cadherin Mouse monoclonal IgG2b 
BD Transduction 
laboratoriesTM 1:100 
HT29, and 
MCF7 
b-catenin 14/Beta-catenin Mouse monoclonal IgG1 
BD Transduction 
laboratoriesTM 1:150 
SW480, and 
HT29 
Vimentin RV202 Mouse monoclonal IgG1 
BD Transduction 
laboratoriesTM 1:50 
MDA-MB-231, 
and Hela 
Gli1 H-300 Rabbit poly clonal IgG 
Santa Cruz 
Biotechnology 1:50 K562 
Gli2 C-10 Mouse monoclonal IgG1 
Santa Cruz 
Biotechnology 1:50 K562 
Gli3 B-4 
Mouse monoclonal 
IgG2b kappa light 
chain 
Santa Cruz 
Biotechnology 1:50 K562 
 
Table 2-12: List of the secondary antibodies used for visualisation of IC. 
Table include a summary of the dilutions and the incubation period. 
 
Antibody Host Reactivity Company Concentration 
Anti-Mouse IgG (H+L) Secondary 
Antibody, Alexa Fluor® 488 Chicken Mouse Life Technologies
 1:100 
Anti-Rabbit IgG (H+L) Secondary 
Antibody, Alexa Fluor® 488 Chicken Rabbit Life Technologies 1:100 
Anti-Mouse IgG (H+L) Secondary 
Antibody, Alexa Fluor® 594 Chicken Mouse Life Technologies 1:100 
Anti-Rabbit IgG (H+L) Secondary 
Antibody, Alexa Fluor® 594 Chicken Rabbit Life Technologies 1:100 
 
2.4 Flow cytometry 
Flow assisted cell cytometry was used to analyse protein expression following 
various treatments. 
2.4.1 Cell preparation and fixation 
Following appropriate treatment, cells were trypsinised and counted before 
centrifugation at 1000xg for 3minutes. Cells were treated by fixation buffer (BD 
Biosciences, UK) for 15minutes at room temperature and then washed in 5ml PBS with 
0.1% (v/v) Triton X-100 (PBS/Triton). Cells were suspended at 1x106 cells/ml in 
blocking buffer and gently mixed, and then incubated at room temperature for 1hour. 
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2.4.2 Immunofluorescent staining 
Cells were then allowed to pellet at room temperature and then the supernatant 
were carefully collected and discarded. Cells were then incubated with primary 
antibody solution (made in blocking buffer) for 1hour at room temperature (Table 
2-11). Cells were allowed to pellet, and supernatant was collected and discarded 
followed by washing three times in PBS/Triton for 5minutes each time. Cells were then 
incubated in secondary antibody solution, made in blocking buffer, for 1hour at room 
temperature (Table 2-11). This was followed by washing three times in PBS/Triton for 
5minutes each time and resuspending the cells in PBS/Triton. 
Controls were prepared for each set of experiments, including control cell lines 
that are positive for the protein of interest (Table 2-11). A negative control for each 
antibody was also included, by incubating the cells in blocking buffer instead of 
primary antibody. This step was necessary to ensure proper quality control measure in 
all experiments. 
2.4.3 Apoptosis assay 
FITC Annexin V apoptosis detection kit I (BD Biosciences, UK) was used for 
identification of the different stages of apoptosis in the cells following treatment 
(Casciola-Rosen et al., 1996). FITC Annexin V is a sensitive probe for identifying 
apoptotic cells and, when used in conjunction with a vital dye such as PI (Propidium 
Iodide), allows the identification of early apoptotic cells (PI negative, FITC Annexin V 
positive). Viable cells with intact membranes exclude PI, whereas the membranes of 
dead and damaged cells are permeable to PI. 
The cells were prepared according to manufacturer’s instructions. In brief, cells 
were washed twice with cold PBS and suspended in 1X Binding buffer at a 
concentration of 1x106 cells/ml. 100µl of that solution (1x105 cells) was transferred to 
an Eppendorf tube and stained with 5µl of FITC Annexin V and 5µl PI (provided in the 
kit), gently mixed and then incubated for 15minutes in the dark. Following this, 400µl 
of 1X Binding buffer was added to each sample and sample analysed by flow cytometry 
within 1hour. 
Apoptosis percentage in cells were determined using FITC Annexin V apoptosis 
detection kit I (BD Biosciences, UK) (2.4.3). Several appropriate controls were added to 
ensure proper analysis and for quality control measures. Unstained control for each cell 
line was included for each experiment. Two positive controls for each cell line were 
also included by incubating cells in heat block for 10 seconds at 60°C, one was stained 
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with FITC Annexin V and one stained with PI. One untreated control was added for 
each cell line used to determine the baseline of normal apoptosis in cells and to ensure 
that the cells were not subjected to damage during experimental setting. 
Samples and controls were analysed using BD AccuriTM C6 (BD Biosciences, 
UK) and data was analysed using BD AccuriTM C6 Plus software (BD Biosciences, UK). 
Gating was conducted on unstained control (Figure 2-3-A). Compensation for FITC/PI 
signal overlap is conducted using positive FITC control, positive PI control and mixed 
control (positive FITC: positive PI) (Figure 2-3-B). 
 
 
 
Figure 2-3, Example of gating strategy used for measuring breast cancer cell lines 
integrity and compensation technique used to measure positive cells in each flow 
cytometry channel. 
This figure shows gating strategy used for breast cancer cell line to exclude dead cells, debris and cellular 
doubling, using gated region shown in the first plot, using 10,000 events analysed each time. (A) Shows 
unstained breast cancer cells in forward and side scatter; also, it shows the gate of live cells. (B) Shows 
unstained cells in FL1 and FL2 detectors. This histogram was used to set threshold for positive cells after 
negative histogram. (C) The positive cells stained with propidium iodide detected in FL2. (D) The 
positive cells stained with primary Annexin V-FITC conjugated fluorescence antibody detected in FL1. 
(E) Compensation control (combination of cells stained with Annexin V-FITC conjugated fluorescence 
antibody only and cells stained with PI only) was used to set the compensation level for differentiating 
the FL1 and FL2 signal. 
 
2.4.4 Flow cytometric technique 
All flow cytometry analysis was performed using a BD AccuriTM C6 (BD 
Biosciences, UK) and data was analysed using the BD AccuriTM C6 Plus software (BD 
Biosciences, UK). A single cell population was gated based on appropriate size on the 
basis of forward scatter (FCS-A) versus side scatter (SSC-A). A total of 10,000 events 
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for each sample was measured, and all experiments were repeated a minimum of three 
times. Increased fluorescence was compared to unstained controls for all proteins 
investigated. Computational analysis was performed using the BD AccuriTM C6 Plus 
software. 
Cells were gated to exclude debris and cellular doubling, and analysis was based 
on collecting 10,000 events through the gate as shown in (Figure 3-3). Flow cytometry 
was used as well to measure the percentage of positive cells as well as the median 
fluorescence intensity (MFI), which provided an indication of the overall level of 
protein in cells. All comparisons were done by one-way analysis of variance (ANOVA) 
test prepared using SPSS and GraphPad Prism software for data analysis. Negative 
control (secondary only), positive controls (Table 2-2), and unstained cell control was 
included in the experiments. 
 
 
 
Figure 2-4, Example of the gating strategy used for measuring breast cancer cell 
lines integrity and compensation technique used to measure the positive cells in 
each flow cytometry channel. 
This figure shows the gating strategy used for breast cancer cell line to exclude cellular doubling, using 
the gated region shown in the first plot, using 10,000 events analysed each time. (A) Shows the unstained 
breast cancer cells in forward and side scatter, also, it shows the gate of the live cells. (B) Shows the 
unstained cells in FL1 detector. This histogram was used to set the threshold for the positive cells after 
the negative histogram. (C) The positive cells stained with the primary and secondary conjugate 
fluorescence antibody detected in FL1. 
 
2.5 Migration and in vitro invasion assays 
2.5.1 Transwell filter assay 
Cell migration assays were carried out using a Transwell filter migration assay 
as previously described (Efstathiou et al., 1999; Qualtrough et al., 2007). In brief, insert 
filters of 8µm pore size (Merc Millipore, UK), were coated with 500µl of 10µg/ml 
VitroCol® human collagen type I solution (Cell Systems, USA). Cell invasion assays 
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were carried out using 8 µm pore size Corning BioCoatTM Matrigel® Invasion Chambers 
with BD Matrigel® Matrix (Fisher Scientific, UK) as described previously (Qualtrough 
et al., 2007; Qualtrough et al., 2015). 24hours prior to assay, cells were lifted using 
trypsin, counted and resuspended to a final concentration of 1x105 cells/ml in calcium-
free-DMEM with 2% FBS (with or without treatment). The lower chamber was filled 
with calcium-free-DMEM with 5%FBS, to act as an attractant, and 2ml of cell solution 
(2x105 cells) was added to each filter. Following 24hours of incubation at 37°C, cells 
attached to the filter were fixed for 10minutes in 100% methanol and stained using 
Mayer’s haematoxylin (BDH, UK). Cells were removed from the upper filter surface 
with a cotton swab, while those on the lower filter surface were considered migratory 
and counted in ten separate fields at 200 times magnifications. Three independent 
experiments were carried out in triplicate, and the data are expressed as mean ±SDM. 
Statistical analysis of this data performed using the Student’s t-test. Differences were 
considered significant when the p-value was <0.05. 
2.6 Statistical analysis 
All value quoted represent mean ± Standard Deviation of the mean (S.D.) of the 
sample unless otherwise stated. While some data has been normalised to aid graphical 
display, all statistical analyses were performed on raw data. Graphical representation 
and basic data manipulation were conducted in GraphPad Prism 6 for Mac. The 
majority of statistical analysis was performed using SPSS version 17 used. 
Where samples were found to be normally distributed a paired T-test, or two-
sample T-test was utilised for statistical analysis, with each sample compared with 
relevant controls. A p-value of 0.05 or below was considered to be significant. Non-
normal distributions were analysed using the Mann-Whitney test for unpaired samples; 
in the case of comparing more than two groups, a Kruskal-Wallis test was performed. If 
significant differences were indicated, Mann-Whitney analysis was subsequently 
performed between groups with Bonferroni correction to identify where the significant 
differences can be found. 
2.7 Immunohistochemical analysis 
2.7.1 Human tissues and ethical approval 
Surgically resected human tissue (formalin-fixed paraffin-embedded) was 
selected and anonymised by a qualified histopathologist from the tissue archives at the 
Department of Histopathology, Bristol Royal Infirmary. All tissue was obtained under 
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approval from the NHS Health Research Authority (Ref: 11/SW/0127) and UWE ethics 
committee. All methods were performed in accordance with the NHS Health Research 
Authority guidelines and regulations. 
2.7.2 Tissue sectioning and rehydration 
Paraffin blocks containing embedded human breast tissue were sectioned at 
4µm using a microtome (Leica RM2235) (Leica, Germany) and mounted on superfrost 
Plus glass slides (Thermo-Fisher, UK). Sections were allowed to adhere for at least 
30minutes in an oven at 60°C followed by deparaffinisation in two changes of 
Histoclear (National Diagnostics, USA) for 5minutes. Slides used in this study were 
serial sections probed with antibodies against the markers while one section was stained 
with H&E (Haematoxylin and Eosin) to show details of tissue structure. Sections were 
then deparaffinised with Histoclear (National Diagnostics) and rehydrated using a 
series of ethanol concentrations and dH2O. Sections were rehydrated gradually in 
descending concentrations of ethanol and in dH2O. Antigen unmasking was performed 
by heating in 0.01M/L citrate buffer (pH6.0) using a 95-100°C water bath for 
30minutes then allowing the sections to cool to room temperature in the buffer. Slides 
were then moved to running tap water. 
2.7.3 Immunohistochemistry staining procedure 
Endogenous peroxidases were quenched with 3% (v/v) H2O2 for 5minutes 
(BDH, UK). Slides were incubated in blocking serum (Goat or horse serum (Vector 
Labs, UK) diluted in PBS for 30minutes at room temperature, then incubated in primary 
antibody overnight at 4°C. Antibodies used were anti-human (Table 2-13). 
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Table 2-13: List of the primary antibodies used for Immunohistochemistry (IHC). 
These were the primary antibodies used in this study and their origin. Also, listed are the dilutions and 
the incubation period used in this study. 
 
Antibody Clone Isotype Company Concentration 
E-cadherin 4A2C7 Mouse monoclonal IgG1-kappa 
InvitrogenTM, Life 
Technologies 1:100 
b-catenin 14/Beta-catenin Mouse monoclonal IgG1 
BD Transduction 
laboratoriesTM 1:100 
Gli1 H-300 Rabbit poly clonal IgG Santa Cruz Biotechnology 1:100 
Gli2 C-10 Mouse monoclonal IgG1 Santa Cruz Biotechnology 1:200 
Gli3 B-4 Mouse monoclonal IgG2b kappa light chain Santa Cruz Biotechnology 1:150 
Smoothened E-5 Mouse monoclonal IgG2a kappa light chain Santa Cruz Biotechnology 1:100 
Progesterone PgR636 Mouse monoclonal IgG1-kappa 
Dakocytomation, Agilent 
Technologies 1:200 
ER a 1D5 Mouse monoclonal IgG Dakocytomation, Agilent Technologies 1:200 
HER2  Rabbit monoclonal IgG Fisher Scientific 1:400 
Ki67/MK167 SP6 Rabbit monoclonal IgG Fisher Scientific  
 
The next day, slides were washed in PBS and then incubated with suitable 
biotinylated secondary antibodies for 1hour at room temperature (Table 2-14). The 
secondary antibody was prepared from the Universal Elite Kit (Vector Labs, UK). 
Following the secondary antibody incubation, the Avidin-biotin complex (ABC) 
reagent from the Vectastain® Elite kit was prepared in PBS according to the 
manufacturer’s instructions. The slides were washed three times in PBS and then 
incubated in the ABC reagent for 30minutes. Slides were washed three times for 
5minutes with PBS. The slides were then incubated in Diaminobenzidine 
tetrahydrochloride (DAB) to produce the chromogen (Dakocytomation, Cambridge, 
UK). Tissue was then counterstained by Meyer’s haematoxylin (BDH, UK) for 
3minutes and washed in running tap water for 5minutes. Slides were dehydrated in a 
series of increasing concentrations of alcohol and cleared in two changes in Histoclear 
for 5minutes in each, followed by mounting in DPX (Distyrene, a plasticizer, and 
xylene) (BDH, UK). Secondary only controls were included in each batch to ensure 
specificity of immunoreactivity. 
 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
67 
 
  
Table 2-14: List of the secondary antibodies used for visualisation of IHC. 
Table include a summary of the dilation and the incubation period. 
 
Antibody Clone Host Reactivity Company Concentration 
Anti-Rabbit IgG BA-1100 Horse Rabbit Vectorlabs 1:50 
Anti-Mouse IgG BA-2000 Horse Mouse Vectorlabs 1:50 
 
2.7.4 Scoring and analysis 
Stained tissue was scored by semi-quantitative analysis under the light 
microscope according to immune reactive scoring (IRS) (Remmele and Stegner, 1987; 
Kaemmerer et al., 2012) (Table 2-15). 10 fields were selected in each sample and 
scored using the IRS criteria (Table 2-15). The IRS score includes evaluation of the 
reaction intensity and the relative percentage of positive tumour cells. 5 fields were 
selected from the tumour centre and five at the invasive front of the tumour (if 
available). The invasive front is defined here as an area of three-to six layers of cells at 
the border of the tumour mass or the scatter of tumour cells between the edge of the 
tumour and the surrounding stroma (Eiro et al., 2012; Gong et al., 2013). Additionally, 
nuclear staining in the ten fields was scored according to the scheme used by Volante et 
al. (2007) for Gli1, Gli2, Gli3 and b-catenin (Table 2-15).  
The scores were compared between the invasive front and the tumour centre. 
The nuclear scores for the tumour centre were also compared to the nuclear score of the 
invasive front. 
Representative images of the immune reaction were obtained using a GT slide 
scanner (GT Vision, UK) and photomicrographs of stained tissue were acquired using 
Leica microscope (Leica, Germany).  
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Table 2-15: IRS and IRS classification and scoring system. 
Table include a summary of the scoring method used. 
 
Percentage of positive cells Staining intensity 
Proportion of 
stained cells (%) 
Score 
Intensity of 
staining 
Score 
0 0 No colour reaction 0 
< 10 1 Mild reaction 1 
10 - 50 2 Moderate reaction 2 
51 - 80 3 Intense reaction 3 
> 80 4 
IRS classification 
IRS Score = Percentage x Staining 
intensity 
Points (0 - 12) Description 
0 - 1 Negative 0 = Negative 
2 - 3 Mild 1 = 
Positive, weak 
expression 
4 - 8 Moderate 2 = Positive, mild expression 
9 - 12 Strongly positive 3 = Positive, strong reaction 
 
Table 2-16: Nuclear scoring system. 
Table include a summary of the nuclear scoring method used. 
 
Nuclear staining score Score 
< 10 % of cells in tumour have nuclear staining 1 
10 % - 50 % of cells in tumour have nuclear staining 2 
≥ 51 % of cells in tumour have nuclear staining 3 
 
2.7.5 Tissue imaging 
All stained tissue was imaged using the GT Vision scanner (GT Vision, UK). 
Also, photomicrographs of stained tissue presented here were acquired using the Nikon 
camera under the Leica microscope (Leica, Germany). 
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2.7.6 Statistical analysis of IHC scores 
All statistical analysis was performed using the SPSS software version 24 (SPSS 
GmbH Software, Germany). p-value<0.05 were considered to be statistically 
significant. Kendall’s Tau B test was used for determination of correlations between the 
expression of proteins and clinicopathological characteristics. One-way ANOVAs 
analysis was used for comparison of difference in expression levels.  
The correlation analysis was conducted between the pathology report criteria 
(age, size, stage, grade, histological subtype, molecular subgroup, hormone receptor 
positivity, lymph node involvement) with (percentage positivity, intensity of immune 
reaction, IRS class and nuclear score) of (Gli1, Gli2 and Gli3) in tumour centre and at 
invasive front. All correlations were conducted, and the data presented were results that 
showed high correlations. 
2.7.7 Confirmation of subtype of breast cancer samples showed that all selected 
cases followed the classification specified in the pathology report 
First, H&E staining of all tumour samples in this cohort verified that there was 
tumour present in sections (Figure 11-4). All sections were assigned codes before 
staining and scoring to avoid bias during analysis, and all scores were assessed by at 
least three researchers with any mismatches were assessed in joint consultation and a 
score agreed upon. Antibodies were verified using both negative and positive controls. 
Breast tumour tissue sections were immunohistochemically stained using 
antibodies raised against ER, PR and HER2, to verify their classification according to 
prognostic marker expression profile. Detection of these markers was carried out in 
accordance with the methodology of Dean and Rhodes (2014). Immunoreactivity was 
assessed using standardised methods (Leake et al., 2000; Rakha et al., 2015). 
Table 2-17 summarises the numbers of sections stained with each antibody 
investigated. Table 11-1 summarises the clinicopathological parameters from the 
pathology report for the samples in this cohort. The numbers of cases in each stain was 
not the same due to variations during section preparation, antibody optimisation and 
duration of experimentation. Table 11-2 shows the numbers of cases and the 
corresponding histological subtype according to the pathology reports. Lymph node 
(Table 11-3-A) and metastasis (Table 11-3-B) status of the cases that represent the 
sections investigated by antibody staining (b-catenin, E-cadherin, Gli1, Gli2 and Gli3). 
Correlations to metastasis was not conducted because of low numbers of confirmed 
metastatic cases in the cohort used (Table 11-3-B). 
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The correlation between the expression of proteins (Gli1, Gli2, Gli3, b-catenin 
and E-cadherin) in tumour centre and at invasive front as well as correlation of nuclear 
localisation were conducted on all parameters. Data shown in the result section were the 
data that had high correlation with statistical significance the rest of the data were 
shown in Table 11-12-Table 11-20 
 
Table 2-17: Numbers of sections stained by each antibody in this study 
Total number of sections stained by each antibody by IHC. Antibodies investigated in this study were (b-
catenin, E-cadherin, Gli1, Gli2 and Gli3). 
 
Stain b-catenin E-cadherin Gli1 Gli2 Gli3 
Total 37 23 48 29 23 
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3. Chapter Three: Defining an EMT Model for Breast Cancer 
3.1 Introduction 
Breast cancer is the second most common cause of cancer death for females in the 
UK. Cancer metastasis is responsible for 90% of all cancer-related deaths. Invasion and 
metastasis are one of the hallmarks of cancer, and the dysregulation of epithelial-
mesenchymal transition is one of the key mechanisms by which metastasis is 
accomplished (Tsai and Yang, 2013; Wang and Zhou, 2013). To assess for the ability of 
breast cancer cells to undergo EMT an in vitro model most be utilised to stimulate 
EMT-like changes in breast cancer cell lines. Having such model is essential for the 
understanding of the regulation of this process and for varying if the EMT process is 
varied depending on the molecular subclassification of breast cancer.  
Sarrio et al. (2008), found that the normal-like breast cancer cell line (MCF10A) 
was more susceptible to EMT-like change when subjected to stress caused by decreased 
cell-cell contact. They suggested that this was due to the basal-like molecular signature, 
therefore, suggesting that basal-like breast cancer could be further down the EMT 
spectrum (Sarrio et al., 2008). However, since that study the susceptibility of basal-like 
breast cancer cells to EMT compared to other subtypes. The seeding density approach 
as proposed and facilitated by Conacci-Sorrell et al. (2003) study and in Sarrio et al. 
(2008) could produce an interesting tool to study EMT-like in breast cancer cell lines. 
Using this approach could be promising in giving indications of the EMT status in each 
sub-classification of breast cancer which has not been reported using this approach 
before. So, the hypothesis of this study is that all breast cancer cell lines have EMT 
capabilities depending on the subtype to which they belong. Also, it is hypothesised that 
some of the breast cancer cell lines, basal in particular, could be further down in the 
EMT pathway (Figure 3-1). 
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Figure 3-1, Hypothesis of the position of cells within the EMT spectrum depending 
on the molecular classification of breast cancer cell lines in the pathway. 
The pathway of EMT in cancer involves the loss of epithelial criteria and acquisition of mesenchymal 
markers that allow the dissociation of the cells from the tumour mass and subsequent invasion. The 
hypothesis is that the breast cancer cell lines are arranged in the EMT line with some subtypes further 
down the pathway closer to the mesenchymal phenotype. 
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3.1.1 Aim 
To develop an in vitro cell density-based model of EMT in breast cancer cell 
lines, allowing comparison of the different subtypes of breast cancer. 
3.1.2 Objectives 
- To culture breast cancer cell lines at a gradual decrease of seeding density and 
observe the morphological changes (cellular contact, spreading, and spindle 
formation). 
- To select the densities at which there were significant morphological changes. 
- To assess the expression of E-cadherin, b-catenin and vimentin at the selected 
densities, and thereby to evaluate the status of EMT in breast cancer cell lines 
with changing in density. 
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3.2 Results 
3.2.1 Changes in breast cancer cell lines morphology were observed with 
different seeding densities 
Observations were made under phase contrast microscope to assess for 
morphological changes in response to altered cellular density in order to determine the 
confluency of the culture and to select the densities for further analysis. After 24hours 
of incubation, cells were observed under phase contrast and images were captured. The 
highest density selected was based on the confluency level, cell-cell contact and the 
degree of cellular stacking up (stratification). Other densities were selected according to 
apparent morphological transformations including cellular spreading, or an increase in 
rounded and spindle shaped cells. 
Several morphological changes were observed and recorded during the seeding 
density experiments. These include changes in the degree of cell-cell contact, cellular 
spreading and spindle cell formation. Other criteria were considered unfavourable 
changes because they were associated with increased in morphological signs of 
apoptosis and were therefore avoided. These include the formation of stratification 
(stacking up of cells leading to decreased cellular viability and poor culture conditions) 
and very low densities (increased in cell death due to anoikis and very low 
proliferation) (Figure 3-2 to Figure 3-4). 
3.2.1.1 Selecting the number of cells in the high density 
The maximum density was determined by seeding the cells at different densities 
and counting the number of cells that can cover 95% of the culture vessel after 24 hours 
incubation (Error! Reference source not found.). Stratification, or stacking up of 
cells, results in poor viability as a result of hypoxia and limitation of medium/waste 
exchange. Thus, the density selected was with minimal stratification.   
The MDA-MB-361 cell line required the highest numbers of cells per cm2 
(4.8x104), even though, the selected density showed less than 95% confluency. MDA-
MB-453, MCF7 and MDA-MB-231 required (2.8x104, 2x104 and 1.3x104 cells per cm2 
respectively). The cell lines that required the least number of cells as a monolayer were 
BT20 and MCF10A (1x104 cells per cm2) (Error! Reference source not found.). In 
addition, it was observed that cell lines from the same molecular subtype had different 
degrees of cellular spreading and cell-cell adherence (Figure 3-6). 
All breast cancer cell lines formed stratification at high density. It was observed 
that luminal breast cancer cell lines (MCF7 and MDA-MB-361) and basal-cell lines 
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(MCF10A and BT20) needed additional mixing to ensure proper dissociation of cells 
and longer incubation in trypsin. The cell lines (MDA-MB-361, MDA-MB-453, BT20, 
and MDA-MB-231) showed an ability to form stratification at all densities (Figure 3-2). 
The highest density of the MDA-MB-361 cell line was selected that covered less than 
95% of the tissue culture surface, because this cell line formed condensed colonies with 
an increased tendency to form stratifications of cells. At the selected highest density of 
MDA-MB-361, the cells showed the least stratification and highest cell-cell contact as 
seen in Figure 3-2, Figure 3-3 and Figure 3-6. 
 
 
 
Figure 3-2, Phase contrast microscopic images showing stratification of breast 
cancer cells in cultures at high and low densities 
Stratification changes associated with reduction in seeding density of breast cancer cell lines (MCF7, 
MDA-MB-361, MDA-MB-453, BT20, MDA-MB-231 and MCF10A) were highlighted in this figure. (A) 
cellular stratification at high densities, (Red) arrows point to areas of stratification. (B) cellular 
stratification at low densities, red arrows point to areas of stratification. All images were taken at 200 
times magnification power using the Leica phase contrast microscope. This figure is representative of 
three biological repeats with similar observation. 
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Figure 3-3, Phase contrast microscopic images comparing degree of cell-cell 
contact seen between cells in cultures at high and low densities 
Cell-cell contact changes associated with different seeding densities of breast cancer cell lines (MCF7, 
MDA-MB-361, MDA-MB-453, BT20, MDA-MB-231, BT20, and MCF10A) were highlighted in this 
figure. (A) cell-cell contact at high density; (Blue) arrows point to areas of cell-cell contact. (B) cell-cell 
contact at low density; blue arrows point to areas of cell-cell contact. All images were taken at 200 times 
magnification power using the Leica phase contrast microscope. This figure is representative of three 
biological repeats with similar observation. 
 
3.2.1.2 Selection of the densities that showed the most potent morphological 
changes in cell-cell contact, spindle cells, rounded cells and cellular 
spreading 
Luminal (MCF7, and MDA-MB-361) and normal-like breast cancer cell line 
(MCF10A) had a more differentiated morphology of epithelial cobblestone morphology 
with tight cell-cell contact (Figure 3-3). There was an increase in rounded cells as the 
density of the culture decreases (Figure 3-4). Also, there was an increase in cellular 
spreading towards the edges of the colonies at low densities (Figure 3-5). MCF7, MDA-
MB-361 and MCF10A showed increased fibroblastic morphology in the isolated cells 
with less cell-cell contact and at the borders of colonies (Figure 3-3).  
The TNBC cell line MDA-MB-453 had rounded grape-like morphology with a 
lesser degree of cellular spreading (Figure 3-5). This cell line showed poor cell-cell 
contact as well as weak cellular attachment to the culture surface (Figure 3-3).  
BT20 and MDA-MB-231 (triple-negative and basal-like) breast cancer cell line 
had obvious fibroblastic morphology (Figure 3-4) with a high degree of cellular 
spreading (Figure 3-5). BT20 shows an ability to form cell-cell contacts at all densities 
that increase inversely to seeding density (Figure 3-3-A). MDA-MB-231 showed a 
fibroblastic morphology that did not change in the rest of the densities (Figure 3-4). 
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BT20 and MDA-MB-231 cells showed increased cellular spreading and formation of 
flat cells at the medium density, which is a pattern not seen in the other cell lines 
(Figure 3-3-B). Thus, the medium density was selected for further analysis for all the 
cell lines to cover all observed morphological changes. 
 
 
 
Figure 3-4, Phase contrast microscopic images highlighting formation of round 
cells and spindle-shaped cells seen in breast cancer cell line cultures at high and 
low density 
Changes in rounded cells and spindle-shaped cells with decrease in seeding density were highlighted in 
this figure. (A) formation of round cells (Green arrows) and spindle-shaped cells (Purple arrows) at high 
density. (B) and at low density. All images were taken in 200 times magnification power using the phase 
contrast microscope. This figure is a representative of three biological repeats with similar observation. 
 
 
 
Figure 3-5, Phase contrast microscopic images highlighting cellular spreading seen 
in breast cancer cell line cultures compared inside and at border of cell line 
colonies 
Changes in cellular spreading associated with decrease of seeding density were highlighted in this figure. 
Cellular spreading increases at the borders of the cell lines colonies. Bars added to compare cellular 
spread inside and at border of colonies. All images were taken in 200 times magnification power using 
the phase contrast microscope. This figure is a representative of three biological repeats with similar 
observation. 
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3.2.1.3 Three densities showed potent morphological changes seen by phase 
contrast microscopy and therefore selected for markers analysis 
By observing morphological criteria including; the degree of stratification, cell 
spreading, cell-cell contact and presence of spindle and rounded shaped cells, three 
seeding densities were selected for further analysis (Figure 3-6). The high seeding 
density was selected where cells formed a lesser degree of stratification while covering 
as much as possible of the tissue culture surface. The lowest was the density in which 
the cells had less cell-cell contact with minimal morphological signs of apoptosis and 
cellular death. A medium density was also selected for each cell line, in this density 
cellular morphology was mixed especially in BT20 and MDA-MB-231. The number of 
cells per cm2 is listed in Table 3-1. 
 
Table 3-1: The seeding densities of breast cancer cell lines per 1cm2 of culture 
surface area. 
This table lists the numbers of cells seeded at each seeding density per cm2. The breast cancer cell lines 
are arranged according to their molecular subclassification. 
 
Cell lines Molecular classification 
Cell number/cm2 
High Medium Low 
MCF7 Luminal A 2x104 6.6x103 2.2x102 
MDA-MB-361 Luminal B HER2 overexpressing 4.8x104 1.6x104 5.3x103 
MDA-MB-453 Triple-negative Unclassified 2.8x104 9.3x103 3.1x103 
BT20 Triple-negative and Basal A 1x104 3.3x103 1.1x103 
MDA-MB-231 Triple-negative and Basal B 1.2x104 4.2x103 1.4x103 
MCF10A Triple-negative and Basal B/ Normal-Like 1x104 3.3x103 1.1x103 
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Figure 3-6, Phase contrast microscope images of breast cancer cell lines at various 
seeding densities (changing in cellular morphology observed with reduction of 
density) 
Summary of morphological changes associated with reduction of densities of breast cancer cell lines 
(MCF7, MDA-MB-361, MDA-MB-453, BT20, MDA-MB-231 and MCF10A). The classifications of 
breast cancer cell lines are highlighted at the far left with the names of cell lines. Selected densities were 
highlighted with a star on top. Blue rectangular highlight (high), red rectangular highlight (medium) and 
green rectangular highlight the (low) densities. The scale bar at the bottom right represents 50µm. All 
pictures were taken at 200 times magnification power using the Leica phase contrast microscope. This 
figure is a representative of three biological repeats with similar observation. 
 
3.2.1.4 Summary of the morphological changes associated with decreasing seeding 
densities 
Epithelial cells have several morphological characteristics including an ability to 
form tight cell-cell contact illustrated as the cobblestone morphology. Also, epithelial 
cells show less cellular spreading because of this tight cell-cell contact. On the other 
hand, the mesenchymal cells display increased cellular spreading with a loss of cell-cell 
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contact and increased spindle-shaped cell formation. The changes were scored 
qualitatively as seen in the summary table below (Table 3-2). This summary provided a 
helpful tool in capturing the most significant morphological changes and detecting the 
patterns associated with a decrease in density. 
 
Table 3-2: Summary of the morphological changes associated with high, medium 
and low density for the breast cancer cell lines. 
This table summarises the morphological changes in high, medium and low densities. These changes are 
represented as a qualitative score (0 to 3) based on the morphological observation.  
 
Breast cancer 
cell lines 
Molecular classification 
Morphological change 
High Medium Low 
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MCF7 Luminal A 0 3 1 1 1 1 2 1 3 
MDA-MB-361 Luminal B HER2 overexpressing 0 3 1 1 2 1 2 1 2 
MDA-MB-453 Triple-negative Unclassified 0 2 0 1 2 0 1 2 0 
BT20 Triple-negative and Basal A 1 2 2 2 3 1 2 0 2 
MDA-MB-231 Triple-negative and Basal B 1 1 2 3 2 1 3 0 3 
MCF10A Triple-negative and Basal B/ 
Normal-Like 
0 3 1 1 2 1 3 1 2 
 
Taken together, it can be seen that all the cell lines showed an increase in 
mesenchymal morphological features with decreasing seeding density. All cell lines 
showed an increase in spindle morphology and cellular spreading with decreasing cell-
cell contact, which are all morphological features of mesenchymal morphological 
change. The luminal cell lines (MCF7 and MDA-MB-361) and the TNBC cell line 
(MDA-MB-453) showed less significant morphological mesenchymal changes 
compared to those observed in all of the basal breast cancer cell lines (BT20, MDA-
MB-231 and MCF10A). 
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3.2.2 Expression of the epithelial marker E-cadherin, b-catenin and the 
mesenchymal marker vimentin in the breast cancer cell lines in response to 
reduction of density 
3.2.2.1 The luminal cell lines MCF7 and MDA-MB-361 and normal-like/basal-like 
cell line MCF10A show reduced E-cadherin expression with decreased 
density 
MCF7, MDA-MB-361 and MCF10A cells were seeded at the three selected 
densities and expression of the proteins (E-cadherin, b-catenin and vimentin) were 
compared using either western blotting (see section 2.2) or flow cytometry (see section 
2.4 and changes in the localisation of these proteins were observed using ICF (see 
section 2.3).  
E-cadherin localisation in MCF7, MDA-MB-361 and MCF10A was observed at 
areas of cell-cell contact (Figure 3-12-A, Figure3-13-A, and Figure 3-14-A). Visible 
cytoplasmic deposits of E-cadherin were more frequent in MCF10A and MDA-MB-361 
at all densities (Figure 3-12-A and Figure 3-14-A). These three cell lines retained the 
honeycomb E-cadherin pattern at the medium and low densities with less uniform 
localisation in cells at the border of colonies. 
The percentage of positively expressing cells in the three cell lines (MCF10A, 
MCF7 and MDA-MB-361) was reduced gradually with reducing seeding density 
(Figure 3-12-B, Figure 3-13-B, and Figure 3-14-B). In the MDA-MB-361 cell line 
(luminal), the decrease in percentage of positive cells was significant between medium 
and low densities (p-value<0.05) (Figure 3-14-B). In the normal-like breast cancer cell 
line MCF10A, the MFI increased significantly from high to medium density (p-
value<0.01) (Figure 3-12-B). MFI of positive MDA-MB-361 cells showed highly 
significant decrease between the high, medium and low density (p-value<0.0001) 
(Figure 3-14-B). Also, median fluorescence intensity (MFI) of cells in the medium 
seeding density was significantly less than that of the lower density (p-value<0.01) 
(Figure 3-14-B).  
MDA-MB-361 showed two populations of E-cadherin positive expressing cells 
as seen using flow cytometry. One of these subpopulations had a higher percentage and 
level expression of E-cadherin compared to the other (Figure 3-13-B).  
Among the three cell lines, MDA-MB-361 had the highest expression of E-
cadherin. The expression of E-cadherin protein decreased with decreasing density in 
MCF10A, MCF7 and MDA-MB-361 (Figure 3-12-C, Figure 3-13-C, and Figure 3-14-
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C). There were significant differences between high and low density in MCF10A (p-
value<0.01) (Figure 3-12-C) and a significant difference between high and medium 
densities (p-value<0.01). There was also a highly significant difference between high 
and low densities (p-value<0.0001) in MDA-MB-361 (Figure3-14-C). 
Overall, it can be concluded that the expression level of E-cadherin decreased in 
both level and cell-cell contact localisation with reducing of cell density in the three cell 
lines (MCF7, MDA-MB-361 (luminal) and MCF10 (normal-like and basal-like)). The 
decrease in E-cadherin expression is can cause activation of EMT, however, analysis of 
other markers is essential to draw a frim conclusion. 
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Figure 3-7, E-Cadherin expression in normal-like breast cancer cell line MCF10A 
(A) immunofluorescence representative images of E-cadherin expression in MCF10A cell line seeded at 
three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary 
antibodies (Green) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica 
fluorescence microscope under 400 times magnification. (B) Flow cytometry results of E-cadherin 
expression levels in MCF10A cells. Overlay histogram on the left is for unstained cells and three 
densities expression. The bar charts on the right show comparison of percentage of E-cadherin expressing 
cells as well as MFI of E-cadherin in three densities. (C) The level of E-cadherin in MCF10A lysates 
corrected against a-Tubulin internal loading control. Results displayed as bars of mean ±S.D. This figure 
is representative of n=3 experiments in triplicate. Statistical analysis was conducted and significant 
differences between samples were indicated by * p-value<0.05, *** p-value<0.01 and **** p-
value<0.0001. 
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Figure 3-8, E-Cadherin expression in luminal breast cancer cell line MCF7 
(A) immunofluorescence representative images of E-cadherin expression in MCF7 cell line seeded at 
three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary 
antibodies (Green) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica 
fluorescence microscope under 400 times magnification. (B) Flow cytometry results of E-cadherin 
expression levels in MCF7 cells. Overlay histogram on the left is for unstained cells and three densities 
expression. The bar charts on the right show comparison of percentage of E-cadherin expressing cells as 
well as MFI of E-cadherin in three densities. (C) The level of E-cadherin in MCF7 lysates corrected 
against a-Tubulin internal loading control. Results displayed as bars of mean ±S.D. This figure is 
representative of n=3 experiments in triplicate. Statistical analysis was conducted and significant 
differences between samples were indicated by * p-value<0.05, *** p-value<0.01 and **** p-
value<0.0001. 
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Figure 3-9, E-Cadherin expression in luminal breast cancer cell line MDA-MB-361 
(A) immunofluorescence representative images of E-cadherin expression in MDA-MB-361 cell line 
seeded at three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) 
secondary antibodies (Green) and the nuclei were stained with DAPI (Blue). Images were obtained using 
Leica fluorescence microscope under 400 times magnification. Scale bars added at the bottom right 
corner of images. (B) Flow cytometry results of E-cadherin expression levels in MDA-MB-361 cells. 
Overlay histogram on the left is for unstained cells and three densities expression. The bar charts on the 
right show comparison of percentage of E-cadherin expressing cells as well as MFI of E-cadherin in three 
densities. (C) The level of E-cadherin in MDA-MB-361 lysates corrected against a-Tubulin internal 
loading control. Results displayed as bars of mean ±S.D. This figure is representative of n=3 experiments 
in triplicate. Statistical analysis was conducted and significant differences between samples were 
indicated by * p-value<0.05, *** p-value<0.01 and **** p-value<0.0001. 
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The localisation of b-catenin at all densities of the three cell lines (MCF10A, 
MCF7 and MDA-MB-361) was found to be high at cell-cell borders as seen by ICF 
(Figure 3-10-A, Figure 3-11-A and Figure 3-12-A). The cytoplasmic localisation of b-
catenin protein became less pronounced with reduction in density in all three cell lines. 
Nuclear localisation was observed in MCF10A and MCF7 cell lines at the medium and 
low density. 
The percentage of b-catenin positive expressing cells was reduced with seeding 
density in MCF10A, MCF7 and MDA-MB-361 with the highest expression of b-
catenin in MCF10A, which is a basal-like cell line. The difference in positive 
expressing cells was highly significant in all comparisons in MCF10A (p-
value<0.0001) (Figure 3-10-B). In MCF7 (luminal), the percentage of positively 
expressing cells declined with a significant difference seen only between medium and 
low density (p-value<0.05) (Figure 3-11-B). MDA-MB-361 showed a slight increase in 
percentage of positive cells between medium and low density with a significant 
difference (p-value<0.0001) (Figure 3-12-B). The percentage decreased from medium 
to low density with a significant difference seen in all comparisons in the same cell line 
(p-value<0.0001) (Figure 3-12-B). Mostly, the MFI of positive b-catenin cells 
decreased with density in the three cell lines. In MCF10A the difference in MFI was 
significant between all comparisons (p-value<0.0001) (Figure 3-10-B). In MDA-MB-
361, the difference in MFI was significant between high and medium as well as 
between high and low density (p-value<0.0001) (Figure 3-12-B). Similar to E-cadherin 
subpopulations seen in MDA-MB-361, subpopulation of MDA-MB-361 had a slightly 
higher expression of b-catenin in the highest density, which was then decreased in 
percentage in medium and low density (Figure 3-12-B). 
The relative expression level of b-catenin protein was reduced with decreasing 
in density in the three cell lines. In MCF10A, the difference in expression of b-catenin 
showed high significance between high and medium as well as between high and low 
density (p-value<0.001) (Figure 3-10-C). 
In conclusion, the expression of b-catenin in MCF10A, MCF7 and MDA-MB-
361 decreased with reduction in seeding density. The localisation of b-catenin at the 
cell-cell contact area also decreased with reducing density.  
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Figure 3-10, b-catenin expression in normal-like breast cancer cell line MCF10A 
(A) immunofluorescence representative images of b-catenin expression in MCF10A cell line seeded at 
three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary 
antibodies (Red) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica 
fluorescence microscope at 400 times magnification. Scale bars added at the bottom right corner of 
images. (B) Flow cytometry results of b-catenin expression levels in MCF10A cells. Overlay histogram 
on the left is for unstained cells and three densities expression. The bar charts on the right show 
comparison of percentage of b-catenin expressing cells as well as MFI of b-catenin in three densities. (C) 
The level of b-catenin in MCF10A lysates corrected against a-Tubulin internal loading control. Results 
displayed as bars of mean ±S.D. This figure is representative of n=3 experiments in triplicate. Statistical 
analysis was conducted and significant differences between samples were indicated by * p-value<0.05, 
*** p-value<0.01 and **** p-value<0.0001. 
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Figure 3-11, b-catenin expression in luminal breast cancer cell line MCF7 
(A) immunofluorescence representative images of b-catenin expression in MCF7 cell line seeded at three 
seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary antibodies 
(Red) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica fluorescence 
microscope at 400 times magnification. Scale bars added at the bottom right corner of images. (B) Flow 
cytometry results of b-catenin expression levels in MCF7 cells. Overlay histogram on the left is for 
unstained cells and three densities expression. The bar charts on the right show comparison of percentage 
of b-catenin expressing cells as well as MFI of b-catenin in three densities. (C) The level of b-catenin in 
MCF7 lysates corrected against a-Tubulin internal loading control. Results displayed as bars of mean 
±S.D. This figure is representative of n=3 experiments in triplicate. Statistical analysis was conducted 
and significant differences between samples were indicated by * p-value<0.05, *** p-value<0.01 and 
**** p-value<0.0001. 
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Figure 3-12, b-catenin expression in luminal breast cancer cell line MDA-MB-361 
(A) immunofluorescence representative images of b-catenin expression in MDA-MB-361 cell line seeded 
at three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary 
antibodies (Red) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica 
fluorescence microscope at 400 times magnification. Scale bars added at the bottom right corner of 
images. (B) Flow cytometry results of b-catenin expression levels in MDA-MB-361 cells. Overlay 
histogram on the left is for unstained cells and three densities expression. The bar charts on the right 
show comparison of percentage of b-catenin expressing cells as well as MFI of b-catenin in three 
densities. (C) The level of b-catenin in MDA-MB-361 lysates corrected against a-Tubulin internal 
loading control. Results displayed as bars of mean ±S.D. This figure is representative of n=3 experiments 
in triplicate. Statistical analysis was conducted and significant differences between samples were 
indicated by * p-value<0.05, *** p-value<0.01 and **** p-value<0.0001. 
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Vimentin is a mesenchymal marker that is increased in epithelial cells 
undergoing EMT, see section 1.3.1.2. Vimentin protein expression was observable in 
the cytoplasm at all densities of MCF10A, MCF7 and MDA-MB-361. A notable 
increase was observed in the expression of the protein in the detaching cells at the 
border of colonies of MCF10A at medium density which increased further at the low 
density (Figure 3-13-A). There was an increase in nuclear localisation of vimentin in 
MCF7 and MCF10A at low density compared to other densities (Figure 3-14-B and 
Figure 3-15-A). 
The percentage of vimentin expressing cells was increased with reducing 
density in MCF10A and MDA-MB-361 but not in MCF7. The difference was highly 
significant between all comparisons in MCF10A and MDA-MB-361 (p < 0.0001) 
(Figure 3-13-B and Figure 3-15-B). The MFI showed a similar trend with increased 
vimentin expression in MCF10A and MDA-MB-361 cells with decreased density 
(Figure 3-13-B and Figure 3-15-B). Conversely, MCF7 showed decrease in vimentin 
with reduction in density (Figure 3-14-B). In the MCF10A cell line, the MFI showed 
strong statistical difference in all comparisons (p-value<0.0001) (Figure 3-13-B). In the 
luminal cell line MCF7, the MFI difference was highly significant in all comparisons 
(p-value<0.0001) (Figure 3-14-B) with a drop in the medium and an increase at low 
density. A subpopulation of MCF10A cells showed greater expression of vimentin, the 
percentage of these cells increased in the low density compared to high and medium as 
observed in the overlapped histogram (Figure 3-13-B). In MDA-MB-361 cells, there 
was a small proportion of cells displaying a lack of vimentin expression which 
increased in the medium density as seen in the overlay histogram (Figure 3-15-B). 
The relative expression of vimentin protein increased with decreasing density in 
the MCF10A and MDA-MB-361 cell lines (Figure 3-13-C and Figure 3-15-C). In 
MCF10A, there was a significant difference between high and low as well as between 
medium and low density (p-value<0.0001) (Figure 3-13-C). The relative level of 
expression was decreased with density in MCF7 (Figure 3-14-C). In conclusion, the 
vimentin protein increased strongly in MCF10A at the low density but did not change 
significantly in MCF7 and MDA-MB-361.  
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Figure 3-13, Vimentin expression in normal-like breast cancer cell line MCF10A 
(A) immunofluorescence representative images of vimentin expression in MCF10A cell line seeded at 
three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary 
antibodies (light teal) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica 
fluorescence microscope under 400 times magnification. Scale bars added at the bottom right corner of 
images. (B) Flow cytometry results of vimentin expression levels in MCF10A cells. Overlay histogram 
on the left is for unstained cells and three densities expression. The bar charts on the right show 
comparison of percentage of vimentin expressing cells as well as MFI of vimentin in three densities. (C) 
The level of vimentin in MCF10A lysates corrected against a-Tubulin internal loading control. Results 
displayed as bars of mean ±S.D. This figure is representative of n=3 experiments in triplicate. Statistical 
analysis was conducted and significant differences between samples were indicated by * p-value<0.05, 
*** p-value<0.01 and **** p-value<0.0001. 
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Figure 3-14, Vimentin expression in luminal breast cancer cell line MCF7 
(A) immunofluorescence representative images of vimentin expression in MCF7 cell line seeded at three 
seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary antibodies 
(light teal) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica fluorescence 
microscope under 400 times magnification. Scale bars added at the bottom right corner of images. (B) 
Flow cytometry results of vimentin expression levels in MCF7 cells. Overlay histogram on the left is for 
unstained cells and three densities expression. The bar charts on the right show comparison of percentage 
of vimentin expressing cells as well as MFI of vimentin in three densities. (C) The level of vimentin in 
MCF7 lysates corrected against a-Tubulin internal loading control. Results displayed as bars of mean 
±S.D. This figure is representative of n=3 experiments in triplicate. Statistical analysis was conducted 
and significant differences between samples were indicated by * p-value<0.05, *** p-value<0.01 and 
**** p-value<0.0001. 
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Figure 3-15, Vimentin expression luminal breast cancer cell line MDA-MB-361 
(A) immunofluorescence representative images of vimentin expression in MDA-MB-361 cell line seeded 
at three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary 
antibodies (light teal) and the nucleus were stained with DAPI (Blue). Images were obtained using Leica 
fluorescence microscope under 400 times magnification. Scale bars added at the bottom right corner of 
images. (B) Flow cytometry results of vimentin expression levels in MDA-MB-361 cells. Overlay 
histogram on the left is for unstained cells and three densities expression. The bar charts on the right 
show comparison of percentage of vimentin expressing cells as well as MFI of vimentin in three 
densities. (C) The level of vimentin in MDA-MB-361 lysates corrected against a-Tubulin internal 
loading control. Results displayed as bars of mean ±S.D. This figure is representative of n=3 experiments 
in triplicate. Statistical analysis was conducted and significant differences between samples were 
indicated by * p-value<0.05, *** p-value<0.01 and **** p-value<0.0001. 
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In comparing the expression pattern and level of the three markers (E-cadherin, 
b-catenin and vimentin) in the three cell lines (MCF10A, MCF7 and MDA-MB-361) 
we can conclude that there was a reduction in the localisation of both E-cadherin and b-
catenin at the cell-cell borders. At the same time, the level of both E-cadherin and b-
catenin decreased with seeding density. Only MCF10A showed a strong increase in 
vimentin with decreasing in density, suggesting increased EMT in the basal cell line 
MCF10A compared to the luminal breast cancer cell lines MCF7 and MDA-MB-361. 
Further analysis and expression of other EMT markers is, however, needed to confirm 
this finding.  
3.2.2.2 The triple-negative cell line MDA-MB-453 showed increased of epithelial 
marker expression with decrease in density 
The triple negative breast cancer cell line MDA-MB-453 was seeded at the three 
selected densities and expression of the proteins (E-cadherin, b-catenin and vimentin) 
were compared using either western blotting (see section 2.2) or flow cytometry (see 
section 2.4 and changes in the localisation of these proteins were observed using ICF 
(see section 2.3).  
E-cadherin localisation in the triple-negative cell line (MDA-MB-453) was 
entirely cytoplasmic and decreased with density (Figure 3-16-A). 
The percentage of positive cells and MFI of E-cadherin expressing MDA-MB-
453 cells showed an increase with reduction in density by flow cytometry. In the MDA-
MB-453 cell line, the percentage of E-cadherin positive cells showed high statistical 
significance when comparing the high and medium or the high and low densities (p-
value<0.0001), and there was a significant difference between the medium and low 
density (p-value<0.01) (Figure 3-16-B). Also, the MFI of MDA-MB-453 positive cells 
showed a significant increase at medium density (p-value<0.0001) and then a 
significant decrease at lower density (p-value<0.0001) (Figure 3-17-B). E-cadherin 
expression increased with decreasing density.  
The expression of E-cadherin in MDA-MB-453 was significant between high 
and low density (p-value<0.05) (Figure 3-17-C). Altogether, the epithelial marker (E-
cadherin) expression was low in the MDA-MB-453 cell line and the level of expression 
showed inverse correlation to density with cytoplasmic localisation. 
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Figure 3-16, E-Cadherin expression in TNBC cell line MDA-MB-453 
(A) immunofluorescence representative images of E-cadherin expression in MDA-MB-453 cell line 
seeded at three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) 
secondary antibodies (Green) and the nuclei were stained with DAPI (Blue). Images were obtained using 
Leica fluorescence microscope under 400 times magnification. Scale bars added at the bottom right 
corner of images. (B) Flow cytometry results of E-cadherin expression levels in MDA-MB-453 cells. 
Overlay histogram on the left is for unstained cells and three densities expression. The bar charts on the 
right show comparison of percentage of E-cadherin expressing cells as well as MFI of E-cadherin in three 
densities. (C) The level of E-cadherin in MDA-MB-453 lysates corrected against a-Tubulin internal 
loading control. Results displayed as bars of mean ±S.D. This figure is representative of n=3 experiments 
in triplicate. Statistical analysis was conducted and significant differences between samples were 
indicated by * p-value<0.05, *** p-value<0.01 and **** p-value<0.0001. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
96 
 
  
The expression of b-catenin protein in MDA-MB-453 cells was cytoplasmic. 
The expression of b-catenin protein was very low and was observed to be mostly in 
cytoplasmic and cell-cell location (Figure 3-17-A). The increase in b-catenin protein 
expression with decreasing in density in MDA-MB-453 was also associated with 
cytoplasmic localisation of the protein. The expression of vimentin was cytoplasmic in 
MDA-MB-453 cells and there was no change in the localisation of the protein with 
changes in density (Figure 3-18-A). 
The percentage of b-catenin positive expressing cells and MFI in MDA-MB-
453 increased with decreased density. In the MDA-MB-453 cell line, the percentage of 
positive b-catenin cells showed a highly significant difference between high and 
medium and high and low density (p-value<0.0001) (Figure 3-17-B). The percentage of 
vimentin expressing cells and the MFI in MDA-MB-453 cells showed an inverse 
correlation with cellular density. There was a significant difference seen in all 
comparisons of percentage of expressing cells and the MFI against seeding density in 
MDA-MB-453 cells (p-value<0.0001) (Figure 3-18-B). 
The relative expression of b-catenin protein in the MDA-MB-453 cell line was 
very low in high density and increased with decreasing density (Figure 3-17-C). The 
difference in expression of the protein was significant between high and low density of 
MDA-MB-453 cells (p-value<0.01) (Figure 3-18-C). Though significant, this increase 
in expression was not substantial. Taken together, MDA-MB-453 had a relatively low 
expression level of E-cadherin, b-catenin and vimentin.  
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Figure 3-17, b-catenin expression in TNBC cell line MDA-MB-453 
(A) immunofluorescence representative images of b-catenin expression in MDA-MB-453 cell line seeded 
at three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary 
antibodies (Red) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica 
fluorescence microscope under 400 times magnification. Scale bars added at the bottom right corner of 
images. (B) Flow cytometry results of b-catenin expression levels in MDA-MB-453 cells. Overlay 
histogram on the left is for unstained cells and three densities expression. The bar charts on the right 
show comparison of percentage of b-catenin expressing cells as well as MFI of b-catenin in three 
densities. (C) The level of b-catenin in MDA-MB-453 lysates corrected against a-Tubulin internal 
loading control Results displayed as bars of mean ±S.D. This figure is representative of n=3 experiments 
in triplicate. Statistical analysis was conducted and significant differences between samples were 
indicated by * p-value<0.05, *** p-value<0.01 and **** p-value<0.0001. 
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Figure 3-18, Vimentin expression in TNBC cell line MDA-MB-453 
(A) immunofluorescence representative images of vimentin expression in MDA-MB-453 cell line seeded 
at three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary 
antibodies (light teal) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica 
fluorescence microscope under 400 times magnification. Scale bars added at the bottom right corner of 
images. (B) Flow cytometry results of vimentin expression levels in MDA-MB-453 cells. Overlay 
histogram on the left is for unstained cells and three densities expression. The bar charts on the right 
show comparison of percentage of vimentin expressing cells as well as MFI of vimentin in three 
densities. (C) The level of vimentin in MDA-MB-453 lysates corrected against a-Tubulin internal 
loading control. Results displayed as bars of mean ±S.D. This figure is representative of n=3 experiments 
in triplicate. Statistical analysis was conducted and significant differences between samples were 
indicated by * p-value<0.05, *** p-value<0.01 and **** p-value<0.0001. 
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3.2.2.3  The basal-cell lines BT20 and MDA-MB-231 showed an increase in 
epithelial marker E-cadherin at the medium density 
The triple negative and basal-like breast cancer cell lines BT20 and MDA-MB-
231 were seeded at the three selected densities and expression of the proteins (E-
cadherin, b-catenin and vimentin) were compared using either western blotting (see 
section 2.2) or flow cytometry (see section 2.4 and changes in the localisation of these 
proteins were observed using ICF (see section 2.3).  
Cytoplasmic localisation of E-cadherin was seen in the ICF images of the triple-
negative and basal-like breast cancer cell lines (BT20 and MDA-MB-231). The BT20 
cell line showed b-catenin localisation at cell-cell borders. The cytoplasmic localisation 
increased with decreasing density in both cell lines (Figure 3-19-A and Figure 3-20-A). 
The percentage positive and MFI of E-cadherin-expressing cells did not change 
significantly in the BT20 cell line (Figure 3-19-B). In the MDA-MB-231 cell line, the 
percentage of positively expressing cells and MFI increased in the medium density 
followed by sharp decrease at the low density. There was a significant difference 
between high and medium, high and low, and medium and low of MDA-MB-231 cell 
line (p-value<0.0001) (Figure 3-20-B). Also, the MFI of MDA-MB-231 showed a 
significant increase at the medium density (p-value<0.0001) and then a significant 
decrease at lower density (p-value<0.0001) (Figure 3-20-B). In MDA-MB-231 at 
medium density, there were two populations with different levels of E-cadherin 
expression as seen in the overlay histogram (Figure 3-20-B). 
The relative expression of E-cadherin protein dropped from the medium to low 
density with significant difference in BT20 cells (p-value<0.05) and in MDA-MB-231 
cell (p-value<0.001) (Figure 3-19-C and Figure 3-20-C). 
In summary, MDA-MB-453 cells showed the same trend of increasing 
expression in the medium density with drop in the low density. The E-cadherin 
expression was cytoplasmic in MDA-MB-231 and there was an increase in cytoplasmic 
E-cadherin in BT20. The localisation of E-cadherin in the cell-cell contact area of BT20 
can indicate stronger cell-cell contact and suggesting increase in epithelial 
morphological change in the medium density of BT20 cell line. In MDA-MB-231, the 
increase in E-cadherin expression was not associated with increase in localisation in the 
cell-cell border, therefore, there was no increase in epithelial phenotype. 
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Figure 3-19, E-Cadherin expression in triple-negative and basal-like breast cancer 
cell line BT20 
(A) immunofluorescence representative images of E-cadherin expression in BT20 cell line seeded at 
three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary 
antibodies (Green) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica 
fluorescence microscope under 400 times magnification. Scale bars added at the bottom right corner of 
images. (B) Flow cytometry results of E-cadherin expression levels in BT20 cells. Overlay histogram on 
the left is for unstained cells and three densities expression. The bar charts on the right show comparison 
of percentage of E-cadherin expressing cells as well as MFI of E-cadherin in three densities. (C) The 
level of E-cadherin in BT20 lysates corrected against a-Tubulin internal loading control. Results 
displayed as bars of mean ±S.D. This figure is representative of n=3 experiments in triplicate. Statistical 
analysis was conducted and significant differences between samples were indicated by * p-value<0.05, 
*** p-value<0.01 and **** p-value<0.0001. 
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Figure 3-20, E-Cadherin expression in triple-negative and basal-like cell line 
MDA-MB-231 
(A) immunofluorescence representative images of E-cadherin expression in MDA-MB-231 cell line 
seeded at three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) 
secondary antibodies (Green) and the nuclei were stained with DAPI (Blue). Images were obtained using 
Leica fluorescence microscope under 400 times magnification. Scale bars added at the bottom right 
corner of images. (B) Flow cytometry results of E-cadherin expression levels in MDA-MB-231 cells. 
Overlay histogram on the left is for unstained cells and three densities expression. The bar charts on the 
right show comparison of percentage of E-cadherin expressing cells as well as MFI of E-cadherin in three 
densities. (C) The level of E-cadherin in MDA-MB-231 lysates corrected against a-Tubulin internal 
loading control. Results displayed as bars of mean ±S.D. This figure is representative of n=3 experiments 
in triplicate. Statistical analysis was conducted and significant differences between samples were 
indicated by * p-value<0.05, *** p-value<0.01 and **** p-value<0.0001. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
102 
 
  
The localisation of b-catenin protein was strong in the area of cell-cell contact 
of the BT20 cell line especially at the medium density (Figure 3-21-A). The expression 
of b-catenin in MDA-MB-231 cells was nuclear and cytoplasmic in both high and 
medium density with increase at cell-cell contacts in the low density (Figure 3-22-A). 
The percentage of positive b-catenin cells was reduced with decreasing density 
in both BT20 and MDA-MB-231. There was a highly significant difference between 
high and medium, high and low, and medium and low densities of BT20 (p-
value<0.0001) (Figure 3-21-B). Similarly, b-catenin expression showed significant 
difference between the high and low and medium and low densities of the MDA-MB-
231 cell line (Figure 3-22-B). In BT20, the MFI also reduced with the decrease in 
density, showing a significant difference between high and medium (p-value<0.001) 
and also between high and low densities (p-value<0.0001) (Figure 3-21-B). MFI of b-
catenin in the MDA-MB-231 cell line was significantly increased from high to medium 
density (p-value<0.01) and then declined with reduced density, showing a significant 
difference (p-value<0.001) (Figure 3-22-B). A small proportion of BT20 and MDA-
MB-231 cells were negative for b-catenin. The percentage of these cells decreased from 
the highest to the lowest density as seen in the overlay histogram (Figure 3-21-B and 
Figure 3-22-B). 
In BT20, the relative expression of b-catenin protein was significantly increased 
between high and medium density (p-value<0.01) and between high and low density (p-
value<0.05) (Figure 3-21-C). In MDA-MB-231 cells, the relative expression of b-
catenin protein was very weak and declined with decreasing density. There was no 
significant difference between all comparisons in the MDA-MB-231 cell line (Figure 
3-22-C). 
In summary, the expression of b-catenin protein in the BT20 cell line increased 
with density reduction. In ICF images of BT20 cells, the localisation of the protein was 
strong in the cell-cell contact area. In MDA-MB-231, the expression of b-catenin 
protein decreased with reducing density without any statistical significance. Strong 
cytoplasmic and nuclear localisation of the protein was observed in both cell lines in the 
medium and low densities. 
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Figure 3-21, b-catenin expression in triple-negative and basal-like breast cancer 
cell line BT20 
(A) immunofluorescence representative images of b-catenin expression in BT20 cell line seeded at three 
seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary antibodies 
(Red) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica fluorescence 
microscope under 400 times magnification. Scale bars added at the bottom right corner of images. (B) 
Flow cytometry results of b-catenin expression levels in BT20 cells. Overlay histogram on the left is for 
unstained cells and three densities expression. The bar charts on the right show comparison of percentage 
of b-catenin expressing cells as well as MFI of b-catenin in three densities. (C) The level of b-catenin in 
BT20 lysates corrected against a-Tubulin internal loading control. Results displayed as bars of mean 
±S.D. This figure is representative of n=3 experiments in triplicate. Statistical analysis was conducted 
and significant differences between samples were indicated by * p-value<0.05, *** p-value<0.01 and 
**** p<0.0001. 
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Figure 3-22, b-catenin expression in triple-negative and basal-like cell line MDA-
MB-231 
(A) immunofluorescence representative images of b-catenin expression in MDA-MB-231 cell line seeded 
at three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary 
antibodies (Red) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica 
fluorescence microscope under 400 times magnification. Scale bars added at the bottom right corner of 
images. (B) Flow cytometry results of b-catenin expression levels in MDA-MB-231 cells. Overlay 
histogram on the left is for unstained cells and three densities expression. The bar charts on the right 
show comparison of percentage of b-catenin expressing cells as well as MFI of b-catenin in three 
densities. (C) The level of b-catenin in MDA-MB-231 lysates corrected against a-Tubulin internal 
loading control. Results displayed as bars of mean S.D. This figure is representative of n=3 experiments 
in triplicate. Statistical analysis was conducted and significant differences between samples were 
indicated by * p-value<0.05, *** p-value0.01 and **** p-value<0.0001. 
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The expression of vimentin was very strong in ICF images of the basal-like and 
triple-negative cell lines BT20 and MDA-MB-231 (Figure 3-23-A and Figure 3-24-A). 
The MDA-MB-231 cells showed the highest expression of vimentin among all the 
breast cancer cell lines used, and it was therefore utilised as positive control. 
Both the percentage of positive cells and the MFI of vimentin expressing cells 
increased as density reduced with the exception of the MFI for MDA-MB-231 at low 
density, that showed drop in expression of the protein. In BT20 cells, there was a highly 
significant difference of both the percentage and MFI compared to density seen 
between high and medium, high and low, and medium and low (p-value<0.0001) 
(Figure 3-23-B). In MDA-MB-231, the difference in the percentage of vimentin 
expressing cells was significant between high and medium (p-value<0.01) and also 
between high and low (p-value<0.001) (Figure 3-24-B). Also, MFI showed a significant 
difference between high and medium, high and low, and medium and low (p-
value<0.0001) (Figure 3-24-B). 
The relative expression of vimentin also increased as density decreased, with the 
exception of the low density of MDA-MB-231, at which they showed a decreased 
expression. In BT20 cells, the difference was significant between high and low, and 
medium and low densities (Figure 3-23-C). In MDA-MB-231 cells, the difference was 
also significant between high and low (p-value<0.01) and medium and low density (p-
value<0.0001) (Figure 3-24-C). 
Taking the expression of E-cadherin, b-catenin and vimentin expression in 
BT20 and MDA-MB-231 cell into account, it can be suggested that these cells 
maintained in an intermediate phase of EMT.  
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Figure 3-23, Vimentin expression in triple-negative and basal-like breast cancer 
cell line BT20 
(A) immunofluorescence representative images of vimentin expression in BT20 cell line seeded at three 
seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary antibodies 
(light teal) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica fluorescence 
microscope under 400 times magnification. Scale bars added at the bottom right corner of images. (B) 
Flow cytometry results of vimentin expression levels in BT20 cells. Overlay histogram on the left is for 
unstained cells and three densities expression. The bar charts on the right show comparison of percentage 
of vimentin expressing cells as well as MFI of vimentin in three densities. (C) The level of vimentin in 
BT20 lysates corrected against a-Tubulin internal loading control. Results displayed as bars of mean 
±S.D. This figure is representative of n=3 experiments in triplicate. Statistical analysis was conducted 
and significant differences between samples were indicated by * p-value<0.05, *** p-value<0.01 and 
**** p-value<0.0001. 
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Figure 3-24, Vimentin expression in triple-negative and basal-like cell line MDA-
MB-231 
(A) immunofluorescence representative images of vimentin expression in MDA-MB-231 cell line seeded 
at three seeding densities (high, medium, and low) labelled with Alexa Fluor® (488 or 594) secondary 
antibodies (light teal) and the nuclei were stained with DAPI (Blue). Images were obtained using Leica 
fluorescence microscope under 400 times magnification. Scale bars added at the bottom right corner of 
images. (B) Flow cytometry results of vimentin expression levels in MDA-MB-231 cells. Overlay 
histogram on the left is for unstained cells and three densities expression. The bar charts on the right 
show comparison of percentage of vimentin expressing cells as well as MFI of vimentin in three 
densities. (C) The level of vimentin in MDA-MB-231 lysates corrected against a-Tubulin internal 
loading control. Results displayed as bars of mean ±S.D. This figure is representative of n=3 experiments 
in triplicate. Statistical analysis was conducted and significant differences between samples were 
indicated by * p-value<0.05, *** p-value<0.01 and **** p-value<0.0001. 
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3.2.2.4 Summary of the status of the expression and localisation of EMT markers in 
breast cancer cell lines 
The table below (Table 3-3) summarises the changes in E-cadherin, b-catenin 
and vimentin in response a reduction in seeding density. Of all the cell lines MDA-MB-
361, BT20, MCF7 and MCF10A cell lines had the strongest expression of E-cadherin. 
It can be concluded in general that both the expression of E-cadherin and the change in 
the expression in response to reduction of the seeding density did not depend on the 
subclassification of the breast cancer cell lines. 
As seen in the summary of the E-cadherin expression levels in the cell lines, 
three patterns of protein level changes can be seen. The three cell lines (MCF10A, 
MCF7, and MDA-MB-361) have high expression of E-cadherin and showed a similar 
pattern of reduction of the protein as seeding density reduced. MDA-MB-453 had very 
low expression of E-cadherin that increased with density reduction. Lastly, in the two 
basal-like and TNBC cell lines (BT20 and MDA-MB-231) E-cadherin protein 
expression increased slightly at the medium density and then reduced in the low 
density. 
The expression of b-catenin protein was higher in MCF10A, MDA-MB-361, 
BT20, MDA-MB-231 and MCF7 cell lines compared to the rest of the cell lines. The 
TNBC cell line (MDA-MB-453) had the lowest expression of b-catenin. The 
expression of b-catenin protein decreased with density reduction in MCF7, MDA-MB-
361, MDA-MB-231, and MCF10A. On the other hand, the expression level increased 
with seeding density in MDA-MB-453, and BT20 cell lines (Table 3-3). 
The basal-like and triple-negative cell line (MDA-MB-231) had the strongest 
expression level of vimentin compared to all other cell lines. This protein increases in 
cells that undergo EMT, therefore, the increase of this marker can be suggestive of a 
more mesenchymal phenotype. The cell lines that showed an increase in this protein 
with reduction in density were MCF10A, BT20 (basal-like and triple-negative) and 
MDA-MB-453 (triple-negative). The expression of vimentin increased in the medium 
density of MDA-MB-231 and then decreased in the low density. This pattern was 
similar to the expression of vimentin seen in MCF7 and MDA-MB-361. 
From all the data analysed previously and the summary in the table below 
(Table 3-3) it can be suggested that three basal-like and TNBC cell lines (BT20, MDA-
MB-231 and MCF10A) increased mesenchymal morphology with decreases in density. 
This was because they showed a decrease in the epithelial marker E-cadherin and an 
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increase in vimentin expression at the lowest density. Also, both BT20 and MDA-MB-
231 show an intermediate phenotype, seen as maintaining high expression of vimentin 
and E-cadherin in all densities (Table 3-2). The luminal cell lines also showed a 
decrease in the epithelial marker (E-cadherin) and an increase in vimentin with 
reduction in density (Table 3-2). MDA-MB-453 cells showed an increase in the 
epithelial marker (E-cadherin) in response to decreasing density. This corresponded to 
the morphological decrease in spindle-shaped cells and in cellular spreading (Table 
3-2).  
 
Table 3-3: Summary of the changes in the marker’s expression levels with seeding 
density of the breast cancer cell lines. 
This table summarise the markers (E-cadherin, b-catenin, and vimentin) changes (expression level and 
localisation) in high, medium and low density. These changes are represented as a qualitative score (0 to 
3) based on the western blotting and ICF observation. The localisation of the protein was indicated as (N 
= Nuclear, C = Cytoplasmic, and M = membrane).  
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MCF7 3 M/C 2 M/1C 2 M/2C 2 M 2 1C/N 2 2C/N 2 2 1 
MDA-MB-361 3 M/C 2 M/0C 2 M/1C 3 M/C 2 M/C 2 M/C 2 2 2 
MDA-MB-453 0 C 1 C 2 C 0 C/N 0 C/N 1 C/N 1 2 0 
BT20 3 M 3 M/C 2 M/C 1 M/C/
N 
3 1C/1N 3 1C/1N 1 1 3 
MDA-MB-231 0 C 1 1C 0 2C 2 2C/N 1 1C/1N 1 C/N 3 3 2 
MCF10A 2 M/C 2 M/1C 1 M/2C 3 M/C 2 M/1C/1
N 
2 M/1C 0 0 2 
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3.3 Discussion 
3.3.1 Cell line morphology follows the subclass of breast cancer and changes in 
response to reducing cell density 
The morphology of the breast cancer cell lines showed several changes with 
alteration in the seeding density depending on the cell line (Figure 3-6). The highest 
seeding density depends on several factors including size, spreading, stratification, 
degree of cell-cell contacts and cellular attachment to the culture surface as observed by 
phase contrast microscopy.  
The cell lines with the smallest degree of cellular spreading and highest degree 
of cellular stratification, such as MDA-MB-361, had the highest seeding density 
compared to other cell lines (Figure 3-5). Also, strong cell-cell contacts observed in 
luminal cells (MCF7, and MDA-MB-361) that visually increased with increasing 
density (Figure 3-3). The three basal breast cancer cell lines (MCF10A, BT20 and 
MDA-MB-231) required the fewest cells for the high density (Table 3-1). 
The luminal breast cancer cell lines (MCF7 and MDA-MB-361) and the normal-
like and basal-like breast cancer cell line (MCF10A) had a classical cobblestone 
epithelial phenotype with tight cell-cell junctions (Figure 3-6) which was described by 
Neve et al. (2006) and by Kenny et al. (2007b). The triple negative cell line MDA-MB-
453 had a grape-like morphology with fewer cell-cell contact and showed increased 
cell-cell adhesions with decreasing density (Figure 3-6) which is similar to the 
morphology observed in 3D culture by Kenny et al. (2007b). 
Basal breast cancer cell line morphology showed more prominent changes as 
seeding density decreased. The epithelial morphology of MCF10A was transformed 
slowly to a fibroblastic type , especially at the lowest density, and was associated with a 
reduction in cell adhesion with more gaps formed between cell clusters, especially at 
colony borders (Figure 3-6). This morphological transformation of MCF10A has also 
been reported previously (Sarrio et al., 2008; Chen et al., 2014; Qu et al., 2015). 
MCF10A cells retained a largely epithelial morphology at all densities used in the 
current study with visibly increased of fibroblastic morphology at the lowest density.  
This can be explained by the fact that EGF was removed from the culture medium after 
24 hours of incubation to reduce the effect of EGF on EMT. The EGF growth factor is a 
well-known mediator of EMT in breast cancer (Antonyak et al., 2004; Lo et al., 2007; 
Drasin et al., 2011; Wang et al., 2012; Zanetti et al., 2015) and also other cancer types 
including ovarian (Cheng et al., 2012), cervical (Ha et al., 2013), hepatocellular 
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carcinoma (Ogunwobi et al., 2012), and colorectal cancer (Sakuma et al., 2012). The 
period of incubation of cells without EGF was 24 hours because the average half-life of 
EGF in cells ranges from 8-24 hours (Sorkin and Duex, 2010).  
The BT20 cell line (basal type A) showed fibroblastic morphology with spindle-
shaped cells at the highest density while maintaining cell-cell adhesion. In the medium 
density BT20 cells had mixed morphology, with an increase in epithelial flat cells and 
more cell-cell adhesions (Figure 3-6). A similar observation was reported by Neve et al. 
(2006) where they found that basal cells of type A have a mixed phenotype including 
well differentiated epithelial type seen in luminal cells, as well as displaying a 
mesenchymal or fibroblastic morphology. This mixed morphology was lost at the 
lowest density with predominated mesenchymal phenotype that have increased spindle 
shape and less cell-cell adhesion. The MDA-MB-231 cell line (basal type B) 
demonstrated a strong mesenchymal morphology with spindle-shaped cells with few to 
no cell-cell adhesions (Figure 3-6). Neve et al. (2006) also noted that the basal type B 
cells showed a less differentiated-phenotype with a fibroblastic morphology. It should 
be noted that in all previous studies basal cells were cultured at a single seeding density.  
The low seeding density used for MCF10A (normal-like/basal-like) was 1.3x103 
cells/cm2 and similar to a “sparse” density selected by Liu et al. (2006b). However, the 
“dense” culture for MCF10A used by Liu et al. (2006b) was 2x105 / cm2, which 
exceeded the highest density used here (1x104/cm2 (Table 3-1)), because in this study 
cellular stacking was eliminated.  
These three densities reflected the growth pattern of normal breast cells. First at 
sparse density, loss of cell-cell contacts results in decreased of cell proliferation with 
cellular resistance to anoikis (Liu et al., 2006b; Onder et al., 2008; Kumar et al., 2011). 
The MCF7 cell line was also reported to show a similar reduction in cell growth when 
seeded at low density in 3D culture (Manuel Iglesias et al., 2013). At high density, 
MCF10A cells reduce proliferation due to cell-cell contact inhibition (Liu et al., 
2006b). The MCF10A showed increased proliferation at the intermediate degree of cell-
cell contact (medium density) (Liu et al., 2006b). This increase in growth was 
previously reported in MCF7 cells at an intermediate density, which then decreased in 
dense cultures (Manuel Iglesias et al., 2013). Therefore, there is an intermediate density 
between dense and sparse culture that was reported to show a significant change in the 
proliferation of cells (Liu et al., 2006b; Manuel Iglesias et al., 2013).  
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3.3.2 Luminal (MCF7 and MDA-MB-361) and normal-like breast cancer 
(MCF10A) cell lines showed increased fibroblastic morphology and 
reduced E-cadherin at low density 
The three cell lines (MCF7, MDA-MB-361 and MCF10A) showed an increase 
in spindle morphology, decreasing cell-cell contact, and increasing cellular spreading 
with reduction in seeding density (Table 3-2). The expression of E-cadherin and b-
catenin proteins was reduced and their localisation at sites of cell-cell contact visually 
reduced as density decreased (Figure 3-7, Figure 3-10, Figure 3-8, Figure 3-11, Figure 
3-9 and Figure 3-12). The expression of vimentin increased as density decreased in 
MDA-MB-361 and MCF10A, suggesting an increased mesenchymal transition. 
However, additional analysis and expression of other markers, including EMT 
transcription factors including Slug, Snail and Twist, is recommended in order to 
confirm this conclusion.  
In MCF7, vimentin expression decreased with density reduction. Previous 
studies have reported that the MCF7 cells were less aggressive due to low expression of 
vimentin as seen by Western blotting (Cai et al., 2013; Shan et al., 2015). Zhang et al. 
(2006) examined the effect of changing the confluency of MCF7 cells on gene 
expression, including genes that controlled EMT, but no further analysis were 
conducted under the effect of confluency (Zhang et al., 2006). 
MCF10A is a normal-like cell line with a basal-like molecular signature that 
made these cells more susceptible to mesenchymal morphological change (Jonsson et 
al., 2007). The expression of E-cadherin protein was shown previously to be lower in 
MCF10A compared to the luminal cell lines (MCF7 and MDA-MB-361) (Chen et al., 
2014). Lombaerts et al. (2006) found that E-cadherin expression was lower due to 
promoter methylation in MCF10A cell line, which may explain why the protein was 
less abundant in this cell line compared with MCF7 and MDA-MB-361. 
The localisation of b-catenin protein in MCF7 and MDA-MB-361 cells showed 
the honeycomb pattern that was retained at all densities (Figure 3-11 and Figure 3-12). 
Both cell lines also showed increased cytoplasmic b-catenin localisation with reduction 
in cellular density. A similar pattern was reported previously in MCF7 at a density 
similar to the highest used here (Cai et al., 2013; Ding et al., 2016). Suzuki and 
Takahashi (2006) found that b-catenin protein co-precipitated with E-cadherin in MCF7 
cells, hence, indicating proper interaction between both proteins to form adherens 
junctions. Benhaj et al. (2006) also investigated b-catenin protein localisation in MCF7 
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and found that it depended on the expression of E-cadherin with cells expressing E-
cadherin showing less nuclear localisation of b-catenin, as confirmed by confocal 
microscopy.  
Most studies showed that E-cadherin expression was localised in the membrane 
in high density MCF10A (Sarrio et al., 2008; Sun et al., 2014a; Qu et al., 2015). 
MCF10A showed membrane localised expression of b-catenin as seen in several 
reports, however they all used a single seeding density (Fournier et al., 2008; Zhang et 
al., 2011; Listerman et al., 2014). Fournier et al. (2008) found that b-catenin co-
localises with E-cadherin, seen under fluorescence microscopy in MCF10A at a single 
density. MCF10A also was reported to express b-catenin using Western blotting 
(Fournier et al., 2008; Sun et al., 2014a). Whereas, Sarrio et al. (2008) found that 
seeding MCF10A cells at a sparse density resulted in a reduction of E-cadherin protein 
expression and increased cytoplasmic and nuclear localisation of b-catenin protein 
compared to increased membrane localisation at the confluent density. 
Similar to the findings in the current study, Shan et al. (2015) found that MCF7 
showed weak vimentin expression, which contributed to their low motility. Yan et al. 
(2012) also attempted to assess the expression level of vimentin in MCF7 and found 
that it was not detectable. 
The mesenchymal morphological change of MCF10A at sparse densities was 
reported previously in several studies (Maeda et al., 2005; Liu et al., 2006b; Sarrio et 
al., 2008; Kim et al., 2011; Marro et al., 2014). The basal signature of this cell line 
caused increased expression of vimentin protein, which increases the susceptibility of 
the cells to mesenchymal morphological change (Qu et al., 2015). Qu et al. (2015) 
suggested that MCF10A cells have a basal-like phenotype while expressing luminal 
features, or that they are luminal cells that are undergoing EMT. Reorganisation of 
vimentin filaments was noticed when these cells were seeded at sparse density, but the 
difference in the levels of vimentin expression between confluence and sparse culture 
was not assessed (Sarrio et al., 2008). The expression of additional markers, such as 
Slug, Snail and Twist, is needed to verify that there was an increase in EMT at lower 
seeding densities in MCF10A. 
3.3.3 The MDA-MB-453 cell line showed an increased epithelial phenotype with 
decreasing seeding density 
The effect of reducing cellular density was not previously reported for the MDA-
MB-453 cell line. The expression levels of EMT markers was studied in a single 
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density of this cell line that was selected usually around the medium or high density 
used here (Blick et al., 2008; Zhang et al., 2008). 
E-cadherin protein was not detectable in MDA-MB-453 cell line using Western 
blotting or PCR (Nieman et al., 1999; Lombaerts et al., 2006). However, we showed 
that MDA-MB-453 had an innately low expression of E-cadherin compared to the other 
breast cancer cell lines (Figure 3-16) which concurs with other reports (Junxia et al., 
2010; Yang et al., 2014). The discrepancies in the reports of E-cadherin expression in 
these studies could be explained by the variation in the densities in which these cells 
were cultured. Low levels of E-cadherin in MDA-MB-453 cell line has been shown due 
to hypermethylation of the CDH1 promoter (Mariner et al., 2004; Junxia et al., 2010; 
Yang et al., 2014). Thus, reinforcing the importance of determining and reporting the 
seeding densities in researches and their effect on the expression of EMT related 
proteins.  
MDA-MB-453 expressed very low levels of b-catenin protein compared to the 
other breast cancer cell lines tested (Figure 3-17) which had also been reported in 
previous studies on this cell line (Nieman et al., 1999; Schlosshauer et al., 2000; Kenny 
et al., 2007b; Sun et al., 2014a). This is the first study to report the difference in this 
protein expression in several seeding densities of MDA-MB-453. Schlosshauer et al. 
(2000) concluded that there were no mutations in b-catenin in MDA-MB-453. The 
same study concluded that abnormalities in the function of b-catenin protein in this cell 
lines was not due to genetic mutations (Schlosshauer et al., 2000; Jiang et al., 2009). 
The expression of vimentin in MDA-MB-453 was low similar to previous reports 
(Lombaerts et al., 2006; Tanaka et al., 2016).  
The estimation of expression levels of these proteins (E-cadherin, b-catenin and 
vimentin) were affected by the threshold of detection of the technique used. Also, 
according to the findings of the current research, the density at which the cells are 
cultured may cause variation in the level of protein. 
Two cell lines that had amplification of the ErbB2 gene (MDA-MB-361 and 
MDA-MB-453) and one that overexpresses of the protein (MDA-MB-361). MDA-MB-
453 showed an increased epithelial morphology and increase in E-cadherin with 
reduction of density. Benhaj et al. (2006) examined the nuclear expression of b-catenin 
and found that there was no nuclear expression in MDA-MB-453. Similarly, Kim et al. 
(2010b) found that very week nuclear b-catenin was found in MDA-MB-453. This is 
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similar to the observation of the location of b-catenin in this study, which conclude that 
there was no cross talk between ErbB2 and Wnt/b-catenin pathway in this cell line.  
3.3.4 The triple-negative and basal-like breast cancer cell lines BT20 and MDA-
MB-231 showed an intermediate phenotype on the EMT spectrum  
The triple-negative and basal-like breast cancer cell lines (BT20 and MDA-MB-
231) showed fibroblastic morphology at all densities used (Figure 3-6). There was a 
noticeable morphological switching at the medium density of these cell lines. Both cell 
lines showed increased cell-cell contact with decreased spindle morphology (Figure 
11-2 and Figure 11-3). The epithelial marker E-cadherin was also increased at the 
medium density in both cell lines (Figure 3-19 and Figure 3-20) with strong 
membranous localisation observed in BT20 (Figure 3-19).  
Memmi et al. (2015), reported that the molecular subtype of breast cancer 
indicated the capacity of cells to undergo invasion through EMT activation. The MDA-
MB-231 cell line (basal type B) is hypothesised here to be further down the EMT 
pathway which was also suggested previously by Xie et al. (2014). Additionally, it was 
found in the same study that MCF10A cells (also basal type B) were able to undergo 
EMT but were not able to initiate tumour formation (Xie et al., 2014). This was also 
confirmed by microarray and gene expression profiling. It was also reported that the 
mesenchymal and basal breast cancer cell lines expressed significantly more vimentin 
compared to the luminal cell lines (Charafe-Jauffret et al., 2006; Neve et al., 2006; 
Kumar et al., 2011). Together with the findings here, it can be concluded that the basal-
like breast cancer cell lines showed signs of EMT with reduction in seeding density. 
The expression level of E-cadherin in BT20 has been previously studied using a 
only single seeding density (around that of the “medium density” used in this study) 
and found it to be highly expressed (Nieman et al., 1999; von Schlippe et al., 2000; 
Hajra et al., 2002; Johnson et al., 2004; Sultan et al., 2005; Shirure et al., 2015). E-
cadherin in BT20 localised at cellular adhesion sites as seen by ICF (Figure 3-19) 
which was also reported to show a similar pattern in other studies (Shirure et al., 2015).  
A low expression level of E-cadherin was reported in the MDA-MB-231 cell 
line and was found to be cytoplasmic by ICF (Lombaerts et al., 2006; Zhang et al., 
2008; Yang et al., 2014). Benton et al. (2009) found that the expression of E-cadherin 
in MDA-MB-231 cells was undetectable when they were grown on a plastic tissue 
culture surface. E-cadherin was also not detected by Western blotting or PCR in other 
studies (Nieman et al., 1999; Graff et al., 2000; Mariner et al., 2004; Sun et al., 2014a; 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
116 
 
  
Zhao et al., 2016). Low expression of E-cadherin explains the aggressive nature of this 
cell line in xenograft studies (Iorns et al., 2012; Kil et al., 2014). 
The promoter of CDH1 (E-cadherin) in MDA-MB-231 has been shown to be 
methylated, explaining the low expression (Benton et al., 2009). Shirure et al. (2015) 
showed a functional link between the low expression of E-cadherin and high expression 
of Slug (an E-cadherin repressor) in MDA-MB-231 cell line compared to BT20 cells 
that has high E-cadherin expression. This was also concluded by Hajra et al. (2002), 
who they found that the inhibition of E-cadherin in MDA-MB-231 was caused by 
increased expression of Slug. However, transcription factors of EMT were not assessed 
in the current study and assessing the changes in expression of such proteins in effect of 
seeding density changes will aid in making stronger conclusions in future studies.  
Lombaerts et al. (2006) found that MDA-MB-231 had a partially methylated E-
cadherin promoter, and flow cytometry analysis showed two subpopulations of E-
cadherin expressing cells, one of these two subpopulations showed low expression of E-
cadherin (Lombaerts et al., 2006). Thus, they concluded that the methylation of the 
CDH-1 promoter in this cell line could be partial and reversible (Lombaerts et al., 
2006). The two populations seen in Lombaerts et al. (2006) was similar to the finding in 
the medium density flow cytometry in this study (Figure 3-20).  The small population 
of cells that had lower expression of E-cadherin could represent a population of cells 
that have increased stem cell characteristics, which gave them additional aggressive 
characteristic. Also, it could show the ability to segregate these cells using the seeding 
density model and to identify them in the medium density. However, further analysis 
and experimentation to assess the expression of stem cell markers and other EMT 
transcription factors to make further conclusions.  
b-catenin expression increased with reduction in density in BT20 cells, with 
localisation of the protein increasing at regions of cell-cell contact at the medium 
density (Figure 3-21). Nieman et al. (1999) and Schlosshauer et al. (2000) also found 
that BT20 and MDA-MB-231 cells expressed b-catenin. They concluded that the loss 
of E-cadherin in MDA-MB-231 cells resulted in reduced in expression of several 
catenin types, including b-catenin (Suzuki and Takahashi, 2006). 
Benhaj et al. (2006) examined b-catenin in BT20 and found that they have weak 
nuclear b-catenin expression. Gilles et al. (2003) reported that BT20 express b-catenin 
and E-cadherin but not vimentin. b-catenin was localised to the membranes, forming 
the epithelial phenotypes of the cells. Furthermore, the localisation of b-catenin protein 
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in MDA-MB-231 was variable across many studies. It was found that the expression of 
b-catenin in MDA-MB-231 was both cytoplasmic and nuclear (Gilles et al., 2003). On 
the other hand, Ravindranath et al. (2011) reported that b-catenin expression was both 
membranous and nuclear in MDA-MB-231. Yan et al. (2012) also measured b-catenin 
protein in MDA-MB-231 and found that most of the protein was in the cytoplasmic and 
membranous fraction compared to a low amount in the nuclear fraction. This variation 
in reports on the localisation and level of b-catenin expression in these cell lines may 
have been due to discrepancies in the seeding densities used and tissue culture method.  
The expression of vimentin increased significantly in BT20 at lower density 
compared to higher density (Figure 3-21). The MDA-MB-231 cell line expressed high 
levels of vimentin protein (as seen in Figure 3-24) and this is consistent with previous 
findings. Sommers et al. (1991) assessed the expression of vimentin in breast cancer 
cell lines using Northern blotting and found the MDA-MB-231 had strong vimentin 
expression. High vimentin expression in MDA-MB-231 was also confirmed by Western 
blotting (Cai et al., 2014). Tanaka et al. (2016) found that changes in vimentin 
expression was significantly correlated with changes in b-catenin expression in MDA-
MB-231. The high expression of vimentin in MDA-MB-231 cells was maintained in 
both the high and medium densities (Figure 3-24). Yuki et al. (2014), concluded that 
the expression of vimentin correlated with the mesenchymal or basal phenotype of 
MDA-MB-231 and MCF10A cells.  
The intermediate status of MDA-MB-231 and BT20 was noted previously in 
several studies and was referred to as partial EMT in previous studies (Grigore et al., 
2016; Saitoh, 2018), hybrid EMT (Jolly et al., 2015; Jolly et al., 2016; Vergara et al., 
2016) and transition states (Pastushenko et al., 2018). The intermediate status of basal-
like breast cancer cell lines (BT20 and MDA-MB-231) is a status termed because the 
MDA-MB-231 and BT20 showed increased in epithelial characteristic when were 
seeded in the medium density. Thus, these cells were able to maintain epithelial and 
mesenchymal phenotype. In medium density, the cells showed increase in the 
expression of E-cadherin with reduction in vimentin and b-catenin.  In high and low 
density, MDA-MB-231 and BT20 cells had mesenchymal phenotype with reduction in 
E-cadherin and b-catenin compared to the medium density. The observation of the 
partial EMT in the medium density in BT20 and MDA-MB-231 cell lines has not been 
observed in vitro, until the time of submitting this work. Further confirmation and 
verification of this status is recommended before drawing further conclusions. The cell 
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density model developed here can be utilised for further understanding of the scope and 
regulation of the intermediate status in those cell lines in breast cancer and other 
epithelial cancers. 
3.3.5 The molecular subtype of breast cancer cell lines did not dictate the 
response to stimuli introduced in the cell density in vitro model 
According to the results and analysis of the expression of E-cadherin and 
vimentin proteins at the three densities, it can be seen that the breast cancer cell lines 
changed both in morphology and in the expression of these markers. The strength of the 
response to lowering the cellular density varied between the cell lines. Further 
experimental verification by analysis of expression level of EMT transcription factors 
Snail, Slug and Twist is required to draw stronger conclusions. The response noticed 
with reducing density can be divided into three types; a classical increase in 
mesenchymal morphology with reduction in E-cadherin and increased vimentin, an 
inverted response characterised by an increase in epithelial morphology with a 
reduction in vimentin and increased E-cadherin, and an intermediate status showed 
mixed response to reduction in density.  
MCF7, MDA-MB-361, MDA-MB-453 are luminal cell lines, yet, MDA-MB-453 
did not follow the pattern of response as the two other luminal cell lines. Similarly, 
MDA-MB-361 and MDA-MB-453 are HER2 amplified cell lines, yet MDA-MB-361 
did not show an inverse EMT like that seen when MDA-MB-453 were subjected to 
lower density. Additionally, MCF10A, BT20 and MDA-MB-231 are basal-like breast 
cancer cell lines and only BT20 and MDA-MB-231 showed the intermediate phenotype 
when cultured in the seeding density experiment. Thus, these findings indicate that the 
molecular subtype of breast cancer cell lines did not predict their response to reduction 
of density, and therefore did not affect EMT associated markers and EMT-related 
morphological changes. 
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3.4 Conclusion 
Reduction of cell density was applied in previous breast cancer studies and was 
sufficient to induce phenotypical switch and variation in cellular functions including 
changes in proliferation, marker expression and pathway activation. The seeding 
density model used in this study successfully induced EMT-like response in all of the 
breast cancer cell lines used provides a useful tool to investigate how cell-cell 
interaction can promote EMT-related changes. Furthermore, identifying the medium 
density anomaly was useful in capturing intermediate phenotypical switches that were 
previously only identified in clinical observation. Additionally, the investigation of 
several cell lines that belong a range of different breast cancer subtypes provides an 
insight into how the subclassification of breast cancer may predict a tumour’s ability to 
undergo EMT due to changes in cell-cell interaction, which has not been attempted 
previously using this approach in vitro. It is also concluded from the use of the cell 
density model that the type of response could not be predicted by the subtype of breast 
cancer cell line. 
The morphological changes associated with reduced in density were paralleled to 
changes in epithelial and mesenchymal marker expression (E-cadherin and vimentin). 
Three types of response to reducing density noted using this model. A subset of breast 
cancer cell lines showed mesenchymal-like morphological changes with decrease in 
density. Another group of breast cancer cell lines showed increase in epithelial-like 
phenotype with reduction in cellular density. Lastly, a group of cell lines showed 
intermediate state, where the cells showed mixed morphology in the medium density. 
This model allowed us to identify the cell lines that can undergo an EMT-like 
response. Thus, this model provides a tool to study the regulation of EMT, especially by 
identifying the cell lines that showed the intermediate status in the medium density. 
MCF10A, BT20 and MDA-MB-231 cells were able to undergo stronger EMT-
associated changes due to the mesenchymal molecular signature as seen in previous 
studies.  
These findings confirm the hypothesis that the EMT is, in fact, a spectrum of 
changes, rather than an absolute status transition. However, the initial hypothesis that 
propensity to undergo EMT depends on, or can be predicted by, the subclass of breast 
cancer was incorrect. Although prognosis varies between tumour subtypes, they are all 
capable of generating life-threatening metastasis through this invasive adaption of cell 
phenotype.   
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4. Chapter four: The Expression of the Hedgehog Signalling Pathway 
in Breast Cancer 
4.1 Introduction 
Despite advances in screening, diagnosis and treatment of breast cancer, it 
remains the most common cause of cancer death in Europe for females and the third 
most common cause of cancer death overall (CRUK, 2017). In the UK the five-year 
survival rate of breast cancer at diagnosis drops from 99% at stage I to 15% at stage IV 
(CRUK, 2017). Nearly 30% of females initially diagnosed with early-stage breast 
cancer go on to develop metastatic disease, months or even years after initial diagnosis 
(Redig and McAllister, 2013). 
The current clinical systems for grading, and staging, along with prognostic 
markers used to stratify breast cancer and predict prognosis, fall short in identifying 
patients with a high-risk of recurrence (Redig and McAllister, 2013). The current 
treatment and management strategies for advanced breast cancers include systemic 
chemotherapy, radiation and surgery with a goal to stabilise the disease especially in a 
metastatic setting (Orlando et al., 2007). Thus, there is a clinical need to find reliable 
prognostic markers that could also be utilised for identifying either metastatic or high-
risk cases. These markers could also be utilised as therapeutic targets that aid in 
treatment, or limit cancer invasion and subsequent metastasis. 
Alteration in the components of Hh signalling are detected in 25% of human 
cancers (Moraes et al., 2007). Overexpression of the Hh pathway signalling 
components in vivo and evidence of activation of Hh signalling in breast cancer were 
documented previously in in vitro models (Kubo et al., 2004; O'Toole et al., 2011). In 
studies conducted on clinical samples, overexpression of crucial components of the Hh 
pathway (including Gli1, Ptch1, and Shh) were more highly expressed in invasive 
carcinoma compared to normal breast tissue (Kubo et al., 2004; O'Toole et al., 2011). 
Several studies correlated the overexpression of Hh ligands with poor clinical 
outcomes, increased invasiveness and high-grade tumours in basal-like breast cancer 
(O'Toole et al., 2011; Li et al., 2012; Han et al., 2015). Hh pathway activation 
associated with several clinicopathological parameters including high proliferation 
index, tumour size, invasion, lymph node metastasis, hormone receptor negativity and 
poor overall survival (Xuan and Lin, 2009; O'Toole et al., 2011; Souzaki et al., 2011). 
Im et al. (2013) assessed Gli1, Gli2 and Gli3 in breast cancer by tissue microarray and 
found they correlated with several clinicopathological parameters. Gli2, in particular, 
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was correlated with the worst overall survival (Im et al., 2013). Concurrent activation 
of Hh signalling within specific molecular subtypes of breast cancer and the prognostic 
consequence is not fully understood and was not studied previously. More investigation 
is required to link changes in expression and localisation of Hh signalling proteins 
(Gli1, Gli2, and Gli3) to the molecular subtypes of breast cancer. 
E-cadherin and β-catenin separately (or combined) are used as markers of EMT in 
breast cancers (Onder et al., 2008; Sarrio et al., 2008; Cheng et al., 2012; Liu et al., 
2015). Localisation and distribution of both proteins changed in response to EMT 
stimuli (either changes in densities, or by treatment) in breast cancer cells in vitro 
(Gilles et al., 2003; Sarrio et al., 2008; Yan et al., 2012; Shan et al., 2015). Results 
from the previous section (3.3) showed that there was a difference in EMT regulation as 
a result of variation of density in vitro. Loss of E-cadherin, and loss or changes in the 
localisation of b-catenin, were reported previously in invasive breast cancer (Lin et al., 
2000; King et al., 2012). 
Most previous work investigating EMT in breast cancer assessed the expression 
of E-cadherin and b-catenin in human tissue sections. This was achieved through 
estimation of expression in the sample and correlating this with the clinicopathological 
criteria. Scientists have suggested that the invasive front of tumours is more suitable to 
investigate EMT (Bryne et al., 1998; Christofori, 2006; Busch et al., 2014). Therefore, 
several studies looked at proteins involved in EMT and compared their expression 
between the tumour centre and the invasive front. For example, E-cadherin and b-
catenin changed in expression and intensity at the invasive front in colorectal (Zlobec 
and Lugli, 2009), parathyroid (Fendrich et al., 2009), and oral carcinoma (Wang et al., 
2009). This approach of comparing E-cadherin and b-catenin expression in different 
regions of the tumour has not been previously reported in breast cancer, although this 
approach has shown promising data in other tumour types. 
Concurrent activation of Wnt and Hedgehog (Hh) signalling has been reported in 
several human cancers including colon (Qualtrough et al., 2015), ovarian (Schmid et 
al., 2011), and basal-cell carcinoma (Yang et al., 2008b; Skvara et al., 2011). Arnold et 
al. (2017) found evidence that linked co-activation of Wnt and Hh signalling to poor 
prognosis in TNBC and decreased overall survival. Arnold et al. (2017) assessed 
nuclear localisation of Gli1 and b-catenin in human breast cancer samples. Combined 
analysis of the localisation of b-catenin, as well as Gli1, Gli2, and Gli3 (members of 
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active Wnt and Hh signalling respectively), has not been reported in previous work on 
mammary tumours. 
Assessing E-cadherin expression in parallel with the comparative distribution and 
localisation of b-catenin, Gli1, Gli2, and Gli3 is vital for understanding how crosstalk 
between both Hh and Wnt could influence EMT in breast cancer. Also, assessment of 
expression and localisation of these proteins in the tumour centre compared with the 
invasive front could uncover correlations between changes in localisation, intensity and 
expression with clinicopathological criteria, tumour subtypes, lymph node invasion and 
metastasis. Investigating the variation in subcellular localisation and expression of b-
catenin and the tissue distribution in tumour centre and at invasive front gives an 
indication of EMT activity. The changes in EMT at the invasive front compared to the 
tumour centre mimic the observed disruption in breast cancer cell lines after stimulation 
of EMT by reduction of density. Moreover, estimating the level of E-cadherin 
expression and comparing its expression in the tumour centre and at the invasive front 
and correlating it with the expression of b-catenin protein provides additional insight 
into the regulation of EMT in breast cancer. This approach of investigation has not been 
reported previously and could aid in the identification of invasion and/or metastatic 
properties during breast cancer progression. 
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4.2 Aim 
- Investigate the expression of hedgehog signalling components in tumour centres 
and at invasive fronts to estimate if this pathway is involved in breast cancer 
progression through metastasis regulation. 
4.2.1 Objectives 
• To investigate and quantify the expression hedgehog signalling components 
(Gli1, Gli2 and Gli3) and EMT-associated proteins (E-cadherin, and b-catenin) 
in cohort of breast cancer samples and correlate this with the clinicopathological 
features and tumour subtypes. 
• To assess the expression of Hh signalling components (Sonic hedgehog, Indian 
hedgehog, Patched, Smoothened, Gli1, Gli2, and Gli3) in a panel of breast 
cancer cell lines and to confirm if breast cancer cell lines can be used to further 
understand the regulation of EMT by Hh signalling in breast cancer.  
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4.3 Results 
4.3.1 Validation of Gli1, Gli2, Gli3, b-catenin and E-cadherin antibodies 
To assess if Hedgehog signalling proteins were expressed in breast cancer clinical 
samples, using serial sections of archival breast cancer tissues were sectioned and 
stained with either Gli1, Gli2, Gli3, b-catenin or E-cadherin antibodies (Figure 4-1). 
Secondary-only controls were added to confirm minimal background staining (Figure 
4-1-B). Adjacent skin tissue in sections was used as positive control for Gli1, Gli2 and 
Gli3 staining (Figure 4-2-C, -D, and -E) (Green et al., 1998; Regl et al., 2002). It was 
also used as positive control for b-catenin and E-cadherin antibodies (Figure 4-2-B and 
-C). As seen in Figure 4-2-A, the level of background did not reach the level of staining 
intensity.  
 
 
 
Figure 4-1, Representative IHC images of serial sections stained with the 
antibodies used in the study compared to the negative control.  
Representative images of serial sections from the same case were stained for b-catenin (C), E-cadherin 
(D), Gli1 (E), Gli2 (F) and Gli3 (G) compared against the negative control (B). (¨) used in 100x images 
to point to the location of immune reaction and (•) used to indicate the location of immune reaction in 
400x images. Images captured by Leica microscope the images (B, C, D, E, F and G) to the left were 
captured at 100X magnification. The images (B, C, D, E, F and G) to the right were captured at 400X 
magnification. Scale bars were added to the bottom right corner of images. 
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Figure 4-2, Adjacent skin tissue was used as a positive control for antibodies 
Adjacent skin tissue in patient samples was used as a positive control for b-catenin (B), E-cadherin (C), 
Gli1 (D), Gli2 (E) and Gli3 (F). Negative control (A) showed no background staining. Images were 
captured by Leica microscope at 100X magnification. (¨ and •) used to indicate location of immune 
reaction. Scale bars were added at the bottom right corner of images. 
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4.3.2 Gli1, Gli2 and Gli3 were expressed in breast cancer with both nuclear and 
cytoplasmic distribution  
Scoring of protein expression in sections was conducted following the percentage 
of positive tumour cells and intensity scores as seen in Figure 4-3 for Gli1, Figure 4-4 
for Gli2 and Figure 4-5 for Gli3. 44 out of 48 cases (91%) were positive for Gli1, and 
all cases were positive for Gli2 and Gli3 (100%) as seen in Figure 4-6.  
Gli1 was positive in more than half of the tumour cells in 23 out of 48 cases 
(48%) (Figure 4-7). 18 out of 29 cases (62%) showed more than 50% positivity for Gli2 
(Figure 4-7). 22 out of 23 cases (95%) cases showed more than 50% positive tumour 
cells for Gli3 (Figure 4-7). 
The score of Gli1 staining intensity showed that about 45%, 31% and 14% of 
cases had intense, moderate and mild staining respectively (Figure 4-8). Gli2 staining 
intensity analysis showed that almost 58%, 17% and 20% of cases had intense, 
moderate and mild staining respectively (Figure 4-8). The intensity of Gli3 staining 
showed that approximately 13%, 43% and 43% of cases had intense, moderate and mild 
staining intensity respectively (Figure 4-8). 
The IRS class of Gli1 staining showed that 39 out of 48 cases (81%) were 
positive with mild to strong expression (Figure 4-9). Gli2 IRS class showed that 26 out 
of 29 cases (89%) were positive with either mild or strong expression (Figure 4-9). The 
IRS class of Gli3 showed that 20 out of 23 cases (87%) were positive with mild or 
strong expression (Figure 4-9). 
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Figure 4-3, Representation of percentage of Gli1 positive tumour cells and the 
intensity of immune reaction in breast cancer sections   
Representative sections stained for Gli1 by IHC. Images were captured by Leica microscope in 400x 
magnification. (A) the percentage of Gli1 positive tumour cells. (B) the intensity of the staining. Scale 
bars were added to the bottom right corner of each image. (¨) was used to indicate the area of positivity 
in images.  
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Figure 4-4, Representation of percentage of Gli2 positive tumour cells and the 
intensity of immune reaction in breast cancer sections   
Representative sections stained for Gli2 by IHC. Images were captured by Leica microscope in 400x 
magnification. (A) the percentage of Gli2 positive tumour cells. (B) the intensity of the staining. Scale 
bars were added to the bottom right corner of each image. (¨) was used to indicate area of positivity in 
images. 
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Figure 4-5, Representation of percentage of Gli3 positive tumour cells and the 
intensity of immune reaction in breast cancer sections   
Representative sections stained for Gli3 by IHC. Images were captured by Leica microscope in 400x 
magnification. (A) the percentage of Gli3 positive tumour cells. (B) the intensity of the staining. Scale 
bars were added to the bottom right corner of each image. (¨) was used to indicate area of positivity in 
images. 
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Figure 4-6, Gli1, Gli2 and Gli3 are expressed in breast cancer samples 
Bar chart presenting the percentage of (positive or negative) breast cancer samples from total cases. The 
table below presents the numbers of (positive or negative) samples and the corresponding percentage of 
expression from total cases. 
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Figure 4-7, Percentage of Gli1, Gli2 and Gli3 positive expressing cells in breast 
cancer samples 
Bar chart presenting the percentage of (0, <10, 10-50, 51-80 and >80) breast cancer samples from total 
cases. The table below presents the numbers of (0. <10, 10-50, 51-80 and >80) samples and the 
corresponding percentage of expression from total cases. 
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Figure 4-8, The intensity of Gli1, Gli2 and Gli3 staining in breast cancer samples 
Bars chart of presenting the percentage of cases which show is showing (no staining, mild, moderate, and 
intense) of Gli1, Gli2 and Gli3 from total breast cancer samples. Table below shows the numbers of 
(positive or negative) breast cancer samples and the corresponding percentage from total cases. 
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Figure 4-9, IRS classes of Gli1, Gli2 and Gli3 staining in breast cancer samples 
Bars chart of presenting the percentage of cases which show (negative, positive with weak expression, 
positive with mild expression and positive with strong expression) of Gli1, Gli2 and Gli3 from total 
breast cancer samples. Table below shows the numbers of (negative, positive with weak expression, 
positive with mild expression and positive with strong expression) breast cancer samples and the 
corresponding percentage from total cases. 
 
A mixture of both cytoplasmic only, nuclear only or both cytoplasmic and 
nuclear staining was detected for Gli1, Gli2 and Gli3 in the breast cancer tissue (Figure 
4-10). The immunoreactivity was often diffuse and sometimes showed low intensity 
especially in the case of Gli3. Final sample number of cases assessed for Gli1, Gli2 and 
Gli3 were 48, 29 and 23, respectively. The clinicopathological criteria of the cases are 
summarised in Table 11-1. 
31 out of 48 (64.6%) cases showed nuclear localisation of Gli1, 29 cases (100%) 
showed nuclear localisation of Gli2 and 20 out of 23 cases (87%) showed nuclear 
localisation of Gli3 (Figure 4-11). 
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Figure 4-10, Cellular distribution of Gli proteins in representative sections 
containing breast cancer tissue 
Representative sections stained for either Gli2, Gli2 or Gli3. Sections were selected to highlight the 
distribution pattern of Gli proteins in breast tissue. (A) section showing cytoplasmic distribution, (B) 
section showing nuclear distribution and (C) section showing both nuclear and cytoplasmic distribution. 
All images were captured by Leica microscope at 600x 
 
 
 
Figure 4-11, Nuclear localisation of Gli1, Gli2 and Gli3 in breast cancer samples 
Bars chart of presenting the percentage of cases which shows (positive or negative) localisation of Gli1, 
Gli2 and Gli3 from total breast cancer samples. Table below shows the numbers of (positive or negative) 
breast cancer samples and the corresponding percentage from total cases. 
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4.3.3 Increased Gli expression was observed at the invasive front of breast cancer 
samples 
To evaluate the correlation between hedgehog signalling and breast cancer 
metastasis, the expression of Gli1, Gli2 and Gli3 were assessed both within the tumour 
centres and also at the invasive fronts. Pearson chi-square statistical analysis were 
conducted to compare the difference in percentage, intensity or IRS class staining of 
Gli1, Gli2 and Gli3 in tumour centre and at invasive front. Kendell’s tau B test was 
used to assess for correlation between the Gli1, Gli2 and Gli3 percentage, intensity or 
IRS class of staining in tumour centre and at invasive front.  
The percentage of positive tumour cells for Gli1 and Gli2 was significantly 
higher at the invasive front compared to the tumour centre (p-value= 0.0001 and p-
value= 0.0001, respectively) (Table 4-1-A and  
 
 
 
 
 
 
 
 
Table 4-2-A). Intensity and IRS scores of Gli1 and Gli2 staining were both higher 
at the invasive front compared with the tumour centre (p-value= 0.0001 and p-
value= 0.0001, respectively) (Table 4-1-B and C,  
 
 
 
 
 
 
 
 
Table 4-2-B and D). There was no significant difference between the 
percentage, intensity and IRS class of Gli3 in the tumour centre and at the invasive 
front (Table 4-3-A, -B and -C).  
There was significant correlation between the percentages, intensities and IRS 
classes of Gli1, Gli2 and Gli3 in tumour centres and invasive fronts. this indicate that as 
the percentage, intensity or IRS class of Gli1, Gli2 and Gli3 increases in the tumour 
centre, it correspondingly increases at the invasive front of the same case. The 
percentage, intensity and IRS class of Gli1 in tumour centre were significantly 
correlated (p-value=0.0001 in all) with those at invasive front (Table 4-1-A, -B and -C, 
Figure 4-12-A, and -B, and Figure 4-13-A, -B and -C) with the highest correlation seen 
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between the IRS class followed by the intensity. The percentage, intensity and IRS class 
of Gli2 staining in tumour centre were significantly correlated (p-value=0.0001 in all) 
with that at invasive front. Similar to Gli1, Gli2 the IRS class had the highest 
correlation followed by intensity (0.683 and 0.656 respectively) (Table 4-2-A, -B and -
C, Figure 4-14-A and -B, and Figure 4-15-A, -B and -C). Gli3 staining percentage, 
intensity and IRS class in tumour centre and invasive front were significantly correlated 
(p-value=0.034, p-value=0.007 and p-value=0.036 respectively). The highest 
correlation of Gli3 was seen in comparing intensity and IRS class (0.603 and 0.481 
correlation coefficient respectively) in tumour centre and at invasive front.  
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Figure 4-12, Gli1 expression was higher in invasive fronts of breast cancer samples   
Representative IHC images of the same breast cancer sample showing higher Gli1 levels in the invasive 
front (B) compared to the tumour centre (A). Images were captured using three different magnifications 
(100X, 200X and 400X) by the Leica microscope. (¨) was used to indicate area of positivity in images. 
 
 
 
 
 
 
Table 4-1: Percentage of positive tumour cells, staining intensity and IRS class of 
Gli1 showed significant difference between tumour centre and invasive front 
Tumour centre and invasive front frequency tables (A) for percentage of positive tumour cells, (B) 
intensity of staining, and (C) IRS class. Pearson Chi-square test was used to estimate the difference 
between tumour centre and invasive front. The Kendall’s Tau B correlation coefficient (between -1 and 
+1) was used to assess for degree of correlation between tumour centre and invasive front. The statistical 
significance of the correlation is indicated as follows: *P= <0.05, **P= <0.01. 
 
A Tumour centre Invasive front No. (%) No. (%) 
Pe
rc
en
ta
ge
 o
f 
po
sit
iv
e 
tu
m
ou
r 
ce
lls
 
0 2 (4.2) 2 (5.4) 
<10 4 (8.3) 1 (2.7) 
10-50 11 (22.9) 4 (10.8) 
51-80 22 (45.8) 19 (51.4) 
>80 9 (18.8) 11 (29.7) 
Total 48 (100) 37 (100) 
Missing 0 11 (22.9) 
Total 48 (100) 48 (100) 
Pearson Chi-Square 0.0001*** 
p-value 0.0001 
Tau B  0.458** 
 
B Tumour Centre  Invasive front  No. (%) No. (%) 
In
te
ns
ity
 o
f 
st
ai
ni
ng
 
No colour  8 (16.7) 5 (13.5) 
Mild  9 (18.8) 2 (5.4) 
Moderate  12 (25) 10 (27) 
Intense  19 (39.6) 20 (54.1) 
Total 48 (100) 37 (100) 
Missing 0 11 (22.9) 
Total 48 (100) 48 (100) 
Pearson Chi-Square 0.0001*** 
p-value 0.0001 
Tau B 0.687** 
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C Tumour Centre Invasive front  No. (%) No. (%) 
IR
S 
cl
as
s 
Negative 9 (18.8) 5 (13.5) 
Positive, weak expression 8 (16.7) 3 (8.1) 
Positive, mild expression 17 (35.4) 12 (32.4) 
Positive, strong expression 14 (29.2) 17 (45.9) 
Total 48 (100) 37 (100) 
System 0 11 (22.9) 
Total 48 (100) 48 (100) 
Pearson Chi-Square 0.0001*** 
p-value 0.0001 
Tau B 0.771** 
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Figure 4-13, Gli1 expression was higher at invasive fronts in breast cancer cohort 
Figure showing comparison of Gli1 levels in tumour centres (to the left) compared to the invasive front 
(to the right). (A) comparison of percentage of positive cells. (B) comparison of intensity of staining. (C) 
comparison of IRS class. 
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Figure 4-14, Gli2 expression was higher in invasive fronts of breast cancer samples   
Representative IHC images of the same breast cancer sample showing higher Gli2 levels in the invasive 
front (B) compared to the tumour centre (A). Images were captured using three different magnifications 
(100X, 200X and 400X) by the Leica microscope. (¨) was used to indicate area of positivity in images. 
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Table 4-2: Percentage of positive tumour cells, staining intensity and IRS class of 
Gli2 showed significant difference between tumour centre and invasive front 
Tumour centre and invasive front frequency tables (A) for percentage of positive tumour cells, (B) 
intensity of staining, and (C) IRS class. Pearson Chi-square test was used to estimate the difference 
between tumour centre and invasive front. The Kendall’s Tau B correlation coefficient (between -1 and 
+1) was used to assess for degree of correlation between tumour centre and invasive front. The statistical 
significance of the correlation is indicated as follows: *P= <0.05, **P= <0.01. 
 
 
 
In
te
ns
ity
 o
f 
st
ai
ni
ng
 
B Tumour centre  Invasive front  No. (%) No. (%) 
No colour  1 (3.4) 0 
Mild  6 (20.7) 4 (13.8) 
Moderate  11 (37.9) 8 (27.6) 
Intense  11 (37.9) 17 (58.6) 
Total 29 (100) 29 (100) 
Pearson Chi-Square 0.0001*** 
p-value 0.0001 
Tau B 0.656** 
 
IR
S 
cl
as
s  
C Tumour centre Invasive front  No. (%) No. (%) 
Negative 2 (6.9) 2 (6.9) 
Positive, weak expression 3 (10.3) 1 (3.4) 
Positive, mild expression 13 (44.8) 9 (31) 
Positive, strong expression 11 (37.9) 17 (58.6) 
Total 29 (100) 29 (100) 
Pearson Chi-Square 0.0001*** 
p-value 0.0001 
Tau B 0.683** 
 
Pe
rc
en
ta
ge
 o
f p
os
iti
ve
 
tu
m
ou
r 
ce
lls
 
A Tumour centre Invasive front No. (%) No. (%) 
0 0 0 
<10 2 (6.9) 2 (6.9) 
10-50 9 (31) 1 (3.4) 
51-80 4 (13.8) 7 (24.1) 
>80 14 (48.3) 19 (65.5) 
Total 29 (100) 29 (100) 
Pearson Chi-Square 0.0001*** 
p-value 0.0001 
Tau B 0.661** 
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Figure 4-15, Gli2 expression was higher at invasive fronts in breast cancer cohort 
Figure showing comparison of Gli2 in tumour centres (to the left) compared to the invasive front (to the 
right). (A) comparison of percentage of positive cells. (B) comparison of intensity of staining. (C) 
comparison of IRS class. 
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Figure 4-16, Gli3 expression was higher in invasive fronts of breast cancer samples   
Representative IHC images of the same breast cancer sample showing higher Gli2 in the invasive front 
(B) compared to the tumour centre (A). Images were captured using three different magnifications (100X, 
200X and 400X) by the Leica microscope. (¨) was used to indicate area of positivity in images. 
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Table 4-3: Correlation between Gli3 staining percentage, intensity and IRS class in 
tumour centres and that at invasive front  
Tumour centre and invasive front frequency tables (A) for percentage of positive tumour cells, (B) 
intensity of staining, and (C) IRS class. Pearson Chi-square test was used to estimate the difference 
between tumour centre and invasive front. The Kendall’s Tau B correlation coefficient (between -1 and 
+1) was used to assess for degree of correlation between tumour centre and invasive front. The statistical 
significance of the correlation is indicated as follows: *P= <0.05, **P= <0.01. 
 
Pe
rc
en
ta
ge
 o
f p
os
iti
ve
 
tu
m
ou
r 
ce
lls
 
A Tumour centre Invasive front No. (%) No. (%) 
0 0 0 
<10 1 (4.3) 0 
10-50 7 (30.4) 0 
51-80 7 (30.4) 6 (33.3) 
>80 8 (34.8) 12 (66.7) 
Total 23 (100) 18 (100) 
Missing 0 5 (21.7) 
Total 23 (100) 23 (100) 
Pearson Chi-Square 0.154 
p-value 0.034 
Tau B 0.477* 
 
In
te
ns
ity
 o
f s
ta
in
in
g 
 B Tumour centre  Invasive front  No. (%) No. (%) 
No colour  0 0 
Mild  11 (47.8) 2 (11.1) 
Moderate  8 (34.8) 10 (55.6) 
Intense  4 (17.4) 6 (33.3) 
Total 23 (100) 18 (100) 
Missing 0 5 (21.7) 
Total 23 (100) 23 (100) 
Pearson Chi-Square 0.079 
p-value 0.007 
Tau B 0.602** 
 
IR
S 
cl
as
s 
C Tumour centre Invasive front  No. (%) No. (%) 
Negative 1 (4.3) 0 
Positive, weak expression 8 (34.8) 0 
Positive, mild expression 11 (47.8) 12 (66.7) 
Positive, strong expression 3 (13) 6 (33.3) 
Total 23 (100) 18 (100) 
Missing 0 5 (21.7) 
Total 23 (100) 23 (100) 
Pearson Chi-Square 0.124 
p-value 0.036 
Tau B 0.481* 
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Figure 4-17, Gli3 expression was higher at invasive fronts in breast cancer cohort 
Figure showing comparison of Gli2 in tumour centres (to the left) compared to the invasive front (to the 
right). (A) comparison of percentage of positive cells. (B) comparison of intensity of staining. (C) 
comparison of IRS class. 
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4.3.4 Increased nuclear localisation of Gli proteins observed at the invasive front 
of breast cancer samples 
The nuclear localisation of Gli1, Gli2 and Gli3 was higher at invasive front 
compared to that in tumour centres as seen in representative images (Figure 4-18, 
Figure 4-19 and Figure 4-20). Pearson Chi-square analysis was used to assess if the 
difference between the nuclear localisation of Gli1, Gli2 and Gli3 in tumour centre and 
at invasive fronts were significant (summarised in Table 4-4-A, -B and -C). Also, 
Kendall’s Tau B test was used to assess for the correlation between the nuclear 
localisation in tumour centres and invasive fronts of Gli1, Gli2 and Gli3 staining 
(summarised in Table 4-4-A, -B and -C). 
The invasive front was identified in 37 out of 48 cases analysed for Gli1. Gli1 
was observed in 31 out of 48 cases (65%) in tumour centres and 27 out of 37 cases at 
invasive fronts (73%) was observed (Table 4-4-A). the invasive front was identified in 
all the cases analysed for Gli2. All cases were positive for nuclear Gli2 (29 cases) in the 
tumour centre and at the invasive front (Table 4-4-B and Figure 4-21-B). The invasive 
front was identified in 16 out of 23 cases analysed for Gli3. Of 23 cases, 97 (87%) 
tumour centres and 16 (96%) invasive fronts were negative for Gli3 (Table 4-4-C and 
Figure 4-21-C).  
Nuclear localisation was more evident  in the invasive front compared to the 
tumour centres for Gli1 (Figure 4-18), Gli2 (Figure 4-19) and Gli3 (Figure 4-20) (p-
value= 0.0001, p-value=0.002 and p-value=0.002, respectively) (Table 4-4-A, Figure 
4-21-A, Table 4-4-B, Figure 4-21-B, Table 4-4-C and Figure 4-21-C). The nuclear 
localisation of Gli1, Gli2 and Gli3 at the invasive front had a significantly positive 
correlation with that in the tumour centre (p-value=0.0001, p-value=0.001 and p-
value=0.002) (Table 4-4-A, Table 4-4-B and Table 4-4-C).  
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Figure 4-18, Nuclear expression of Gli1 in tumour cells is higher in invasive front 
of breast cancer   
Representative IHC images of the same breast cancer sample showing increased nuclear localisation of 
Gli1 in tumour cells in the invasive front (to right) compared to the tumour centre (to left). Images were 
captured using three different magnifications (100X, 400X and 600X) by the Leica microscope. (¨) was 
used to indicate area of positivity in images. 
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Figure 4-19, Nuclear expression of Gli2 in tumour cells is higher in invasive front 
of breast cancer   
Representative IHC images of the same breast cancer sample showing increased nuclear localisation of 
Gli2 in tumour cells in the invasive front (to right) compared to the tumour centre (to left). Images were 
captured using three different magnifications (100X, 400X and 600X) by the Leica microscope. (¨) was 
used to indicate area of positivity in images. 
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Figure 4-20, Nuclear expression of Gli3 in tumour cells is higher in invasive front 
of breast cancer   
Representative IHC images of the same breast cancer sample showing increased nuclear localisation of 
Gli3 in tumour cells in the invasive front (to right) compared to the tumour centre (to left). Images were 
captured using three different magnifications (100X, 400X and 600X) by the Leica microscope. (¨) was 
used to indicate area of positivity in images. 
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Table 4-4: Nuclear expression of Gli1, Gli2 and Gli3 increased at invasive front 
compared to tumour centre 
Tables showing nuclear expression of Gli1 (A), Gli2 (B) and Gli3 (C) in cells in tumour centre and 
invasive front. Pearson Chi-square test was used to estimate the difference between nuclear expression in 
tumour centres and invasive fronts. The Kendall’s Tau B correlation coefficient (between -1 and +1) was 
used to assess for degree of correlation between tumour centre and invasive front. The statistical 
significance of the correlation is indicated as follows: *P= <0.05, **P= <0.01. 
 
 Nuclear expression of Gli1 
A Tumour Centre Invasive Front 
 No. (%) No. (%) 
No nuclear expression 17 (35.4) 10 (27) 
<10% of tumour cells 8 (16.7) 3 (8.1) 
10% - 50% of tumour cells 14 (29.2) 9 (24.3) 
≥51% of tumour cells 9 (18.8) 15 (40.5) 
Total included 48 (100) 37 (100) 
Missing 0 11 (22.0) 
Total 48 (100) 48 (100) 
Pearson Chi-Square 0.0001*** 
p-value 0.0001 
TauB 0.642** 
 
 Nuclear expression of Gli2 
B Tumour Centre Invasive Front 
 No. (%) No. (%) 
No nuclear expression 0 0 
<10% of tumour cells 7 (24.1) 3 (10.3) 
10% - 50% of tumour cells 12 (41.4) 7 (24.1) 
≥51% of tumour cells 10 (34.5) 19 (65.5) 
Total included 29 (100) 29 (100) 
Pearson Chi-Square 0.002** 
p-value 0.001 
TauB 0.582** 
 
 Nuclear expression of Gli3 
C Tumour Centre Invasive Front 
 No. (%) No. (%) 
No nuclear expression 3 (13) 1 (4.3) 
<10% of tumour cells 11 (47.8) 3 (13) 
10% - 50% of tumour cells 5 (21.7) 7 (30.4) 
≥51% of tumour cells 4 (17.4) 5 (21.7) 
Total included 23 (100) 16 (69.6) 
Missing 0 7 (30.4) 
Total 23 (100) 23 (100) 
Pearson Chi-Square 0.002** 
p-value 0.002 
TauB 0.710** 
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Figure 4-21, Gli nuclear expression was higher at invasive fronts in breast cancer 
Figure showing comparison of Gli1 (A) Gli2 (B) and Gli3 (C) nuclear localisation in tumour centres (to 
the left) compared to the invasive front (to the right). 
 
4.3.5 Gli1 expression correlates with size and the nuclear localisation correlated 
with tumour stage at invasive front  
The percentage of Gli1 positive tumour cells increased with an increase in the 
size of the tumour. Gli1 IRS class significantly increased with tumour size with a high 
correlation coefficient (0.311, p-value= 0.046) (Figure 4-22). 
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Figure 4-22, IRS class of Gli1 staining increased in correlation with tumour size 
Figure showed correlation between IRS class of Gli1 and increased tumour size. Comparison between the 
IRS class of Gli1 in 2cm ³ tumours and 2cm < tumour sizes. Table showing the numbers of cases at two 
tumour sizes (2cm ³ or 2cm<) and the corresponding IRS class (negative, positive with weak expression, 
positive with mild expression and positive with strong expression). The correlation was calculated using 
the Kendall’s Tau B test. 
 
The increase in Gli1 nuclear localisation in the tumour centre (Figure 4-23-A) 
had a positive correlation with tumour size. A positive correlation between Gli1 nuclear 
localisation and tumour size was also observed at the invasive front (Figure 4-23-B). A 
stronger correlation was observed at invasive front (0.367, p-value = 0.018) compared 
to that seen in the tumour centre (0.295, p-value =0.027). Therefore, the increase of 
nuclear localisation of Gli1 (with increasing tumour size) was higher at the invasive 
front compared to the tumour centre. Nuclear localisation of Gli1 at the invasive front 
showed correlation with increasing clinical tumour stage (0.317, p-value = 0.043 
(Figure 4-24)).  
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Figure 4-23, Increasing Gli1 nuclear localisation correlates with tumour size in 
tumour centre and at the invasive front 
Figure showing comparison of nuclear localisation of Gli1 (0, <10%, 10-50% and >50%) in two tumour 
sizes (2cm³ or 2cm<) in tumour centre (A) and at invasive front (B). Table showing the numbers of cases 
that have 2cm ³ or 2cm < and the nuclear localisation of Gli1 (presented as 0, <10, 10-50 and >51) in 
these cases. The correlation was calculated using the Kendall’s Tau B test. 
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Figure 4-24, Increased of nuclear localisation of Gli1 at the invasive front 
correlated with tumour stage 
Figure showing correlation between increased Gli1 nuclear localisation and increased tumour stage in 
tumour centre and at invasive front. Table below the figures shows the numbers of cases, the 
corresponding tumour stage (T1, T2, T3 and T4) and the nuclear localisation of Gli1 presented. 
 
4.3.6 Gli2 expression inversely correlates with smaller tumour size, but positively 
with lower stage and grade and less lymph node involvement 
The proportion of Gli2 expression in the tumour centre negatively correlated 
with tumour size (-0.348, p-value = 0.05) (Figure 4-25) as well as with tumour stage (-
0.480, p-value = 0.009) (Figure 4-26). Tumours of smaller size (<2cm) had increased 
expression of Gli2 compared to tumours with sizes more than 2cm (Figure 4-25) and an 
increase in the proportion of Gli2 positive cells in the tumour centre was observed in 
tumours at an earlier stage (Figure 4-26). However, due to lack of cases with stages 3 
and 4, no further conclusion can be drawn. 
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Figure 4-25, The percentage of Gli2 positive tumour cells in the tumour centre 
correlated with smaller tumour size 
Figure showing increase of percentage of Gli1 positive tumour cells correlated with smaller tumour size 
in tumour centre. Table below the pie chart shows numbers of cases, tumour size (2cm ³ or 2cm <) and 
the percentage of Gli2 positive tumour cells (presented as 0, <10, 10-50, 51-80 and >80). The correlation 
was calculated using the Kendall’s Tau B test. 
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Figure 4-26, Increased percentage of Gli2 positive tumour cells in the tumour 
centre correlated with lower tumour stage 
Figure showing increase of percentage of Gli2 positive tumour cells correlated with lower tumour stage 
in tumour centre. The table below the pie chart presents the numbers of cases, tumour stage (T1, T2, T3, 
and T4) and percentage of Gli2 positive tumour cells (presented as 0, <10, 10-50, 51-80 and >80). The 
correlation was calculated using the Kendall’s Tau B test. 
 
Higher percentage of Gli2 expression in the tumour centre was correlated with 
lower lymph node involvement (-0.419, p-value = 0.003) (Figure 4-27). Cases with 
higher IRS class of Gli2 in the tumour centre showed had lower lymph node 
involvement (-0.321, p-value = 0.03) (Figure 4-28). 
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Figure 4-27, The percentage of Gli2 positive tumour cells in the tumour centre 
correlated with low lymph node involvement 
Figure showing increase of percentage of Gli2 positive tumour cells in tumour centre correlated with 
negative lymph node. Table below shows the numbers of cases, lymph node involvement (possible, 
negative or positive) and the percentage of Gli2 positive tumour cells in tumour centre. The correlation 
was calculated using the Kendall’s Tau B test. 
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Figure 4-28, Higher Gli2 IRS class in the tumour centre correlated with low lymph 
node involvement 
Figure showing higher Gli2 IRS class in tumour centre correlated with negative lymph node involvement. 
Table shows the numbers of cases, lymph node involvement (possible, negative and positive) and Gli2 
IRS class (negative, positive with weak expression, positive with mild expression and positive with 
strong expression) in tumour centre. The correlation was calculated using the Kendall’s Tau B test. 
 
4.3.7 Increased Gli3 correlated with younger mean age at diagnosis and hormone 
receptor-positive breast cancer 
The percentage of Gli3 expression at the invasive front correlated with a lower 
age at diagnosis (-0.495, p-value = 0.015). Increased percentage of Gli3 was observed 
with ER positive (0.402, p-value = 0.014) (Figure 4-29) and PR positive tumours 
(0.468, p-value = 0.006) (Figure 4-30).  
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Figure 4-29, The percentage of Gli3 positive tumour cells in tumour centre 
correlated with Oestrogen hormone-positive breast cancer 
Figure showing an increase in the percentage of Gli3 positive tumour cells in correlation with oestrogen 
hormone-positive breast cancer. Table shows the numbers of cases, oestrogen receptor status (negative 
and positive) and the percentage of Gli3 positive tumour cells (presented as 0, <10, 10-50, 51-80, and 
>80). The correlation was calculated using the Kendall’s Tau B test. 
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Figure 4-30, The percentage of Gli3 positive tumour cells in tumour centre 
correlated with progesterone hormone-positive breast cancer 
Figure showing an increase in the percentage of Gli3 positive tumour cells in correlation with hormone-
positive breast cancer. Table shows the numbers of cases, progesterone hormone status (negative and 
positive) and the percentage of Gli3 positive tumour cells (presented as 0, <10, 10-50, 51-80, and >80). 
The correlation was calculated using the Kendall’s Tau B test.  
 
4.3.8 Gli1 and Gli2 were co-expressed in breast cancer samples 
Gli1 and Gli2 were co-expressed in breast cancer samples. Gli1 intensity at the 
invasive front correlated with that of Gli2 at the invasive front (1, p-value = 0) (Figure 
4-31). 
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Figure 4-31, Correlation between Gli1 and Gli2 staining intensity at the invasive 
front 
Figure showing correlation between Gli1 and Gli2 staining intensity at invasive front. This correlation 
confirms a mutual increase of Gli1 and Gli2 intensity at the invasive front and in the tumour centre. 
 
Observation of increased Gli1 nuclear localisation at the invasive front was 
concomitant with an increase in both the proportion and intensity of Gli2 staining in the 
tumour centre (1, p-value = 0 and 1, p-value = 0) (Figure 4-32). This showed that the 
increase in nuclear localisation of Gli1 at the invasive front was co-expressed with 
increased Gli2 expression (percentage, staining intensity and IRS) and nuclear 
localisation at the invasive front.  
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Figure 4-32, Nuclear localisation of Gli1 at the invasive front is correlated with 
Gli2 staining 
Figure showing an increase in Gli1 nuclear localisation in correlation with an increase of Gli2 staining in 
the tumour centre. (A) shows correlation between the percentage of Gli2 positive tumour cells (B) Gli2 
staining intensity (C) IRS class of Gli2 (D) increased nuclear localisation of Gli2 with increased 
localisation of Gli1 at the invasive front. 
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4.3.9 Inverse correlation between Gli1 and Gli3 staining in breast cancer and 
concurrent expression of Gli2 and Gli3 in tumour centre 
Co-expression analysis was conducted on serial sections stained for all proteins. 
The increase of Gli1 staining at the invasive front correlated with a decrease of Gli3 
staining intensity in the tumour centre (0.905, p-value = 0.034) (Figure 4-33). 
 
 
 
Figure 4-33, Increased percentage of Gli1 positive tumour cells in tumour centre is 
correlated with decrease Gli3 intensity in tumour centre 
Figure showing that an increase of the percentage of Gli1 positive expressing cells in tumour centre 
correlated with decreased staining intensity of Gli3 in tumour centre. 
 
4.3.10 Gli proteins expression correlated with E-cadherin alteration in tumour 
centre and at invasive front of breast cancer samples  
Gli1 and Gli3 expression correlated negatively with E-cadherin expression in 
the tumour centre and Gli2 correlated positively with E-cadherin in breast cancer. 
Samples that had high IRS class of E-cadherin in the tumour centre concurrently has 
less nuclear localisation of Gli1 in the tumour centre (-0.700, p-value=0.044) (Figure 
4-34). Thus, suggesting a negative correlation between E-cadherin expression and the 
activation of Hh signalling, measured by the nuclear localisation of Gli1.   
Samples with high Gli2 intensity at the invasive front had high proportion of E-
cadherin positivity in tumour centre (0.728, p-value = 0.046) (Figure 4-35-A) and at the 
invasive front (0.918, p-value = 0.011) (Figure 4-35-C).  Also, samples that had high 
intensity of Gli2 staining at the invasive front concomitantly had high IRS class of E-
cadherin staining in the tumour centre (0.775, p-value = 0.04) (Figure 4-35-B). Samples 
with more evident nuclear localisation of Gli2 in the tumour centre showed high IRS 
class for E-cadherin staining in tumour centre (0.745, p-value = 0.049) (Figure 4-36). It 
is difficult to interpret this finding at Gli2 has dual action, activation and suppression 
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(Figure 0-8). So, there were positive correlation between Gli2 staining at the invasive 
front and E-cadherin staining in tumour centre and at invasive front. These findings 
showed that high Gli2 at the invasive front could be a sign of less tumour invasive, as 
E-cadherin expression is higher in those tumours. 
Similar to Gli2 finding Breast cancer samples that had higher intensity of Gli3 
staining at the invasive front had higher IRS class of E-cadherin staining in the tumour 
centre (-1, p-value = 0.000) (Figure 4-37). Correlation between higher expression of E-
cadherin in the tumour centre and increased Gli2 and Gli3 staining at the invasive front 
suggest that both proteins could indicate reduction of invasion. However, more 
investigation of the function of the Gli proteins in tumour cells is needed to confirm 
these findings.  
 
 
 
Figure 4-34, Reduction of nuclear localisation of Gli1 in tumour centre associated 
with high E-cadherin in tumour centre  
Figure showing that Gli1 nuclear localisation in the tumour centre decreased in association with an 
increase of E-cadherin IRS class at the invasive front. 
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Figure 4-35, Increased of Gli2 staining intensity at the invasive front correlated 
with E-cadherin expression in the tumour centre and at the invasive front 
Figure showing that the percentage of E-cadherin positivity (A) and IRS class (B) in the tumour centre 
correlated with an increase Gli2 intensity at the invasive front. Gli2 staining intensity at invasive front 
also correlated with increased percentage of E-cadherin in the invasive front (C). 
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Figure 4-36, Increased nuclear localisation of Gli2 in the tumour centre associated 
with increased E-cadherin IRS class in the tumour centre 
Figure showing that nuclear Gli2 localisation increased with an increased in IRS class of E-cadherin in 
the tumour centre. 
 
 
 
Figure 4-37, Intensity of Gli3 staining at the invasive front negatively correlated 
with IRS class of E-cadherin staining in the tumour centre 
Figure showing that increased E-cadherin staining in the tumour centre correlated with a decrease in Gli3 
staining at the invasive front. 
 
4.3.11 The Hedgehog signalling (Hh) pathway components were expressed in 
breast cancer cell lines 
The expression of Hh signalling components, Sonic Hedgehog (Shh), Indian 
Hedgehog (Ihh), Patched, Smoothened (Smo), Gli1, Gli2 and Gli3 were evaluated in 
breast cancer cell lines using Western blotting analysis (Figure 4-38-A). As seen in 
Figure 4-38-B the results Smoothened was detected in breast cancer cell lines (MCF7, 
MDA-MB-361, MDA-MB-453 and MDA-MB-231) but was not detected in BT20 and 
MCF10A. Patched was detected in MDA-MB-361and BT20, and was low in MDA-
MB-453 (Figure 4-38-C). The ligands Shh and Ihh were detected in all cell lines 
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(Figure 4-38-D and Figure 4-38-E). Gli1 and Gli3 were also detected in all cell lines 
(Figure 4-38-F and Figure 4-38-H). Gli2 was detected in MCF7, MDA-MB-453, BT20 
and MDA-MB-231 (Figure 4-38-G). 
 
 
 
Figure 4-38, Hedgehog signalling components were expressed in breast cancer cell 
lines 
Figure showing that the Hedgehog (Hh) signalling components (Smo, Patched, Shh, Ihh, Gli1, Gli2 and 
Gli3) were expressed in breast cancer cell lines (MCF10A, MCF7, MDA-MB-361, MDA-MB-453, BT20 
and MDA-MB-231) as seen in Western blotting (A). The corrected ratio of Smoothened (Smo) (B), 
Patched (C), Sonic Hedgehog (Shh) (D), Indian Hedgehog (Ihh) (E), Gli1 (F), Gli2 (G) and Gli3 (F). 
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4.4 Discussion 
Despite advances in the detection and treatment of breast cancer, development of 
metastatic disease remains fatal. In the UK, it is estimated that 20-70% of breast cancer 
cases diagnosed will have secondary or metastatic disease at diagnosis (Dewis and 
Gribbin, 2009). Furthermore, it was reported that the remaining cases have a 35% 
chance of developing metastases within 10 years after initial diagnosis (Dewis and 
Gribbin, 2009). Researchers are looking for new approaches to treat metastatic disease 
due to the failure of current treatment regimens. These current approaches comprise of 
systemic chemotherapy in combination with surgery or radiation, which aim to prolong 
survival rather than prevent metastatic disease. Identifying signalling pathways active 
during breast cancer metastasis is essential for the development of targeted therapy and 
to identify cases that could benefit from targeting these pathways. 
Invasion and metastasis are one of the hallmarks of cancer and the process of 
EMT is involved in the regulation of invasion and metastasis and is also involved in 
normal physiological processes. In the previous section (3.3), data showed that breast 
cancer cell lines exhibited signs of EMT when exposed to external stress by changing 
the degree of cell-cell contact. The ability of breast cancer cells ability to undergo EMT 
was not limited to a specific subtype of breast cancer, but rather depended on other 
factors that are involved in the regulation of this process. Evidence showed that b-
catenin protein, which is involved in the canonical Wnt/b-catenin signalling, has ability 
to crosstalk with other signalling pathways including the Hedgehog (Hh) signalling 
pathway (Garg, 2013). It has also been reported that Hh signalling can act on its own to 
regulate EMT in human cancers (Gonzalez and Medici, 2014). 
To determine the involvement of Hh signalling in breast cancer, Gli1, Gli2 and 
Gli3 were assessed in serial sections from a breast cancer sample cohort using 
immunohistochemistry (IHC). The intensity of staining and percentage of positive cells 
were evaluated in both the tumour centre and invasive front of each sample. The 
expression of E-cadherin was also assessed in serial sections as loss of this protein in 
breast cancer is an indication for poor prognosis. Nuclear localisation of Gli1, Gli2, 
Gli3 and b-catenin was also evaluated. 
The IRS scoring system was selected for estimating the levels of expression in 
breast cancer (Table 2-15). This scoring system was utilised previously for estimating 
the levels of Gli1 in breast cancer (ten Haaf et al., 2009). Kaemmerer et al. (2012) 
reported that the IRS scoring system provided a reliable and uniformed score that was 
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suitable for routine diagnosis. Nuclear localisation was assessed using the scoring 
system suggested by Volante et al. (2007) and used for HER2 scoring in combination 
with IRS scoring by Kaemmerer et al. (2012) in Table 2-16. Adjacent normal tissue 
was present in some samples, but the infrequency of this observation meant that 
comparison of level of expression between normal and breast cancer was possible (data 
not included). 
Analysis of prognostic markers (ER, PR and HER2) status and correlation with 
the clinical criteria of samples tested, showed that ER and PR receptor positivity 
correlated with smaller tumour size, stage and grade (Table 11-5). This concurs with 
previous work that found similar findings using IHC (reviewed by Rakha et al. 
(2010b)), gene-microarray analysis and expression analysis (Sorlie et al., 2001; Sotiriou 
and Pusztai, 2009).  
4.4.1 Gli proteins were expressed in breast cancer with nuclear and cytoplasmic 
distribution 
Lewis and Veltmaat (2004) found that components of the Hh signalling pathway 
were expressed in normal breast tissue. They also found that Gli1, Gli2 and Gli3 were 
expressed in invasive ductal carcinoma at a higher level than that in normal breast 
tissue (Lewis and Veltmaat, 2004). All breast cancer samples used in this study 
expressed Gli2 and Gli3 and 92% of cases were positive for Gli1 (Figure 4-6). 
Previous studies used a binary scoring outcome and included only 100 tumour 
cells from each section in the analysis (Kubo et al., 2004). Souzaki et al. (2011) scored 
five fields and counted 300 tumour cells and considered >50% Gli1 expression as a 
positive result. The combined scoring utilised by IRS method that was introduced by 
Kaemmerer et al. (2012), provided a robust method for assessing the tissue distribution 
of the Gli proteins. This method was used for scoring hormone receptor status in breast 
cancer (Kaemmerer et al., 2012). IRS scoring also uses a scale of positivity that can be 
used separately as percentage of positive tumour cells and intensity (Xu et al., 2010), or 
in combination as IRS classes (ten Haaf et al., 2009).  
The percentage of positivity of tumour cells was highest for Gli3 and Gli2 
respectively and lowest in Gli1 (Figure 4-7) yet the staining intensity of Gli2 and Gli1 
were higher than that for Gli3 (Figure 4-8). Gli2 showed the highest IRS score followed 
by Gli1 then Gli3 (Figure 4-9). In agreement with the current findings, Im et al. (2013) 
showed that Gli2 was the highest expressed Gli member in breast cancer followed by 
Gli1 and Gli3. Gli3 is the repressor form of Gli and loss of Gli3 induces Gli1 
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overexpression and loss of Hh repression. This is essential for normal mammary gland 
development (Hatsell and Cowin, 2006). Therefore, reduced Gli3 expression is 
expected in breast cancer (Figure 4-9). However, no comparison with normal tissue was 
conducted in the current study and confirmation of Gli3 loss in breast cancer samples 
compared to normal breast tissue can be recommended for future work. Similar to 
findings in a previous study reported by Im et al. (2013) nuclear and cytoplasmic 
localisation of Gli proteins was observed in the breast tumours (Figure 4-10). 
4.4.2 Increased Gli1 and Gli2 are found at the invasive front of breast tumours 
The invasive front is defined as the area where tumour cells interact with host 
tissue or organ, it is an area of three to six layers of tumour cells at the front edge (Gao 
et al., 2010; Gong et al., 2013). The expression of Gli1, Gli2 and Gli3 was compared in 
tumour centres and invasive fronts of the samples. This approach of IHC analysis was 
chosen following the notion that the invasive front was the location where EMT is 
observed in cancer (Bryne et al., 1998; Christofori, 2006; Busch et al., 2014).  
Our findings were the first to provide detailed analysis by studying the tissue 
distribution and subcellular localisation of all three Gli proteins. These findings provide 
a better understanding of Hh signalling and its involvement in breast cancer invasion. It 
was observed that the percentage of positive cells, staining intensity and IRS score of 
Gli1 and Gli2 increased significantly at invasive fronts (Table 4-1 and  
 
 
 
 
 
 
 
 
Table 4-2). Increased expression of Gli1 at the invasive front of breast cancer 
was previously reported by ten Haaf et al. (2009). The increase of Gli proteins at the 
invasive front of tumours provides a strong indication that the Hh signalling is active at 
the invasive front where many studies suggested as active site for EMT in cancer 
(Bryne et al., 1998; Christofori, 2006; Busch et al., 2014).  
The estimation of nuclear localisation of Gli proteins is essential for determining 
their function, as indicated previously. Active Hh signalling require nuclear localisation 
of Gli proteins (Figure 0-7). Nuclear localisation of Gli1, Gli2 and Gli3 were increased 
at the invasive front compared to the tumour centre with statistical significance (Figure 
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4-23). 70% of breast cancer samples showed positive Gli1 nuclear localisation (Table 
4-4-A). All samples showed positivity for Gli2 nuclear localisation (Table 4-4-B) and 
90% cases showed positivity for Gli3 nuclear localisation (Table 4-4-C). This indicate 
that Gli proteins were active in most of breast cancer samples. Therefore, further 
analysis of correlation with clinical criteria is encouraged.  
4.4.3 Gli1 overexpression correlated with higher stage, grade and size breast 
tumours  
Assessment of the subcellular localisation of Gli proteins is essential for 
determining the status of Hh signalling (Ruiz i Altaba et al., 2002). Nuclear localisation 
of Gli1 correlated with poor outcome of colon cancer (Ding et al., 2012) 
medulloblastoma (Pizem et al., 2011) and gastric cancer (Kim et al., 2012). Research to 
date alluded to a role of Gli1 in the malignant progression of breast cancer with varied 
expression reported in breast cancer samples using IHC (Kubo et al., 2004; ten Haaf et 
al., 2009). Several studies found that increased Gli1 correlated with poor breast cancer 
prognosis (Kameda et al., 2009; Kwon et al., 2011; Xu et al., 2015). Increased 
immunoreactivity for Gli1 in breast cancer samples has been correlated with high 
tumour stage in several studies Tao et al. (2011), ten Haaf et al. (2009) and Souzaki et 
al. (2011). 
The nuclear localisation of Gli1 is associated with tumour size, and shorter 
recurrence-free and overall survival (Arnold et al., 2017). In agreement with this 
finding, the nuclear localisation of Gli1 was correlated with tumour size in the tumour 
centre and at the invasive front with stronger nuclear localisation at the invasive front 
(Figure 4-23). We also showed that increased nuclear localisation of Gli1 was 
correlated with higher tumour stage with increased nuclear localisation at the invasive 
front of tumours with higher stage (Figure 4-24). Consistent with this, Li et al. (2012) 
found that nuclear localisation of Gli1 was significantly correlated with decreased life 
expectancy. 
Kubo et al. (2004), Kameda et al. (2009), Xu et al. (2010), Souzaki et al. (2011) 
and Kwon et al. (2011) all reported high expression of Gli1 in TNBC in association 
with a poor prognosis and survival. The association of Gli1 expression and HER2 
expression was also reported previously by Jeng et al. (2013). No association with 
molecular subtypes were found after analysing the expression of Gli1 tissue distribution 
and subcellular localisation in this study. This could be because the number of cases 
included in this study were less than that in previous studies. Bigger sample size is 
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required in order to find if there were correlation between Gli1 expression and 
molecular subtypes of breast cancer.  
4.4.4 Gli2 and Gli3 expression correlate with favourable clinical criteria  
Gli2 is a bi-functional protein that has two functional domains, an activator and 
a repressor, whereby proteolytic processing is required to determine function (Pan et 
al., 2006). The oncogenic property of Gli2 overexpression was reported in basal-cell 
carcinoma (Tojo et al., 2003) hepatocellular carcinoma (Zhang et al., 2014) and 
prostate cancer (Thiyagarajan et al., 2007). Gli3 is expressed as a full-length inactive 
protein that requires cleavage for translocation to the nucleus where it functions as a Hh 
signalling repressor (Ruiz i Altaba et al., 2002). Several studies reported that there was 
an activator form for Gli3, however it is not clear if this was context-dependent or 
indeed if it was tissue-specific (Wang et al., 2011a; Lee et al., 2013). 
Several studies assessed the expression Gli2 and Gli3 in human breast cancer 
samples. To date very few studies used combined assessment of all three parameters 
(expression, tissue distribution and subcellular localisation) of Gli2 and Gli3 in breast 
cancer. Lewis (2001) found that disruption of Gli2 function resulted in mammary ductal 
hyperplasia. Im et al. (2013) assessed the expression of Gli1, Gli2 and Gli3 and 
reported that Gli3 expression correlated with tumour stage and increased tumour size. 
They also reported that Gli2 correlated with ER status while Gli3 correlated with HER2 
positive status (Im et al., 2013). Contradictory to the previous finding, Gli2 expression 
correlated with smaller tumour size (Figure 4-25) whereas increased expression of Gli2 
correlated with lower tumour stage (Figure 4-26) and grade (Error! Reference source 
not found.). The percentage of and IRS class of Gli2 expression in tumour centre was 
inversely associated with lymph node involvement (Figure 4-27 and Figure 4-28). 
Thiyagarajan et al. (2007) also reported that Gli2 overexpression accelerated the growth 
of prostate tumours. Yet, loss of Gli2 was seen in high-grade and larger breast tumours 
as seen here. 
Gli3 expression correlated significantly with younger mean age at diagnosis and 
hormone-positive breast cancer (Figure 4-29) which contradicts the findings of previous 
studies (Im et al., 2013). The cause of difference between the correlation between Gli3 
expression and the molecular subtypes of breast cancer could be due to the difference in 
the method of assessment of IHC. In previous studies, Gli proteins expressions were 
assessed in all the tissue section without taking into account the importance of 
assessment of tissue distribution.  
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4.4.5 Gli1 and Gli2 were co-expressed in breast cancer samples while Gli1 
increase was associated with reduction of Gli3 
Gli1 and Gli2 were co-expressed in breast cancer samples in the tumour centre 
and at the invasive front (Figure 4-31). As seen in Figure 4-32, increased Gli2 
expression was associated with increased nuclear localisation of Gli1 in the tumour 
centre and at the invasive front. Therefore, suggesting that these Gli proteins may have 
similar functions. This finding is novel and encourages further investigation of the co-
expression and/or knockdown of Gli1 and Gli2 in cell lines. Schnidar et al. (2009) 
demonstrated that the synergistic effect of Gli1/ Gli2 and EGFR signalling promotes 
oncogenic modification of the Gli target genes, thus promoting cancer. Similar 
investigative approach is encouraged based on these findings using breast cancer cell 
lines.  
Gli3 in breast tissue was reported to have an antagonistic effect to Gli1; in fact, 
co-expression of Gli1 and Gli3 led to mutual antagonism of Hh signalling in mice (Bai 
and Joyner, 2001). Here, we found that increased Gli1 expression corresponded to 
decreased Gli3 expression (Figure 4-33). This finding confirms that increased activation 
of Hh signalling was associated with loss of Gli3 expression and increased Gli1. This is 
the first study to report co-expression analysis of both Gli1 and Gli3, but no further 
conclusion can be made until analysis of Gli1 and Gli3 expression were done on larger 
sample size.  
4.4.6 Correlation between Hh and Wnt/b-catenin in breast cancer samples 
Several studies confirmed increased nuclear localisation of b-catenin at the 
invasive front compared to the tumour centre is indicative of EMT-like change in colon 
(Zlobec and Lugli, 2009), parathyroid (Fendrich et al., 2009), and oral carcinomas 
(Wang et al., 2009). To confirm the relationship between Hh activation and increased 
EMT, Gli1, Gli2 and Gli2 expression data was correlated with that for b-catenin and E-
cadherin. Changes in b-catenin expression were found to be associated with EMT in 
colon cancer (Batlle et al., 2002) and in breast cancer (Gong et al., 2013). Tissue 
distribution of b-catenin was investigated by Wang et al. (2011b) and they reported that 
increased expression levels and nuclear localisation were observed at the invasive front 
of colon tumours. Detailed analysis of tissue distribution in combination with 
subcellular localisation of b-catenin in breast cancer was not investigated at this level of 
detail previously. 
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In the current study, no correlation was found between the expression of Gli 
proteins and b-catenin. Nuclear localisation of Gli2 was associated with increased E-
cadherin expression in the tumour centre (Figure 4-36). This finding is in disagreement 
with previous finding. Alexaki et al. (2010) found increased expression of Gli2 was 
observed at the invasive front of melanoma and was associated with a loss of E-
cadherin. Thus, indicating that there is a link between the Gli2 protein tissue 
distribution and cancer invasion by regulating E-cadherin expression in that type of 
cancer. This finding was different to the current data, which could either suggest that 
the regulation of Hh in breast tumours or that further analysis of tissue distribution and 
subcellular localisation is required. Additionally, the restriction of the small sample size 
in this study limit the ability to draw further conclusions.  
Arnold et al. (2017) was the first study to report co-expression of Gli1 and b-
catenin in breast cancer. They concluded that co-activation of Hh signalling and Wnt 
signalling occurs in breast cancer as they observed increased nuclear expression of Gli1 
and b-catenin (Arnold et al., 2017). However, their analysis did not include assessment 
of tissue distribution. Further analysis is required in the current cohort, and a larger 
sample size is needed to confirm the finding, crosstalk was also associated with loss of 
E-cadherin.  
4.4.7 The Hedgehog (Hh) signalling pathway components were expressed in 
breast cancer cell lines 
Theunissen and de Sauvage (2009) suggested that breast cancer invasion may be 
mediated through both autocrine and paracrine Hh signalling, which is also consistent 
with other studies (Habib and O'Shaughnessy, 2016; Hanna and Shevde, 2016). 
However, the difference in the roles of autocrine and paracrine Hh signalling in breast 
cancer has not been investigated. The study by Varnat et al. (2010) used human colon 
cancer cell lines and reported that expression of Shh, PTCH and Gli1 was detected in 
the epithelium,. Szczepny et al. (2017) used a mouse model of small cell lung cancer 
and found that autocrine, ligand-dependent signalling has increased tumour progression.  
In order to investigate the potentially autocrine activity of Hh signalling, and 
possible crosstalk with Wnt signalling, in vitro investigation using breast cancer cell 
lines can be performed. Several studies have investigated the expression of these 
proteins in breast cancer cell lines. Previous researchers found that all components of 
Hh signalling including; Smo, Ptch1, Ptch2, Shh, Ihh, Dhh, Gli1, Gli2, and Gli3 were 
expressed in breast cancer cell lines (Kubo et al., 2004; Mukherjee et al., 2006; 
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Kameda et al., 2009; Thomas et al., 2011; Diao et al., 2016; Song et al., 2016). Here, 
same finding is confirmed in those cell lines in order to use them for functional and 
mechanistic analysis (Figure 4-38). 
Breast cancer cell lines can be utilised to investigate the Hh signalling and 
assess for crosstalk with Wnt. MCF7 (luminal) and MDA-MB-231 (basal and triple 
negative) were used for further in vitro analysis (see chapter 5). Han et al. (2015) found 
that MDA-MB-231 cells expressed low levels of Gli1 and high Gli2 levels and Gli3 
using Western blotting similar to that observed in the current findings (Figure 4-38). Fu 
et al. (2016) and Di Mauro et al. (2017) found that MCF7 expressed Gli1 and Gli2 
proteins at a slightly higher level than that seen in MDA-MB-231, which is similar to 
our data (Figure 4-38). Mukherjee et al. (2006) found that MCF7 and MDA-MB-231 
cells expressed high levels of Gli1 compared to normal breast cells which was even 
higher in MDA-MB-231. Taken together, both cell lines (MCF7 and MDA-MB-231) 
were selected for functional and mechanistic investigation as both cell lines show 
expression of most of the Hh signalling proteins. Also, these cell lines are 
representative of both luminal, triple negative and basal-like breast cancers.  
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4.5 Conclusion 
There were signs of EMT-like in breast cancer cell lines according to the 
alteration of E-cadherin and b-catenin expression seen after culturing the cell lines in 
the density model in vitro (chapter 3). Upon reviewing the literature (Flemban and 
Qualtrough, 2015), Hh signalling was a promising target for investigation because of its 
involvement in the early developmental stages of mammary gland development. 
Here, we showed that Hh signalling was involved in breast cancer invasive front, 
the site of active EMT (Bryne et al., 1998; Christofori, 2006; Busch et al., 2014), by 
assessing expression of Gli1, Gli2 and Gli3 in a cohort of breast cancer patient samples.  
To determine whether Hh signalling may play a role in breast cancer invasion and 
metastasis, estimation of Gli1, Gli2 and Gli3 expression in both the tumour centre and 
at the invasive front was conducted. It was shown that all three Gli proteins were 
expressed in breast cancer with variation of tissue distribution and subcellular 
localisation. Gli1 and Gli2 were found higher at the invasive front of tumours with 
increased nuclear localisation for Gli1, Gli2 and Gli3. Therefore, indicating an active 
role in the regulation of breast cancer invasion. This confirmed the hypothesis that Hh 
signalling may indeed effect breast cancer prognosis and present as a potential 
therapeutic target. At the time of submitting the work, this research was the first to 
assess tissue distribution of Gli1, Gli2 and Gli3 with estimation of subcellular 
localisation at two tissue locations. 
To confirm the involvement of Hh signalling in the regulation of EMT in breast 
cancer, the expression of E-cadherin and b-catenin was analysed for association with 
Gli1, Gli2 and Gli3 expression in the tumour centre and at the invasive front. Bigger 
sample size and further analysis is required to assess the relationship between the Hh 
signalling pathway and b-catenin. This is because as analysis of the current number of 
samples did not show any significant correlation. Increased expression of Gli1 was 
correlated with loss of E-cadherin. However, increased Gli2 staining and nuclear 
localisation was correlated with increased E-cadherin, therefore, suggesting a different 
role of Gli2 in breast cancer. All these data encourage further investigation of the role 
of Hh signalling in the regulation of EMT in breast cancer using cell lines.  
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5. Chapter Five: The Effect of Inhibiting the Hedgehog Signalling 
Pathway in Breast Cancer Cell Lines 
5.1 Introduction 
 In animal models, dysregulation of Hh signalling results in an increased chance 
of developing breast cancer (Zhang et al., 2009). Several studies found a constant 
activation of Hh signalling in breast cancer cell lines, reinforcing the importance of 
autocrine signalling in this model as discussed in 4.4.7 (Kubo et al., 2004; Mukherjee et 
al., 2006; Kameda et al., 2009; Thomas et al., 2011; Diao et al., 2016; Song et al., 
2016). This sustained activation of the Hh pathway increased proliferation of breast 
cancer cells (Moraes et al., 2007). Thus, several studies suggested targeting Hh for 
breast cancer treatment. 
Researchers studied inhibiting Hh signalling in breast cancer cell lines and in 
vivo using a range of inhibitors, and also by gene silencing, and measured the effect of 
this inhibition on cancer cell proliferation, cell death and invasion. These studies are 
collected and summarised in Table 5-1. Breast cancer cell lines were treated with 
cyclopamine, a naturally-occurring inhibitor of the Hh signalling pathway, which 
caused inhibition of proliferation in a dose-dependent manner (Kubo et al., 2004; 
Mukherjee et al., 2006; Kameda et al., 2009). Zhang et al. (2009) also showed that 
inhibiting Hh signalling in both oestrogen receptor-positive and -negative breast cancer 
reduced cell growth. Several studies found that Hh inhibition in breast cancer cell lines 
resulted in the inhibition of motility and invasion (Kameda et al., 2009; Kwon et al., 
2011; Souzaki et al., 2011; Thomas et al., 2011). 
As summarised in Table 5-1 the vast majority of in vitro studies that showed 
that Hh inhibition caused decreased cell proliferation, yield and increased cell death. 
The in vivo studies showed similar outcomes and suggested that inhibition of Hh 
signalling showed promising anti-tumour effects in a therapeutic setting. The 
measurement of the effect of Hh inhibition on the level of Gli protein expression and 
localisation, which provide a direct indicator of the functional status of the pathway, 
were not explored in previous work.  
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Table 5-1: The inhibition of Hh signalling in breast cancer has been a topic of 
intense investigation. 
This table summarises some of the breast cancer studies that have inhibited the Hh signalling pathway 
and includes the type of model, inhibitor used, and general effect resulted from this inhibition. 
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(Kubo et al., 
2004) Cyclopamine 
Panel of breast cancer cell 
lines 
- ¯ - - - - 
(Mukherjee et al., 
2006) Cyclopamine  - - - - ­  - 
(Wolf et al., 2007) Cyclopamine  - ¯ ¯ - - Ptch ­ following inhibition 
(Zhang et al., 
2009) Cyclopamine  - ¯  - - - - 
(Tanaka et al., 
2009) Cyclopamine  - ¯  - - - - 
(Souzaki et al., 
2011) Cyclopamine  - - - ¯ - - 
(Thomas et al., 
2011) 
Small 
interfering 
RNA for Gli1 
- ¯ - ¯ ­  ¯ following inhibition  
(Matevossian and 
Resh, 2015) 
RU-SKI43 
and LDE225 - ¯  - - - - 
(Song et al., 2016) Cyclopamine  - - - - ¯ ¯ Slug and ­E-cadherin  
(Bao et al., 2016) Vismodegib - - - ¯ - 
¯ in MMPs, ¯ Smo, ¯ 
Gli1 nuclear 
localisation 
(Kameda et al., 
2009) Cyclopamine  TN  - ¯ - ¯ - - 
(Diao et al., 2016) GANT61 tamoxifen resistant - ¯ - - ¯ - 
(Liu et al., 2006a) Cyclopamine  Primary mammary cells - - - - - ¯ stem cell markers expression cells  
(Che et al., 2013) Cyclopamine MCF7 and MDA-MB-231 - ¯ ¯ - - ¯ cyclin D expression 
(Diao et al., 2016) GANT61 tamoxifen resistant - ¯  - ¯ - 
(Das et al., 2011) Cyclopamine TN and HER2+ve  
 
Animal xenographt 
- - ¯ - ¯ ligand secretion  
(Chai et al., 2013) Cyclopamine  TN  ¯ - - ­ - 
(Zhuang et al., 
2013) Cyclopamine  
Panel of breast cancer cell 
lines - - - ­ - 
(Han et al., 2015) 
Vismodegib, 
GANT61 and 
LDE225 
Panel of breast cancer cell 
lines  ¯ - - ­ - 
(Benvenuto et al., 
2016) 
GDC-0449 
and GANT61 
Panel of breast cancer cell 
lines ¯ - - ­ - 
(Di Mauro et al., 
2017) LDE225 
primary breast cancer and 
cell lines ¯ - - - - 
(Heller et al., 
2012) 
Cyclopamine 
and LDE225 - ¯ - - ¯ - 
(Ramaswamy et 
al., 2012) Vismodegib - ¯ - - - - 
 
The effect of the inhibition of Hh signalling on other EMT regulatory pathways 
including Wnt/b-catenin signalling (described in Figure 0-9 and Figure 0-10) was not 
reported previously. In fact, crosstalk between Hh and Wnt pathways in breast cancer is 
poorly understood, even though it has been proven to be co-affected in epithelial 
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tumours such as colon cancer (Qualtrough et al., 2015). Additionally, Arnold et al. 
(2017) recently concluded that there is combined activation of Hh and Wnt signalling in 
TNBC cases showing increased risk of recurrence. We confirmed in the previous 
section (Figure 4-38) that there was a correlation between Hh signalling protein 
expression and changes in the level of b-catenin expression and nuclear localisation. 
Qualtrough et al. (2015) found that inhibition of Hh signalling induced expression of E-
cadherin and reduced invasion in colon cancer cell lines whilst reducing catenin related 
proteins. 
Due to the promising data from previous cell line and in vivo work, clinical 
trials commenced to using Hh signalling inhibitors in several types of solid tumours 
including advanced breast cancer, as summarised in Table 5-2. A Phase I clinical trial 
was completed that included advanced TN, hormone receptor-positive and metastatic 
breast cancers. Two more Phase II clinical trials are currently recruiting including one 
that specifically recruits breast cancer patients (NCT02694224); no results have been 
yet been published for these trials (Martin et al., 2015). 
 
Table 5-2: Clinical trials of Hh inhibitors that involved breast cancer patients  
This table summarises the clinical trials conducted or active that involved treating breast cancer cases 
with Hh inhibitors. 
 
Clinical trails Conditions Phase/Aims Drug Status 
NCT01576666 
Advanced solid tumours 
including triple-negative, 
(ER+ve, ER-ve, HER2-ve) 
metastatic breast cancer 
Phase Ib Oral LDE225 in combination with BKM120 Completed 
NCT02465060 
Solid tumours or lymphomas 
including breast cancers 
(metastatic) 
Phase II  Several Recruiting 
NCT02027376 Triple-negative advanced breast cancer Phase Ib 
LDE225 in combination 
with docetaxel 
Active, not 
recruiting 
(estimated end in 
May 2017) 
NCT02694224 Breast cancer Phase II  
Vismodegib in 
combination with 
neoadjuvant chemotherapy 
Recruiting 
(estimated end in 
December 2018) 
NCT01071564 Metastatic breast cancers that cannot be removed by surgery Phase I 
Vismodegib or other drugs 
(Notch inhibitor) Terminated 
NCT01757327 Stage II-III ER
+ve and HER2-ve 
breast cancer Phase II LDE225 
Withdrawn (Poor 
accrual) 
 
 The NCT01071564 and NCT01757327 clinical trials recruited TNBC and 
advanced metastatic breast cancers specifically. However, the NCT01071564 trial was 
terminated, and NCT01757327 was withdrawn before completion due to poor accrual. 
The preliminary data published showed that there is a lack of therapeutic efficacy as 
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seen in these two trials that were terminated (Habib and O'Shaughnessy, 2016). In the 
absence of results from other trials, it is difficult to determine the cause of failure of the 
treatment regimens used (Habib and O'Shaughnessy, 2016). Also, the efficacy of Hh 
inhibition on breast cancer might not be specific to a particular subtype of breast cancer. 
Increased activation of Hh signalling was not restricted to advanced TNBC, it was also 
shown in advanced hormone-positive tumours (Sun et al., 2014b; Diao et al., 2016). It 
would seem prudent therefore, to assess the level of expression and activity of Hh 
signalling in breast cancer patient samples prior to administration of treatment to ensure 
proper selection of patients that would benefit. 
Alteration of the expression levels of the Hh pathway components in breast 
cancer is not well-defined. Thus, understanding the functional consequences of the 
activation of Hh signalling in the breast cancer cells requires analysis and studies at the 
cellular level in a tractable model. The relationship between both the expression and the 
localisation of Gli proteins within the cellular compartments of breast cancer cells, and 
the functional consequence of this, remains poorly understood. Additionally, the 
potential crosstalk between Hh and Wnt signalling has not been elucidated in breast 
cancer. Further investigation of these pathways in breast cancer could lead to the 
identification of novel therapeutic targets particularly for advanced and metastatic 
disease which is currently incurable and has a poor prognosis. 
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5.1.1 Aims 
• To study the effect of inhibiting hedgehog signalling (Hh) on breast cancer cells 
in vitro. 
• To investigate the potential crosstalk between the Hh pathway and Wnt 
signalling in the regulation of EMT in breast cancer. 
5.1.2 Objectives 
• To inhibit Hh signalling in breast cancer cell lines using cyclopamine or 
LDE225 at three concentrations (1, 5 and 10µM) then: 
o To assess the effect of Hh inhibition on cell yield, viability and cell 
death in a panel of cell lines representing the different molecular 
subtypes of breast cancer. 
o To analyse the expression level and subcellular localisation of E-
cadherin, b-catenin, Gli1, Gli2, and Gli3 in the breast cancer cell lines in 
response to Hh inhibition. 
o Evaluate the effect of Hh inhibition on cellular motility and invasion of 
breast cancer cell lines. 
o To assess the effect of these treatments on output of canonical Wnt 
signalling activity. 
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5.2 Results 
5.2.1 Hedgehog inhibition with cyclopamine or LDE225 reduces cell yield in 
breast cancer cell lines 
To understand the effect of Hh inhibition on growth, viability and cell death of 
breast cancer cells, two breast cancer cell lines were treated for 48hours with either 
cyclopamine or LDE225 (1, 5 or 10µM), and cell yield, viability, and cell death were 
assessed. Cells were harvested following 48hours of treatment and the number of live 
and dead cells were counted using viability staining (acridine orange and propidium 
iodide (AO/PI)). Viability and cell death are presented as mean viable and dead cells as 
a percentage of the total. 
Treatment with cyclopamine or LDE225 caused a reduction in both cell yield 
and the viability of MCF7 cells (luminal A), shown in Figure 5-1. The viability of 
MCF7 decreased by 4% following 5µM and 10µM cyclopamine treatment (p-
value<0.001 and p-value<0.001, respectively) as seen in Figure 5-1-B. MCF7 cell death 
doubled following 5µM and 10µM cyclopamine treatment (p-value<0.01 and p-
value<0.001, respectively) shown in Figure 5-1-C. MCF7 cell yield showed a 20% and 
46% reduction following 5µM (p-value<0.001) and 10µM (p-value<0.0001) LDE225 
treatment, respectively compared to the vehicle control as summarised in Figure 5-1-D. 
Viability of MCF7 showed a 3% and 5% reduction following 5µM (p-value<0.0001) 
and 10µM (p-value<0.0001) LDE225 treatment, respectively, as seen in Figure 5-1-E. 
MCF7 cell death doubled following 5µM and 10µM LDE225 treatment (p-
value<0.0001 and p-value<0.0001, respectively) as shown in Figure 5-1-F. 
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Figure 5-1, Reduction of cell yield and viability of MCF7 cell line following 
treatment with either cyclopamine or LDE225. 
Comparison of the cell yields (A and D), viability (B and E) and percentage of dead (C and F) MCF7 
cells following 48 hours of treatment with two Hh inhibitors (cyclopamine or LDE225) at three 
concentrations (1µM, 5µM and 10µM) compared to vehicle control. Change in yield following inhibition 
with cyclopamine (A) or LDE225 (D) treatment. Results displayed as bars of means of numbers of cells ± 
S.D. Changes in the viability of MCF7 cells following inhibition by cyclopamine (B) and LDE225 (E). 
Change in percentage of dead MCF7 cells following inhibition with cyclopamine (C) and LDE225 (F). 
Results displayed as bars of mean percentages of cells ± S.D. This figure is representative of n=3 
experiments in triplicate. Statistical analysis was conducted, and significant differences between samples 
were indicated by *=p-value<0.05, **=p-value<0.01, ***=p-value<0.001 and ****=p-value<0.0001. 
 
Treatment with cyclopamine or LDE225 caused a reduction in MDA-MB-231 
(triple-negative and basal-like) cell yield and viability in a dose-dependent manner as 
summarised in Figure 5-2. Following cyclopamine treatment MDA-MB-231 cell yield 
showed a 6% decrease at 5µM (p-value<0.05) and 20% decrease at 10µM (p-
value<0.0001) seen in Figure 5-2-A. The viability of MDA-MB-231 cells reduced in a 
dose-dependent manner following 1µM, 5µM and 10µM cyclopamine treatment (p-
value<0.01, p-value<0.0001 and p-value 0.0001) seen in Figure 5-2-B. Cell death 
showed a 2% (p-value<0.01), 2.5% (p-value<0.0001) and 4% (p-value<0.0001) 
increase following 1µM, 5µM and 10µM treatment with cyclopamine, respectively, as 
seen in Figure 5-2-C. Following treatment with LDE225 cell yield decreased by 24% at 
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1µM (p-value<0.05), 19% at 5µM and 43% 10µM (p-value<0.01) as seen in Figure 
5-2-D. The viability of MDA-MB-231 decreased in a dose-dependent manner following 
LDE225 treatment, however, the change was not statistically significant (Figure 5-2-E). 
The percentage of dead cells increased accordingly following LDE225 treatment 
without significant difference (Figure 5-2-F). 
 
 
 
Figure 5-2, Reduction of cell yield and viability of MDA-MB-231 cell line following 
treatment with either cyclopamine or LDE225. 
Comparison of the cell yields (A and D), viability (B and E) and percentage of dead (C and F) MDA-
MB-231 cells following 48 hours of treatment with two Hh inhibitors (cyclopamine or LDE225) at three 
concentrations (1µM, 5µM and 10µM) compared to vehicle control. Change in yield following inhibition 
with cyclopamine (A) or LDE225 (D) treatment. Results displayed as bars of means of numbers of cells ± 
S.D. Changes in the viability of MDA-MB-231 cells following inhibition with cyclopamine (B) and 
LDE225 (E). Change in percentage of dead MDA-MB-231 cells following inhibition with cyclopamine 
(C) and LDE225 (F). Results displayed as bars of means percentages of cells ±S.D. This figure is 
representative of n=3 experiments in triplicate. Statistical analysis was conducted, and significant 
differences between samples were indicated by *=p-value<0.05, **=p-value<0.01, ***=p-value<0.001 
and ****=p-value<0.0001. 
 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
185 
 
  
5.2.2 Higher apoptosis in MCF7 than MDA-MB-231 following inhibition of Hh 
signalling 
An apoptosis assay (Casciola-Rosen et al., 1996) was utilised to see if the 
reduction in cell yield was caused by increased cell death of breast cancer cell lines 
after treatment with either cyclopamine or LDE225. FITC Annexin V detection was 
used to identify levels of apoptosis in MCF7 and MDA-MB-231 cells following 
48hours of treatment. Probing the cells with Annexin V in combination with PI allowed 
distinction between early and late apoptotic cells, or dead cells (final stages of apoptotic 
death or might have undergone necrosis) in samples by means of flow cytometry. 
In MCF7 cells, 1, 5 and 10µM of cyclopamine orLDE225 caused an increase in 
the percentage of dead cells (10%, 20% and 20% respectively) compared to the vehicle 
control (Figure 5-5-A and B). The percentage of dead cells following treatment showed 
a highly significant difference when compared with the vehicle control (p-
value<0.0001) (Figure 5-5-A and B). 
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Figure 5-3, Increase in MCF7 cells (luminal A) apoptosis following cyclopamine or 
LDE225 treatment. 
Comparison of the mean percentages of live (Blue), early apoptotic (Green), late apoptotic (Orange) and 
dead (Red) MCF7 cells following 48 hours of treatment with cyclopamine or LDE225 at 1µM, 5µM and 
10µM. Stacked bars of apoptosis assay results of percentages of live, early and late apoptosis and dead 
cells following cyclopamine (A) or LDE225 treatment (B). Below are tables that summarise the statistical 
comparisons between all variables. Results displayed as stacked columns of means percentage of cells ± 
S.D. This figure is representative of n=3 experiments in triplicate. Statistical analysis was conducted, and 
significant differences between samples were indicated by *p-value<0.05, **p-value<0.01, ***p-value< 
0.001 and ****p-value<0.0001 
 
The triple-negative and basal-like breast cancer cell line MDA-MB-231 (Figure 
5-4) showed less cell death following treatment compared to MCF7 (Figure 5-3). The 
percentage of cell death increased in a dose-dependent manner following treatment of 
MDA-MB-231 with cyclopamine or LDE225 for 48hours (Figure 5-4-A and B). 
Treatment of MDA-MB-231 cells with cyclopamine showed an increased in cell death 
to 2% at the highest concentration with statistical significance (Figure 5-4-A). The 
percentage of cell death following 48hours of LDE225 treatment (Figure 5-4-B) was 
higher than that seen following cyclopamine treatment (Figure 5-4-A). The increase in 
apoptosis following 5 and 10µM LDE225 treatment was twice as much as that seen in 
the vehicle control which was statistically significant (Figure 5-4-B). It should be noted 
that MCF7 cell line showed increased early apoptosis compared to increased late 
apoptosis percentage in MDA-MB-231 cell lines.  
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
187 
 
  
 
 
Figure 5-4, Increase MDA-MB-231 (triple-negative and basal) apoptosis following 
cyclopamine or LDE225 treatment. 
Comparison of the mean percentages of live (Blue), early apoptotic (Green), late apoptotic (Orange) and 
dead (Red) MDA-MB-231 cells following 48 hours of treatment with cyclopamine or LDE225 at 1µM, 
5µM and 10µM. Stacked bars of apoptosis assay results of percentages of live, early and late apoptosis 
and dead cells following cyclopamine (A) or LDE225 treatment (B). Below are tables that summarise the 
statistical comparisons between all variables. Results displayed as stacked columns of means percentage 
of cells ± S.D. This figure is representative of n=3 experiments in triplicate. Statistical analysis was 
conducted, and significant differences between samples were indicated by *p-value<0.05, **p-
value<0.01, ***p-value< 0.001 and ****p-value<0.0001. 
 
5.2.3 Localisation and level of Gli1 in breast cancer cell lines (MCF7 and MDA-
MB-231) 
Gli1, Gli2 and Gli3 were expressed in MCF7 and MDA-MB-231 cell lines in 
the vehicle control as seen in Figure 5-5. Gli1 showed cytoplasmic and nuclear 
localisation in MCF7 and MDA-MB-231 as shown in Figure 5-5-A and Figure 5-5-B. 
Gli2 showed relatively high cytoplasmic and low nuclear localisation in MCF7 cells as 
seen in Figure 5-5-B and showed high nuclear and low cytoplasmic localisation in 
MDA-MB-231 cells as seen in Figure 5-5-E. Gli3 was mainly nuclear in both cell lines 
with low cytoplasmic levels as seen in Figure 5-5-C and Figure 5-5-F. 
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Figure 5-5, Expression of Gli1, Gli2, and Gli3 in MCF7 and MDA-MB-231. 
Immunofluorescence Z stacked images of MCF7 and MDA-MB-231 cells captured under confocal 
microscope at 630x magnifications. MCF7 and MDA-MB-231 cells were double stained by b-catenin 
(Red) and Gli1 (green) antibodies (A and D). MCF7 and MDA-MB-231 cells were stained by Gli2 (Red) 
(B and E). MCF7 and MDA-MB-231 cells were double stained with E-cadherin (Red) and Gli3 (Green) 
(C and F). Cells were visualised by fluorescence labelled secondary antibodies Alexa Fluor® (488 and 
594). DAPI stain was used to stain nuclei of cells (Blue). 
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5.2.4 Decreased Gli1 expression and nuclear localisation is concomitant with 
increased nuclear localisation of Gli2 and Gli3 in breast cancer cell lines 
following treatment with cyclopamine or LDE225 
The expression of the Gli proteins following treatment were assessed for 
changes in level of expression using flow cytometry and for changes in localisation of 
proteins using Immunocytofluorescence (ICF). As seen in the histograms and bar charts 
that represent flow cytometry data, Gli1 expression increased following treatment with 
cyclopamine or LDE225 in MCF7 (Figure 5-6) and MDA-MB-231 (Figure 5-7). A 
notable decrease in Gli1 expression was observed following 5µM and 10µM LDE225 
treatment in both cell lines compared to the alteration observed following cyclopamine 
treatment (Figure 5-6). ICF images of MCF7 (Figure 5-6) and MDA-MB-231 (Figure 
5-7) apparently contradicted the flow cytometry expression results and showed that the 
overall protein level was decreased following treatment with either cyclopamine or 
LDE225 (Figure 5-6 and Figure 5-7). 
Increased Gli1 expression in MCF7 (Figure 5-6-A, B and Figure 5-7-A, B) and 
MDA-MB-231 cells (Figure 5-8-A, B, and Figure 5-9-A and B) showed by flow 
cytometry analysis could be a result of cytoplasmic accumulation of Gli1 due to 
inhibition of Hh signalling by cyclopamine (Figure 5-6-E and F and Figure 5-7-E and 
F) or 1µM LDE225 (Figure 5-8-A and B, Figure 5-9-A and B). The increase in 
cytoplasmic protein shown in flow cytometry as an increase in expression level and 
then decreased in cells treated with more than 5µM of cyclopamine or LDE225. There 
was increased punctate Gli1 in the cytoplasm of MCF7 and MDA-MB-231 cells 
following treatment as seen in ICF images of Figure 5-6 and Figure 5-7. 
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Figure 5-6, Alteration of Gli1 protein localisation and expression level in MCF7 
following cyclopamine treatment. 
Flow cytometry analysis of expression of Gli1 protein in MCF7 cells (A) percentage expression (B) MFI 
and (C) overlay histogram chart. Immunofluorescence Z stacked images of MCF7 cells captured using 
confocal microscope at 630x magnifications. MCF7 cells were double stained with b-catenin (Red) and 
Gli1 (green) antibodies. Vehicle control (D) MCF7 cells following 1µM and 10µM (F) treatment with 
cyclopamine for 48hours. Cells were visualised with fluorescence labelled secondary antibodies Alexa 
Fluor® (488 and 594). DAPI stain was used to stain cell nuclei (Blue). 
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Figure 5-7, Alteration of Gli1 localisation and expression MCF7 following 
treatment with LDE225. 
Flow cytometry analysis of expression of Gli1 protein in MCF7 cells (A) percentage expression (B) MFI 
and (C) overlay histogram chart. Immunofluorescence Z stacked images of MCF7 cells captured using 
confocal microscope at 630x magnifications. MCF7 cells were double stained with b-catenin (Red) and 
Gli1 (green) antibodies. Vehicle control (D) MCF7 cells following 1µM and 10µM (F) treatment with 
LDE225 for 48hours. Cells were visualised with fluorescence labelled secondary antibodies Alexa 
Fluor® (488 and 594). DAPI stain was used to stain cell nuclei (Blue). 
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Figure 5-8, Alteration of Gli1 protein expression and localisation in MDA-MB-231 
following cyclopamine treatment. 
Flow cytometry analysis of expression of Gli1 protein in MDA-MB-231 cells (A) percentage expression 
(B) MFI and (C) overlay histogram chart. Immunofluorescence Z stacked images of MDA-MB-231 cells 
captured using confocal microscope at 630x magnifications. MDA-MB-231 cells were double stained 
with b-catenin (Red) and Gli1 (green) antibodies. Vehicle control (D) MDA-MB-231 cells following 
1µM and 10µM (F) treatment with cyclopamine for 48hours. Cells were visualised with fluorescence 
labelled secondary antibodies Alexa Fluor® (488 and 594). DAPI stain was used to stain cell nuclei 
(Blue). 
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Figure 5-9, Alteration in Gli1 expression and localisation in MDA-MB-231 
following treatment with LDE225. 
Flow cytometry analysis of expression of Gli1 protein in MDA-MB-231 cells (A) percentage expression 
(B) MFI and (C) overlay histogram chart. Immunofluorescence Z stacked images of MDA-MB-231 cells 
captured using confocal microscope at 630x magnifications. MDA-MB-231 cells were double stained 
with b-catenin (Red) and Gli1 (green) antibodies. Vehicle control (D) MDA-MB-231 cells following 
1µM and 10µM (F) treatment with LDE225 for 48hours. Cells were visualised by fluorescence labelled 
secondary antibodies Alexa Fluor® (488 and 594). DAPI stain was used to stain nucleus of cells (Blue). 
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Gli2 level decreased in MCF7 cells following treatment with either cyclopamine 
or LDE225 as seen in, Figure 5-10-A and B, and Figure 5-11-A and B. Nuclear 
localisation of Gli2 increased in MCF7 cells without observable alteration of 
cytoplasmic levels following cyclopamine treatment (Figure 5-10-E and F), while 
showing notable reduction in cytoplasmic levels following LDE225 treatment (Figure 
5-11-E and F). In MCF7, the inhibition by LDE225 increased nuclear localisation of 
Gli2 (Figure 5-11-E and F) which was reflected as a reduction in expression seen by 
flow cytometry (Figure 5-11-A and B). 
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Figure 5-10, Reduction of Gli2 expression following cyclopamine treatment in 
MCF7. 
Flow cytometry analysis of expression of Gli2 protein in MCF7 cells (A) percentage expression (B) MFI 
and (C) overlay histogram chart. Immunofluorescence Z stacked images of MCF7 cells captured using 
confocal microscope at 630x magnifications. MCF7 cells were stained with Gli2 (Red) antibody. Vehicle 
control (D) MCF7 cells following 1µM and 10µM (F) treatment with cyclopamine for 48hours. Cells 
were visualised by fluorescence labelled secondary antibodies Alexa Fluor® (594). DAPI stain was used 
to stain cell nuclei (Blue).  
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Figure 5-11, Increased nuclear Gli2 and reduction of overall Gli2 expression in 
MCF7 following treatment with LDE225. 
Flow cytometry analysis of expression of Gli2 protein in MCF7 cells (A) percentage expression (B) MFI 
and (C) overlay histogram chart. Immunofluorescence Z stacked images of MCF7 cells captured using 
confocal microscope at 630x magnifications. MCF7 cells were stained with Gli2 (Red) antibody. Vehicle 
control (D) MCF7 cells following 1µM and 10µM (F) treatment with LDE225 for 48hours. Cells were 
visualised with fluorescence labelled secondary antibodies Alexa Fluor® (594). DAPI stain was used to 
stain cell nuclei (Blue). 
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Figure 5-12, Alteration of Gli2 expression and localisation in MDA-MB-231 
following cyclopamine treatment. 
Flow cytometry analysis of expression of Gli2 protein in MDA-MB-231 cells (A) percentage expression 
(B) MFI and (C) overlay histogram chart. Immunofluorescence Z stacked images of MDA-MB-231 cells 
captured using confocal microscope at 630x magnifications. MDA-MB-231 cells were stained with Gli2 
(Red) antibody. Vehicle control (D) MDA-MB-231 cells following 1µM and 10µM (F) treatment with 
cyclopamine for 48hours. Cells were visualised with fluorescence labelled secondary antibodies Alexa 
Fluor® (594). DAPI stain was used to stain cell nuclei (Blue). 
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Figure 5-13, Alteration of Gli2 expression and localisation in MDA-MB-231 
following treatment with LDE225. 
Flow cytometry analysis of expression of Gli2 protein in MDA-MB-231 cells (A) percentage expression 
(B) MFI and (C) overlay histogram chart. Immunofluorescence Z stacked images of MDA-MB-231 cells 
captured using confocal microscope at 630x magnifications. MDA-MB-231 cells were stained with Gli2 
(Red) and antibody. Vehicle control (D) MDA-MB-231 cells following 1µM and 10µM (F) treatment 
with LDE225 for 48hours. Cells were visualised with fluorescence labelled secondary antibodies Alexa 
Fluor® (594). DAPI stain was used to stain cell nuclei (Blue). 
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Following cyclopamine treatment, the overall expression of Gli3 decreased in 
MCF7 as seen in Figure 5-14-A and B and ICF images showed increase of Gli3 nuclear 
accumulation in Figure 5-14-E and F. Gli3 decreased to a lesser degree following 
LDE225 treatment of MCF7 as shown in Figure 5-15-A and B with less nuclear 
localisation as observed in Figure 5-15-E and F. Gli3 expression in MDA-MB-231 
increased as seen in Figure 5-16-A and B with a dose-dependent increase in nuclear 
localisation as observed in ICF images in Figure 5-16-E and F. Treatment with LDE225 
decreases Gli3 expression in MDA-MB-231 cells as seen by flow cytometry results in 
Figure 5-17-A and B, concurrent with increased nuclear localisation, as observed in ICF 
images in Figure 5-17-E and F. 
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Figure 5-14, Alteration of Gli3 expression following cyclopamine treatment in 
MCF7. 
Flow cytometry analysis of expression of Gli2 protein in MCF7 cells (A) percentage expression (B) MFI 
and (C) overlay histogram chart. Immunofluorescence Z stacked images of MCF7 cells captured using 
confocal microscope at 630x magnifications. MCF7 cells were stained with Gli3 (Green) and E-cadherin 
(Red) antibodies. Vehicle control (D) MCF7 cells following 1µM and 10µM (F) treatment with 
cyclopamine for 48hours. Cells were visualised with fluorescence labelled secondary antibodies Alexa 
Fluor® (488 and 594). DAPI stain was used to stain cell nuclei (Blue). 
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Figure 5-15, Alteration of Gli3 localisation and expression in MCF7 following 
treatment with LDE225. 
Flow cytometry analysis of expression of Gli3 protein in MCF7 cells (A) percentage expression (B) MFI 
and (C) overlay histogram chart. Immunofluorescence Z stacked images of MCF7 cells captured under 
confocal microscope at 630x magnifications. MCF7 cells were stained with Gli3 (Green) and E-cadherin 
(Red) antibodies. Vehicle control (D) MCF7 cells following 1µM and 10µM (F) treatment with LDE225 
for 48hours. Cells were visualised by fluorescence labelled secondary antibodies Alexa Fluor® (488 and 
594). DAPI stain was used to stain cell nuclei (Blue). 
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Figure 5-16, Alteration of Gli3 expression and localisation following cyclopamine 
treatment of MDA-MB-231. 
Flow cytometry analysis of expression of Gli3 protein in MDA-MB-231 cells (A) percentage expression 
(B) MFI and (C) overlay histogram chart. Immunofluorescence Z stacked images of MDA-MB-231 cells 
captured under confocal microscope at 630x magnifications. MDA-MB-231 cells were stained with Gli3 
(Green) and E-cadherin (Red) antibodies. Vehicle control (D) MDA-MB-231 cells following 1µM and 
10µM (F) treatment with cyclopamine for 48hours. Cells were visualised with fluorescence labelled 
secondary antibodies Alexa Fluor® (488 and 594). DAPI stain was used to stain cell nuclei (Blue). 
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Figure 5-17, Alteration of Gli3 expression and localisation in MDA-MB-231 
following treatment with LDE225. 
Flow cytometry analysis of expression of Gli3 protein in MDA-MB-231 cells (A) percentage expression 
(B) MFI and (C) overlay histogram chart. Immunofluorescence Z stacked images of MDA-MB-231 cells 
captured under confocal microscope at 630x magnifications. MDA-MB-231 cells were stained with Gli3 
(Green) and E-cadherin (Red) antibodies. Vehicle control (D) MDA-MB-231 cells following 1µM and 
10µM (F) treatment with LDE225 for 48hours. Cells were visualised with fluorescence labelled 
secondary antibodies Alexa Fluor® (488 and 594). DAPI stain was used to stain cell nuclei (Blue). 
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5.2.5 Reduction of b-catenin expression in MCF7 and MDA-MB-231 cells 
following inhibition of Hh signalling 
b-catenin protein is involved in the regulation of EMT via Wnt signalling and 
changes in the expression of this protein are implicated in EMT-associated change in 
human cancers (Shan et al., 2015). Hence, assessment of nuclear accumulation and 
changes in expression of b-catenin was assessed following treatment of breast cancer 
cell lines with either cyclopamine or LDE225 using flow cytometry, whereby, changes 
in positivity (percentage of positive cells) and MFI (level of expression) were 
evaluated. 
Positivity of b-catenin expression was represented at percentage of positive cells 
and changes in the level of expression in the population of positive cells were 
represented in the graph as median fluorescence intensity (MFI). b-catenin positivity 
decreased in MCF7 cells following cyclopamine or LDE225 treatment and the level of 
b-catenin expression increased as summarised in Figure 5-31. The positivity of b-
catenin decreased by 2% (p-value<0.01), 4% (p-value<0.0001) and 5% (p-
value<0.0001) following 1µM, 5µM and 10µM cyclopamine treatment as seen in 
Figure 5-31. The level of b-catenin expression in MCF7 increased by 20% (p-
value<0.01), by 40% (p-value<0.0001) and 30% (p-value<0.0001) as presented in 
(Figure 5-31-B). Following treatment of MCF7 with 1µM, 5µM and 10µM LDE225, b-
catenin positivity decreased by 45% (p-value<0.0001), 45% (p-value<0.0001) and 51% 
(p-value<0.0001), respectively as seen in Figure 5-31-D. The overlay histograms 
showed a population of low expressing cells that increased in number in dose-
dependent manner following cyclopamine (Figure 5-31-C) or LDE225 treatment 
(Figure 5-31-F).  
The positivity and level of b-catenin expression in MDA-MB-231 cells 
decreased in a dose-dependent manner following treatment with either cyclopamine or 
LDE225 as summarised in Figure 5-19. The positivity of b-catenin decreased by 0.5% 
(p-value<0.01), 0.5% (p-value<0.01) and 1 % (p-value<0.0001) following 1µM, 5µM 
and 10µM cyclopamine treatment as seen in Figure 5-19-A. The level of b-catenin 
expression following cyclopamine treatment in MDA-MB-231 cells decreased by 8% 
(p-value<0.0001) and 20% (p-value<0.0001) as presented in Figure 5-19-B. As shown 
in Figure 5-19-D, b-catenin positivity decreased by 1% (p-value<0.0001), 1% (p-
value<0.0001) and 2% (p-value<0.0001) at 1µM, 5µM 10µM LDE225, respectively. 
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MFI, as shown in Figure 5-19-E, decreased by 13% (p-value<0.0001), 17% (p-
value<0.0001) and 24% (p-value<0.0001) at 1µM, 5µM and 10µM LDE225 treatment, 
respectively. Overlay histograms showed a population of low to none expressing cells 
that increase at the highest concentration of both cyclopamine and LDE225 treatment 
(Figure 5-19-C and F). 
 
 
 
Figure 5-18, Reduction of b-catenin in luminal breast cancer cell line MCF7 
following treatment with either cyclopamine or LDE225. 
Presentation of percentage of b-catenin protein expression in MCF7 following treatment with either 
cyclopamine or LDE225 at 1µM, 5µM and 10µM. Percentage of positive cells were estimated using flow 
cytometry, and SW480 cell line was used as positive control for b-catenin protein expression. Bars 
present the percentage of b-catenin positive cells and MFI of b-catenin following treatment with 
cyclopamine (A and B) or LDE225 (D and E). Results displayed as bars of MFI ± S.D. Overlap 
histograms of the b-catenin protein in MCF7 cells, comparing (unstained cells, vehicle control, 1µM, 
5µM, and 10µM) of cyclopamine treatment (C) and LDE225 treatment (F). This figure is representative 
of n=3 experiments in triplicate. Statistical analysis was conducted, and significant difference between 
samples was indicated by * p-value<0.05, ** p-value<0.01, *** p-value<0.001 and **** p-
value<0.0001. 
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Figure 5-19, Reduction of b-catenin in the triple-negative and basal-like breast 
cancer cell line MDA-MB-231 following treatment with cyclopamine or LDE225. 
Presentation of percentage of b-catenin protein expression in MDA-MB-231 following treatment with 
either cyclopamine or LDE225 at 1µM, 5µM and 10µM. Percentage of positive cells were estimated 
using flow cytometry, and SW480 cell line was used as positive control for b-catenin protein expression. 
Bars present the percentage of b-catenin positive cells and MFI of b-catenin following treatment with 
cyclopamine (A and B) or LDE225 (D and E). Results displayed as bars of MFI ± S.D. Overlap 
histograms of the b-catenin protein in MDA-MB-231 cells, comparing (unstained cells, vehicle control, 
1µM, 5µM, and 10µM) of cyclopamine treatment (C) and LDE225 treatment (F). This figure is 
representative of n=3 experiments in triplicate. Statistical analysis was conducted, and significant 
difference between samples was indicated by * p-value<0.05, ** p-value<0.01, *** p-value<0.001 and 
**** p-value<0.0001. 
 
5.2.6 Increased E-cadherin in breast cancer cell lines following treatment with 
cyclopamine or LDE225 
The expression level of E-cadherin protein was assessed to evaluate the effect of 
Hh inhibition on epithelial marker expression in MCF7 and MDA-MB-231 cells. E-
cadherin increased in a dose-dependent manner in MCF7 following treatment with 
either cyclopamine or LDE225 as summarised in Figure 5-33. The positivity of E-
cadherin in MCF7 cells increased by 5% (p-value<0.01) and 7% (p-value<0.001) at 
1µM and 10µM, respectively as shown in Figure 5-33-A. MFI of E-cadherin in MCF7 
cells decreased by 18% (p-value<0.0001) and 6% (p-value 0.05) as seen in Figure 5-33-
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B. Using Western blotting, E-cadherin in MCF7 showed a four-fold increase (p-
value<0.05) and 5-fold increase (p-value<0.05) in MCF7 following 5µM and 10µM 
cyclopamine treatment compared to the vehicle control as seen in Figure 5-33-D and 
Figure 5-33-E. By flow cytometry the positivity of E-cadherin in MCF7 following 
1µM, 5µM and 10µM LDE225 treatment increased by 5% (p-value<0.001), 8% (p-
value<0.0001) and 9% (p-value<0.0001), respectively as seen in Figure 5-33-F. The 
level (MFI) of E-cadherin expression in MCF7 following 10µM LDE225 treatment 
increased by 35% (p-value<0.0001) compared to the vehicle control as presented in 
Figure 5-20-G. The ratio of E-cadherin expression in MCF7 following 1µM, 5µM and 
10µM LDE225 treatment showed 1.8-fold increase (p-value<0.01), 5.2-fold increase 
(p-value<0.0001) and eight-fold increase (p-value<0.0001) compared to the vehicle 
control as seen in Figure 5-33-I and Figure 5-33-J. The overlap histogram showed that 
there was a population of low-to-negative expressing cells observed before and after 
treatment with all concentrations cyclopamine or LDE225 (Figure 5-33-C and H). 
The positivity of E-cadherin in MDA-MB-231 cells increased following 
treatment with cyclopamine or LDE225 as summarised in Figure 5-21. As seen in 
Figure 5-21-A, the positivity of E-cadherin in MDA-MB-231 cells increased by 16% 
(p-value<0.0001) following 10µM cyclopamine treatment. E-cadherin protein showed 
1.5% increase and 3.5% increase following 5µM and 10µM cyclopamine treatment in 
MDA-MB-231 compared to the vehicle control (Figure 5-21). The positivity and MFI 
of E-cadherin in MDA-MB-231 cells decreased by 6% (p-value<0.0001) following 
1µM LDE225 treatment as seen in Figure 5-21-F and Figure 5-21-G. Positivity of E-
cadherin showed a 4% increase (p-value<0.0001) in MDA-MB-231 after 10µM 
treatment with LDE225, as shown in Figure 5-21-I and Figure 5-21-J. 
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Figure 5-20, E-cadherin expression increased in a dose-dependent manner 
following treatment with cyclopamine or LDE225 of MCF7 cell line. 
Expression of E-cadherin protein in MCF7 following treatment with two types of Hh inhibitors 
(cyclopamine or LDE225) at 1µM, 5µM and 10µM. Percentage of positive cells were estimated by flow 
cytometry (A, B, C, F, G, and H). HT29 cell line was used as a positive control for E-cadherin protein 
expression. The relative expression of E-cadherin protein was estimated by Western blotting and was 
corrected against loading control a-tubulin. The ratios presented were calculated as relative expression 
against vehicle control (D, E, I, and J). Bars present the percentage of E-cadherin positive cells following 
cyclopamine treatment (A) or LDE225 (F). Results displayed as bars of means of percentages of cells ± 
S.D. Bars present MFI of E-cadherin following cyclopamine treatment (B) or LDE225 treatment (G). 
Results displayed as bars of MFI ± S.D. Overlap histograms of E-cadherin protein in MCF7 cells, 
comparing (unstained cells, vehicle control, 1µM, 5µM, and 10µM) of cyclopamine treatment (C) or 
LDE225 treatment (H). The relative expression of E-cadherin in MCF7 cells following treatment with 
cyclopamine (E) or LDE225 (J) at three concentrations for 48 hours. Results displayed as bars of 
averages of corrected ratio of E-cadherin protein ± S.D. E-cadherin protein band at 120 kDa following 
cyclopamine treatment (D) or LDE225 treatment (I) compared against vehicle control and bands of 
loading control protein a-tubulin at 50 kDa band sizes. This figure is representative of n=3 experiments 
in triplicate. Statistical analysis was conducted, and significant differences between samples were 
indicated by * p-value<0.05, ** p-value<0.01, *** p-value<0.001 and **** p-value<0.0001. 
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Figure 5-21, E-cadherin expression increased in MDA-MB-231 cells following 
treatment with cyclopamine or LDE225. 
Expression of E-cadherin protein in MDA-MB-231 following treatment with two types of Hh inhibitors 
(cyclopamine or LDE225) at 1µM, 5µM and 10µM. Percentage of positive cells were estimated by flow 
cytometry (A, B, C, F, G, and H). HT29 cell line was used as a positive control for E-cadherin protein 
expression. The relative expression of E-cadherin protein was estimated by Western blotting and was 
corrected against loading control a-tubulin. The ratios presented were calculated as relative expression 
against vehicle control (D, E, I, and J). Bars present the percentage of E-cadherin positive cells following 
cyclopamine treatment (A) or LDE225 (F). Results displayed as bars of means of percentages of cells ± 
S.D. Bars present MFI of E-cadherin following cyclopamine treatment (B) or LDE225 treatment (G). 
Results displayed as bars of MFI ± S.D. Overlap histograms of E-cadherin protein in MCF7 cells, 
comparing (unstained cells, vehicle control, 1µM, 5µM, and 10µM) of cyclopamine treatment (C) or 
LDE225 treatment (H). The relative expression of E-cadherin in MDA-MB-231 cells following treatment 
with cyclopamine (E) or LDE225 (J) at three concentrations for 48 hours. Results displayed as bars of 
averages of corrected ratio of E-cadherin protein ± S.D. E-cadherin protein band at 120 kDa following 
cyclopamine treatment (D) or LDE225 treatment (I) compared against vehicle control and bands of 
loading control protein a-tubulin at 50 kDa band sizes. This figure is representative of n=3 experiments 
in triplicate. Statistical analysis was conducted, and significant differences between samples were 
indicated by * p-value<0.05, ** p-value<0.01, *** p-value<0.001 and **** p-value<0.0001. 
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5.2.7 Inhibition of Hh signalling with cyclopamine or LDE225 decreases motility 
and invasion of breast cancer cells 
The number of migrated and invaded cells were counted and presented as 
average cells/field and compared against the vehicle control. One concentration of 
treatment (1µM) was selected, to eliminate the bystander reduction of motility of cells 
due to increased apoptosis (Figure 5-3 and Figure 5-4). 
The inhibition of Hh signalling in MCF7 cells with cyclopamine (Figure 5-22-
A) or LDE225 (Figure 5-22-B) caused a decrease in the number of migrated cells 
without reaching statistical significance (Figure 5-22-A and B). There was a 20 % 
reduction in the average number of cells that invaded the Matrigel® following both 
treatments. The average number of cells/field that invaded was reduced following 
cyclopamine (p-value < 0.01) or LDE225 (p-value<0.01) (Figure 5-22-C and D). 
Treatment of MDA-MB-231 with either cyclopamine or LDE225 resulted in a 
significant reduction in cell migration by 8% and 16% respectively (p-value<0.05 and 
p-value<0.0001 respectively), as shown in Figure 5-23-A and B. The average number 
of cells that invaded the Matrigel® matrix was reduced in both treatments by 12 and 
20% respectively with a significant decrease seen following LDE225 treatment (p-
value<0.01) (Figure 5-23-D). 
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Figure 5-22, Reduction in the cellular motility and invasion of MCF7 cells 
following treatment with cyclopamine or LDE225. 
Average number of cells/field of MCF7. A and B show average of migrated cells following cyclopamine 
(A) or LDE225 (B) treatment for 24 hours compared to the vehicle control (Blue). C and D representing 
averages of invading MCF7 cells following treatment with either cyclopamine (C) or LDE225 (D) 
compared to the vehicle control (Blue). Representatives microscopic images of fields of inserts (vehicle 
control, cyclopamine, or LDE225 treated cells) visualised by haematoxylin staining (blue cells). Results 
displayed as bars of mean ± S.D. This figure is representative of n=3 experiments in triplicate. Statistical 
analysis was conducted, and significant differences between samples were indicated by * p-value<0.05, 
***p-value<0.01 and **** p-value<0.0001. 
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Figure 5-23, Reduction in the cellular motility and invasion of MDA-MB-231 cells 
following treatment with cyclopamine or LDE225. 
Average number of cells/field of MDA-MB-231. A and B show average of migrated cells following 
cyclopamine (A) or LDE225 (B) treatment for 24 hours compared to the vehicle control (Blue). C and D 
representing averages of invading MDA-MB-231 cells following treatment with either cyclopamine (C) 
or LDE225 (D) compared to the vehicle control (Blue). Representatives microscopic images of fields of 
inserts (vehicle control, cyclopamine, or LDE225 treated cells) visualised by haematoxylin staining (blue 
cells). Results displayed as bars of mean ± S.D. This figure is representative of n=3 experiments in 
triplicate. Statistical analysis was conducted, and significant differences between samples were indicated 
by * p-value<0.05, ***p-value<0.01 and **** p-value<0.0001. 
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5.2.8 Treatment with cyclopamine or LDE225 reduced b-catenin-related 
transcription in MCF7 and MDA-MB-231 
A TOPFLASH reporter assay for Wnt/b-catenin signalling was used to assess 
the effect of treatment with either cyclopamine or LDE225 on canonical Wnt signalling 
by measuring the catenin-related transcription (CRT). Following reporter plasmid 
transfection, cells were treated for 24hours with either cyclopamine or LDE225 (1µM), 
and then lysed to measure CRT. 
The colorectal cancer cell line SW480 was included as a positive control for the 
transfection procedure (high TOPFLASH activity). This cell line was transfected 
previously by Qualtrough et al. (2015) and the results obtained here were similar to 
those observed previously, confirming successful transfection. Furthermore, treatment 
of SW480 with cyclopamine showed an equivalent inhibition of CRT reporter activity 
to that reported by Qualtrough et al. (2015). It was also noted that treatment with 
LDE225 resulted in a 50% reduction in CRT in SW480, which was greater than the 
effect observed with cyclopamine treatment (Figure 5-24-C). 
The data showed CRT reduction in MCF7 (Figure 5-24-A) and MDA-MB-231 
cells (Figure 5-24-B) with either cyclopamine or LDE225. The reduction of CRT level 
in MCF7 was significant following cyclopamine (p-value<0.0001). The difference 
between the CRT level in MCF7 following treatment with either cyclopamine or 
LDE225 treatments were also significant (p-value<0.001) (Figure 5-24-A). A 
statistically significant reduction in CRT was observed in MDA-MB-231 following 
treatment with cyclopamine (p-value<0.05) or LDE225 (p-value<0.0001) compared to 
the vehicle control (Figure 5-24-B). 
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Figure 5-24, CRT of MCF7, MDA-MB-231 and SW480 cells reduced following 
treatment with cyclopamine of LDE225 
The b-CRT reporter levels (fold control) following 24 hours of treatment with 1µM of cyclopamine or 
1µM of LDE225 compared to vehicle control for A- MCF7 cells, B- MDA-MB-231 cells, and SW480. 
Data showed activity of TOPFLASH reporter, corrected against FOPFLASH and normalised to Renilla 
control plasmid (transfection efficiency control). The data represented mean from three separate 
experiments performed in triplicate and value shown as fold control ±S.D. Statistical analysis was 
conducted, and significant differences between samples were indicated by * p-value<0.05, ** p-
value<0.01, *** p-value<0.001 and **** p-value<0.0001.  
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5.3 Discussion 
5.3.1 Inhibition of Hedgehog (Hh) signalling in MCF7 (luminal) and MDA-MB-
231 (triple-negative and basal-like) reduced cell yield and increased cell 
death 
Two cell lines were selected to assess the effect of Hh inhibition by treatment 
with cyclopamine or LDE225. MCF7 (luminal) and MDA-MB-231 (TNBC and basal-
like) are considered representative for their molecular subtypes of breast cancer. MCF7 
cells have epithelial morphology with low metastatic ability, while MDA-MB-231 cells 
have mesenchymal morphology with high metastatic ability (Kenny et al., 2007a; 
Rizwan et al., 2015). 
Several previous studies reported the effect of inhibiting Hh signalling using 
cyclopamine on breast cancer cell lines, summarised in Table 5-1, as cyclopamine is a 
naturally-occurring plant alkaloid and the first identified Hh inhibitor (Bryden et al., 
1971). High concentrations (higher than 10µM) of cyclopamine may cause off-target 
effects (Yauch et al., 2008) and non-specific cytotoxicity (Lipinski et al., 2008). Thus, 
doses over 10µM for both treatments were avoided in experimentations. 
Previous work has shown that high concentrations of cyclopamine (20µM) 
caused significantly reduced proliferation of both MCF7 and MDA-MB-231 
(Mukherjee et al., 2006; Zhang et al., 2009). However, Kubo et al. (2004) showed that 
at 10µM, cyclopamine reduced viability but not proliferation of MCF7 and MDA-MB-
231. As shown in Figure 5-1-A, treatment with cyclopamine caused a dose-dependent 
decrease of MCF7 cell yield, however, this decrease did not reach statistical 
significance potentially due to inter-experimental variation. Whereas, treatment of 
MDA-MB-231 cells with 5µM and 10µM cyclopamine caused a decrease of cell yield 
(p-value<0.05, and p-value<0.0001, respectively as shown in Figure 5-2-A. 
Cyclopamine also decreased the viability of MCF7 and MDA-MB-231 in a dose-
dependent manner, as seen in Figure 5-1-B and Figure 5-2-B. In concurrence, Thomas 
et al. (2011) showed that cyclopamine treatment decreased proliferation in breast 
cancer cell lines. 
LDE225 was discovered in 2010 in a high throughput in vitro screen (Pan et al., 
2010). It is a small molecule inhibitor that antagonises Smoothened (Smo) preventing it 
from transducing the downstream Hh signal and activating the Gli transcription factors 
(Jain et al., 2017). This inhibitor was approved by the US Food and Drug 
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Administration for the treatment of basal-cell carcinoma following a successful Phase II 
clinical trial (Dummer et al., 2016). 
LDE225 treatment causes reduced proliferation of several other cancer types 
including melanoma (Jalili et al., 2013), non-small cell lung carcinoma (Della Corte et 
al., 2015) and ovarian cancer (Steg et al., 2012). Since its success in preliminary 
clinical trials, relatively few studies have used it for inhibiting Hh signalling to 
investigate its potential therapeutic effect in breast cancer cells. Heller et al. (2012) and 
Matevossian and Resh (2015) reported that LDE225 reduced breast cancer cell line 
proliferation in vitro. Their findings concur with the current results. We showed that 
inhibition of Hh signalling in MCF7 and MDA-MB-231 by LDE225 resulted in 
reduction of cell yield and cell viability in a dose-dependent manner as summarised in 
Figure 5-1 and Figure 5-2. Treatment with LDE225 in animal xenografts also dose-
dependently caused inhibition of breast cancer cell proliferation (Han et al., 2015; Di 
Mauro et al., 2017). 
In combination with a reduction in cell yield, we showed that treatment with 
cyclopamine or LDE225 increased apoptosis in MCF7 and MDA-MB-231 cells as seen 
in Figure 5-3 and Figure 5-4. Previous studies reported that cyclopamine reduced cell 
yield by increasing MCF7 and MDA-MB-231 apoptosis (Mukherjee et al., 2006; Zhang 
et al., 2009; Zhuang et al., 2013). The effect of LDE225 on apoptosis in breast cancer 
cells has not, however, been previously reported. Nonetheless, LDE225 is known to 
induce apoptosis in other human cancer cell lines including melanoma (Jalili et al., 
2013), gastric cancer (Han et al., 2009), and prostate cancer (Shigemura et al., 2011). 
In summary, the inhibition of Hh signalling in breast cancer cell lines showed a 
dose-dependent decrease in cell yield with a concomitant induction of cell death. The 
MCF7 cell line proved more sensitive to this growth inhibition than MDA-MB-231. 
Correspondingly, more cell death was seen in MCF7 cells than in MDA-MB-231 
following treatment with either cyclopamine or LDE225. Also, it was notable that most 
apoptosis seen in MCF7 is early apoptosis whereas most apoptosis seen in MDA-MB-
231 cells were late apoptosis. This could be due to the duration of treatment, or a 
difference in mechanisms of oncogene/tumour suppressor imbalances between the two 
cell lines. 
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5.3.2 Gli protein expression levels and localisation were altered following 
inhibition of Hh signalling by cyclopamine and LDE225 
Gli proteins are zinc-finger transcription factors that have activator and 
repressor forms (Ruiz i Altaba et al., 2007). Gli1 is expressed as an active from while 
Gli2 and Gli3 have two forms (active and inactive) (Figure 0-8) (Ruiz i Altaba et al., 
2007). The level of expression and localisation of the three Gli proteins reflects the 
status of the Hh signalling pathway (Figure 0-7) (Ruiz i Altaba et al., 2007) and 
alteration in expression levels and subcellular localisation were documented previously 
in human cancers (Ruiz i Altaba et al., 2002). Estimation of nuclear localisation of Gli 
proteins in breast cancer samples indicated the status of Hh signalling and assessing 
nuclear localisation correlated with several clinicopathological characteristics (ten Haaf 
et al., 2009; Li et al., 2012). Here we used flow cytometry to assess Gli proteins 
expression levels and immunocytofluorescence (ICF) for investigation of subcellular 
localisation changes in response to hedgehog pathway inhibition. 
Herein, Gli proteins levels were not compared between cell lines and 
observation of variation of localisation following treatment was assessed visually using 
confocal microscopy. Most of previously published work focussed on studying the 
alteration of Gli1 only. Until the time of submitting this work, regulation of Gli1, Gli2 
and Gli3 proteins localisation following Hh inhibition has not been reported and this is 
the first study to show alteration of level and subcellular localisation of Gli proteins in 
breast cancer cells after Hh inhibition using either cyclopamine or LDE225. 
The data showed that MCF7 and MDA-MB-231 expressed Gli1, Gli2 and Gli3 
(Figure 5-5) which was similar to the findings of previous studies (Kubo et al., 2004; 
Dennler et al., 2007; ten Haaf et al., 2009; Zhang et al., 2009; Ramaswamy et al., 2012; 
Wang et al., 2014; Song et al., 2016; Kurebayashi et al., 2017). Also, nuclear 
localisation of Gli1 was higher in MCF7 than MDA-MB-231, which concurs with 
finding of Wolf et al. (2007). They also reported that high expression of Gli1 in MCF7 
correlated with higher Gli reporter activity than that seen in MDA-MB-231 which 
confirmed that the nuclear localisation of Gli1 indicates increased Hh activity in breast 
cancer (Wolf et al., 2007). Other studies also showed that Gli1 had nuclear and 
cytoplasmic localisation in MCF7 but cytoplasmic in MDA-MB-231 (Kubo et al., 
2004; Kameda et al., 2009). 
Alteration of Gli1 localisation following LDE225 treatment in breast cancer cell 
lines was not reported previously. Decreased expression of Gli1 was reported in 
previous work on breast cancer cell lines (Kubo et al., 2004; Zhang et al., 2009; 
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Thomas et al., 2011). Kubo et al. (2004) also showed Gli1 expression in MCF7 cells 
was reduced following treatment with cyclopamine without changing subcellular 
localisation. However, current data were captured under higher magnification and co-
localisation using Z-stack confocal microscopy imaging which is more suitable and 
sensitive for assessing alteration of subcellular localisation. In MDA-MB-231 cells, 
treatment with cyclopamine decreased both nuclear and cytoplasmic localisation of 
Gli1 (Figure 5-8-A and B). However, LDE225 caused a reduction in nuclear and 
cytoplasmic localisation of Gli1 in multiple myeloma (Blotta et al., 2012). Treatment of 
MCF7 and MDA-MB-231 cells with LDE225 caused reduced nuclear Gli1 in a dose-
dependent manner greater than that observed following cyclopamine treatment (Figure 
5-8). This suggests a more potent effect of LDE225 in reducing of Hh activity in breast 
cancer cell lines. The reduction in nuclear localisation was visibly pronounced in MCF7 
cells especially after treatment with LDE225 at the highest dose (10µM). 
In breast cancer, overexpression of Gli1 was also associated with active 
proliferation and high mitotic activity in an animal model (Fiaschi et al., 2009). The 
inhibition of Hh signalling caused a reduction in Gli1 expression in MCF7 and MDA-
MB-231 cells (Table 5-5 and Table 5-6) and this reduction was associated with 
decrease in cell yield after 48hours (Figure 5-3 and Figure 5-4). Kameda et al. (2009) 
and Colavito et al. (2014) showed that knocking down of Gli1 caused a significant 
reduction in cell proliferation compared to vehicle control. Diao et al. (2016) indicated 
that inhibiting Gli1 by siRNA resulted in a significant reduction in cell proliferation. 
MCF7 and MDA-MB-231 showed reduced cell yield following 48hours treatment with 
cyclopamine or LDE225 which is consistent with previous findings (Figure 5-3 and 
Figure 5-4).  
Im et al. (2013) evaluated Hh related protein expression in breast cancer 
samples and showed that expression of Gli2 was associated with the worst overall 
survival. Alteration of Gli2 protein localisation in breast cell lines following Hh 
inhibition by cyclopamine or LDE225 was not previously reported. Inhibition of Hh 
signalling by GANT61 (a Gli1 and Gli2 blocker and inhibitor of Gli mediated 
transcription) in MCF7 resulted in reduction of Gli2 expression, however no analysis of 
treatment effect on the nuclear localisation was assessed in this study (Kurebayashi et 
al., 2017). Here, data showed that Gli2 expression was reduced following treatment 
with either cyclopamine or LDE225 (Figure 5-3). 
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Song et al. (2016) showed that MDA-MB-231 had strong expression of Gli1 
and Gli2 and that inhibition of Hh signalling by cyclopamine resulted in a reduction of 
both Gli1 and Gli2. This agrees with our data as we showed that inhibition of Hh 
signalling in MDA-MB-231 cells by 1µM and 5µM cyclopamine significantly 
decreased Gli2 expression (Figure 5-12-A and B). The inhibition by cyclopamine also 
caused increased nuclear localisation of Gli2 in MDA-MB-231 (Figure 5-12-E and F). 
Following LDE225 treatment, there was increased expression of Gli2 in a dose-
dependent manner (Figure 5-12 and Figure 5-13–A and B) with a notable reduction in 
cytoplasmic localisation (Figure 5-13-E and F). 
Gli3 is the suppressor form of the Gli proteins and it is expressed as a full-length 
inactive form that requires cleavage for activation (Figure 0-8) (Ruiz i Altaba et al., 
2007). High expression of Gli3 in colorectal cancer was associated with a poorly-
differentiated histological grade (Iwasaki et al., 2013). None of the previous work in 
breast cancer studied the effect of inhibiting Hh signalling on expression and 
localisation of Gli3 in breast cancer cell lines. High expression of Gli3 was seen in 
luminal epithelial cells of the developing mammary gland (Hatsell and Cowin, 2006). 
This increased expression was associated with decreased activation of Hh signalling 
that is required during that stage of breast cancer development (Hatsell and Cowin, 
2006). 
5.3.3 Reduction in catenin related transcription following treatment with 
cyclopamine or LDE225 in MCF7 and MDA-MB-231 cells 
To ascertain whether there is crosstalk between Hh and Wnt signalling, the 
expression of b-catenin protein was assessed by flow cytometry and ICF following Hh 
pathway inhibition. CRT was measured using the TOPFLASH reporter assay (Korinek 
et al., 1997) and compared following treatment with either cyclopamine or LDE225 at 
1µM (Figure 5-24). Qualtrough et al. (2015) showed that CRT was reduced following 
inhibiting Hh signalling with cyclopamine in colon cancer cell lines in a dose-
dependent manner compared to the vehicle control. Here, SW480 (a colon cancer cell 
line), used previously by Qualtrough et al. (2015), was used as a positive control, and 
similar reduction of CRT was seen following treatment with 1µM cyclopamine (Figure 
5-24-C). In addition, following treatment with 1µM LDE225 CRT was reduced to half 
the level of the vehicle control, which is greater than the reduction seen following 
cyclopamine treatment (Figure 5-24-C). 
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This is the first study to investigate the effect of inhibiting Hh signalling on the 
Wnt/b-catenin pathway in breast cancer cells. Recently, Arnold et al. (2017) showed 
that there was a correlation between the simultaneous activation of both signalling 
pathways and a poorer prognosis in TNBC patients.  
The expression and subcellular localisation of b-catenin in response to Hh 
inhibition has not previously been reported in breast cancer. Inhibition of Hh, by 
cyclopamine or LDE225, led to reduction of b-catenin expression in both cell lines 
studied here (Table 5-3). This decrease in expression was also accompanied by 
increased cell membrane localisation and decreased cytoplasmic and nuclear 
localisation, noted especially in the luminal cell line MCF7 (Table 5-11 and Table 5-
12). 
Ulloa et al. (2007) showed that Gli3 which is synthesised in the absence of Hh 
signalling can antagonise b-catenin. This offers a potential explanation for the findings 
presented here, as inhibition of Hh caused an increase in the nuclear localisation of Gli3 
in both cell lines ( 
Table 5-5), and this was associated with a decrease in CRT. Furthermore, 
Maeda et al. (2006) showed that Gli1 transcriptional activity was enhanced by b-
catenin, whereas here we showed that a decrease in nuclear localisation of Gli1, 
following inhibition of Hh signalling, is associated with reduced activity of b-catenin. 
Therefore, the findings presented here suggest that there is an interaction between these 
signalling pathways in breast cancer cells, and although further analysis is required, this 
may have serious relevance for the clinical management of breast cancer. 
 
Table 5-3: Decrease in b-catenin protein in a dose-dependent manner following 
cyclopamine or LDE225 in MCF7 and MDA-MB-231 cell lines. 
Summary of changes in the level of b-catenin expression following the inhibition of Hh signalling by two 
treatments (cyclopamine or LDE225) at three concentrations (1µM, 5µM, and 10µM). Arrows indicate 
the change in expression of b-catenin compared to vehicle control. 
 
Treatment 1µM cyclopamine 
5µM 
cyclopamine 
10µM 
cyclopamine 
1µM 
LDE225 
5µM 
LDE225 
10µM 
LDE225 
MCF7 ¯ ¯¯ ¯¯¯ ¯¯¯ ¯¯¯ ¯¯¯ 
MDA-MB-231 ¯ ¯ ¯ ¯ ¯ ¯ 
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Table 5-4: Decrease in cytoplasmic b-catenin in MCF7 cell line following inhibition 
of Hh pathway by either cyclopamine or LDE225. 
Summary of changes in b-catenin cytoplasmic localisation following treatment with cyclopamine or 
LDE225 at two concentrations of treatment (1µM and 10µM) for 48 hours. Arrows indicate qualitative 
observation of level of cytoplasmic localisation of b-catenin compared to that seen in vehicle control. 
 
Treatment 1 µM cyclopamine 
10 µM 
cyclopamine 1 µM LDE225 10 µM LDE225 
MCF7 ¯ ¯¯ ¯ ¯¯ 
MDA-MB-231 - - - - 
 
Table 5-5: Decrease in the nuclear localisation of b-catenin in MCF7 cells 
following inhibition of the Hh signalling. 
This table summarises the effect of Hh inhibition by cyclopamine and LDE225 on the nuclear 
localisation of b-catenin protein at two concentrations of the treatment (1 µM and 10 µM) for 48 hours. 
Arrows indicate the qualitative observation of the level of expression of the marker compared to the 
vehicle control. 
 
Treatment 1 µM cyclopamine 
10 µM 
cyclopamine 1 µM LDE225 10 µM LDE225 
MCF7 ¯ ¯ ¯ ¯¯ 
MDA-MB-231 - - - - 
 
5.3.4 Inhibition of Hh signalling by cyclopamine and LDE225 induced the 
expression of E-cadherin and reduced motility and invasion in both MCF7 
and MDA-MB-231 cells 
Cellular changes associated with EMT is a critical component in human cancer 
metastasis including breast cancer (Sarrio et al., 2008; Wang and Zhou, 2013). In 
associated with EMT-like changes many of the transcription factors act as repressors 
for the epithelial adhesion molecule E-cadherin and subsequently promote invasion and 
metastasis (Hajra et al., 2002; Peinado et al., 2004). Therefore, E-cadherin expression 
levels were assessed following inhibition of Hh signalling by either cyclopamine or 
LDE225. The effect of Hh inhibition on motility and invasion of breast cancer cell lines 
by a single concentration of treatments (1µM) was also measured. The selection of this 
dose was based on previous findings (Figure 5-3 and Figure 5-4). At 1µM, no 
significant induction of cell death was seen, which would cause decreased motility and 
invasion scores due to the presence of fewer cells in the assay. 
In human breast cancer samples, Fiaschi et al. (2009) showed that cells with 
high Gli1 expression lacked expression of E-cadherin and increased possibility of 
metastatic spread. Also, O'Toole et al. (2011) used in vivo models to show that 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
222 
 
  
increased tumour grade and invasion was associated with an increased activation of Hh 
signalling in breast cancer cells by manipulating Hh ligand secretion. 
E-cadherin protein expression increased in both cell lines assessed in this study 
following 48 hours treatment with cyclopamine or LDE225 in a dose-dependent manner 
(Table 5-10). 
Membrane localisation of E-cadherin increased in MCF7 cells following 
inhibition by either cyclopamine or LDE225 while cytoplasmic localisation increased in 
MDA-MB-231 (Table 5-7 and Table 5-8). Concurring with this finding, Song et al. 
(2016) showed that E-cadherin increased in breast cancer cells following inhibition of 
Hh signalling using cyclopamine for 72 hours. They concluded that canonical Hh 
pathway activation is essential for enhancing migration capacity of breast cancer cells 
by reducing E-cadherin and increasing the production of matrix metalloproteases (Song 
et al., 2016). In colon cancer, Qualtrough et al. (2015) showed that inhibition of Hh 
signalling by cyclopamine stimulated the expression of E-cadherin in benign and 
malignant colorectal tumour cell lines. 
 
Table 5-6: Increase in E-cadherin expression following treatment with 
cyclopamine or LDE225 in MCF7 and MDA-MB-231. 
Alteration in E-cadherin expression following inhibition of Hh signalling by cyclopamine or LDE225 at 
three concentrations (1µM, 5µM, and 10µM). Arrows indicate change in expression of protein compared 
to vehicle control. 
 
 Treatment 1µM cyclopamine 
5µM 
cyclopamine 
10µM 
cyclopamine 
1µM 
LDE225 
5µM 
LDE225 
10µM 
LDE225 
E-cadherin 
MCF7 ­ ­­ ­­­ ­ ­ ­­ 
MDA-MB-231 - ­ ­­ - - ­­ 
 
Table 5-7: Increase in the membrane localisation of E-cadherin in MCF7 cell line 
following inhibition of the Hh signalling by cyclopamine and LDE225. 
Effect of inhibiting Hh signalling by cyclopamine or LDE225 on membrane localisation of E-cadherin at 
two concentrations (1µM and 10µM) for 48hours. Arrows indicate qualitative observation of level of 
membrane localisation of E-cadherin compared to vehicle control. 
 
 Treatment 1µM cyclopamine 
10µM 
cyclopamine 1µM LDE225 10µM LDE225 
E-cadherin 
MCF7 - ­­ ­ ­ 
MDA-MB-231 - - - - 
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Table 5-8: Increase in E-cadherin cytoplasmic localisation in both cell lines 
following inhibition of Hh signalling. 
Effect of Hh signalling inhibition by cyclopamine or LDE225 on the cytoplasmic localisation of E-
cadherin following treatment with two concentrations (1µM and 10µM) for 48hours. Arrows indicate 
qualitative observation of level of cytoplasmic E-cadherin compared to vehicle control. 
 
 Treatment 1 µM cyclopamine 
10 µM 
cyclopamine 
1 µM 
LDE225 
10 µM 
LDE225 
E-cadherin 
MCF7 ­ ­ ­ ­ 
MDA-MB-231 ­ ­ ­ ­ 
 
The inhibition of Hh signalling in breast cancer cell lines (MCF7 and MDA-
MB-231) by cyclopamine or LDE225 caused significant reduction in the motility and 
invasion of both cell lines (Table 5-9). The MCF7 cell line was less motile than MDA-
MB-231, which is expected because MDA-MB-231 is a more aggressive cell line and 
displays a more mesenchymal phenotype (Rizwan et al., 2015). Furthermore, treatment 
with either one of the inhibitors resulted in a significant decrease in MCF7 cell invasion 
through Matrigel™ (Table 5-9). In MDA-MB-231 cells, the reduction of both motility 
and invasion was more significant following inhibition by LDE225 (Table 5-9) 
suggesting a differential effect of inhibitors dependent on the breast cancer subtype. 
Kameda et al. (2009) showed that treatment of MDA-MB-231 with 10µM and 30µM 
cyclopamine reduced invasion in a dose-dependent manner. A similar inhibition of 
invasion was observed following knocking down Gli1 in MDA-MB-231 (Kameda et 
al., 2009; Kwon et al., 2011). Here, the assessment of Gli1 localisation and level of 
expression showed that decreased expression and nuclear localisation of Gli1 was 
associated with decrease in motility and invasion of breast cancer cells. 
 
Table 5-9: inhibition of Hh signalling caused decrease in motility and invasion of 
breast cancer cells. 
Effect of inhibiting Hh signalling by 1µM cyclopamine or LDE225 on motility and invasion of MCF7 
and MDA-MB-231 cells. Changes in motility and invasion of cells was indicated as arrows compared to 
vehicle control. 
 
Cell lines Assay 
Treatment 
1µM cyclopamine 1µM LDE225 
MCF7 Motility ¯ ¯ Invasion  ¯¯¯ ¯¯¯ 
MDA-MB-231 Motility ¯ ¯¯ Invasion  ¯ ¯¯¯ 
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5.4 Conclusion 
The cell viability, cell yield and apoptosis showed that the inhibition of the Hh 
signalling using either cyclopamine or LDE225 resulted in reduction of cellular 
viability and cell yield. This is the first study to show this effect and compared it 
between two cell lines that represent to two molecular subtypes of breast cancer 
(luminal and TNBC). Most of the cell death were early apoptosis in MCF7 (luminal) 
seen following Hh inhibition, whereas, in MDA-MB-231 (Basal and TNBC) most cell 
death was late cell death. 
Assessment of the level of expression and localisation of the Gli proteins was 
novel in this study and was not investigated previously. Also, comparing the expression 
level and subcellular localisation following Hh inhibition using either cyclopamine or 
LDE225 in two cell lines that belong to two molecular subgroup of breast cancer was 
not conducted previously. The Gli protein expression analysis and changes of 
localisation of the proteins showed that there was a difference in the mechanism of 
action of the pathway in the two breast cancer cell lines. Suggesting a key difference in 
the way the two cell lines respond to each drug and difference in the cell trafficking of 
the Gli proteins between both cell lines. This can also explain why the changes in 
viability, cell yield and apoptosis levels varied between the two cell lines.  
The Hedgehog (Hh) signalling pathway is potentially involved in tumour invasion 
and it may be facilitated by stimulating EMT-like changes in the cells.  
Evaluation of the effect of Hh inhibition on CRT is also novel for the current 
study. We were able to show reduction in CRT for the first time in vitro as a result of 
Hh inhibition in breast cancer, thereby, confirming the potential crosstalk between these 
signalling pathways and highlighting them as a potential regulator of EMT in this 
disease. The association between decreased CRT and the decrease in expression and 
nuclear localisation of Gli1 support this conclusion. Also, the increase in nuclear Gli3 
indicates that in breast cancer this protein may have an inhibitory effect on b-catenin, 
which merits further investigation. Inhibition of Hh signalling by cyclopamine or 
LDE225 treatment caused significant reduction of motility and invasion of MCF7 and 
MDA-MB-231 cells.  
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6. Chapter Six: General Discussion 
90% of breast cancer-related deaths are caused by distant metastasis (Tsai and 
Yang, 2013). Identifying pathways involved the regulation of metastasis is crucial for 
developing targeted treatments. Understanding alteration of these pathways could lead 
to better selection of patients that would benefit from such treatment. EMT is a 
regulatory process that is involved in many normal physiological processes and is also 
involved in cancer metastasis (Wang and Zhou, 2013). This study aimed to investigate 
the process of EMT in breast cancer and to understand the regulation of this process. 
This study also aimed to identify a pathway potentially involved in the regulation of 
EMT in breast cancer and to investigate the effect of inhibiting this pathway. 
6.1 Breast cancer cell lines undergo changes associated with EMT when 
subjected to a stimulus using a cell-density-based model 
An in vitro cell density-based model was developed to investigate EMT using breast 
cancer cell lines. This model produces a stimulus that provokes EMT in breast cancer 
cells by reducing the degree of cell-cell contact. To evaluate the effect of these changes 
in cell-cell interaction, cellular morphology and the expression of E-cadherin, b-catenin 
and vimentin were assessed. Using this model, we were able to show that breast cancer 
cell lines undergo morphological changes associated with EMT. Assessment of E-
cadherin, b-catenin and vimentin confirmed that breast cancer cell lines undergo 
alteration in expression levels, and localisation of proteins indicative of EMT-
associated change. 
Initially, we hypothesised that the molecular subtype of breast cancer can influence 
their ability to undergo EMT. Upon investigating a panel of breast cancer cell lines 
representing the major molecular subtypes of breast cancers, we were able to confirm 
that all cell lines were able to undergo EMT-associated change. All cell lines showed 
morphological alteration with associated changes in both the level and localisation of E-
cadherin, b-catenin and vimentin proteins. However, the propensity of breast cancer 
cell lines to undergo EMT was not dictated by the molecular subtype to which they 
belong to. All breast cancer cell lines were equally able to undergo EMT when 
subjected density-based stimulus. Also, the confirmation that breast cancer cell lines 
from different molecular subtypes were able to undergo EMT, has an impact on 
understanding breast cancer invasion and metastasis in vivo. 
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Changes in b-catenin localisation indicated potential activation of Wnt/b-catenin 
signalling in breast cancer cell lines. The morphology, and both the expression and 
localisation of EMT-related proteins showed that in the high-density culture the cells 
had more epithelial phenotype and in the lower density they showed a more 
mesenchymal phenotype. In one cell line the opposite was observed. Furthermore, two 
TNBC cell lines showed significant changes in the medium density with increased 
epithelial phenotype. Thus, medium density was standardised as the seeding density for 
all further analysis. 
6.2 Gli1, Gli2 and Gli3 expression showed that Hh signalling may be involved in 
breast cancer metastasis and suggests crosstalk with Wnt/b-catenin 
signalling 
Previous work showed that Hh signalling works in parallel with Wnt/b-catenin 
during the phases of mammary gland development (reviewed by Flemban and 
Qualtrough, 2015). Thus, investigation of the co-activation of Wnt and Hh signalling in 
a cohort of breast cancer samples was carried out in combination with of assessment of 
tissue distribution and subcellular localisation. Recent work showed that there was co-
expression of Wnt/b-catenin and Hh signalling in breast cancer samples (Arnold et al., 
2017).  
Most previous works focused on studying Gli1 and b-catenin, alone or in 
combination. What previous studies overlooked was assessing the tissue distribution of 
these proteins together with their subcellular localisation. Also, in our data, we 
combined evaluating Hh and Wnt/b-catenin proteins with the estimation of E-cadherin 
status in both the tumour centre and at the invasive front. Altogether this approach 
provided new insight into the assessment of EMT in breast cancer. 
Analysis showed that Hh signalling was expressed in breast cancer samples and that 
the expression of Gli proteins was higher at the invasive front where EMT is thought to 
be active. The analysis confirmed that there was a correlation between Hh and Wnt/b-
catenin signalling activation that occurred at the invasive front. Also, activation of Hh 
signalling in breast cancer correlated with decreased E-cadherin. Previous work 
confirmed overexpression of specific components compared to normal mammary cells 
(Mukherjee et al., 2006). Activation of Hh signalling in the tumour may suggests that 
breast cancer cells develop an autocrine activation loop of Hh signalling instead of 
depending on paracrine signalling (Theunissen and de Sauvage, 2009).  
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6.3 Inhibition of Hh signalling with cyclopamine or LDE225 caused an alteration 
in EMT and reduced CRT 
Two cell lines were selected (MCF7 and MDA-MB-231) and treated with 
cyclopamine or LDE225 to assess the effect on viability, cell yield and cell death. 
Analysis showed that breast cancer cell lines showed inhibition of proliferation, 
measured as cell yield, following 48hours treatment. The treatments increased cell 
death, with reduced viability, in a dose-dependent manner. Treatment with cyclopamine 
or LDE225 caused an alteration of both the localisation and level of expression of Gli 
proteins that confirmed a direct effect of the drug on the Hh signalling pathway activity. 
Also, the effect of Hh inhibition on cell yield and cell death concurred with in vivo 
observations, as we showed that Gli1 expression and nuclear localisation correlated 
with increased tumour size. This was in agreement with previous findings showing the 
effect of Hh inhibition in vivo and found that treatment with a Hh inhibitor resulted in a 
reduction of tumour size (Benvenuto et al., 2016).  
Hh inhibition reduced both cell motility and invasion through extracellular matrix in 
vitro. This reduced of motility was associated with altered levels and localisation of E-
cadherin and b-catenin. Together with the increase in E-cadherin expression these data 
suggest that inhibition of Hh signalling with cyclopamine or LDE225 resulted in a 
reduction of EMT in breast cancer and decreased cancer cell motility. This showed that 
inhibition of Hh signalling using either cyclopamine or LDE225 cause reduction in 
EMT-associated changes, which could translate to utilising the Hh signalling for 
metastatic cancer therapy.  
To further investigate the potential crosstalk between Hh and Wnt/b-catenin, CRT 
was measured using the TOPFLASH reporter assay (Korinek et al., 1997). Data showed 
that inhibition of Hh signalling in breast cancer cell lines resulted in the reduction of 
CRT which was reflected in the changes in both the expression and localisation of b-
catenin. Thus, we were able to confirm the crosstalk between Hh and Wnt signalling 
pathways.  
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7. General Conclusion 
Our data confirmed that breast cancer cells undergo EMT-like change that is not 
governed by the molecular subtype of breast cancer cell lines. The in vitro density 
model provides a useful tool for understanding EMT in breast cancer.  
Screening for the expression of Gli1, Gli2 and Gli3 in a cohort of patient samples 
showed that Hh signalling is active in breast cancer. Correlation of increased expression 
of Gli proteins with the invasive front suggests an association between Hh signalling 
and EMT. Expression of the components of the Hh pathway in breast cancer human 
samples and also in cell lines led to the investigation of autocrine signalling in vitro 
using cell lines. In vitro data showed that inhibition of Hh signalling has both anti-
tumour growth and anti-metastatic effects which could be exploited therapeutically to 
reduce mortality due to this incurable disease. Following the treatment of two cell lines 
with cyclopamine or LDE225 both cell yield and viability decreased, while cell death 
increased, in a dose-dependent manner. Activated Hh signalling observed in vivo 
correlated with increased tumour size, which is a prognostic indicator and can be 
explained by the in vitro data showing that Hh inhibition causes reduced cell yield. 
However, further investigation is required to understand the mechanism of this 
correlation. These findings support utilising Gli proteins as prognostic markers to 
identify patients that could benefit from targeted therapy. This also may reduce clinical 
trial failure in the future.  
Further analysis of tissue distribution and subcellular localisation showed that Hh 
signalling activation was associated with Wnt/b-catenin and E-cadherin expression. b-
catenin expression and localisation and CRT levels showed that Hh inhibition with 
cyclopamine or LDE225 treatment co-inhibited Wnt/b-catenin signalling. Hh inhibition 
may be of therapeutic benefit in a percentage of breast cancer patients. These patients 
once correctly identified and treated using Hh inhibitors could show reduced tumour 
growth and reduced propensity for metastasis, thereby greatly improving prognosis for 
this subset of breast cancer patients.  
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8. Limitations 
Due to limitations in time and resources, the assessment of EMT transcription 
factors including Slug, Snail, and Twist was not conducted after subjecting breast 
cancer cell lines to EMT-associated change using the seeding density model. Also, 
these transcription factors were not evaluated after inhibition of Hh signalling using 
cyclopamine and LDE225. There was a limitation of the number of patient samples 
used in this study by staining and evaluation of the full patient samples cohort. To 
improve statistical analysis the sample size should be at least 48 cases for Fisher’s exact 
test and 220 cases for Chi-square test (calculated with GPower 3.0.10). This would 
allow confirmation of the relationship between Gli1, Gli2, Gli3, b-catenin and E-
cadherin expression and the clinicopathological characteristics. Assessing Gli1, Gli2, 
and Gli3 in a full cohort could provide additional information and strengthen the 
statistical significance and conclusions drawn. Further confirmation of the effect of Hh 
inhibition on the outputs of Hh signalling could have been assessed using Gli reporters. 
Despite these limitations, this study has furthered our knowledge of the role of Hh 
signalling in breast cancer, its potential influence on patient prognosis, and highlights 
its therapeutic potential in the globally most common cancer diagnosed in females.  
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9. Future Direction 
- To assess the changes of EMT-related transcription factors such as Slug, Snail 
and Twist in response to changes in seeding density.  
- To investigate the effect of Hh signalling inhibition on the levels of Hh and 
Wnt-specific target genes together with EMT transcription factors such as Slug, 
Snail, Twist, Zeb and LEF-1. 
- To evaluate the expression of other Hh signalling components including Smo, 
Patched and Shh in breast cancer samples. 
- To investigate the expression of Gli1, Gli2, Gli3, b-catenin and E-cadherin in a 
larger cohort of breast cancer samples. To improve statistical analysis the 
sample size should be at least 48 cases for Fisher’s exact test and 220 cases for 
Chi-square test (calculated with GPower 3.0.10) then to analyse for correlation 
between marker expression and clinical criteria.  
- Determine the effect of expression of Gli1, Gli2 and Gli3 expression on both the 
short-term and long-term survival of patients to assess whether these proteins 
have prognostic value together with meta-analysis of associated pathological 
report criteria. 
- Analysis of changes in nuclear co-localisation of Gli proteins in breast cancer 
cell lines using imaging software to provide semi-quantitative data, such as 
velocity software.  
- Use monoclonal antibodies specific for the activator form of Gli proteins and 
compare to the repressor forms.  
- To eliminate the possibility of off-target effect,s using Shh rescue (by Shh add 
back to the system) and checking the effect of Hh inhibition using treatments on 
CRT and E-cadherin expression and localisation. 
- To assess the effect of Hh signalling inhibition on the cell cycle of breast cancer 
cell lines. 
- To confirm the effect of cyclopamine or LDE225 treatment on outputs of Hh 
signalling using Gli reporters. 
- Cell sorting of treated cell lines could provide analysis of subpopulations of 
breast cancer cells. 
 
  
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
231 
 
  
10. References  
Aberger, F. and Ruiz, I. A. A. (2014). Context-dependent signal 
integration by the GLI code: the oncogenic load, pathways, 
modifiers and implications for cancer therapy. Semin Cell 
Dev Biol, 33, pp. 93-104. 
Aberle, H., Bauer, A., Stappert, J., Kispert, A. and Kemler, R. 
(1997). beta-catenin is a target for the ubiquitin-
proteasome pathway. EMBO J, 16(13), pp. 3797-3804. 
Adams, C. L. and Nelson, W. J. (1998). Cytomechanics of 
cadherin-mediated cell-cell adhesion. Curr Opin Cell Biol, 
10(5), pp. 572-577. 
Aden, D. P., Fogel, A., Plotkin, S., Damjanov, I. and Knowles, B. B. 
(1979). Controlled synthesis of HBsAg in a differentiated 
human liver carcinoma-derived cell line. Nature, 282(5739), 
pp. 615-616. 
Agyeman, A., Jha, B. K., Mazumdar, T. and Houghton, J. A. 
(2014). Mode and specificity of binding of the small 
molecule GANT61 to GLI determines inhibition of GLI-DNA 
binding. Oncotarget, 5(12), pp. 4492-4503. 
Agyeman, A., Mazumdar, T. and Houghton, J. A. (2012). 
Regulation of DNA damage following termination of 
Hedgehog (HH) survival signaling at the level of the GLI 
genes in human colon cancer. Oncotarget, 3(8), pp. 854-
868. 
Akram, M. and Siddiqui, S. A. (2012). Breast cancer management: 
past, present and evolving. Indian J Cancer, 49(3), pp. 277-
282. 
Aleskandarany, M. A., Negm, O. H., Green, A. R., Ahmed, M. A., 
Nolan, C. C., Tighe, P. J., Ellis, I. O. and Rakha, E. A. (2014). 
Epithelial mesenchymal transition in early invasive breast 
cancer: an immunohistochemical and reverse phase 
protein array study. Breast Cancer Res Treat, 145(2), pp. 
339-348. 
Alexaki, V. I., Javelaud, D., Van Kempen, L. C., Mohammad, K. S., 
Dennler, S., Luciani, F., Hoek, K. S., Juarez, P., Goydos, J. S., 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
232 
 
  
Fournier, P. J., Sibon, C., Bertolotto, C., Verrecchia, F., 
Saule, S., Delmas, V., Ballotti, R., Larue, L., Saiag, P., Guise, 
T. A. and Mauviel, A. (2010). GLI2-mediated melanoma 
invasion and metastasis. J Natl Cancer Inst, 102(15), pp. 
1148-1159. 
Alvarez-Medina, R., Cayuso, J., Okubo, T., Takada, S. and Marti, 
E. (2008). Wnt canonical pathway restricts graded Shh/Gli 
patterning activity through the regulation of Gli3 
expression. Development, 135(2), pp. 237-247. 
Antonyak, M. A., Miller, A. M., Jansen, J. M., Boehm, J. E., 
Balkman, C. E., Wakshlag, J. J., Page, R. L. and Cerione, R. A. 
(2004). Augmentation of tissue transglutaminase 
expression and activation by epidermal growth factor 
inhibit doxorubicin-induced apoptosis in human breast 
cancer cells. J Biol Chem, 279(40), pp. 41461-41467. 
Arnedos, M., Bihan, C., Delaloge, S. and Andre, F. (2012). Triple-
negative breast cancer: are we making headway at least? 
Ther Adv Med Oncol, 4(4), pp. 195-210. 
Arnold, K. M., Pohlig, R. T. and Sims-Mourtada, J. (2017). Co-
activation of Hedgehog and Wnt signaling pathways is 
associated with poor outcomes in triple negative breast 
cancer. Oncol Lett, 14(5), pp. 5285-5292. 
Atkins, H., Hayward, J. L., Klugman, D. J. and Wayte, A. B. (1972). 
Treatment of early breast cancer: a report after ten years 
of a clinical trial. Br Med J, 2(5811), pp. 423-429. 
Badve, S., Dabbs, D. J., Schnitt, S. J., Baehner, F. L., Decker, T., 
Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. 
R., Palacios, J., Rakha, E. A., Richardson, A. L., Schmitt, F. C., 
Tan, P. H., Tse, G. M., Weigelt, B., Ellis, I. O. and Reis-Filho, 
J. S. (2011). Basal-like and triple-negative breast cancers: a 
critical review with an emphasis on the implications for 
pathologists and oncologists. Mod Pathol, 24(2), pp. 157-
167. 
Bai, C. B. and Joyner, A. L. (2001). Gli1 can rescue the in vivo 
function of Gli2. Development, 128(24), pp. 5161-5172. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
233 
 
  
Bao, C., Kim, M. C., Chen, J., Song, J., Ko, H. W. and Lee, H. J. 
(2016). Sulforaphene Interferes with Human Breast Cancer 
Cell Migration and Invasion through Inhibition of Hedgehog 
Signaling. J Agric Food Chem, 64(27), pp. 5515-5524. 
Barker, N., van de Wetering, M. and Clevers, H. (2008). The 
intestinal stem cell. Genes Dev, 22(14), pp. 1856-1864. 
Barsky, S. H. and Karlin, N. J. (2006). Mechanisms of disease: 
breast tumor pathogenesis and the role of the 
myoepithelial cell. Nat Clin Pract Oncol, 3(3), pp. 138-151. 
Barton, M. B., Elmore, J. G. and Fletcher, S. W. (1999). Breast 
symptoms among women enrolled in a health maintenance 
organization: frequency, evaluation, and outcome. Ann 
Intern Med, 130(8), pp. 651-657. 
Batlle, E., Henderson, J. T., Beghtel, H., van den Born, M. M., 
Sancho, E., Huls, G., Meeldijk, J., Robertson, J., van de 
Wetering, M., Pawson, T. and Clevers, H. (2002). Beta-
catenin and TCF mediate cell positioning in the intestinal 
epithelium by controlling the expression of EphB/ephrinB. 
Cell, 111(2), pp. 251-263. 
Behrens, I., Kamm, W., Dantzig, A. H. and Kissel, T. (2004). 
Variation of peptide transporter (PepT1 and HPT1) 
expression in Caco-2 cells as a function of cell origin. J 
Pharm Sci, 93(7), pp. 1743-1754. 
Behrens, J., Mareel, M. M., Van Roy, F. M. and Birchmeier, W. 
(1989). Dissecting tumor cell invasion: epithelial cells 
acquire invasive properties after the loss of uvomorulin-
mediated cell-cell adhesion. J Cell Biol, 108(6), pp. 2435-
2447. 
Benhaj, K., Akcali, K. C. and Ozturk, M. (2006). Redundant 
expression of canonical Wnt ligands in human breast 
cancer cell lines. Oncol Rep, 15(3), pp. 701-707. 
Benton, G., Crooke, E. and George, J. (2009). Laminin-1 induces 
E-cadherin expression in 3-dimensional cultured breast 
cancer cells by inhibiting DNA methyltransferase 1 and 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
234 
 
  
reversing promoter methylation status. FASEB J, 23(11), pp. 
3884-3895. 
Benvenuto, M., Masuelli, L., De Smaele, E., Fantini, M., Mattera, 
R., Cucchi, D., Bonanno, E., Di Stefano, E., Frajese, G. V., 
Orlandi, A., Screpanti, I., Gulino, A., Modesti, A. and Bei, R. 
(2016). In vitro and in vivo inhibition of breast cancer cell 
growth by targeting the Hedgehog/GLI pathway with SMO 
(GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget, 7(8), 
pp. 9250-9270. 
Berman, D. M., Karhadkar, S. S., Hallahan, A. R., Pritchard, J. I., 
Eberhart, C. G., Watkins, D. N., Chen, J. K., Cooper, M. K., 
Taipale, J., Olson, J. M. and Beachy, P. A. (2002). 
Medulloblastoma growth inhibition by hedgehog pathway 
blockade. Science, 297(5586), pp. 1559-1561. 
Berman, D. M., Karhadkar, S. S., Maitra, A., Montes De Oca, R., 
Gerstenblith, M. R., Briggs, K., Parker, A. R., Shimada, Y., 
Eshleman, J. R., Watkins, D. N. and Beachy, P. A. (2003). 
Widespread requirement for Hedgehog ligand stimulation 
in growth of digestive tract tumours. Nature, 425(6960), 
pp. 846-851. 
Berx, G., Cleton-Jansen, A. M., Strumane, K., de Leeuw, W. J., 
Nollet, F., van Roy, F. and Cornelisse, C. (1996). E-cadherin 
is inactivated in a majority of invasive human lobular breast 
cancers by truncation mutations throughout its 
extracellular domain. Oncogene, 13(9), pp. 1919-1925. 
Bevers, T. B., Anderson, B. O., Bonaccio, E., Buys, S., Daly, M. B., 
Dempsey, P. J., Farrar, W. B., Fleming, I., Garber, J. E., 
Harris, R. E., Heerdt, A. S., Helvie, M., Huff, J. G., Khakpour, 
N., Khan, S. A., Krontiras, H., Lyman, G., Rafferty, E., Shaw, 
S., Smith, M. L., Tsangaris, T. N., Williams, C., Yankeelov, T. 
and National Comprehensive Cancer, N. (2009). NCCN 
clinical practice guidelines in oncology: breast cancer 
screening and diagnosis. J Natl Compr Canc Netw, 7(10), 
pp. 1060-1096. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
235 
 
  
Bienz, M. (1999). APC: the plot thickens. Curr Opin Genet Dev, 
9(5), pp. 595-603. 
Binns, W., Thacker, E. J., James, L. F. and Huffman, W. T. (1959). 
A congenital cyclopiantype malformation in lambs. J Am 
Vet Med Assoc, 134(4), pp. 180-183. 
Blick, T., Widodo, E., Hugo, H., Waltham, M., Lenburg, M. E., 
Neve, R. M. and Thompson, E. W. (2008). Epithelial 
mesenchymal transition traits in human breast cancer cell 
lines. Clin Exp Metastasis, 25(6), pp. 629-642. 
Blotta, S., Jakubikova, J., Calimeri, T., Roccaro, A. M., Amodio, N., 
Azab, A. K., Foresta, U., Mitsiades, C. S., Rossi, M., Todoerti, 
K., Molica, S., Morabito, F., Neri, A., Tagliaferri, P., Tassone, 
P., Anderson, K. C. and Munshi, N. C. (2012). Canonical and 
noncanonical Hedgehog pathway in the pathogenesis of 
multiple myeloma. Blood, 120(25), pp. 5002-5013. 
Boice, J. D., Jr., Preston, D., Davis, F. G. and Monson, R. R. (1991). 
Frequent chest X-ray fluoroscopy and breast cancer 
incidence among tuberculosis patients in Massachusetts. 
Radiat Res, 125(2), pp. 214-222. 
Bonadonna, G., Brusamolino, E., Valagussa, P., Rossi, A., 
Brugnatelli, L., Brambilla, C., De Lena, M., Tancini, G., 
Bajetta, E., Musumeci, R. and Veronesi, U. (1976). 
Combination chemotherapy as an adjuvant treatment in 
operable breast cancer. N Engl J Med, 294(8), pp. 405-410. 
Brambilla, C., De Lena, M., Rossi, A., Valagussa, P. and 
Bonadonna, G. (1976). Response and survival in advanced 
breast cancer after two non-cross-resistant combinations. 
Br Med J, 1(6013), pp. 801-804. 
Brennan, D., Chen, X., Cheng, L., Mahoney, M. and Riobo, N. A. 
(2012). Noncanonical Hedgehog signaling. Vitam Horm, 88, 
pp. 55-72. 
Brinton, L. A., Hoover, R. and Fraumeni, J. F., Jr. (1983a). 
Epidemiology of minimal breast cancer. JAMA, 249(4), pp. 
483-487. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
236 
 
  
Brinton, L. A., Hoover, R. and Fraumeni, J. F., Jr. (1983b). 
Reproductive factors in the aetiology of breast cancer. Br J 
Cancer, 47(6), pp. 757-762. 
Brinton, L. A., Schairer, C., Hoover, R. N. and Fraumeni, J. F., Jr. 
(1988). Menstrual factors and risk of breast cancer. Cancer 
Invest, 6(3), pp. 245-254. 
Briscoe, J. and Therond, P. (2005). Hedgehog signaling: from the 
Drosophila cuticle to anti-cancer drugs. Dev Cell, 8(2), pp. 
143-151. 
Brisken, C., Heineman, A., Chavarria, T., Elenbaas, B., Tan, J., Dey, 
S. K., McMahon, J. A., McMahon, A. P. and Weinberg, R. A. 
(2000). Essential function of Wnt-4 in mammary gland 
development downstream of progesterone signaling. 
Genes Dev, 14(6), pp. 650-654. 
Bryden, M. M., Evans, H. E. and Keeler, R. F. (1971). Cyclopia in 
sheep caused by plant teratogens. J Anat, 110(Pt 3), pp. 
507. 
Bryne, M., Boysen, M., Alfsen, C. G., Abeler, V. M., Sudbo, J., 
Nesland, J. M., Kristensen, G. B., Piffko, J. and Bankfalvi, A. 
(1998). The invasive front of carcinomas. The most 
important area for tumour prognosis? Anticancer Res, 
18(6B), pp. 4757-4764. 
Bukholm, I. K., Nesland, J. M., Karesen, R., Jacobsen, U. and 
Borresen-Dale, A. L. (1998). E-cadherin and alpha-, beta-, 
and gamma-catenin protein expression in relation to 
metastasis in human breast carcinoma. J Pathol, 185(3), pp. 
262-266. 
Busch, E. L., McGraw, K. A. and Sandler, R. S. (2014). The 
potential for markers of epithelial-mesenchymal transition 
to improve colorectal cancer outcomes: a systematic 
review. Cancer Epidemiol Biomarkers Prev, 23(7), pp. 1164-
1175. 
Cai, J., Guan, H., Fang, L., Yang, Y., Zhu, X., Yuan, J., Wu, J. and Li, 
M. (2013). MicroRNA-374a activates Wnt/beta-catenin 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
237 
 
  
signaling to promote breast cancer metastasis. J Clin Invest, 
123(2), pp. 566-579. 
Cai, K., Jiang, L., Wang, J., Zhang, H., Wang, X., Cheng, D. and 
Dou, J. (2014). Downregulation of beta-catenin decreases 
the tumorigenicity, but promotes epithelial-mesenchymal 
transition in breast cancer cells. J Cancer Res Ther, 10(4), 
pp. 1063-1070. 
Cailleau, R., Olive, M. and Cruciger, Q. V. (1978). Long-term 
human breast carcinoma cell lines of metastatic origin: 
preliminary characterization. In Vitro, 14(11), pp. 911-915. 
Cailleau, R., Young, R., Olive, M. and Reeves, W. J., Jr. (1974). 
Breast tumor cell lines from pleural effusions. J Natl Cancer 
Inst, 53(3), pp. 661-674. 
Cao, X., Geradts, J., Dewhirst, M. W. and Lo, H. W. (2012). 
Upregulation of VEGF-A and CD24 gene expression by the 
tGLI1 transcription factor contributes to the aggressive 
behavior of breast cancer cells. Oncogene, 31(1), pp. 104-
115. 
Carter, C. L., Allen, C. and Henson, D. E. (1989). Relation of tumor 
size, lymph node status, and survival in 24,740 breast 
cancer cases. Cancer, 63(1), pp. 181-187. 
Casciola-Rosen, L., Rosen, A., Petri, M. and Schlissel, M. (1996). 
Surface blebs on apoptotic cells are sites of enhanced 
procoagulant activity: implications for coagulation events 
and antigenic spread in systemic lupus erythematosus. Proc 
Natl Acad Sci U S A, 93(4), pp. 1624-1629. 
Caussinus, E., Colombelli, J. and Affolter, M. (2008). Tip-cell 
migration controls stalk-cell intercalation during Drosophila 
tracheal tube elongation. Curr Biol, 18(22), pp. 1727-1734. 
Chai, F., Zhou, J., Chen, C., Xie, S., Chen, X., Su, P. and Shi, J. 
(2013). The Hedgehog inhibitor cyclopamine antagonizes 
chemoresistance of breast cancer cells. Onco Targets Ther, 
6, pp. 1643-1647. 
Chakrabarti, R., Hwang, J., Andres Blanco, M., Wei, Y., Lukacisin, 
M., Romano, R. A., Smalley, K., Liu, S., Yang, Q., Ibrahim, T., 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
238 
 
  
Mercatali, L., Amadori, D., Haffty, B. G., Sinha, S. and Kang, 
Y. (2012). Elf5 inhibits the epithelial-mesenchymal 
transition in mammary gland development and breast 
cancer metastasis by transcriptionally repressing Snail2. 
Nat Cell Biol, 14(11), pp. 1212-1222. 
Chao, Y. L., Shepard, C. R. and Wells, A. (2010). Breast carcinoma 
cells re-express E-cadherin during mesenchymal to 
epithelial reverting transition. Mol Cancer, 9, pp. 179. 
Charafe-Jauffret, E., Ginestier, C., Monville, F., Finetti, P., 
Adelaide, J., Cervera, N., Fekairi, S., Xerri, L., Jacquemier, J., 
Birnbaum, D. and Bertucci, F. (2006). Gene expression 
profiling of breast cell lines identifies potential new basal 
markers. Oncogene, 25(15), pp. 2273-2284. 
Che, J., Zhang, F. Z., Zhao, C. Q., Hu, X. D. and Fan, S. J. (2013). 
Cyclopamine is a novel Hedgehog signaling inhibitor with 
significant anti-proliferative, anti-invasive and anti-
estrogenic potency in human breast cancer cells. Oncol 
Lett, 5(4), pp. 1417-1421. 
Chekhun, S., Bezdenezhnykh, N., Shvets, J. and Lukianova, N. 
(2013). Expression of biomarkers related to cell adhesion, 
metastasis and invasion of breast cancer cell lines of 
different molecular subtype. Exp Oncol, 35(3), pp. 174-179. 
Chen, A., Beetham, H., Black, M. A., Priya, R., Telford, B. J., Guest, 
J., Wiggins, G. A., Godwin, T. D., Yap, A. S. and Guilford, P. J. 
(2014). E-cadherin loss alters cytoskeletal organization and 
adhesion in non-malignant breast cells but is insufficient to 
induce an epithelial-mesenchymal transition. BMC Cancer, 
14, pp. 552. 
Chen, M. H., Yip, G. W., Tse, G. M., Moriya, T., Lui, P. C., Zin, M. 
L., Bay, B. H. and Tan, P. H. (2008). Expression of basal 
keratins and vimentin in breast cancers of young women 
correlates with adverse pathologic parameters. Mod 
Pathol, 21(10), pp. 1183-1191. 
Chen, Y. T., Stewart, D. B. and Nelson, W. J. (1999). Coupling 
assembly of the E-cadherin/beta-catenin complex to 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
239 
 
  
efficient endoplasmic reticulum exit and basal-lateral 
membrane targeting of E-cadherin in polarized MDCK cells. 
J Cell Biol, 144(4), pp. 687-699. 
Cheng, J. C., Auersperg, N. and Leung, P. C. (2012). EGF-induced 
EMT and invasiveness in serous borderline ovarian tumor 
cells: a possible step in the transition to low-grade serous 
carcinoma cells? PLoS One, 7(3), pp. e34071. 
Christofori, G. (2006). New signals from the invasive front. 
Nature, 441(7092), pp. 444-450. 
Chu, E. Y., Hens, J., Andl, T., Kairo, A., Yamaguchi, T. P., Brisken, 
C., Glick, A., Wysolmerski, J. J. and Millar, S. E. (2004). 
Canonical WNT signaling promotes mammary placode 
development and is essential for initiation of mammary 
gland morphogenesis. Development, 131(19), pp. 4819-
4829. 
Chuang, P. T. and McMahon, A. P. (1999). Vertebrate Hedgehog 
signalling modulated by induction of a Hedgehog-binding 
protein. Nature, 397(6720), pp. 617-621. 
Cichon, M. A., Nelson, C. M. and Radisky, D. C. (2015). Regulation 
of epithelial-mesenchymal transition in breast cancer cells 
by cell contact and adhesion. Cancer Inform, 14(Suppl 3), 
pp. 1-13. 
Clark, A. G. and Vignjevic, D. M. (2015). Modes of cancer cell 
invasion and the role of the microenvironment. Curr Opin 
Cell Biol, 36, pp. 13-22. 
Clevers, H. and Nusse, R. (2012). Wnt/beta-catenin signaling and 
disease. Cell, 149(6), pp. 1192-1205. 
Coates, A. S., Keshaviah, A., Thurlimann, B., Mouridsen, H., 
Mauriac, L., Forbes, J. F., Paridaens, R., Castiglione-Gertsch, 
M., Gelber, R. D., Colleoni, M., Lang, I., Del Mastro, L., 
Smith, I., Chirgwin, J., Nogaret, J. M., Pienkowski, T., 
Wardley, A., Jakobsen, E. H., Price, K. N. and Goldhirsch, A. 
(2007). Five years of letrozole compared with tamoxifen as 
initial adjuvant therapy for postmenopausal women with 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
240 
 
  
endocrine-responsive early breast cancer: update of study 
BIG 1-98. J Clin Oncol, 25(5), pp. 486-492. 
Colavito, S. A., Zou, M. R., Yan, Q., Nguyen, D. X. and Stern, D. F. 
(2014). Significance of glioma-associated oncogene 
homolog 1 (GLI1) expression in claudin-low breast cancer 
and crosstalk with the nuclear factor kappa-light-chain-
enhancer of activated B cells (NFkappaB) pathway. Breast 
Cancer Res, 16(5), pp. 444. 
Colditz, G. A., Stampfer, M. J., Willett, W. C., Hennekens, C. H., 
Rosner, B. and Speizer, F. E. (1990). Prospective study of 
estrogen replacement therapy and risk of breast cancer in 
postmenopausal women. JAMA, 264(20), pp. 2648-2653. 
Cole, M. P., Jones, C. T. and Todd, I. D. (1971). A new anti-
oestrogenic agent in late breast cancer. An early clinical 
appraisal of ICI46474. Br J Cancer, 25(2), pp. 270-275. 
Coleman, M. P., Quaresma, M., Berrino, F., Lutz, J. M., De 
Angelis, R., Capocaccia, R., Baili, P., Rachet, B., Gatta, G., 
Hakulinen, T., Micheli, A., Sant, M., Weir, H. K., Elwood, J. 
M., Tsukuma, H., Koifman, S., GA, E. S., Francisci, S., 
Santaquilani, M., Verdecchia, A., Storm, H. H., Young, J. L. 
and Group, C. W. (2008). Cancer survival in five continents: 
a worldwide population-based study (CONCORD). Lancet 
Oncol, 9(8), pp. 730-756. 
Conacci-Sorrell, M., Simcha, I., Ben-Yedidia, T., Blechman, J., 
Savagner, P. and Ben-Ze'ev, A. (2003). Autoregulation of E-
cadherin expression by cadherin-cadherin interactions: the 
roles of beta-catenin signaling, Slug, and MAPK. J Cell Biol, 
163(4), pp. 847-857. 
Conway, K., Edmiston, S. N., Cui, L., Drouin, S. S., Pang, J., He, M., 
Tse, C. K., Geradts, J., Dressler, L., Liu, E. T., Millikan, R. and 
Newman, B. (2002). Prevalence and spectrum of p53 
mutations associated with smoking in breast cancer. 
Cancer Res, 62(7), pp. 1987-1995. 
Cooper, A. (1840). On the anatomy of the breast, Longman, 
Orme, Green, Brown, and Longmans. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
241 
 
  
Cooper, M. K., Porter, J. A., Young, K. E. and Beachy, P. A. (1998). 
Teratogen-mediated inhibition of target tissue response to 
Shh signaling. Science, 280(5369), pp. 1603-1607. 
Corbit, K. C., Aanstad, P., Singla, V., Norman, A. R., Stainier, D. Y. 
and Reiter, J. F. (2005). Vertebrate Smoothened functions 
at the primary cilium. Nature, 437(7061), pp. 1018-1021. 
CRUK. (2017). Available from: 
http://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-
type/breast-cancer/incidence-invasive [Accessed 
17/11/2017 2017]. 
Cui, W., Wang, L. H., Wen, Y. Y., Song, M., Li, B. L., Chen, X. L., Xu, 
M., An, S. X., Zhao, J., Lu, Y. Y., Mi, X. Y. and Wang, E. H. 
(2010). Expression and regulation mechanisms of Sonic 
Hedgehog in breast cancer. Cancer Sci, 101(4), pp. 927-933. 
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, 
M., Forbes, J. F. and investigators, A. L. (2010). Effect of 
anastrozole and tamoxifen as adjuvant treatment for early-
stage breast cancer: 10-year analysis of the ATAC trial. 
Lancet Oncol, 11(12), pp. 1135-1141. 
D'Amato, C., Rosa, R., Marciano, R., D'Amato, V., Formisano, L., 
Nappi, L., Raimondo, L., Di Mauro, C., Servetto, A., Fulciniti, 
F., Cipolletta, A., Bianco, C., Ciardiello, F., Veneziani, B. M., 
De Placido, S. and Bianco, R. (2014). Inhibition of Hedgehog 
signalling by NVP-LDE225 (Erismodegib) interferes with 
growth and invasion of human renal cell carcinoma cells. Br 
J Cancer, 111(6), pp. 1168-1179. 
Daly, C. S., Flemban, A., Shafei, M., Conway, M. E., Qualtrough, 
D. and Dean, S. J. (2017). Hypoxia modulates the stem cell 
population and induces EMT in the MCF-10A breast 
epithelial cell line. Oncol Rep. 
Daniel, C. W., Robinson, S. and Silberstein, G. B. (1996). The role 
of TGF-beta in patterning and growth of the mammary 
ductal tree. J Mammary Gland Biol Neoplasia, 1(4), pp. 
331-341. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
242 
 
  
Das, S., Samant, R. S. and Shevde, L. A. (2011). Hedgehog 
signaling induced by breast cancer cells promotes 
osteoclastogenesis and osteolysis. J Biol Chem, 286(11), pp. 
9612-9622. 
de Ruijter, T. C., Veeck, J., de Hoon, J. P., van Engeland, M. and 
Tjan-Heijnen, V. C. (2011). Characteristics of triple-negative 
breast cancer. J Cancer Res Clin Oncol, 137(2), pp. 183-192. 
Dean, S. J. and Rhodes, A. (2014). Triple negative breast cancer: 
the role of metabolic pathways. Malays J Pathol, 36(3), pp. 
155-162. 
Della Corte, C. M., Bellevicine, C., Vicidomini, G., Vitagliano, D., 
Malapelle, U., Accardo, M., Fabozzi, A., Fiorelli, A., Fasano, 
M., Papaccio, F., Martinelli, E., Troiani, T., Troncone, G., 
Santini, M., Bianco, R., Ciardiello, F. and Morgillo, F. (2015). 
SMO Gene Amplification and Activation of the Hedgehog 
Pathway as Novel Mechanisms of Resistance to Anti-
Epidermal Growth Factor Receptor Drugs in Human Lung 
Cancer. Clin Cancer Res, 21(20), pp. 4686-4697. 
Denef, N., Neubuser, D., Perez, L. and Cohen, S. M. (2000). 
Hedgehog induces opposite changes in turnover and 
subcellular localization of patched and smoothened. Cell, 
102(4), pp. 521-531. 
Dennler, S., Andre, J., Alexaki, I., Li, A., Magnaldo, T., ten Dijke, 
P., Wang, X. J., Verrecchia, F. and Mauviel, A. (2007). 
Induction of sonic hedgehog mediators by transforming 
growth factor-beta: Smad3-dependent activation of Gli2 
and Gli1 expression in vitro and in vivo. Cancer Res, 67(14), 
pp. 6981-6986. 
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., 
Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P. and Narod, 
S. A. (2007). Triple-negative breast cancer: clinical features 
and patterns of recurrence. Clin Cancer Res, 13(15 Pt 1), pp. 
4429-4434. 
Derksen, P. W., Liu, X., Saridin, F., van der Gulden, H., 
Zevenhoven, J., Evers, B., van Beijnum, J. R., Griffioen, A. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
243 
 
  
W., Vink, J., Krimpenfort, P., Peterse, J. L., Cardiff, R. D., 
Berns, A. and Jonkers, J. (2006). Somatic inactivation of E-
cadherin and p53 in mice leads to metastatic lobular 
mammary carcinoma through induction of anoikis 
resistance and angiogenesis. Cancer Cell, 10(5), pp. 437-
449. 
Deugnier, M. A., Moiseyeva, E. P., Thiery, J. P. and Glukhova, M. 
(1995). Myoepithelial cell differentiation in the developing 
mammary gland: progressive acquisition of smooth muscle 
phenotype. Dev Dyn, 204(2), pp. 107-117. 
Deugnier, M. A., Teuliere, J., Faraldo, M. M., Thiery, J. P. and 
Glukhova, M. A. (2002). The importance of being a 
myoepithelial cell. Breast Cancer Res, 4(6), pp. 224-230. 
Dewis, R. and Gribbin, J. (2009).  Breast Cancer: Diagnosis and 
Treatment: An Assessment of Need,Cardiff (UK). 
Dey, N., Young, B., Abramovitz, M., Bouzyk, M., Barwick, B., De, 
P. and Leyland-Jones, B. (2013). Differential activation of 
Wnt-beta-catenin pathway in triple negative breast cancer 
increases MMP7 in a PTEN dependent manner. PLoS One, 
8(10), pp. e77425. 
Di Mauro, C., Rosa, R., D'Amato, V., Ciciola, P., Servetto, A., 
Marciano, R., Orsini, R. C., Formisano, L., De Falco, S., 
Cicatiello, V., Di Bonito, M., Cantile, M., Collina, F., 
Chambery, A., Veneziani, B. M., De Placido, S. and Bianco, 
R. (2017). Hedgehog signalling pathway orchestrates 
angiogenesis in triple-negative breast cancers. Br J Cancer, 
116(11), pp. 1425-1435. 
Diao, Y., Azatyan, A., Rahman, M. F., Zhao, C., Zhu, J., Dahlman-
Wright, K. and Zaphiropoulos, P. G. (2016). Blockade of the 
Hedgehog pathway downregulates estrogen receptor alpha 
signaling in breast cancer cells. Oncotarget, 7(44), pp. 
71580-71593. 
Ding, F., Wang, M., Du, Y., Du, S., Zhu, Z. and Yan, Z. (2016). BHX 
Inhibits the Wnt Signaling Pathway by Suppressing beta-
catenin Transcription in the Nucleus. Sci Rep, 6, pp. 38331. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
244 
 
  
Ding, M. and Wang, X. (2017). Antagonism between Hedgehog 
and Wnt signaling pathways regulates tumorigenicity. 
Oncol Lett, 14(6), pp. 6327-6333. 
Ding, Y. L., Zhou, Y., Xiang, L., Ji, Z. P. and Luo, Z. H. (2012). 
Expression of glioma-associated oncogene homolog 1 is 
associated with invasion and postoperative liver metastasis 
in colon cancer. Int J Med Sci, 9(5), pp. 334-338. 
Dixon, A. R., Ellis, I. O., Elston, C. W. and Blamey, R. W. (1991). A 
comparison of the clinical metastatic patterns of invasive 
lobular and ductal carcinomas of the breast. Br J Cancer, 
63(4), pp. 634-635. 
Dixon, J. M., Anderson, T. J., Page, D. L., Lee, D. and Duffy, S. W. 
(1982). Infiltrating lobular carcinoma of the breast. 
Histopathology, 6(2), pp. 149-161. 
Drasin, D. J., Robin, T. P. and Ford, H. L. (2011). Breast cancer 
epithelial-to-mesenchymal transition: examining the 
functional consequences of plasticity. Breast Cancer Res, 
13(6), pp. 226. 
Dummer, R., Guminski, A., Gutzmer, R., Dirix, L., Lewis, K. D., 
Combemale, P., Herd, R. M., Kaatz, M., Loquai, C., Stratigos, 
A. J., Schulze, H. J., Plummer, R., Gogov, S., Pallaud, C., Yi, 
T., Mone, M., Chang, A. L., Cornelis, F., Kudchadkar, R., 
Trefzer, U., Lear, J. T., Sellami, D. and Migden, M. R. (2016). 
The 12-month analysis from Basal Cell Carcinoma 
Outcomes with LDE225 Treatment (BOLT): A phase II, 
randomized, double-blind study of sonidegib in patients 
with advanced basal cell carcinoma. J Am Acad Dermatol, 
75(1), pp. 113-125 e115. 
Dwedar, F. I., Khalil, G. I., Nayer, S. A. and Farouk, A. (2016). 
Aberrant Vimentin Methylation Is Characteristic of Breast 
Cancer. Advances in Breast Cancer Research, 5(04), pp. 150. 
Early Breast Cancer Trialists' Collaborative, G. (2005). Effects of 
chemotherapy and hormonal therapy for early breast 
cancer on recurrence and 15-year survival: an overview of 
the randomised trials. Lancet, 365(9472), pp. 1687-1717. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
245 
 
  
Easton, D. F., Ford, D. and Bishop, D. T. (1995). Breast and 
ovarian cancer incidence in BRCA1-mutation carriers. 
Breast Cancer Linkage Consortium. Am J Hum Genet, 56(1), 
pp. 265-271. 
Eblaghie, M. C., Song, S. J., Kim, J. Y., Akita, K., Tickle, C. and Jung, 
H. S. (2004). Interactions between FGF and Wnt signals and 
Tbx3 gene expression in mammary gland initiation in 
mouse embryos. J Anat, 205(1), pp. 1-13. 
Edge, S. B. and Compton, C. C. (2010). The American Joint 
Committee on Cancer: the 7th edition of the AJCC cancer 
staging manual and the future of TNM. Ann Surg Oncol, 
17(6), pp. 1471-1474. 
Efstathiou, J. A., Liu, D., Wheeler, J. M., Kim, H. C., Beck, N. E., 
Ilyas, M., Karayiannakis, A. J., Mortensen, N. J., Kmiot, W., 
Playford, R. J., Pignatelli, M. and Bodmer, W. F. (1999). 
Mutated epithelial cadherin is associated with increased 
tumorigenicity and loss of adhesion and of responsiveness 
to the motogenic trefoil factor 2 in colon carcinoma cells. 
Proc Natl Acad Sci U S A, 96(5), pp. 2316-2321. 
Eifel, P., Axelson, J. A., Costa, J., Crowley, J., Curran, W. J., Jr., 
Deshler, A., Fulton, S., Hendricks, C. B., Kemeny, M., 
Kornblith, A. B., Louis, T. A., Markman, M., Mayer, R. and 
Roter, D. (2001). National Institutes of Health Consensus 
Development Conference Statement: adjuvant therapy for 
breast cancer, November 1-3, 2000. J Natl Cancer Inst, 
93(13), pp. 979-989. 
Eiro, N., Pidal, I., Fernandez-Garcia, B., Junquera, S., Lamelas, M. 
L., del Casar, J. M., Gonzalez, L. O., Lopez-Muniz, A. and 
Vizoso, F. J. (2012). Impact of CD68/(CD3+CD20) ratio at 
the invasive front of primary tumors on distant metastasis 
development in breast cancer. PLoS One, 7(12), pp. 
e52796. 
Elston, C. W. and Ellis, I. O. (1991). Pathological prognostic 
factors in breast cancer. I. The value of histological grade in 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
246 
 
  
breast cancer: experience from a large study with long-
term follow-up. Histopathology, 19(5), pp. 403-410. 
Evrard, A., Cuq, P., Ciccolini, J., Vian, L. and Cano, J. P. (1999). 
Increased cytotoxicity and bystander effect of 5-
fluorouracil and 5-deoxy-5-fluorouridine in human 
colorectal cancer cells transfected with thymidine 
phosphorylase. Br J Cancer, 80(11), pp. 1726-1733. 
Ewald, A. J., Brenot, A., Duong, M., Chan, B. S. and Werb, Z. 
(2008). Collective epithelial migration and cell 
rearrangements drive mammary branching morphogenesis. 
Dev Cell, 14(4), pp. 570-581. 
Farmer, P., Bonnefoi, H., Becette, V., Tubiana-Hulin, M., 
Fumoleau, P., Larsimont, D., Macgrogan, G., Bergh, J., 
Cameron, D., Goldstein, D., Duss, S., Nicoulaz, A. L., Brisken, 
C., Fiche, M., Delorenzi, M. and Iggo, R. (2005). 
Identification of molecular apocrine breast tumours by 
microarray analysis. Oncogene, 24(29), pp. 4660-4671. 
Fendrich, V., Waldmann, J., Feldmann, G., Schlosser, K., Konig, 
A., Ramaswamy, A., Bartsch, D. K. and Karakas, E. (2009). 
Unique expression pattern of the EMT markers Snail, Twist 
and E-cadherin in benign and malignant parathyroid 
neoplasia. Eur J Endocrinol, 160(4), pp. 695-703. 
Fiaschi, M., Rozell, B., Bergstrom, A. and Toftgard, R. (2009). 
Development of mammary tumors by conditional 
expression of GLI1. Cancer Res, 69(11), pp. 4810-4817. 
Fidler, I. J. and Kripke, M. L. (1977). Metastasis results from 
preexisting variant cells within a malignant tumor. Science, 
197(4306), pp. 893-895. 
Fisher, B., Redmond, C., Fisher, E. R., Bauer, M., Wolmark, N., 
Wickerham, D. L., Deutsch, M., Montague, E., Margolese, R. 
and Foster, R. (1985). Ten-year results of a randomized 
clinical trial comparing radical mastectomy and total 
mastectomy with or without radiation. N Engl J Med, 
312(11), pp. 674-681. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
247 
 
  
Fisher, B., Redmond, C., Poisson, R., Margolese, R., Wolmark, N., 
Wickerham, L., Fisher, E., Deutsch, M., Caplan, R., Pilch, Y. 
and et al. (1989). Eight-year results of a randomized clinical 
trial comparing total mastectomy and lumpectomy with or 
without irradiation in the treatment of breast cancer. N 
Engl J Med, 320(13), pp. 822-828. 
Flemban, A. and Qualtrough, D. (2015). The Potential Role of 
Hedgehog Signaling in the Luminal/Basal Phenotype of 
Breast Epithelia and in Breast Cancer Invasion and 
Metastasis. Cancers (Basel), 7(3), pp. 1863-1884. 
Fogh, J., Fogh, J. M. and Orfeo, T. (1977). One hundred and 
twenty-seven cultured human tumor cell lines producing 
tumors in nude mice. J Natl Cancer Inst, 59(1), pp. 221-226. 
Fournier, A. K., Campbell, L. E., Castagnino, P., Liu, W. F., Chung, 
B. M., Weaver, V. M., Chen, C. S. and Assoian, R. K. (2008). 
Rac-dependent cyclin D1 gene expression regulated by 
cadherin- and integrin-mediated adhesion. J Cell Sci, 121(Pt 
2), pp. 226-233. 
Fu, J., Rodova, M., Nanta, R., Meeker, D., Van Veldhuizen, P. J., 
Srivastava, R. K. and Shankar, S. (2013). NPV-LDE-225 
(Erismodegib) inhibits epithelial mesenchymal transition 
and self-renewal of glioblastoma initiating cells by 
regulating miR-21, miR-128, and miR-200. Neuro Oncol, 
15(6), pp. 691-706. 
Fu, Y. Z., Yan, Y. Y., He, M., Xiao, Q. H., Yao, W. F., Zhao, L., Wu, 
H. Z., Yu, Z. J., Zhou, M. Y., Lv, M. T., Zhang, S. S., Chen, J. J. 
and Wei, M. J. (2016). Salinomycin induces selective 
cytotoxicity to MCF-7 mammosphere cells through 
targeting the Hedgehog signaling pathway. Oncol Rep, 
35(2), pp. 912-922. 
Gallet, A. and Therond, P. P. (2005). Temporal modulation of the 
Hedgehog morphogen gradient by a patched-dependent 
targeting to lysosomal compartment. Dev Biol, 277(1), pp. 
51-62. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
248 
 
  
Gao, M. Q., Kim, B. G., Kang, S., Choi, Y. P., Park, H., Kang, K. S. 
and Cho, N. H. (2010). Stromal fibroblasts from the 
interface zone of human breast carcinomas induce an 
epithelial-mesenchymal transition-like state in breast 
cancer cells in vitro. J Cell Sci, 123(Pt 20), pp. 3507-3514. 
Gao, Q., Yuan, Y., Gan, H. Z. and Peng, Q. (2015). Resveratrol 
inhibits the hedgehog signaling pathway and epithelial-
mesenchymal transition and suppresses gastric cancer 
invasion and metastasis. Oncol Lett, 9(5), pp. 2381-2387. 
Garg, M. (2013). Epithelial-mesenchymal transition - activating 
transcription factors - multifunctional regulators in cancer. 
World J Stem Cells, 5(4), pp. 188-195. 
Geddes, D. T. (2007). Inside the lactating breast: the latest 
anatomy research. J Midwifery Womens Health, 52(6), pp. 
556-563. 
Geyer, F. C., Lacroix-Triki, M., Savage, K., Arnedos, M., Lambros, 
M. B., MacKay, A., Natrajan, R. and Reis-Filho, J. S. (2011). 
beta-Catenin pathway activation in breast cancer is 
associated with triple-negative phenotype but not with 
CTNNB1 mutation. Mod Pathol, 24(2), pp. 209-231. 
Gilles, C., Polette, M., Mestdagt, M., Nawrocki-Raby, B., Ruggeri, 
P., Birembaut, P. and Foidart, J. M. (2003). Transactivation 
of vimentin by beta-catenin in human breast cancer cells. 
Cancer Res, 63(10), pp. 2658-2664. 
Giudici, D., Ornati, G., Briatico, G., Buzzetti, F., Lombardi, P. and 
di Salle, E. (1988). 6-Methylenandrosta-1,4-diene-3,17-
dione (FCE 24304): a new irreversible aromatase inhibitor. J 
Steroid Biochem, 30(1-6), pp. 391-394. 
Gong, P., Wang, Y., Liu, G., Zhang, J. and Wang, Z. (2013). New 
insight into Ki67 expression at the invasive front in breast 
cancer. PLoS One, 8(1), pp. e54912. 
Gonnissen, A., Isebaert, S. and Haustermans, K. (2015). Targeting 
the Hedgehog signaling pathway in cancer: beyond 
Smoothened. Oncotarget, 6(16), pp. 13899-13913. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
249 
 
  
Gonzalez, D. M. and Medici, D. (2014). Signaling mechanisms of 
the epithelial-mesenchymal transition. Sci Signal, 7(344), 
pp. re8. 
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., 
Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., 
Giordano, S. H., Goetz, M. P., Goldstein, L. J., Isakoff, S. J., 
Lyons, J., Marcom, P. K., Mayer, I. A., McCormick, B., 
Moran, M. S., O'Regan, R. M., Patel, S. A., Pierce, L. J., 
Reed, E. C., Salerno, K. E., Schwartzberg, L. S., Sitapati, A., 
Smith, K. L., Smith, M. L., Soliman, H., Somlo, G., Telli, M., 
Ward, J. H., Shead, D. A. and Kumar, R. (2017). NCCN 
Guidelines Insights: Breast Cancer, Version 1.2017. J Natl 
Compr Canc Netw, 15(4), pp. 433-451. 
Graff, J. R., Gabrielson, E., Fujii, H., Baylin, S. B. and Herman, J. G. 
(2000). Methylation patterns of the E-cadherin 5' CpG 
island are unstable and reflect the dynamic, heterogeneous 
loss of E-cadherin expression during metastatic 
progression. J Biol Chem, 275(4), pp. 2727-2732. 
Green, J., Leigh, I. M., Poulsom, R. and Quinn, A. G. (1998). Basal 
cell carcinoma development is associated with induction of 
the expression of the transcription factor Gli-1. Br J 
Dermatol, 139(5), pp. 911-915. 
Grigore, A. D., Jolly, M. K., Jia, D., Farach-Carson, M. C. and 
Levine, H. (2016). Tumor Budding: The Name is EMT. Partial 
EMT. J Clin Med, 5(5). 
Grosse-Wilde, A., Fouquier d'Herouel, A., McIntosh, E., Ertaylan, 
G., Skupin, A., Kuestner, R. E., del Sol, A., Walters, K. A. and 
Huang, S. (2015). Stemness of the hybrid 
Epithelial/Mesenchymal State in Breast Cancer and Its 
Association with Poor Survival. PLoS One, 10(5), pp. 
e0126522. 
Group, B. I. G. C., Mouridsen, H., Giobbie-Hurder, A., Goldhirsch, 
A., Thurlimann, B., Paridaens, R., Smith, I., Mauriac, L., 
Forbes, J., Price, K. N., Regan, M. M., Gelber, R. D. and 
Coates, A. S. (2009). Letrozole therapy alone or in sequence 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
250 
 
  
with tamoxifen in women with breast cancer. N Engl J Med, 
361(8), pp. 766-776. 
Gudjonsson, T., Ronnov-Jessen, L., Villadsen, R., Rank, F., Bissell, 
M. J. and Petersen, O. W. (2002). Normal and tumor-
derived myoepithelial cells differ in their ability to interact 
with luminal breast epithelial cells for polarity and 
basement membrane deposition. J Cell Sci, 115(Pt 1), pp. 
39-50. 
Guo, W., Keckesova, Z., Donaher, J. L., Shibue, T., Tischler, V., 
Reinhardt, F., Itzkovitz, S., Noske, A., Zurrer-Hardi, U., Bell, 
G., Tam, W. L., Mani, S. A., van Oudenaarden, A. and 
Weinberg, R. A. (2012). Slug and Sox9 cooperatively 
determine the mammary stem cell state. Cell, 148(5), pp. 
1015-1028. 
Gupta, S., Takebe, N. and Lorusso, P. (2010). Targeting the 
Hedgehog pathway in cancer. Ther Adv Med Oncol, 2(4), 
pp. 237-250. 
Gusterson, B. A. and Stein, T. (2012). Human breast 
development. Semin Cell Dev Biol, 23(5), pp. 567-573. 
Ha, G. H., Kim, J. L. and Breuer, E. K. (2013). TACC3 is essential 
for EGF-mediated EMT in cervical cancer. PLoS One, 8(8), 
pp. e70353. 
Habib, J. G. and O'Shaughnessy, J. A. (2016). The hedgehog 
pathway in triple-negative breast cancer. Cancer Med, 
5(10), pp. 2989-3006. 
Hajra, K. M., Chen, D. Y. and Fearon, E. R. (2002). The SLUG zinc-
finger protein represses E-cadherin in breast cancer. 
Cancer Res, 62(6), pp. 1613-1618. 
Halin, C., Mora, J. R., Sumen, C. and von Andrian, U. H. (2005). In 
vivo imaging of lymphocyte trafficking. Annu Rev Cell Dev 
Biol, 21, pp. 581-603. 
Halsted, W. S. (1907). I. The Results of Radical Operations for the 
Cure of Carcinoma of the Breast. Ann Surg, 46(1), pp. 1-19. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
251 
 
  
Hamperl, H. (1970). The myothelia (myoepithelial cells). Normal 
state; regressive changes; hyperplasia; tumors. Curr Top 
Pathol, 53, pp. 161-220. 
Han, B., Qu, Y., Jin, Y., Yu, Y., Deng, N., Wawrowsky, K., Zhang, X., 
Li, N., Bose, S., Wang, Q., Sakkiah, S., Abrol, R., Jensen, T. 
W., Berman, B. P., Tanaka, H., Johnson, J., Gao, B., Hao, J., 
Liu, Z., Buttyan, R., Ray, P. S., Hung, M. C., Giuliano, A. E. 
and Cui, X. (2015). FOXC1 Activates Smoothened-
Independent Hedgehog Signaling in Basal-like Breast 
Cancer. Cell Rep, 13(5), pp. 1046-1058. 
Han, M. E., Lee, Y. S., Baek, S. Y., Kim, B. S., Kim, J. B. and Oh, S. 
O. (2009). Hedgehog signaling regulates the survival of 
gastric cancer cells by regulating the expression of Bcl-2. Int 
J Mol Sci, 10(7), pp. 3033-3043. 
Hanahan, D. and Weinberg, R. A. (2011). Hallmarks of cancer: the 
next generation. Cell, 144(5), pp. 646-674. 
Hankey, B. F., Curtis, R. E., Naughton, M. D., Boice, J. D., Jr. and 
Flannery, J. T. (1983). A retrospective cohort analysis of 
second breast cancer risk for primary breast cancer 
patients with an assessment of the effect of radiation 
therapy. J Natl Cancer Inst, 70(5), pp. 797-804. 
Hanna, A. and Shevde, L. A. (2016). Erratum to: 'Hedgehog 
signaling: modulation of cancer properties and tumor 
microenvironment'. Mol Cancer, 15(1), pp. 35. 
Harvey, E. B., Schairer, C., Brinton, L. A., Hoover, R. N. and 
Fraumeni, J. F., Jr. (1987). Alcohol consumption and breast 
cancer. J Natl Cancer Inst, 78(4), pp. 657-661. 
Hase, K., Shatney, C., Johnson, D., Trollope, M. and Vierra, M. 
(1993). Prognostic value of tumor "budding" in patients 
with colorectal cancer. Dis Colon Rectum, 36(7), pp. 627-
635. 
Hassiotou, F. and Geddes, D. (2013). Anatomy of the human 
mammary gland: Current status of knowledge. Clin Anat, 
26(1), pp. 29-48. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
252 
 
  
Hatsell, S. J. and Cowin, P. (2006). Gli3-mediated repression of 
Hedgehog targets is required for normal mammary 
development. Development, 133(18), pp. 3661-3670. 
Haverty, P. M., Lin, E., Tan, J., Yu, Y., Lam, B., Lianoglou, S., Neve, 
R. M., Martin, S., Settleman, J., Yauch, R. L. and Bourgon, R. 
(2016). Reproducible pharmacogenomic profiling of cancer 
cell line panels. Nature, 533(7603), pp. 333-337. 
Hay, E. D. and Zuk, A. (1995). Transformations between 
epithelium and mesenchyme: normal, pathological, and 
experimentally induced. Am J Kidney Dis, 26(4), pp. 678-
690. 
Hazan, R. B., Phillips, G. R., Qiao, R. F., Norton, L. and Aaronson, 
S. A. (2000). Exogenous expression of N-cadherin in breast 
cancer cells induces cell migration, invasion, and 
metastasis. J Cell Biol, 148(4), pp. 779-790. 
He, Y., Liu, Z., Qiao, C., Xu, M., Yu, J. and Li, G. (2014). Expression 
and significance of Wnt signaling components and their 
target genes in breast carcinoma. Mol Med Rep, 9(1), pp. 
137-143. 
Heimann, R., Lan, F., McBride, R. and Hellman, S. (2000). 
Separating favorable from unfavorable prognostic markers 
in breast cancer: the role of E-cadherin. Cancer Res, 60(2), 
pp. 298-304. 
Heller, E., Hurchla, M. A., Xiang, J., Su, X., Chen, S., Schneider, J., 
Joeng, K. S., Vidal, M., Goldberg, L., Deng, H., Hornick, M. 
C., Prior, J. L., Piwnica-Worms, D., Long, F., Cagan, R. and 
Weilbaecher, K. N. (2012). Hedgehog signaling inhibition 
blocks growth of resistant tumors through effects on tumor 
microenvironment. Cancer Res, 72(4), pp. 897-907. 
Hemalatha, A., Suresh, T. N. and Kumar, M. L. (2013). Expression 
of vimentin in breast carcinoma, its correlation with Ki67 
and other histopathological parameters. Indian J Cancer, 
50(3), pp. 189-194. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
253 
 
  
Hennighausen, L. and Robinson, G. W. (2001). Signaling 
pathways in mammary gland development. Dev Cell, 1(4), 
pp. 467-475. 
Hens, J. R. and Wysolmerski, J. J. (2005). Key stages of mammary 
gland development: molecular mechanisms involved in the 
formation of the embryonic mammary gland. Breast Cancer 
Res, 7(5), pp. 220-224. 
Herrmann, H. and Aebi, U. (2004). Intermediate filaments: 
molecular structure, assembly mechanism, and integration 
into functionally distinct intracellular Scaffolds. Annu Rev 
Biochem, 73, pp. 749-789. 
Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, 
J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., 
Chandrasekharan, S., Backlund, M. G., Yin, Y., Khramtsov, 
A. I., Bastein, R., Quackenbush, J., Glazer, R. I., Brown, P. H., 
Green, J. E., Kopelovich, L., Furth, P. A., Palazzo, J. P., 
Olopade, O. I., Bernard, P. S., Churchill, G. A., Van Dyke, T. 
and Perou, C. M. (2007). Identification of conserved gene 
expression features between murine mammary carcinoma 
models and human breast tumors. Genome Biol, 8(5), pp. 
R76. 
Hong, T., Watanabe, K., Ta, C. H., Villarreal-Ponce, A., Nie, Q. and 
Dai, X. (2015). An Ovol2-Zeb1 Mutual Inhibitory Circuit 
Governs Bidirectional and Multi-step Transition between 
Epithelial and Mesenchymal States. PLoS Comput Biol, 
11(11), pp. e1004569. 
Howard, B. A. and Gusterson, B. A. (2000). Human breast 
development. J Mammary Gland Biol Neoplasia, 5(2), pp. 
119-137. 
Huangfu, D., Liu, A., Rakeman, A. S., Murcia, N. S., Niswander, L. 
and Anderson, K. V. (2003). Hedgehog signalling in the 
mouse requires intraflagellar transport proteins. Nature, 
426(6962), pp. 83-87. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
254 
 
  
Huber, M. A., Kraut, N. and Beug, H. (2005). Molecular 
requirements for epithelial-mesenchymal transition during 
tumor progression. Curr Opin Cell Biol, 17(5), pp. 548-558. 
Hui, M., Cazet, A., Nair, R., Watkins, D. N., O'Toole, S. A. and 
Swarbrick, A. (2013). The Hedgehog signalling pathway in 
breast development, carcinogenesis and cancer therapy. 
Breast Cancer Res, 15(2), pp. 203. 
Hulsken, J., Birchmeier, W. and Behrens, J. (1994). E-cadherin 
and APC compete for the interaction with beta-catenin and 
the cytoskeleton. J Cell Biol, 127(6 Pt 2), pp. 2061-2069. 
Hunt, N. C., Douglas-Jones, A. G., Jasani, B., Morgan, J. M. and 
Pignatelli, M. (1997). Loss of E-cadherin expression 
associated with lymph node metastases in small breast 
carcinomas. Virchows Arch, 430(4), pp. 285-289. 
Im, S., Choi, H. J., Yoo, C., Jung, J. H., Jeon, Y. W., Suh, Y. J. and 
Kang, C. S. (2013). Hedgehog related protein expression in 
breast cancer: gli-2 is associated with poor overall survival. 
Korean J Pathol, 47(2), pp. 116-123. 
Imhof, B. A., Vollmers, H. P., Goodman, S. L. and Birchmeier, W. 
(1983). Cell-cell interaction and polarity of epithelial cells: 
specific perturbation using a monoclonal antibody. Cell, 
35(3 Pt 2), pp. 667-675. 
Ingham, P. W. and McMahon, A. P. (2001). Hedgehog signaling in 
animal development: paradigms and principles. Genes Dev, 
15(23), pp. 3059-3087. 
Iorns, E., Drews-Elger, K., Ward, T. M., Dean, S., Clarke, J., Berry, 
D., El Ashry, D. and Lippman, M. (2012). A new mouse 
model for the study of human breast cancer metastasis. 
PLoS One, 7(10), pp. e47995. 
Iwasaki, H., Nakano, K., Shinkai, K., Kunisawa, Y., Hirahashi, M., 
Oda, Y., Onishi, H. and Katano, M. (2013). Hedgehog Gli3 
activator signal augments tumorigenicity of colorectal 
cancer via upregulation of adherence-related genes. Cancer 
Sci, 104(3), pp. 328-336. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
255 
 
  
Jain, S., Song, R. and Xie, J. (2017). Sonidegib: mechanism of 
action, pharmacology, and clinical utility for advanced basal 
cell carcinomas. Onco Targets Ther, 10, pp. 1645-1653. 
Jalili, A., Mertz, K. D., Romanov, J., Wagner, C., Kalthoff, F., 
Stuetz, A., Pathria, G., Gschaider, M., Stingl, G. and 
Wagner, S. N. (2013). NVP-LDE225, a potent and selective 
SMOOTHENED antagonist reduces melanoma growth in 
vitro and in vivo. PLoS One, 8(7), pp. e69064. 
Janda, C. Y., Waghray, D., Levin, A. M., Thomas, C. and Garcia, K. 
C. (2012). Structural basis of Wnt recognition by Frizzled. 
Science, 337(6090), pp. 59-64. 
Javed, A. and Lteif, A. (2013). Development of the human breast. 
Semin Plast Surg, 27(1), pp. 5-12. 
Jeanes, A., Gottardi, C. J. and Yap, A. S. (2008). Cadherins and 
cancer: how does cadherin dysfunction promote tumor 
progression? Oncogene, 27(55), pp. 6920-6929. 
Jeng, K. S., Sheen, I. S., Jeng, W. J., Lin, C. C., Lin, C. K., Su, J. C., 
Yu, M. C. and Fang, H. Y. (2013). High expression of patched 
homolog-1 messenger RNA and glioma-associated 
oncogene-1 messenger RNA of sonic hedgehog signaling 
pathway indicates a risk of postresection recurrence of 
hepatocellular carcinoma. Ann Surg Oncol, 20(2), pp. 464-
473. 
Jenkins, D. (2009). Hedgehog signalling: emerging evidence for 
non-canonical pathways. Cell Signal, 21(7), pp. 1023-1034. 
Jiang, Y., Zou, L., Zhang, C., He, S., Cheng, C., Xu, J., Lu, W., Zhang, 
Y., Zhang, H., Wang, D. and Shen, A. (2009). PPARgamma 
and Wnt/beta-Catenin pathway in human breast cancer: 
expression pattern, molecular interaction and 
clinical/prognostic correlations. J Cancer Res Clin Oncol, 
135(11), pp. 1551-1559. 
Johnson, E., Theisen, C. S., Johnson, K. R. and Wheelock, M. J. 
(2004). R-cadherin influences cell motility via Rho family 
GTPases. J Biol Chem, 279(30), pp. 31041-31049. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
256 
 
  
Jolly, M. K., Boareto, M., Huang, B., Jia, D., Lu, M., Ben-Jacob, E., 
Onuchic, J. N. and Levine, H. (2015). Implications of the 
Hybrid Epithelial/Mesenchymal Phenotype in Metastasis. 
Front Oncol, 5, pp. 155. 
Jolly, M. K., Tripathi, S. C., Jia, D., Mooney, S. M., Celiktas, M., 
Hanash, S. M., Mani, S. A., Pienta, K. J., Ben-Jacob, E. and 
Levine, H. (2016). Stability of the hybrid 
epithelial/mesenchymal phenotype. Oncotarget, 7(19), pp. 
27067-27084. 
Jonsson, G., Staaf, J., Olsson, E., Heidenblad, M., Vallon-
Christersson, J., Osoegawa, K., de Jong, P., Oredsson, S., 
Ringner, M., Hoglund, M. and Borg, A. (2007). High-
resolution genomic profiles of breast cancer cell lines 
assessed by tiling BAC array comparative genomic 
hybridization. Genes Chromosomes Cancer, 46(6), pp. 543-
558. 
Junxia, W., Ping, G., Yuan, H., Lijun, Z., Jihong, R., Fang, L., Min, 
L., Xi, W., Ting, H., Ke, D. and Huizhong, Z. (2010). Double 
strand RNA-guided endogeneous E-cadherin up-regulation 
induces the apoptosis and inhibits proliferation of breast 
carcinoma cells in vitro and in vivo. Cancer Sci, 101(8), pp. 
1790-1796. 
Kaemmerer, D., Peter, L., Lupp, A., Schulz, S., Sanger, J., Baum, R. 
P., Prasad, V. and Hommann, M. (2012). Comparing of IRS 
and Her2 as immunohistochemical scoring schemes in 
gastroenteropancreatic neuroendocrine tumors. Int J Clin 
Exp Pathol, 5(3), pp. 187-194. 
Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F. and Jones, 
L. W. (1979). Establishment and characterization of a 
human prostatic carcinoma cell line (PC-3). Invest Urol, 
17(1), pp. 16-23. 
Kallergi, G., Papadaki, M. A., Politaki, E., Mavroudis, D., 
Georgoulias, V. and Agelaki, S. (2011). Epithelial to 
mesenchymal transition markers expressed in circulating 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
257 
 
  
tumour cells of early and metastatic breast cancer patients. 
Breast Cancer Res, 13(3), pp. R59. 
Kalluri, R. and Weinberg, R. A. (2009). The basics of epithelial-
mesenchymal transition. J Clin Invest, 119(6), pp. 1420-
1428. 
Kameda, C., Tanaka, H., Yamasaki, A., Nakamura, M., Koga, K., 
Sato, N., Kubo, M., Kuroki, S., Tanaka, M. and Katano, M. 
(2009). The Hedgehog pathway is a possible therapeutic 
target for patients with estrogen receptor-negative breast 
cancer. Anticancer Res, 29(3), pp. 871-879. 
Karayiannakis, A. J., Nakopoulou, L., Gakiopoulou, H., 
Keramopoulos, A., Davaris, P. S. and Pignatelli, M. (2001). 
Expression patterns of beta-catenin in in situ and invasive 
breast cancer. Eur J Surg Oncol, 27(1), pp. 31-36. 
Karhadkar, S. S., Bova, G. S., Abdallah, N., Dhara, S., Gardner, D., 
Maitra, A., Isaacs, J. T., Berman, D. M. and Beachy, P. A. 
(2004). Hedgehog signalling in prostate regeneration, 
neoplasia and metastasis. Nature, 431(7009), pp. 707-712. 
Kasper, M., Jaks, V., Fiaschi, M. and Toftgard, R. (2009). 
Hedgehog signalling in breast cancer. Carcinogenesis, 30(6), 
pp. 903-911. 
Kaufman, M. W., Marti, J. R., Gallager, H. S. and Hoehn, J. L. 
(1984). Carcinoma of the breast with pseudosarcomatous 
metaplasia. Cancer, 53(9), pp. 1908-1917. 
Kedeshian, P., Sternlicht, M. D., Nguyen, M., Shao, Z. M. and 
Barsky, S. H. (1998). Humatrix, a novel myoepithelial 
matrical gel with unique biochemical and biological 
properties. Cancer Lett, 123(2), pp. 215-226. 
Keeler, R. F. and Binns, W. (1964). Chemical Compounds of 
Veratrum Californicum Related to Congenital Ovine 
Cyclopian Malformations: Extraction of Active Material. 
Proc Soc Exp Biol Med, 116, pp. 123-127. 
Kenny, P., Lee, G., Myers, C., Neve, R., Semeiks, J., Spellman, P., 
Lorenz, K., Lee, E., Barcellos-Hoff, M., Petersen, O., Gray, J. 
and Bissell, M. (2007a). The morphologies of breast cancer 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
258 
 
  
cell lines in three-dimensional assays correlate with their 
profiles of gene expression. Molecular oncology, 1(1), pp. 
84-96. 
Kenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M., Semeiks, J. R., 
Spellman, P. T., Lorenz, K., Lee, E. H., Barcellos-Hoff, M. H., 
Petersen, O. W., Gray, J. W. and Bissell, M. J. (2007b). The 
morphologies of breast cancer cell lines in three-
dimensional assays correlate with their profiles of gene 
expression. Mol Oncol, 1(1), pp. 84-96. 
Khramtsov, A. I., Khramtsova, G. F., Tretiakova, M., Huo, D., 
Olopade, O. I. and Goss, K. H. (2010). Wnt/beta-catenin 
pathway activation is enriched in basal-like breast cancers 
and predicts poor outcome. Am J Pathol, 176(6), pp. 2911-
2920. 
Kil, W. H., Kim, S. M., Lee, J. E., Park, K. S. and Nam, S. J. (2014). 
Anticancer effect of silibinin on the xenograft model using 
MDA-MB-468 breast cancer cells. Ann Surg Treat Res, 
87(4), pp. 167-173. 
Kim, J. H., Shin, H. S., Lee, S. H., Lee, I., Lee, Y. S., Park, J. C., Kim, 
Y. J., Chung, J. B. and Lee, Y. C. (2010a). Contrasting activity 
of Hedgehog and Wnt pathways according to gastric cancer 
cell differentiation: relevance of crosstalk mechanisms. 
Cancer Sci, 101(2), pp. 328-335. 
Kim, J. Y., Ko, G. H., Lee, Y. J., Ha, W. S., Choi, S. K., Jung, E. J., 
Jeong, C. Y., Ju, Y. T., Jeong, S. H. and Hong, S. C. (2012). 
Prognostic value of sonic hedgehog protein expression in 
gastric cancer. Jpn J Clin Oncol, 42(11), pp. 1054-1059. 
Kim, N. G., Koh, E., Chen, X. and Gumbiner, B. M. (2011). E-
cadherin mediates contact inhibition of proliferation 
through Hippo signaling-pathway components. Proc Natl 
Acad Sci U S A, 108(29), pp. 11930-11935. 
Kim, S. Y., Dunn, I. F., Firestein, R., Gupta, P., Wardwell, L., 
Repich, K., Schinzel, A. C., Wittner, B., Silver, S. J., Root, D. 
E., Boehm, J. S., Ramaswamy, S., Lander, E. S. and Hahn, W. 
C. (2010b). CK1epsilon is required for breast cancers 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
259 
 
  
dependent on beta-catenin activity. PLoS One, 5(2), pp. 
e8979. 
King, T. D., Suto, M. J. and Li, Y. (2012). The Wnt/beta-catenin 
signaling pathway: a potential therapeutic target in the 
treatment of triple negative breast cancer. J Cell Biochem, 
113(1), pp. 13-18. 
Kish, T. and Corry, L. (2016). Sonidegib (Odomzo) for the 
Systemic Treatment of Adults With Recurrent, Locally 
Advanced Basal Cell Skin Cancer. P T, 41(5), pp. 322-325. 
Klymkowsky, M. W. and Savagner, P. (2009). Epithelial-
mesenchymal transition: a cancer researcher's conceptual 
friend and foe. Am J Pathol, 174(5), pp. 1588-1593. 
Kokkinos, M. I., Wafai, R., Wong, M. K., Newgreen, D. F., 
Thompson, E. W. and Waltham, M. (2007). Vimentin and 
epithelial-mesenchymal transition in human breast cancer-
-observations in vitro and in vivo. Cells Tissues Organs, 
185(1-3), pp. 191-203. 
Kopan, R. (2002). Notch: a membrane-bound transcription 
factor. J Cell Sci, 115(Pt 6), pp. 1095-1097. 
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., 
Kinzler, K. W., Vogelstein, B. and Clevers, H. (1997). 
Constitutive transcriptional activation by a beta-catenin-Tcf 
complex in APC-/- colon carcinoma. Science, 275(5307), pp. 
1784-1787. 
Korinek, V., Barker, N., Willert, K., Molenaar, M., Roose, J., 
Wagenaar, G., Markman, M., Lamers, W., Destree, O. and 
Clevers, H. (1998). Two members of the Tcf family 
implicated in Wnt/beta-catenin signaling during 
embryogenesis in the mouse. Mol Cell Biol, 18(3), pp. 1248-
1256. 
Koscielny, S., Tubiana, M., Le, M. G., Valleron, A. J., Mouriesse, 
H., Contesso, G. and Sarrazin, D. (1984). Breast cancer: 
relationship between the size of the primary tumour and 
the probability of metastatic dissemination. Br J Cancer, 
49(6), pp. 709-715. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
260 
 
  
Kowalski, P. J., Rubin, M. A. and Kleer, C. G. (2003). E-cadherin 
expression in primary carcinomas of the breast and its 
distant metastases. Breast Cancer Res, 5(6), pp. R217-222. 
Kratochwil, K. (1986). Tissue combination and organ culture 
studies in the development of the embryonic mammary 
gland. Dev Biol (N Y 1985), 4, pp. 315-333. 
Kubo, M., Nakamura, M., Tasaki, A., Yamanaka, N., Nakashima, 
H., Nomura, M., Kuroki, S. and Katano, M. (2004). 
Hedgehog signaling pathway is a new therapeutic target for 
patients with breast cancer. Cancer Res, 64(17), pp. 6071-
6074. 
Kumar, S., Park, S. H., Cieply, B., Schupp, J., Killiam, E., Zhang, F., 
Rimm, D. L. and Frisch, S. M. (2011). A pathway for the 
control of anoikis sensitivity by E-cadherin and epithelial-
to-mesenchymal transition. Mol Cell Biol, 31(19), pp. 4036-
4051. 
Kurebayashi, J., Koike, Y., Ohta, Y., Saitoh, W., Yamashita, T., 
Kanomata, N. and Moriya, T. (2017). Anti-cancer stem cell 
activity of a hedgehog inhibitor GANT61 in estrogen 
receptor-positive breast cancer cells. Cancer Sci, 108(5), pp. 
918-930. 
Kwon, Y. J., Hurst, D. R., Steg, A. D., Yuan, K., Vaidya, K. S., Welch, 
D. R. and Frost, A. R. (2011). Gli1 enhances migration and 
invasion via up-regulation of MMP-11 and promotes 
metastasis in ERalpha negative breast cancer cell lines. Clin 
Exp Metastasis, 28(5), pp. 437-449. 
Lancet. (1997). Breast cancer and hormone replacement 
therapy: collaborative reanalysis of data from 51 
epidemiological studies of 52,705 women with breast 
cancer and 108,411 women without breast cancer. 
Collaborative Group on Hormonal Factors in Breast Cancer. 
Lancet, 350(9084), pp. 1047-1059. 
Land, C. E., Boice, J. D., Jr., Shore, R. E., Norman, J. E. and 
Tokunaga, M. (1980). Breast cancer risk from low-dose 
exposures to ionizing radiation: results of parallel analysis 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
261 
 
  
of three exposed populations of women. J Natl Cancer Inst, 
65(2), pp. 353-376. 
Lasfargues, E. Y. and Ozzello, L. (1958). Cultivation of human 
breast carcinomas. J Natl Cancer Inst, 21(6), pp. 1131-1147. 
Leake, R., Barnes, D., Pinder, S., Ellis, I., Anderson, L., Anderson, 
T., Adamson, R., Rhodes, T., Miller, K. and Walker, R. 
(2000). Immunohistochemical detection of steroid 
receptors in breast cancer: a working protocol. UK 
Receptor Group, UK NEQAS, The Scottish Breast Cancer 
Pathology Group, and The Receptor and Biomarker Study 
Group of the EORTC. J Clin Pathol, 53(8), pp. 634-635. 
Lee, M. Y., Sun, L. and Veltmaat, J. M. (2013). Hedgehog and Gli 
signaling in embryonic mammary gland development. J 
Mammary Gland Biol Neoplasia, 18(2), pp. 133-138. 
Lee, S. T., Welch, K. D., Panter, K. E., Gardner, D. R., Garrossian, 
M. and Chang, C. W. (2014). Cyclopamine: from cyclops 
lambs to cancer treatment. J Agric Food Chem, 62(30), pp. 
7355-7362. 
Leibovitz, A., Stinson, J. C., McCombs, W. B., 3rd, McCoy, C. E., 
Mazur, K. C. and Mabry, N. D. (1976). Classification of 
human colorectal adenocarcinoma cell lines. Cancer Res, 
36(12), pp. 4562-4569. 
Lemmon, M. A. and Schlessinger, J. (2010). Cell signaling by 
receptor tyrosine kinases. Cell, 141(7), pp. 1117-1134. 
Lewis, M. T. (2001). Hedgehog signaling in mouse mammary 
gland development and neoplasia. J Mammary Gland Biol 
Neoplasia, 6(1), pp. 53-66. 
Lewis, M. T., Ross, S., Strickland, P. A., Sugnet, C. W., Jimenez, E., 
Scott, M. P. and Daniel, C. W. (1999). Defects in mouse 
mammary gland development caused by conditional 
haploinsufficiency of Patched-1. Development, 126(22), pp. 
5181-5193. 
Lewis, M. T. and Veltmaat, J. M. (2004). Next stop, the twilight 
zone: hedgehog network regulation of mammary gland 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
262 
 
  
development. J Mammary Gland Biol Neoplasia, 9(2), pp. 
165-181. 
Lewis-Tuffin, L. J., Rodriguez, F., Giannini, C., Scheithauer, B., 
Necela, B. M., Sarkaria, J. N. and Anastasiadis, P. Z. (2010). 
Misregulated E-cadherin expression associated with an 
aggressive brain tumor phenotype. PLoS One, 5(10), pp. 
e13665. 
Li, J. and Zhou, B. P. (2011). Activation of beta-catenin and Akt 
pathways by Twist are critical for the maintenance of EMT 
associated cancer stem cell-like characters. BMC Cancer, 
11, pp. 49. 
Li, Q. and Mattingly, R. R. (2008). Restoration of E-cadherin cell-
cell junctions requires both expression of E-cadherin and 
suppression of ERK MAP kinase activation in Ras-
transformed breast epithelial cells. Neoplasia, 10(12), pp. 
1444-1458. 
Li, Y., Yang, W., Yang, Q. and Zhou, S. (2012). Nuclear localization 
of GLI1 and elevated expression of FOXC2 in breast cancer 
is associated with the basal-like phenotype. Histol 
Histopathol, 27(4), pp. 475-484. 
Liberio, M. S., Sadowski, M. C., Soekmadji, C., Davis, R. A. and 
Nelson, C. C. (2014). Differential effects of tissue culture 
coating substrates on prostate cancer cell adherence, 
morphology and behavior. PLoS One, 9(11), pp. e112122. 
Liedtke, C. and Kiesel, L. (2012). Breast cancer molecular 
subtypes--modern therapeutic concepts for targeted 
therapy of a heterogeneous entity. Maturitas, 73(4), pp. 
288-294. 
Lin, S. Y., Xia, W., Wang, J. C., Kwong, K. Y., Spohn, B., Wen, Y., 
Pestell, R. G. and Hung, M. C. (2000). Beta-catenin, a novel 
prognostic marker for breast cancer: its roles in cyclin D1 
expression and cancer progression. Proc Natl Acad Sci U S 
A, 97(8), pp. 4262-4266. 
Lipinski, R. J., Hutson, P. R., Hannam, P. W., Nydza, R. J., 
Washington, I. M., Moore, R. W., Girdaukas, G. G., 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
263 
 
  
Peterson, R. E. and Bushman, W. (2008). Dose- and route-
dependent teratogenicity, toxicity, and pharmacokinetic 
profiles of the hedgehog signaling antagonist cyclopamine 
in the mouse. Toxicol Sci, 104(1), pp. 189-197. 
Listerman, I., Gazzaniga, F. S. and Blackburn, E. H. (2014). An 
investigation of the effects of the core protein telomerase 
reverse transcriptase on Wnt signaling in breast cancer 
cells. Mol Cell Biol, 34(2), pp. 280-289. 
Liu, C. Y., Lin, H. H., Tang, M. J. and Wang, Y. K. (2015). Vimentin 
contributes to epithelial-mesenchymal transition cancer 
cell mechanics by mediating cytoskeletal organization and 
focal adhesion maturation. Oncotarget, 6(18), pp. 15966-
15983. 
Liu, S., Cong, Y., Wang, D., Sun, Y., Deng, L., Liu, Y., Martin-
Trevino, R., Shang, L., McDermott, S. P., Landis, M. D., 
Hong, S., Adams, A., D'Angelo, R., Ginestier, C., Charafe-
Jauffret, E., Clouthier, S. G., Birnbaum, D., Wong, S. T., 
Zhan, M., Chang, J. C. and Wicha, M. S. (2014). Breast 
cancer stem cells transition between epithelial and 
mesenchymal states reflective of their normal 
counterparts. Stem Cell Reports, 2(1), pp. 78-91. 
Liu, S., Dontu, G., Mantle, I. D., Patel, S., Ahn, N. S., Jackson, K. 
W., Suri, P. and Wicha, M. S. (2006a). Hedgehog signaling 
and Bmi-1 regulate self-renewal of normal and malignant 
human mammary stem cells. Cancer Res, 66(12), pp. 6063-
6071. 
Liu, W. F., Nelson, C. M., Pirone, D. M. and Chen, C. S. (2006b). E-
cadherin engagement stimulates proliferation via Rac1. J 
Cell Biol, 173(3), pp. 431-441. 
Lo, H. W., Hsu, S. C., Xia, W., Cao, X., Shih, J. Y., Wei, Y., 
Abbruzzese, J. L., Hortobagyi, G. N. and Hung, M. C. (2007). 
Epidermal growth factor receptor cooperates with signal 
transducer and activator of transcription 3 to induce 
epithelial-mesenchymal transition in cancer cells via up-
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
264 
 
  
regulation of TWIST gene expression. Cancer Res, 67(19), 
pp. 9066-9076. 
Lombaerts, M., van Wezel, T., Philippo, K., Dierssen, J. W., 
Zimmerman, R. M., Oosting, J., van Eijk, R., Eilers, P. H., van 
de Water, B., Cornelisse, C. J. and Cleton-Jansen, A. M. 
(2006). E-cadherin transcriptional downregulation by 
promoter methylation but not mutation is related to 
epithelial-to-mesenchymal transition in breast cancer cell 
lines. Br J Cancer, 94(5), pp. 661-671. 
Lozzio, C. B. and Lozzio, B. B. (1975). Human chronic 
myelogenous leukemia cell-line with positive Philadelphia 
chromosome. Blood, 45(3), pp. 321-334. 
Lundgren, K., Nordenskjold, B. and Landberg, G. (2009). Hypoxia, 
Snail and incomplete epithelial-mesenchymal transition in 
breast cancer. Br J Cancer, 101(10), pp. 1769-1781. 
Ma, H., Li, H. Q. and Zhang, X. (2013). Cyclopamine, a naturally 
occurring alkaloid, and its analogues may find wide 
applications in cancer therapy. Curr Top Med Chem, 13(17), 
pp. 2208-2215. 
Maeda, M., Johnson, K. R. and Wheelock, M. J. (2005). Cadherin 
switching: essential for behavioral but not morphological 
changes during an epithelium-to-mesenchyme transition. J 
Cell Sci, 118(Pt 5), pp. 873-887. 
Maeda, O., Kondo, M., Fujita, T., Usami, N., Fukui, T., Shimokata, 
K., Ando, T., Goto, H. and Sekido, Y. (2006). Enhancement 
of GLI1-transcriptional activity by beta-catenin in human 
cancer cells. Oncol Rep, 16(1), pp. 91-96. 
Mahler-Araujo, B., Savage, K., Parry, S. and Reis-Filho, J. S. 
(2008). Reduction of E-cadherin expression is associated 
with non-lobular breast carcinomas of basal-like and triple 
negative phenotype. J Clin Pathol, 61(5), pp. 615-620. 
Mailleux, A. A., Spencer-Dene, B., Dillon, C., Ndiaye, D., Savona-
Baron, C., Itoh, N., Kato, S., Dickson, C., Thiery, J. P. and 
Bellusci, S. (2002). Role of FGF10/FGFR2b signaling during 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
265 
 
  
mammary gland development in the mouse embryo. 
Development, 129(1), pp. 53-60. 
Malhotra, G. K., Zhao, X., Band, H. and Band, V. (2010). 
Histological, molecular and functional subtypes of breast 
cancers. Cancer Biol Ther, 10(10), pp. 955-960. 
Mamuya, F. A. and Duncan, M. K. (2012). aV integrins and TGF-
beta-induced EMT: a circle of regulation. J Cell Mol Med, 
16(3), pp. 445-455. 
Manuel Iglesias, J., Beloqui, I., Garcia-Garcia, F., Leis, O., 
Vazquez-Martin, A., Eguiara, A., Cufi, S., Pavon, A., 
Menendez, J. A., Dopazo, J. and Martin, A. G. (2013). 
Mammosphere formation in breast carcinoma cell lines 
depends upon expression of E-cadherin. PLoS One, 8(10), 
pp. e77281. 
Marigo, V., Davey, R. A., Zuo, Y., Cunningham, J. M. and Tabin, C. 
J. (1996). Biochemical evidence that patched is the 
Hedgehog receptor. Nature, 384(6605), pp. 176-179. 
Mariner, D. J., Davis, M. A. and Reynolds, A. B. (2004). EGFR 
signaling to p120-catenin through phosphorylation at Y228. 
J Cell Sci, 117(Pt 8), pp. 1339-1350. 
Marro, M., Nieva, C., Sanz-Pamplona, R. and Sierra, A. (2014). 
Molecular monitoring of epithelial-to-mesenchymal 
transition in breast cancer cells by means of Raman 
spectroscopy. Biochim Biophys Acta, 1843(9), pp. 1785-
1795. 
Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J. 
P., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, 
E., Guevin, R., Howell, A., Fornander, T., Hainsworth, J., 
Coleman, R., Vinholes, J., Modiano, M., Pinter, T., Tang, S. 
C., Colwell, B., Prady, C., Provencher, L., Walde, D., 
Rodriguez-Lescure, A., Hugh, J., Loret, C., Rupin, M., Blitz, 
S., Jacobs, P., Murawsky, M., Riva, A., Vogel, C. and Breast 
Cancer International Research Group, I. (2005). Adjuvant 
docetaxel for node-positive breast cancer. N Engl J Med, 
352(22), pp. 2302-2313. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
266 
 
  
Martin, M., Ruiz-Borrego, M., Trigo, J. M., Antolin, S., Garcia-
Saenz, J. A., Hernando, A., Ocaña, A., Rojo, F., Lopez-
Tarruella, S., Corral, J., Ribelles, N., Calvo, L., Moreno, F., 
Caballero, R. and Carrasco, E. (2015). Abstract OT1-1-06: A 
phase I study of LDE225 in combination with docetaxel in 
patients with triple negative (TN) advanced breast cancer 
(ABC): GEICAM/2012-12 (EDALINE study). Cancer Research, 
75(9 Supplement), pp. OT1-1-06-OT01-01-06. 
Martinez, V. and Azzopardi, J. G. (1979). Invasive lobular 
carcinoma of the breast: incidence and variants. 
Histopathology, 3(6), pp. 467-488. 
Mascotti, K., McCullough, J. and Burger, S. R. (2000). HPC 
viability measurement: trypan blue versus acridine orange 
and propidium iodide. Transfusion, 40(6), pp. 693-696. 
Matevossian, A. and Resh, M. D. (2015). Hedgehog 
Acyltransferase as a target in estrogen receptor positive, 
HER2 amplified, and tamoxifen resistant breast cancer 
cells. Mol Cancer, 14, pp. 72. 
Mazumdar, T., DeVecchio, J., Agyeman, A., Shi, T. and Houghton, 
J. A. (2011). The GLI genes as the molecular switch in 
disrupting Hedgehog signaling in colon cancer. Oncotarget, 
2(8), pp. 638-645. 
McCready, J., Arendt, L. M., Rudnick, J. A. and Kuperwasser, C. 
(2010). The contribution of dynamic stromal remodeling 
during mammary development to breast carcinogenesis. 
Breast Cancer Res, 12(3), pp. 205. 
McGuire, W. L. and Clark, G. M. (1992). Prognostic factors and 
treatment decisions in axillary-node-negative breast 
cancer. N Engl J Med, 326(26), pp. 1756-1761. 
McMahon, A. P., Ingham, P. W. and Tabin, C. J. (2003). 
Developmental roles and clinical significance of hedgehog 
signaling. Curr Top Dev Biol, 53, pp. 1-114. 
Meisner, A. L., Fekrazad, M. H. and Royce, M. E. (2008). Breast 
disease: benign and malignant. Med Clin North Am, 92(5), 
pp. 1115-1141, x. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
267 
 
  
Memmi, E. M., Sanarico, A. G., Giacobbe, A., Peschiaroli, A., 
Frezza, V., Cicalese, A., Pisati, F., Tosoni, D., Zhou, H., 
Tonon, G., Antonov, A., Melino, G., Pelicci, P. G. and 
Bernassola, F. (2015). p63 Sustains self-renewal of 
mammary cancer stem cells through regulation of Sonic 
Hedgehog signaling. Proc Natl Acad Sci U S A, 112(11), pp. 
3499-3504. 
Mestdagt, M., Polette, M., Buttice, G., Noel, A., Ueda, A., Foidart, 
J. M. and Gilles, C. (2006). Transactivation of MCP-1/CCL2 
by beta-catenin/TCF-4 in human breast cancer cells. Int J 
Cancer, 118(1), pp. 35-42. 
Micalizzi, D. S., Farabaugh, S. M. and Ford, H. L. (2010). 
Epithelial-mesenchymal transition in cancer: parallels 
between normal development and tumor progression. J 
Mammary Gland Biol Neoplasia, 15(2), pp. 117-134. 
Michno, K., Boras-Granic, K., Mill, P., Hui, C. C. and Hamel, P. A. 
(2003). Shh expression is required for embryonic hair 
follicle but not mammary gland development. Dev Biol, 
264(1), pp. 153-165. 
Mickey, D. D., Stone, K. R., Wunderli, H., Mickey, G. H., Vollmer, 
R. T. and Paulson, D. F. (1977). Heterotransplantation of a 
human prostatic adenocarcinoma cell line in nude mice. 
Cancer Res, 37(11), pp. 4049-4058. 
Miele, L., Miao, H. and Nickoloff, B. J. (2006). NOTCH signaling as 
a novel cancer therapeutic target. Curr Cancer Drug 
Targets, 6(4), pp. 313-323. 
Millet, A. V. and Dirbas, F. M. (2002). Clinical management of 
breast pain: a review. Obstet Gynecol Surv, 57(7), pp. 451-
461. 
Moll, R., Mitze, M., Frixen, U. H. and Birchmeier, W. (1993). 
Differential loss of E-cadherin expression in infiltrating 
ductal and lobular breast carcinomas. Am J Pathol, 143(6), 
pp. 1731-1742. 
Moraes, R. C., Zhang, X., Harrington, N., Fung, J. Y., Wu, M. F., 
Hilsenbeck, S. G., Allred, D. C. and Lewis, M. T. (2007). 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
268 
 
  
Constitutive activation of smoothened (SMO) in mammary 
glands of transgenic mice leads to increased proliferation, 
altered differentiation and ductal dysplasia. Development, 
134(6), pp. 1231-1242. 
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., 
Vogelstein, B. and Kinzler, K. W. (1997). Activation of beta-
catenin-Tcf signaling in colon cancer by mutations in beta-
catenin or APC. Science, 275(5307), pp. 1787-1790. 
Morrow, C. M., Mruk, D., Cheng, C. Y. and Hess, R. A. (2010). 
Claudin and occludin expression and function in the 
seminiferous epithelium. Philos Trans R Soc Lond B Biol Sci, 
365(1546), pp. 1679-1696. 
Moussaif, M. and Sze, J. Y. (2009). Intraflagellar 
transport/Hedgehog-related signaling components couple 
sensory cilium morphology and serotonin biosynthesis in 
Caenorhabditis elegans. J Neurosci, 29(13), pp. 4065-4075. 
Mukherjee, S., Frolova, N., Sadlonova, A., Novak, Z., Steg, A., 
Page, G. P., Welch, D. R., Lobo-Ruppert, S. M., Ruppert, J. 
M., Johnson, M. R. and Frost, A. R. (2006). Hedgehog 
signaling and response to cyclopamine differ in epithelial 
and stromal cells in benign breast and breast cancer. 
Cancer Biol Ther, 5(6), pp. 674-683. 
Murone, M., Luoh, S. M., Stone, D., Li, W., Gurney, A., Armanini, 
M., Grey, C., Rosenthal, A. and de Sauvage, F. J. (2000). Gli 
regulation by the opposing activities of fused and 
suppressor of fused. Nat Cell Biol, 2(5), pp. 310-312. 
Nagafuchi, A. and Takeichi, M. (1989). Transmembrane control 
of cadherin-mediated cell adhesion: a 94 kDa protein 
functionally associated with a specific region of the 
cytoplasmic domain of E-cadherin. Cell Regul, 1(1), pp. 37-
44. 
Nakopoulou, L., Mylona, E., Papadaki, I., Kavantzas, N., 
Giannopoulou, I., Markaki, S. and Keramopoulos, A. (2006). 
Study of phospho-beta-catenin subcellular distribution in 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
269 
 
  
invasive breast carcinomas in relation to their phenotype 
and the clinical outcome. Mod Pathol, 19(4), pp. 556-563. 
NCCP. (2002). Policies and managerial guidelines for national 
cancer control programs. Rev Panam Salud Publica, 12(5), 
pp. 366-370. 
Nelson, C. M., Khauv, D., Bissell, M. J. and Radisky, D. C. (2008). 
Change in cell shape is required for matrix 
metalloproteinase-induced epithelial-mesenchymal 
transition of mammary epithelial cells. Journal of cellular 
biochemistry, 105(1), pp. 25-33. 
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., 
Clark, L., Bayani, N., Coppe, J. P., Tong, F., Speed, T., 
Spellman, P. T., DeVries, S., Lapuk, A., Wang, N. J., Kuo, W. 
L., Stilwell, J. L., Pinkel, D., Albertson, D. G., Waldman, F. 
M., McCormick, F., Dickson, R. B., Johnson, M. D., Lippman, 
M., Ethier, S., Gazdar, A. and Gray, J. W. (2006). A collection 
of breast cancer cell lines for the study of functionally 
distinct cancer subtypes. Cancer Cell, 10(6), pp. 515-527. 
Nieman, M. T., Prudoff, R. S., Johnson, K. R. and Wheelock, M. J. 
(1999). N-cadherin promotes motility in human breast 
cancer cells regardless of their E-cadherin expression. J Cell 
Biol, 147(3), pp. 631-644. 
Nozawa, Y. I., Lin, C. and Chuang, P. T. (2013). Hedgehog 
signaling from the primary cilium to the nucleus: an 
emerging picture of ciliary localization, trafficking and 
transduction. Curr Opin Genet Dev, 23(4), pp. 429-437. 
Nusse, R. and Clevers, H. (2017). Wnt/beta-Catenin Signaling, 
Disease, and Emerging Therapeutic Modalities. Cell, 169(6), 
pp. 985-999. 
Nusslein-Volhard, C. and Wieschaus, E. (1980). Mutations 
affecting segment number and polarity in Drosophila. 
Nature, 287(5785), pp. 795-801. 
O'Shaughnessy, J. (2005). Extending survival with chemotherapy 
in metastatic breast cancer. Oncologist, 10 Suppl 3, pp. 20-
29. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
270 
 
  
O'Toole, S. A., Machalek, D. A., Shearer, R. F., Millar, E. K., Nair, 
R., Schofield, P., McLeod, D., Cooper, C. L., McNeil, C. M., 
McFarland, A., Nguyen, A., Ormandy, C. J., Qiu, M. R., 
Rabinovich, B., Martelotto, L. G., Vu, D., Hannigan, G. E., 
Musgrove, E. A., Christ, D., Sutherland, R. L., Watkins, D. N. 
and Swarbrick, A. (2011). Hedgehog overexpression is 
associated with stromal interactions and predicts for poor 
outcome in breast cancer. Cancer Res, 71(11), pp. 4002-
4014. 
Ogunwobi, O. O., Wang, T., Zhang, L. and Liu, C. (2012). 
Cyclooxygenase-2 and Akt mediate multiple growth-factor-
induced epithelial-mesenchymal transition in human 
hepatocellular carcinoma. J Gastroenterol Hepatol, 27(3), 
pp. 566-578. 
Oka, H., Shiozaki, H., Kobayashi, K., Inoue, M., Tahara, H., 
Kobayashi, T., Takatsuka, Y., Matsuyoshi, N., Hirano, S., 
Takeichi, M. and et al. (1993). Expression of E-cadherin cell 
adhesion molecules in human breast cancer tissues and its 
relationship to metastasis. Cancer Res, 53(7), pp. 1696-
1701. 
Oloumi, A., McPhee, T. and Dedhar, S. (2004). Regulation of E-
cadherin expression and beta-catenin/Tcf transcriptional 
activity by the integrin-linked kinase. Biochim Biophys Acta, 
1691(1), pp. 1-15. 
Onder, T. T., Gupta, P. B., Mani, S. A., Yang, J., Lander, E. S. and 
Weinberg, R. A. (2008). Loss of E-cadherin promotes 
metastasis via multiple downstream transcriptional 
pathways. Cancer Res, 68(10), pp. 3645-3654. 
Orlando, L., Colleoni, M., Fedele, P., Cusmai, A., Rizzo, P., 
D'Amico, M., Chetri, M. C. and Cinieri, S. (2007). 
Management of advanced breast cancer. Ann Oncol, 18 
Suppl 6, pp. vi74-76. 
Overgaard, M. (1999). Overview of randomized trials in high risk 
breast cancer patients treated with adjuvant systemic 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
271 
 
  
therapy with or without postmastectomy irradiation. Semin 
Radiat Oncol, 9(3), pp. 292-299. 
Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, 
M., Bach, F., Kjaer, M., Gadeberg, C. C., Mouridsen, H. T., 
Jensen, M. B. and Zedeler, K. (1997). Postoperative 
radiotherapy in high-risk premenopausal women with 
breast cancer who receive adjuvant chemotherapy. Danish 
Breast Cancer Cooperative Group 82b Trial. N Engl J Med, 
337(14), pp. 949-955. 
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, 
F. L., Walker, M. G., Watson, D., Park, T., Hiller, W., Fisher, 
E. R., Wickerham, D. L., Bryant, J. and Wolmark, N. (2004). 
A multigene assay to predict recurrence of tamoxifen-
treated, node-negative breast cancer. N Engl J Med, 
351(27), pp. 2817-2826. 
Pan, S., Wu, X., Jiang, J., Gao, W., Wan, Y., Cheng, D., Han, D., Liu, 
J., Englund, N. P., Wang, Y., Peukert, S., Miller-Moslin, K., 
Yuan, J., Guo, R., Matsumoto, M., Vattay, A., Jiang, Y., Tsao, 
J., Sun, F., Pferdekamper, A. C., Dodd, S., Tuntland, T., 
Maniara, W., Kelleher, J. F., 3rd, Yao, Y. M., Warmuth, M., 
Williams, J. and Dorsch, M. (2010). Discovery of NVP-
LDE225, a Potent and Selective Smoothened Antagonist. 
ACS Med Chem Lett, 1(3), pp. 130-134. 
Pan, Y., Bai, C. B., Joyner, A. L. and Wang, B. (2006). Sonic 
hedgehog signaling regulates Gli2 transcriptional activity by 
suppressing its processing and degradation. Mol Cell Biol, 
26(9), pp. 3365-3377. 
Paredes, J., Correia, A. L., Ribeiro, A. S., Milanezi, F., Cameselle-
Teijeiro, J. and Schmitt, F. C. (2008). Breast carcinomas that 
co-express E- and P-cadherin are associated with p120-
catenin cytoplasmic localisation and poor patient survival. J 
Clin Pathol, 61(7), pp. 856-862. 
Pasca di Magliano, M. and Hebrok, M. (2003). Hedgehog 
signalling in cancer formation and maintenance. Nat Rev 
Cancer, 3(12), pp. 903-911. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
272 
 
  
Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., 
Revenco, T., Boumahdi, S., Van Keymeulen, A., Brown, D., 
Moers, V., Lemaire, S., De Clercq, S., Minguijon, E., Balsat, 
C., Sokolow, Y., Dubois, C., De Cock, F., Scozzaro, S., 
Sopena, F., Lanas, A., D'Haene, N., Salmon, I., Marine, J. C., 
Voet, T., Sotiropoulou, P. A. and Blanpain, C. (2018). 
Identification of the tumour transition states occurring 
during EMT. Nature, 556(7702), pp. 463-468. 
Patsialou, A., Wyckoff, J., Wang, Y., Goswami, S., Stanley, E. R. 
and Condeelis, J. S. (2009). Invasion of human breast 
cancer cells in vivo requires both paracrine and autocrine 
loops involving the colony-stimulating factor-1 receptor. 
Cancer Res, 69(24), pp. 9498-9506. 
Pearson, G. W. and Hunter, T. (2007). Real-time imaging reveals 
that noninvasive mammary epithelial acini can contain 
motile cells. J Cell Biol, 179(7), pp. 1555-1567. 
Peddi, P. F., Ellis, M. J. and Ma, C. (2012). Molecular basis of 
triple negative breast cancer and implications for therapy. 
Int J Breast Cancer, 2012, pp. 217185. 
Peinado, H., Portillo, F. and Cano, A. (2004). Transcriptional 
regulation of cadherins during development and 
carcinogenesis. Int J Dev Biol, 48(5-6), pp. 365-375. 
Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., 
Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. 
A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S. X., 
Lonning, P. E., Borresen-Dale, A. L., Brown, P. O. and 
Botstein, D. (2000). Molecular portraits of human breast 
tumours. Nature, 406(6797), pp. 747-752. 
Peyrieras, N., Hyafil, F., Louvard, D., Ploegh, H. L. and Jacob, F. 
(1983). Uvomorulin: a nonintegral membrane protein of 
early mouse embryo. Proc Natl Acad Sci U S A, 80(20), pp. 
6274-6277. 
Pfahler, G. E. (1932). Summary of Results that can be Obtained 
by Irradiation in Cancer. Bull N Y Acad Med, 8(12), pp. 702-
716. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
273 
 
  
Phillips, S. and Kuperwasser, C. (2014). SLUG: Critical regulator of 
epithelial cell identity in breast development and cancer. 
Cell Adh Migr, 8(6), pp. 578-587. 
Phillips, S., Prat, A., Sedic, M., Proia, T., Wronski, A., Mazumdar, 
S., Skibinski, A., Shirley, S. H., Perou, C. M., Gill, G., Gupta, 
P. B. and Kuperwasser, C. (2014). Cell-state transitions 
regulated by SLUG are critical for tissue regeneration and 
tumor initiation. Stem Cell Reports, 2(5), pp. 633-647. 
Pizem, J., Popovic, M. and Cor, A. (2011). Expression of Gli1 and 
PARP1 in medulloblastoma: an immunohistochemical study 
of 65 cases. J Neurooncol, 103(3), pp. 459-467. 
Polyak, K. and Weinberg, R. A. (2009). Transitions between 
epithelial and mesenchymal states: acquisition of 
malignant and stem cell traits. Nat Rev Cancer, 9(4), pp. 
265-273. 
Porfiri, E., Rubinfeld, B., Albert, I., Hovanes, K., Waterman, M. 
and Polakis, P. (1997). Induction of a beta-catenin-LEF-1 
complex by wnt-1 and transforming mutants of beta-
catenin. Oncogene, 15(23), pp. 2833-2839. 
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., 
Herschkowitz, J. I., He, X. and Perou, C. M. (2010). 
Phenotypic and molecular characterization of the claudin-
low intrinsic subtype of breast cancer. Breast Cancer Res, 
12(5), pp. R68. 
Press, M. F., Finn, R. S., Cameron, D., Di Leo, A., Geyer, C. E., 
Villalobos, I. E., Santiago, A., Guzman, R., Gasparyan, A., 
Ma, Y., Danenberg, K., Martin, A. M., Williams, L., Oliva, C., 
Stein, S., Gagnon, R., Arbushites, M. and Koehler, M. T. 
(2008). HER-2 gene amplification, HER-2 and epidermal 
growth factor receptor mRNA and protein expression, and 
lapatinib efficacy in women with metastatic breast cancer. 
Clin Cancer Res, 14(23), pp. 7861-7870. 
Price, M. A. (2006). CKI, there's more than one: casein kinase I 
family members in Wnt and Hedgehog signaling. Genes 
Dev, 20(4), pp. 399-410. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
274 
 
  
Proia, T. A., Keller, P. J., Gupta, P. B., Klebba, I., Jones, A. D., 
Sedic, M., Gilmore, H., Tung, N., Naber, S. P., Schnitt, S., 
Lander, E. S. and Kuperwasser, C. (2011). Genetic 
predisposition directs breast cancer phenotype by dictating 
progenitor cell fate. Cell Stem Cell, 8(2), pp. 149-163. 
Pronobis, M. I., Rusan, N. M. and Peifer, M. (2015). A novel 
GSK3-regulated APC:Axin interaction regulates Wnt 
signaling by driving a catalytic cycle of efficient betacatenin 
destruction. Elife, 4, pp. e08022. 
Pruthi, S. (2001). Detection and evaluation of a palpable breast 
mass. Mayo Clin Proc, 76(6), pp. 641-647; quiz 647-648. 
Qu, Y., Han, B., Yu, Y., Yao, W., Bose, S., Karlan, B. Y., Giuliano, A. 
E. and Cui, X. (2015). Evaluation of MCF10A as a Reliable 
Model for Normal Human Mammary Epithelial Cells. PLoS 
One, 10(7), pp. e0131285. 
Qualtrough, D., Buda, A., Gaffield, W., Williams, A. C. and 
Paraskeva, C. (2004). Hedgehog signalling in colorectal 
tumour cells: induction of apoptosis with cyclopamine 
treatment. Int J Cancer, 110(6), pp. 831-837. 
Qualtrough, D., Kaidi, A., Chell, S., Jabbour, H. N., Williams, A. C. 
and Paraskeva, C. (2007). Prostaglandin F(2alpha) 
stimulates motility and invasion in colorectal tumor cells. 
Int J Cancer, 121(4), pp. 734-740. 
Qualtrough, D., Rees, P., Speight, B., Williams, A. C. and 
Paraskeva, C. (2015). The Hedgehog Inhibitor Cyclopamine 
Reduces beta-Catenin-Tcf Transcriptional Activity, Induces 
E-Cadherin Expression, and Reduces Invasion in Colorectal 
Cancer Cells. Cancers (Basel), 7(3), pp. 1885-1899. 
Qureshi, H. S., Linden, M. D., Divine, G. and Raju, U. B. (2006). E-
cadherin status in breast cancer correlates with histologic 
type but does not correlate with established prognostic 
parameters. Am J Clin Pathol, 125(3), pp. 377-385. 
Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., 
Basco, V. E., Wilson, K. S., Knowling, M. A., Coppin, C. M., 
Paradis, M., Coldman, A. J. and Olivotto, I. A. (1997). 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
275 
 
  
Adjuvant radiotherapy and chemotherapy in node-positive 
premenopausal women with breast cancer. N Engl J Med, 
337(14), pp. 956-962. 
Rakha, E. A., Abd El Rehim, D., Pinder, S. E., Lewis, S. A. and Ellis, 
I. O. (2005). E-cadherin expression in invasive non-lobular 
carcinoma of the breast and its prognostic significance. 
Histopathology, 46(6), pp. 685-693. 
Rakha, E. A. and Chan, S. (2011). Metastatic triple-negative 
breast cancer. Clin Oncol (R Coll Radiol), 23(9), pp. 587-600. 
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., 
Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., 
Brunet, J. S., Akslen, L. A., Evans, A. J., Blamey, R., Reis-
Filho, J. S., Foulkes, W. D. and Ellis, I. O. (2009). Triple-
negative breast cancer: distinguishing between basal and 
nonbasal subtypes. Clin Cancer Res, 15(7), pp. 2302-2310. 
Rakha, E. A., Pinder, S. E., Bartlett, J. M., Ibrahim, M., Starczynski, 
J., Carder, P. J., Provenzano, E., Hanby, A., Hales, S., Lee, A. 
H., Ellis, I. O. and National Coordinating Committee for 
Breast, P. (2015). Updated UK Recommendations for HER2 
assessment in breast cancer. J Clin Pathol, 68(2), pp. 93-99. 
Rakha, E. A., Reis-Filho, J. S., Baehner, F., Dabbs, D. J., Decker, T., 
Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. 
R., Palacios, J., Richardson, A. L., Schnitt, S. J., Schmitt, F. C., 
Tan, P. H., Tse, G. M., Badve, S. and Ellis, I. O. (2010a). 
Breast cancer prognostic classification in the molecular era: 
the role of histological grade. Breast Cancer Res, 12(4), pp. 
207. 
Rakha, E. A., Reis-Filho, J. S. and Ellis, I. O. (2008). Basal-like 
breast cancer: a critical review. J Clin Oncol, 26(15), pp. 
2568-2581. 
Rakha, E. A., Reis-Filho, J. S. and Ellis, I. O. (2010b). Combinatorial 
biomarker expression in breast cancer. Breast Cancer Res 
Treat, 120(2), pp. 293-308. 
Ramaswamy, B., Lu, Y., Teng, K. Y., Nuovo, G., Li, X., Shapiro, C. L. 
and Majumder, S. (2012). Hedgehog signaling is a novel 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
276 
 
  
therapeutic target in tamoxifen-resistant breast cancer 
aberrantly activated by PI3K/AKT pathway. Cancer Res, 
72(19), pp. 5048-5059. 
Ramaswamy, S., Ross, K. N., Lander, E. S. and Golub, T. R. (2003). 
A molecular signature of metastasis in primary solid 
tumors. Nat Genet, 33(1), pp. 49-54. 
Ramsbottom, S. A. and Pownall, M. E. (2016). Regulation of 
Hedgehog Signalling Inside and Outside the Cell. J Dev Biol, 
4(3), pp. 23. 
Ravindranath, A., Yuen, H. F., Chan, K. K., Grills, C., Fennell, D. A., 
Lappin, T. R. and El-Tanani, M. (2011). Wnt-beta-catenin-
Tcf-4 signalling-modulated invasiveness is dependent on 
osteopontin expression in breast cancer. Br J Cancer, 
105(4), pp. 542-551. 
Reddy, P., Liu, L., Ren, C., Lindgren, P., Boman, K., Shen, Y., 
Lundin, E., Ottander, U., Rytinki, M. and Liu, K. (2005). 
Formation of E-cadherin-mediated cell-cell adhesion 
activates AKT and mitogen activated protein kinase via 
phosphatidylinositol 3 kinase and ligand-independent 
activation of epidermal growth factor receptor in ovarian 
cancer cells. Mol Endocrinol, 19(10), pp. 2564-2578. 
Redig, A. J. and McAllister, S. S. (2013). Breast cancer as a 
systemic disease: a view of metastasis. J Intern Med, 
274(2), pp. 113-126. 
Regl, G., Neill, G. W., Eichberger, T., Kasper, M., Ikram, M. S., 
Koller, J., Hintner, H., Quinn, A. G., Frischauf, A. M. and 
Aberger, F. (2002). Human GLI2 and GLI1 are part of a 
positive feedback mechanism in Basal Cell Carcinoma. 
Oncogene, 21(36), pp. 5529-5539. 
Reifenberger, J., Wolter, M., Weber, R. G., Megahed, M., 
Ruzicka, T., Lichter, P. and Reifenberger, G. (1998). 
Missense mutations in SMOH in sporadic basal cell 
carcinomas of the skin and primitive neuroectodermal 
tumors of the central nervous system. Cancer Res, 58(9), 
pp. 1798-1803. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
277 
 
  
Remmele, W. and Stegner, H. E. (1987). [Recommendation for 
uniform definition of an immunoreactive score (IRS) for 
immunohistochemical estrogen receptor detection (ER-ICA) 
in breast cancer tissue]. Pathologe, 8(3), pp. 138-140. 
Ribeiro, A. S., Sousa, B., Carreto, L., Mendes, N., Nobre, A. R., 
Ricardo, S., Albergaria, A., Cameselle-Teijeiro, J. F., 
Gerhard, R., Soderberg, O., Seruca, R., Santos, M. A., 
Schmitt, F. and Paredes, J. (2013). P-cadherin functional 
role is dependent on E-cadherin cellular context: a proof of 
concept using the breast cancer model. J Pathol, 229(5), 
pp. 705-718. 
Ricardo, S., Vieira, A. F., Gerhard, R., Leitao, D., Pinto, R., 
Cameselle-Teijeiro, J. F., Milanezi, F., Schmitt, F. and 
Paredes, J. (2011). Breast cancer stem cell markers CD44, 
CD24 and ALDH1: expression distribution within intrinsic 
molecular subtype. J Clin Pathol, 64(11), pp. 937-946. 
Rijsewijk, F., Schuermann, M., Wagenaar, E., Parren, P., Weigel, 
D. and Nusse, R. (1987). The Drosophila homolog of the 
mouse mammary oncogene int-1 is identical to the 
segment polarity gene wingless. Cell, 50(4), pp. 649-657. 
Rimkus, T. K., Carpenter, R. L., Qasem, S., Chan, M. and Lo, H. W. 
(2016). Targeting the Sonic Hedgehog Signaling Pathway: 
Review of Smoothened and GLI Inhibitors. Cancers (Basel), 
8(2). 
Rizwan, A., Cheng, M., Bhujwalla, Z. M., Krishnamachary, B., 
Jiang, L. and Glunde, K. (2015). Breast cancer cell 
adhesome and degradome interact to drive metastasis. NPJ 
Breast Cancer, 1, pp. 15017. 
Robinson, G. W., Karpf, A. B. and Kratochwil, K. (1999). 
Regulation of mammary gland development by tissue 
interaction. J Mammary Gland Biol Neoplasia, 4(1), pp. 9-
19. 
Roose, J., Huls, G., van Beest, M., Moerer, P., van der Horn, K., 
Goldschmeding, R., Logtenberg, T. and Clevers, H. (1999). 
Synergy between tumor suppressor APC and the beta-
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
278 
 
  
catenin-Tcf4 target Tcf1. Science, 285(5435), pp. 1923-
1926. 
Rorth, P. (2009). Collective cell migration. Annu Rev Cell Dev Biol, 
25, pp. 407-429. 
Rosa, M., Han, H. S., Ismail-Khan, R., Allam-Nandyala, P. and Bui, 
M. M. (2015). Beta-catenin expression patterns in matched 
pre- and post-neoadjuvant chemotherapy-resistant breast 
cancer. Ann Clin Lab Sci, 45(1), pp. 10-16. 
Rosen, P. P., Groshen, S., Kinne, D. W. and Hellman, S. (1989a). 
Contralateral breast carcinoma: an assessment of risk and 
prognosis in stage I (T1N0M0) and stage II (T1N1M0) 
patients with 20-year follow-up. Surgery, 106(5), pp. 904-
910. 
Rosen, P. P., Groshen, S., Saigo, P. E., Kinne, D. W. and Hellman, 
S. (1989b). Pathological prognostic factors in stage I 
(T1N0M0) and stage II (T1N1M0) breast carcinoma: a study 
of 644 patients with median follow-up of 18 years. J Clin 
Oncol, 7(9), pp. 1239-1251. 
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., 
Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, 
M., Wagner, P., Morandi, P., Fan, C., Rabiul, I., Ross, J. S., 
Hortobagyi, G. N. and Pusztai, L. (2005). Breast cancer 
molecular subtypes respond differently to preoperative 
chemotherapy. Clin Cancer Res, 11(16), pp. 5678-5685. 
Rubin, L. L. and de Sauvage, F. J. (2006). Targeting the Hedgehog 
pathway in cancer. Nat Rev Drug Discov, 5(12), pp. 1026-
1033. 
Ruiz i Altaba, A. (1998). Combinatorial Gli gene function in floor 
plate and neuronal inductions by Sonic hedgehog. 
Development, 125(12), pp. 2203-2212. 
Ruiz i Altaba, A., Mas, C. and Stecca, B. (2007). The Gli code: an 
information nexus regulating cell fate, stemness and 
cancer. Trends Cell Biol, 17(9), pp. 438-447. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
279 
 
  
Ruiz i Altaba, A., Sanchez, P. and Dahmane, N. (2002). Gli and 
hedgehog in cancer: tumours, embryos and stem cells. Nat 
Rev Cancer, 2(5), pp. 361-372. 
Saegusa, M., Hashimura, M., Kuwata, T. and Okayasu, I. (2009). 
Requirement of the Akt/beta-catenin pathway for uterine 
carcinosarcoma genesis, modulating E-cadherin expression 
through the transactivation of slug. Am J Pathol, 174(6), pp. 
2107-2115. 
Saitoh, M. (2018). Involvement of partial EMT in cancer 
progression. J Biochem. 
Sakakura, T., Kusano, I., Kusakabe, M., Inaguma, Y. and 
Nishizuka, Y. (1987). Biology of mammary fat pad in fetal 
mouse: capacity to support development of various fetal 
epithelia in vivo. Development, 100(3), pp. 421-430. 
Sakuma, K., Aoki, M. and Kannagi, R. (2012). Transcription 
factors c-Myc and CDX2 mediate E-selectin ligand 
expression in colon cancer cells undergoing EGF/bFGF-
induced epithelial-mesenchymal transition. Proc Natl Acad 
Sci U S A, 109(20), pp. 7776-7781. 
Sanchez, P., Hernandez, A. M., Stecca, B., Kahler, A. J., DeGueme, 
A. M., Barrett, A., Beyna, M., Datta, M. W., Datta, S. and 
Ruiz i Altaba, A. (2004). Inhibition of prostate cancer 
proliferation by interference with SONIC HEDGEHOG-GLI1 
signaling. Proc Natl Acad Sci U S A, 101(34), pp. 12561-
12566. 
Sarrio, D., Rodriguez-Pinilla, S. M., Hardisson, D., Cano, A., 
Moreno-Bueno, G. and Palacios, J. (2008). Epithelial-
mesenchymal transition in breast cancer relates to the 
basal-like phenotype. Cancer Res, 68(4), pp. 989-997. 
Savagner, P. (2010). The epithelial-mesenchymal transition 
(EMT) phenomenon. Ann Oncol, 21 Suppl 7, pp. vii89-92. 
Schatzkin, A., Jones, D. Y., Hoover, R. N., Taylor, P. R., Brinton, L. 
A., Ziegler, R. G., Harvey, E. B., Carter, C. L., Licitra, L. M., 
Dufour, M. C. and et al. (1987). Alcohol consumption and 
breast cancer in the epidemiologic follow-up study of the 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
280 
 
  
first National Health and Nutrition Examination Survey. N 
Engl J Med, 316(19), pp. 1169-1173. 
Scherer, W. F., Syverton, J. T. and Gey, G. O. (1953). Studies on 
the propagation in vitro of poliomyelitis viruses. IV. Viral 
multiplication in a stable strain of human malignant 
epithelial cells (strain HeLa) derived from an epidermoid 
carcinoma of the cervix. J Exp Med, 97(5), pp. 695-710. 
Schlange, T., Matsuda, Y., Lienhard, S., Huber, A. and Hynes, N. E. 
(2007). Autocrine WNT signaling contributes to breast 
cancer cell proliferation via the canonical WNT pathway 
and EGFR transactivation. Breast Cancer Res, 9(5), pp. R63. 
Schlosshauer, P. W., Brown, S. A., Eisinger, K., Yan, Q., 
Guglielminetti, E. R., Parsons, R., Ellenson, L. H. and 
Kitajewski, J. (2000). APC truncation and increased beta-
catenin levels in a human breast cancer cell line. 
Carcinogenesis, 21(7), pp. 1453-1456. 
Schmid, S., Bieber, M., Zhang, F., Zhang, M., He, B., Jablons, D. 
and Teng, N. N. (2011). Wnt and hedgehog gene pathway 
expression in serous ovarian cancer. Int J Gynecol Cancer, 
21(6), pp. 975-980. 
Schneider, U., Schwenk, H. U. and Bornkamm, G. (1977). 
Characterization of EBV-genome negative "null" and "T" 
cell lines derived from children with acute lymphoblastic 
leukemia and leukemic transformed non-Hodgkin 
lymphoma. Int J Cancer, 19(5), pp. 621-626. 
Schnidar, H., Eberl, M., Klingler, S., Mangelberger, D., Kasper, M., 
Hauser-Kronberger, C., Regl, G., Kroismayr, R., Moriggl, R., 
Sibilia, M. and Aberger, F. (2009). Epidermal growth factor 
receptor signaling synergizes with Hedgehog/GLI in 
oncogenic transformation via activation of the 
MEK/ERK/JUN pathway. Cancer Res, 69(4), pp. 1284-1292. 
Seal, M. D. and Chia, S. K. (2010). What is the difference between 
triple-negative and basal breast cancers? Cancer J, 16(1), 
pp. 12-16. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
281 
 
  
Selli, C., Erac, Y. and Tosun, M. (2016). Effects of cell seeding 
density on real-time monitoring of anti-proliferative effects 
of transient gene silencing. J Biol Res (Thessalon), 23, pp. 
20. 
Shan, S., Lv, Q., Zhao, Y., Liu, C., Sun, Y., Xi, K., Xiao, J. and Li, C. 
(2015). Wnt/beta-catenin pathway is required for epithelial 
to mesenchymal transition in CXCL12 over expressed 
breast cancer cells. Int J Clin Exp Pathol, 8(10), pp. 12357-
12367. 
Shigemura, K., Huang, W. C., Li, X., Zhau, H. E., Zhu, G., Gotoh, A., 
Fujisawa, M., Xie, J., Marshall, F. F. and Chung, L. W. (2011). 
Active sonic hedgehog signaling between androgen 
independent human prostate cancer cells and 
normal/benign but not cancer-associated prostate stromal 
cells. Prostate, 71(16), pp. 1711-1722. 
Shirure, V. S., Liu, T., Delgadillo, L. F., Cuckler, C. M., Tees, D. F., 
Benencia, F., Goetz, D. J. and Burdick, M. M. (2015). CD44 
variant isoforms expressed by breast cancer cells are 
functional E-selectin ligands under flow conditions. Am J 
Physiol Cell Physiol, 308(1), pp. C68-78. 
Siitonen, S. M., Kononen, J. T., Helin, H. J., Rantala, I. S., Holli, K. 
A. and Isola, J. J. (1996). Reduced E-cadherin expression is 
associated with invasiveness and unfavorable prognosis in 
breast cancer. Am J Clin Pathol, 105(4), pp. 394-402. 
Silberstein, G. B., Flanders, K. C., Roberts, A. B. and Daniel, C. W. 
(1992). Regulation of mammary morphogenesis: evidence 
for extracellular matrix-mediated inhibition of ductal 
budding by transforming growth factor-beta 1. Dev Biol, 
152(2), pp. 354-362. 
Sims, A. H., Howell, A., Howell, S. J. and Clarke, R. B. (2007). 
Origins of breast cancer subtypes and therapeutic 
implications. Nat Clin Pract Oncol, 4(9), pp. 516-525. 
Singh, B. N., Doyle, M. J., Weaver, C. V., Koyano-Nakagawa, N. 
and Garry, D. J. (2012). Hedgehog and Wnt coordinate 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
282 
 
  
signaling in myogenic progenitors and regulate limb 
regeneration. Dev Biol, 371(1), pp. 23-34. 
Singletary, S. E. (2003). Rating the risk factors for breast cancer. 
Ann Surg, 237(4), pp. 474-482. 
Skvara, H., Kalthoff, F., Meingassner, J. G., Wolff-Winiski, B., 
Aschauer, H., Kelleher, J. F., Wu, X., Pan, S., Mickel, L., 
Schuster, C., Stary, G., Jalili, A., David, O. J., Emotte, C., 
Antunes, A. M., Rose, K., Decker, J., Carlson, I., Gardner, H., 
Stuetz, A., Bertolino, A. P., Stingl, G. and De Rie, M. A. 
(2011). Topical treatment of Basal cell carcinomas in nevoid 
Basal cell carcinoma syndrome with a smoothened 
inhibitor. J Invest Dermatol, 131(8), pp. 1735-1744. 
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. 
and McGuire, W. L. (1987). Human breast cancer: 
correlation of relapse and survival with amplification of the 
HER-2/neu oncogene. Science, 235(4785), pp. 177-182. 
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., 
Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., 
Pegram, M., Baselga, J. and Norton, L. (2001). Use of 
chemotherapy plus a monoclonal antibody against HER2 
for metastatic breast cancer that overexpresses HER2. N 
Engl J Med, 344(11), pp. 783-792. 
Sodergren, S. C., Copson, E., White, A., Efficace, F., Sprangers, 
M., Fitzsimmons, D., Bottomley, A. and Johnson, C. D. 
(2016). Systematic Review of the Side Effects Associated 
With Anti-HER2-Targeted Therapies Used in the Treatment 
of Breast Cancer, on Behalf of the EORTC Quality of Life 
Group. Target Oncol, 11(3), pp. 277-292. 
Sommers, C. L., Thompson, E. W., Torri, J. A., Kemler, R., 
Gelmann, E. P. and Byers, S. W. (1991). Cell adhesion 
molecule uvomorulin expression in human breast cancer 
cell lines: relationship to morphology and invasive 
capacities. Cell Growth Differ, 2(8), pp. 365-372. 
Song, L., Wang, W., Liu, D., Zhao, Y., He, J., Wang, X., Dai, Z., 
Zhang, H. and Li, X. (2016). Targeting of sonic hedgehog-Gli 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
283 
 
  
signaling: A potential therapeutic target for patients with 
breast cancer. Oncol Lett, 12(2), pp. 1027-1033. 
Sorkin, A. and Duex, J. E. (2010). Quantitative analysis of 
endocytosis and turnover of epidermal growth factor (EGF) 
and EGF receptor. Curr Protoc Cell Biol, Chapter 15, pp. Unit 
15 14. 
Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, 
H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., 
Thorsen, T., Quist, H., Matese, J. C., Brown, P. O., Botstein, 
D., Lonning, P. E. and Borresen-Dale, A. L. (2001). Gene 
expression patterns of breast carcinomas distinguish tumor 
subclasses with clinical implications. Proc Natl Acad Sci U S 
A, 98(19), pp. 10869-10874. 
Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, 
A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., Demeter, J., 
Perou, C. M., Lonning, P. E., Brown, P. O., Borresen-Dale, A. 
L. and Botstein, D. (2003). Repeated observation of breast 
tumor subtypes in independent gene expression data sets. 
Proc Natl Acad Sci U S A, 100(14), pp. 8418-8423. 
Sotiriou, C. and Pusztai, L. (2009). Gene-expression signatures in 
breast cancer. N Engl J Med, 360(8), pp. 790-800. 
Soule, H. D., Maloney, T. M., Wolman, S. R., Peterson, W. D., Jr., 
Brenz, R., McGrath, C. M., Russo, J., Pauley, R. J., Jones, R. 
F. and Brooks, S. C. (1990). Isolation and characterization of 
a spontaneously immortalized human breast epithelial cell 
line, MCF-10. Cancer Res, 50(18), pp. 6075-6086. 
Soule, H. D., Vazguez, J., Long, A., Albert, S. and Brennan, M. 
(1973). A human cell line from a pleural effusion derived 
from a breast carcinoma. J Natl Cancer Inst, 51(5), pp. 
1409-1416. 
Souzaki, M., Kubo, M., Kai, M., Kameda, C., Tanaka, H., Taguchi, 
T., Tanaka, M., Onishi, H. and Katano, M. (2011). Hedgehog 
signaling pathway mediates the progression of non-
invasive breast cancer to invasive breast cancer. Cancer Sci, 
102(2), pp. 373-381. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
284 
 
  
Souzaki, R., Tajiri, T., Souzaki, M., Kinoshita, Y., Tanaka, S., 
Kohashi, K., Oda, Y., Katano, M. and Taguchi, T. (2010). 
Hedgehog signaling pathway in neuroblastoma 
differentiation. J Pediatr Surg, 45(12), pp. 2299-2304. 
Stamataki, D., Ulloa, F., Tsoni, S. V., Mynett, A. and Briscoe, J. 
(2005). A gradient of Gli activity mediates graded Sonic 
Hedgehog signaling in the neural tube. Genes Dev, 19(5), 
pp. 626-641. 
Stecca, B. and Ruiz, I. A. A. (2010). Context-dependent regulation 
of the GLI code in cancer by HEDGEHOG and non-
HEDGEHOG signals. J Mol Cell Biol, 2(2), pp. 84-95. 
Steg, A. D., Katre, A. A., Bevis, K. S., Ziebarth, A., Dobbin, Z. C., 
Shah, M. M., Alvarez, R. D. and Landen, C. N. (2012). 
Smoothened antagonists reverse taxane resistance in 
ovarian cancer. Mol Cancer Ther, 11(7), pp. 1587-1597. 
Steinberg, K. K., Thacker, S. B., Smith, S. J., Stroup, D. F., Zack, M. 
M., Flanders, W. D. and Berkelman, R. L. (1991). A meta-
analysis of the effect of estrogen replacement therapy on 
the risk of breast cancer. JAMA, 265(15), pp. 1985-1990. 
Sternlicht, M. D. (2006). Key stages in mammary gland 
development: the cues that regulate ductal branching 
morphogenesis. Breast Cancer Res, 8(1), pp. 201. 
Strober, W. (2001). Trypan blue exclusion test of cell viability. 
Curr Protoc Immunol, Appendix 3, pp. Appendix 3B. 
Sultan, A. S., Xie, J., LeBaron, M. J., Ealley, E. L., Nevalainen, M. T. 
and Rui, H. (2005). Stat5 promotes homotypic adhesion 
and inhibits invasive characteristics of human breast cancer 
cells. Oncogene, 24(5), pp. 746-760. 
Sun, Q., Cibas, E. S., Huang, H., Hodgson, L. and Overholtzer, M. 
(2014a). Induction of entosis by epithelial cadherin 
expression. Cell Res, 24(11), pp. 1288-1298. 
Sun, Y., Wang, Y., Fan, C., Gao, P., Wang, X., Wei, G. and Wei, J. 
(2014b). Estrogen promotes stemness and invasiveness of 
ER-positive breast cancer cells through Gli1 activation. Mol 
Cancer, 13, pp. 137. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
285 
 
  
Sundfeldt, K. (2003). Cell-cell adhesion in the normal ovary and 
ovarian tumors of epithelial origin; an exception to the 
rule. Mol Cell Endocrinol, 202(1-2), pp. 89-96. 
Suzuki, K. and Takahashi, K. (2006). Induction of E-cadherin 
endocytosis by loss of protein phosphatase 2A expression 
in human breast cancers. Biochem Biophys Res Commun, 
349(1), pp. 255-260. 
Szczepny, A., Rogers, S., Jayasekara, W. S. N., Park, K., McCloy, R. 
A., Cochrane, C. R., Ganju, V., Cooper, W. A., Sage, J., 
Peacock, C. D., Cain, J. E., Burgess, A. and Watkins, D. N. 
(2017). The role of canonical and non-canonical Hedgehog 
signaling in tumor progression in a mouse model of small 
cell lung cancer. Oncogene, 36(39), pp. 5544-5550. 
Takeichi, M. (1991). Cadherin cell adhesion receptors as a 
morphogenetic regulator. Science, 251(5000), pp. 1451-
1455. 
Tanaka, H., Nakamura, M., Kameda, C., Kubo, M., Sato, N., 
Kuroki, S., Tanaka, M. and Katano, M. (2009). The 
Hedgehog signaling pathway plays an essential role in 
maintaining the CD44+CD24-/low subpopulation and the 
side population of breast cancer cells. Anticancer Res, 
29(6), pp. 2147-2157. 
Tanaka, K., Tokunaga, E., Inoue, Y., Yamashita, N., Saeki, H., 
Okano, S., Kitao, H., Oki, E., Oda, Y. and Maehara, Y. (2016). 
Impact of Expression of Vimentin and Axl in Breast Cancer. 
Clin Breast Cancer, 16(6), pp. 520-526 e522. 
Tang, Y., Wang, Y., Kiani, M. F. and Wang, B. (2016). 
Classification, Treatment Strategy, and Associated Drug 
Resistance in Breast Cancer. Clin Breast Cancer, 16(5), pp. 
335-343. 
Tao, Y., Mao, J., Zhang, Q. and Li, L. (2011). Overexpression of 
Hedgehog signaling molecules and its involvement in triple-
negative breast cancer. Oncol Lett, 2(5), pp. 995-1001. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
286 
 
  
Tarin, D., Thompson, E. W. and Newgreen, D. F. (2005). The 
fallacy of epithelial mesenchymal transition in neoplasia. 
Cancer Res, 65(14), pp. 5996-6000; discussion 6000-5991. 
ten Haaf, A., Bektas, N., von Serenyi, S., Losen, I., Arweiler, E. C., 
Hartmann, A., Knuchel, R. and Dahl, E. (2009). Expression of 
the glioma-associated oncogene homolog (GLI) 1 in human 
breast cancer is associated with unfavourable overall 
survival. BMC Cancer, 9, pp. 298. 
Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., 
Roberts, D. J., Lauwers, G. Y., Qi, Y. P., Gysin, S., Fernandez-
del Castillo, C., Yajnik, V., Antoniu, B., McMahon, M., 
Warshaw, A. L. and Hebrok, M. (2003). Hedgehog is an 
early and late mediator of pancreatic cancer tumorigenesis. 
Nature, 425(6960), pp. 851-856. 
Theunissen, J. W. and de Sauvage, F. J. (2009). Paracrine 
Hedgehog signaling in cancer. Cancer Res, 69(15), pp. 6007-
6010. 
Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour 
progression. Nat Rev Cancer, 2(6), pp. 442-454. 
Thiery, J. P., Acloque, H., Huang, R. Y. and Nieto, M. A. (2009). 
Epithelial-mesenchymal transitions in development and 
disease. Cell, 139(5), pp. 871-890. 
Thiyagarajan, S., Bhatia, N., Reagan-Shaw, S., Cozma, D., 
Thomas-Tikhonenko, A., Ahmad, N. and Spiegelman, V. S. 
(2007). Role of GLI2 transcription factor in growth and 
tumorigenicity of prostate cells. Cancer Res, 67(22), pp. 
10642-10646. 
Thomas, Z. I., Gibson, W., Sexton, J. Z., Aird, K. M., Ingram, S. M., 
Aldrich, A., Lyerly, H. K., Devi, G. R. and Williams, K. P. 
(2011). Targeting GLI1 expression in human inflammatory 
breast cancer cells enhances apoptosis and attenuates 
migration. Br J Cancer, 104(10), pp. 1575-1586. 
Tian, X., Liu, Z., Niu, B., Zhang, J., Tan, T. K., Lee, S. R., Zhao, Y., 
Harris, D. C. and Zheng, G. (2011). E-cadherin/beta-catenin 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
287 
 
  
complex and the epithelial barrier. J Biomed Biotechnol, 
2011, pp. 567305. 
Tobon, H. and Salazar, H. (1974). Ultrastructure of the human 
mammary gland. I. Development of the fetal gland 
throughout gestation. J Clin Endocrinol Metab, 39(3), pp. 
443-456. 
Tojo, M., Kiyosawa, H., Iwatsuki, K., Nakamura, K. and Kaneko, F. 
(2003). Expression of the GLI2 oncogene and its isoforms in 
human basal cell carcinoma. Br J Dermatol, 148(5), pp. 892-
897. 
Tran, H. D., Luitel, K., Kim, M., Zhang, K., Longmore, G. D. and 
Tran, D. D. (2014). Transient SNAIL1 expression is necessary 
for metastatic competence in breast cancer. Cancer Res, 
74(21), pp. 6330-6340. 
Tretli, S. (1989). Height and weight in relation to breast cancer 
morbidity and mortality. A prospective study of 570,000 
women in Norway. Int J Cancer, 44(1), pp. 23-30. 
Trimboli, A. J., Fukino, K., de Bruin, A., Wei, G., Shen, L., Tanner, 
S. M., Creasap, N., Rosol, T. J., Robinson, M. L., Eng, C., 
Ostrowski, M. C. and Leone, G. (2008). Direct evidence for 
epithelial-mesenchymal transitions in breast cancer. Cancer 
Res, 68(3), pp. 937-945. 
Tsai, J. H. and Yang, J. (2013). Epithelial-mesenchymal plasticity 
in carcinoma metastasis. Genes Dev, 27(20), pp. 2192-2206. 
Ulloa, F., Itasaki, N. and Briscoe, J. (2007). Inhibitory Gli3 activity 
negatively regulates Wnt/beta-catenin signaling. Curr Biol, 
17(6), pp. 545-550. 
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., 
Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., 
Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., 
Roberts, C., Linsley, P. S., Bernards, R. and Friend, S. H. 
(2002). Gene expression profiling predicts clinical outcome 
of breast cancer. Nature, 415(6871), pp. 530-536. 
van Amerongen, R., Bowman, A. N. and Nusse, R. (2012). 
Developmental stage and time dictate the fate of 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
288 
 
  
Wnt/beta-catenin-responsive stem cells in the mammary 
gland. Cell Stem Cell, 11(3), pp. 387-400. 
van Dam, P. A., Van Goethem, M. L., Kersschot, E., Vervliet, J., 
Van den Veyver, I. B., De Schepper, A. and Buytaert, P. 
(1988). Palpable solid breast masses: retrospective single- 
and multimodality evaluation of 201 lesions. Radiology, 
166(2), pp. 435-439. 
van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H., Hart, A. A., 
Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., 
Marton, M. J., Parrish, M., Atsma, D., Witteveen, A., Glas, 
A., Delahaye, L., van der Velde, T., Bartelink, H., Rodenhuis, 
S., Rutgers, E. T., Friend, S. H. and Bernards, R. (2002). A 
gene-expression signature as a predictor of survival in 
breast cancer. N Engl J Med, 347(25), pp. 1999-2009. 
van Genderen, C., Okamura, R. M., Farinas, I., Quo, R. G., 
Parslow, T. G., Bruhn, L. and Grosschedl, R. (1994). 
Development of several organs that require inductive 
epithelial-mesenchymal interactions is impaired in LEF-1-
deficient mice. Genes Dev, 8(22), pp. 2691-2703. 
Van Keymeulen, A., Fioramonti, M., Centonze, A., Bouvencourt, 
G., Achouri, Y. and Blanpain, C. (2017). Lineage-Restricted 
Mammary Stem Cells Sustain the Development, 
Homeostasis, and Regeneration of the Estrogen Receptor 
Positive Lineage. Cell Rep, 20(7), pp. 1525-1532. 
Van Keymeulen, A., Rocha, A. S., Ousset, M., Beck, B., 
Bouvencourt, G., Rock, J., Sharma, N., Dekoninck, S. and 
Blanpain, C. (2011). Distinct stem cells contribute to 
mammary gland development and maintenance. Nature, 
479(7372), pp. 189-193. 
van Roy, F. and Berx, G. (2008). The cell-cell adhesion molecule 
E-cadherin. Cell Mol Life Sci, 65(23), pp. 3756-3788. 
Varnat, F., Zacchetti, G. and Ruiz i Altaba, A. (2010). Hedgehog 
pathway activity is required for the lethality and intestinal 
phenotypes of mice with hyperactive Wnt signaling. Mech 
Dev, 127(1-2), pp. 73-81. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
289 
 
  
Veltmaat, J. M., Van Veelen, W., Thiery, J. P. and Bellusci, S. 
(2004). Identification of the mammary line in mouse by 
Wnt10b expression. Dev Dyn, 229(2), pp. 349-356. 
Vergara, D., Simeone, P., Franck, J., Trerotola, M., Giudetti, A., 
Capobianco, L., Tinelli, A., Bellomo, C., Fournier, I., Gaballo, 
A., Alberti, S., Salzet, M. and Maffia, M. (2016). Translating 
epithelial mesenchymal transition markers into the clinic: 
Novel insights from proteomics. EuPA Open Proteomics, 10, 
pp. 31-41. 
Volante, M., Brizzi, M. P., Faggiano, A., La Rosa, S., Rapa, I., 
Ferrero, A., Mansueto, G., Righi, L., Garancini, S., Capella, 
C., De Rosa, G., Dogliotti, L., Colao, A. and Papotti, M. 
(2007). Somatostatin receptor type 2A 
immunohistochemistry in neuroendocrine tumors: a 
proposal of scoring system correlated with somatostatin 
receptor scintigraphy. Mod Pathol, 20(11), pp. 1172-1182. 
von Schlippe, M., Marshall, J. F., Perry, P., Stone, M., Zhu, A. J. 
and Hart, I. R. (2000). Functional interaction between E-
cadherin and alphav-containing integrins in carcinoma 
cells. Journal of cell science, 113 ( Pt 3), pp. 425-437. 
Vora, H. H., Patel, N. A., Rajvik, K. N., Mehta, S. V., Brahmbhatt, 
B. V., Shah, M. J., Shukla, S. N. and Shah, P. M. (2009). 
Cytokeratin and vimentin expression in breast cancer. Int J 
Biol Markers, 24(1), pp. 38-46. 
Vorherr, H. (1974). The Breast: Morphology, Physiology, and 
Lactation, Academic Press. 
Vutskits, G. V., Salmon, P., Mayor, L., Vutskits, L., Cudre-
Mauroux, C., Soriano, J., Montesano, R., Maillet, P. and 
Sappino, A. P. (2006). A role for atm in E-cadherin-
mediated contact inhibition in epithelial cells. Breast 
Cancer Res Treat, 99(2), pp. 143-153. 
Wang, F., Xu, L., Guo, C., Ke, A., Hu, G., Xu, X., Mo, W., Yang, L., 
Huang, Y., He, S. and Wang, X. (2011a). Identification of 
RegIV as a novel GLI1 target gene in human pancreatic 
cancer. PLoS One, 6(4), pp. e18434. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
290 
 
  
Wang, L., Cheng, H., Liu, Y., Wang, L., Yu, W., Zhang, G., Chen, B., 
Yu, Z. and Hu, S. (2011b). Prognostic value of nuclear beta-
catenin overexpression at invasive front in colorectal 
cancer for synchronous liver metastasis. Ann Surg Oncol, 
18(6), pp. 1553-1559. 
Wang, X., Zhang, J., Fan, M., Zhou, Q., Deng, H., Aisharif, M. J. 
and Chen, X. (2009). The expression of E-cadherin at the 
invasive tumor front of oral squamous cell carcinoma: 
immunohistochemical and RT-PCR analysis with 
clinicopathological correlation. Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod, 107(4), pp. 547-554. 
Wang, X., Zhang, N., Huo, Q., Sun, M., Dong, L., Zhang, Y., Xu, G. 
and Yang, Q. (2014). Huaier aqueous extract inhibits stem-
like characteristics of MCF7 breast cancer cells via 
inactivation of hedgehog pathway. Tumour Biol, 35(11), pp. 
10805-10813. 
Wang, Y., Ande, S. R. and Mishra, S. (2012). Overexpression of 
phospho mutant forms of transglutaminase 2 
downregulates epidermal growth factor receptor. Biochem 
Biophys Res Commun, 417(1), pp. 251-255. 
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., 
Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, 
M. E., Yu, J., Jatkoe, T., Berns, E. M., Atkins, D. and Foekens, 
J. A. (2005). Gene-expression profiles to predict distant 
metastasis of lymph-node-negative primary breast cancer. 
Lancet, 365(9460), pp. 671-679. 
Wang, Y. and Zhou, B. P. (2011). Epithelial-mesenchymal 
transition in breast cancer progression and metastasis. Chin 
J Cancer, 30(9), pp. 603-611. 
Wang, Y. and Zhou, B. P. (2013). Epithelial-mesenchymal 
Transition---A Hallmark of Breast Cancer Metastasis. Cancer 
Hallm, 1(1), pp. 38-49. 
Wang, Z., Zhang, H., Hou, J., Niu, J., Ma, Z., Zhao, H. and Liu, C. 
(2015). Clinical implications of beta-catenin protein 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
291 
 
  
expression in breast cancer. Int J Clin Exp Pathol, 8(11), pp. 
14989-14994. 
Warburton, M. J., Ormerod, E. J., Monaghan, P., Ferns, S. and 
Rudland, P. S. (1981). Characterization of a myoepithelial 
cell line derived from a neonatal rat mammary gland. J Cell 
Biol, 91(3 Pt 1), pp. 827-836. 
Watkins, D. N., Berman, D. M., Burkholder, S. G., Wang, B., 
Beachy, P. A. and Baylin, S. B. (2003). Hedgehog signalling 
within airway epithelial progenitors and in small-cell lung 
cancer. Nature, 422(6929), pp. 313-317. 
Watson, C. J. and Khaled, W. T. (2008). Mammary development 
in the embryo and adult: a journey of morphogenesis and 
commitment. Development, 135(6), pp. 995-1003. 
Watt, F. M. (1988). Effect of seeding density on stability of the 
differentiated phenotype of pig articular chondrocytes in 
culture. J Cell Sci, 89 ( Pt 3), pp. 373-378. 
Weigelt, B., Geyer, F. C. and Reis-Filho, J. S. (2010). Histological 
types of breast cancer: how special are they? Mol Oncol, 
4(3), pp. 192-208. 
Weigelt, B., Peterse, J. L. and van 't Veer, L. J. (2005). Breast 
cancer metastasis: markers and models. Nat Rev Cancer, 
5(8), pp. 591-602. 
Weiss, L., Holmes, J. C. and Ward, P. M. (1983). Do metastases 
arise from pre-existing subpopulations of cancer cells? Br J 
Cancer, 47(1), pp. 81-89. 
Wellings, S. R. and Jensen, H. M. (1973). On the origin and 
progression of ductal carcinoma in the human breast. J 
Natl Cancer Inst, 50(5), pp. 1111-1118. 
Wellings, S. R., Jensen, H. M. and Marcum, R. G. (1975). An atlas 
of subgross pathology of the human breast with special 
reference to possible precancerous lesions. J Natl Cancer 
Inst, 55(2), pp. 231-273. 
Westermark, B., Ponten, J. and Hugosson, R. (1973). 
Determinants for the establishment of permanent tissue 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
292 
 
  
culture lines from human gliomas. Acta Pathol Microbiol 
Scand A, 81(6), pp. 791-805. 
Wheelock, M. J., Soler, A. P. and Knudsen, K. A. (2001). Cadherin 
junctions in mammary tumors. J Mammary Gland Biol 
Neoplasia, 6(3), pp. 275-285. 
WHO (2008) The global burden of disease : 2004 update. in  
Geneva : World Health Organization. pp. 146. Avialable 
from: http://www.who.int/iris/handle/10665/43942 
Wicking, C., Evans, T., Henk, B., Hayward, N., Simms, L. A., 
Chenevix-Trench, G., Pietsch, T. and Wainwright, B. (1998). 
No evidence for the H133Y mutation in SONIC HEDGEHOG 
in a collection of common tumour types. Oncogene, 16(8), 
pp. 1091-1093. 
Wodarz, A. and Nusse, R. (1998). Mechanisms of Wnt signaling in 
development. Annu Rev Cell Dev Biol, 14, pp. 59-88. 
Wolf, I., Bose, S., Desmond, J. C., Lin, B. T., Williamson, E. A., 
Karlan, B. Y. and Koeffler, H. P. (2007). Unmasking of 
epigenetically silenced genes reveals DNA promoter 
methylation and reduced expression of PTCH in breast 
cancer. Breast Cancer Res Treat, 105(2), pp. 139-155. 
Woodward, W. A., Strom, E. A., Tucker, S. L., McNeese, M. D., 
Perkins, G. H., Schechter, N. R., Singletary, S. E., Theriault, 
R. L., Hortobagyi, G. N., Hunt, K. K. and Buchholz, T. A. 
(2003). Changes in the 2003 American Joint Committee on 
Cancer staging for breast cancer dramatically affect stage-
specific survival. J Clin Oncol, 21(17), pp. 3244-3248. 
Wu, Y., Ginther, C., Kim, J., Mosher, N., Chung, S., Slamon, D. and 
Vadgama, J. V. (2012). Expression of Wnt3 activates 
Wnt/beta-catenin pathway and promotes EMT-like 
phenotype in trastuzumab-resistant HER2-overexpressing 
breast cancer cells. Mol Cancer Res, 10(12), pp. 1597-1606. 
Xie, G., Ji, A., Yuan, Q., Jin, Z., Yuan, Y., Ren, C., Guo, Z., Yao, Q., 
Yang, K., Lin, X. and Chen, L. (2014). Tumour-initiating 
capacity is independent of epithelial-mesenchymal 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
293 
 
  
transition status in breast cancer cell lines. Br J Cancer, 
110(10), pp. 2514-2523. 
Xie, J., Murone, M., Luoh, S. M., Ryan, A., Gu, Q., Zhang, C., 
Bonifas, J. M., Lam, C. W., Hynes, M., Goddard, A., 
Rosenthal, A., Epstein, E. H., Jr. and de Sauvage, F. J. (1998). 
Activating Smoothened mutations in sporadic basal-cell 
carcinoma. Nature, 391(6662), pp. 90-92. 
Xu, J., Huang, G., Zhang, Z., Zhao, J., Zhang, M., Wang, Y., Liu, Z. 
and Lu, J. (2015). Up-Regulation of Glioma-Associated 
Oncogene Homolog 1 Expression by Serum Starvation 
Promotes Cell Survival in ER-Positive Breast Cancer Cells. 
Cell Physiol Biochem, 36(5), pp. 1862-1876. 
Xu, L., Chen, Y. G. and Massague, J. (2000). The nuclear import 
function of Smad2 is masked by SARA and unmasked by 
TGFbeta-dependent phosphorylation. Nat Cell Biol, 2(8), 
pp. 559-562. 
Xu, L., Kwon, Y. J., Frolova, N., Steg, A. D., Yuan, K., Johnson, M. 
R., Grizzle, W. E., Desmond, R. A. and Frost, A. R. (2010). 
Gli1 promotes cell survival and is predictive of a poor 
outcome in ERalpha-negative breast cancer. Breast Cancer 
Res Treat, 123(1), pp. 59-71. 
Xuan, Y. and Lin, Z. (2009). Expression of Indian Hedgehog 
signaling molecules in breast cancer. J Cancer Res Clin 
Oncol, 135(2), pp. 235-240. 
Yamashita, N., Tokunaga, E., Kitao, H., Hisamatsu, Y., Taketani, 
K., Akiyoshi, S., Okada, S., Aishima, S., Morita, M. and 
Maehara, Y. (2013). Vimentin as a poor prognostic factor 
for triple-negative breast cancer. J Cancer Res Clin Oncol, 
139(5), pp. 739-746. 
Yan, D., Avtanski, D., Saxena, N. K. and Sharma, D. (2012). Leptin-
induced epithelial-mesenchymal transition in breast cancer 
cells requires beta-catenin activation via Akt/GSK3- and 
MTA1/Wnt1 protein-dependent pathways. J Biol Chem, 
287(11), pp. 8598-8612. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
294 
 
  
Yang, J., Li, T., Gao, C., Lv, X., Liu, K., Song, H., Xing, Y. and Xi, T. 
(2014). FOXO1 3'UTR functions as a ceRNA in repressing 
the metastases of breast cancer cells via regulating miRNA 
activity. FEBS Lett, 588(17), pp. 3218-3224. 
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. 
A., Come, C., Savagner, P., Gitelman, I., Richardson, A. and 
Weinberg, R. A. (2004). Twist, a master regulator of 
morphogenesis, plays an essential role in tumor metastasis. 
Cell, 117(7), pp. 927-939. 
Yang, J. and Weinberg, R. A. (2008). Epithelial-mesenchymal 
transition: at the crossroads of development and tumor 
metastasis. Dev Cell, 14(6), pp. 818-829. 
Yang, M. H., Wu, M. Z., Chiou, S. H., Chen, P. M., Chang, S. Y., Liu, 
C. J., Teng, S. C. and Wu, K. J. (2008a). Direct regulation of 
TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol, 
10(3), pp. 295-305. 
Yang, S. H., Andl, T., Grachtchouk, V., Wang, A., Liu, J., Syu, L. J., 
Ferris, J., Wang, T. S., Glick, A. B., Millar, S. E. and Dlugosz, 
A. A. (2008b). Pathological responses to oncogenic 
Hedgehog signaling in skin are dependent on canonical 
Wnt/beta3-catenin signaling. Nat Genet, 40(9), pp. 1130-
1135. 
Yassin, M. A., Leknes, K. N., Pedersen, T. O., Xing, Z., Sun, Y., Lie, 
S. A., Finne-Wistrand, A. and Mustafa, K. (2015). Cell 
seeding density is a critical determinant for copolymer 
scaffolds-induced bone regeneration. J Biomed Mater Res 
A, 103(11), pp. 3649-3658. 
Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T., Tian, H., Ahn, C. P., 
Marshall, D., Fu, L., Januario, T., Kallop, D., Nannini-Pepe, 
M., Kotkow, K., Marsters, J. C., Rubin, L. L. and de Sauvage, 
F. J. (2008). A paracrine requirement for hedgehog 
signalling in cancer. Nature, 455(7211), pp. 406-410. 
Yen, C.-F., Wang, H.-S., Lee, C.-L. and Liao, S.-K. (2014). Roles of 
integrin-linked kinase in cell signaling and its perspectives 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
295 
 
  
as a therapeutic target. Gynecology and Minimally Invasive 
Therapy, 3(3), pp. 67-72. 
Yoshida, C. and Takeichi, M. (1982). Teratocarcinoma cell 
adhesion: identification of a cell-surface protein involved in 
calcium-dependent cell aggregation. Cell, 28(2), pp. 217-
224. 
Yoshimoto, A. N., Bernardazzi, C., Carneiro, A. J., Elia, C. C., 
Martinusso, C. A., Ventura, G. M., Castelo-Branco, M. T. 
and de Souza, H. S. (2012). Hedgehog pathway signaling 
regulates human colon carcinoma HT-29 epithelial cell line 
apoptosis and cytokine secretion. PLoS One, 7(9), pp. 
e45332. 
Yue, D., Li, H., Che, J., Zhang, Y., Tseng, H. H., Jin, J. Q., Luh, T. M., 
Giroux-Leprieur, E., Mo, M., Zheng, Q., Shi, H., Zhang, H., 
Hao, X., Wang, C., Jablons, D. M. and He, B. (2014). 
Hedgehog/Gli promotes epithelial-mesenchymal transition 
in lung squamous cell carcinomas. J Exp Clin Cancer Res, 33, 
pp. 34. 
Yuki, K., Yoshida, Y., Inagaki, R., Hiai, H. and Noda, M. (2014). E-
cadherin-downregulation and RECK-upregulation are 
coupled in the non-malignant epithelial cell line MCF10A 
but not in multiple carcinoma-derived cell lines. Sci Rep, 4, 
pp. 4568. 
Zanetti, A., Affatato, R., Centritto, F., Fratelli, M., Kurosaki, M., 
Barzago, M. M., Bolis, M., Terao, M., Garattini, E. and 
Paroni, G. (2015). All-trans-retinoic Acid Modulates the 
Plasticity and Inhibits the Motility of Breast Cancer Cells: 
ROLE OF NOTCH1 AND TRANSFORMING GROWTH FACTOR 
(TGFbeta). J Biol Chem, 290(29), pp. 17690-17709. 
Zeisberg, M. and Neilson, E. G. (2009). Biomarkers for epithelial-
mesenchymal transitions. J Clin Invest, 119(6), pp. 1429-
1437. 
Zhang, A., Chen, G., Meng, L., Wang, Q., Hu, W., Xi, L., Gao, Q., 
Wang, S., Zhou, J., Xu, G., Meng, L. and Ma, D. (2008). 
Antisense-Snail transfer inhibits tumor metastasis by 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
296 
 
  
inducing E-cadherin expression. Anticancer Res, 28(2A), pp. 
621-628. 
Zhang, D. W., Li, H. Y., Lau, W. Y., Cao, L. Q., Li, Y., Jiang, X. F., 
Yang, X. W. and Xue, P. (2014). Gli2 silencing enhances 
TRAIL-induced apoptosis and reduces tumor growth in 
human hepatoma cells in vivo. Cancer Biol Ther, 15(12), pp. 
1667-1676. 
Zhang, X., Emerald, B. S., Mukhina, S., Mohankumar, K. M., 
Kraemer, A., Yap, A. S., Gluckman, P. D., Lee, K. O. and 
Lobie, P. E. (2006). HOXA1 is required for E-cadherin-
dependent anchorage-independent survival of human 
mammary carcinoma cells. J Biol Chem, 281(10), pp. 6471-
6481. 
Zhang, X., Harrington, N., Moraes, R. C., Wu, M. F., Hilsenbeck, S. 
G. and Lewis, M. T. (2009). Cyclopamine inhibition of 
human breast cancer cell growth independent of 
Smoothened (Smo). Breast Cancer Res Treat, 115(3), pp. 
505-521. 
Zhang, Y., Yan, W. and Chen, X. (2011). Mutant p53 disrupts 
MCF-10A cell polarity in three-dimensional culture via 
epithelial-to-mesenchymal transitions. J Biol Chem, 
286(18), pp. 16218-16228. 
Zhao, P., Guo, S., Tu, Z., Di, L., Zha, X., Zhou, H. and Zhang, X. 
(2016). Grhl3 induces human epithelial tumor cell 
migration and invasion via downregulation of E-cadherin. 
Acta Biochim Biophys Sin (Shanghai), 48(3), pp. 266-274. 
Zhu, H., Zhang, G., Wang, Y., Xu, N., He, S., Zhang, W., Chen, M., 
Liu, M., Quan, L., Bai, J. and Xu, N. (2010). Inhibition of 
ErbB2 by Herceptin reduces survivin expression via the 
ErbB2-beta-catenin/TCF4-survivin pathway in ErbB2-
overexpressed breast cancer cells. Cancer Sci, 101(5), pp. 
1156-1162. 
Zhuang, Z., Lininger, R. A., Man, Y. G., Albuquerque, A., Merino, 
M. J. and Tavassoli, F. A. (1997). Identical clonality of both 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
297 
 
  
components of mammary carcinosarcoma with differential 
loss of heterozygosity. Mod Pathol, 10(4), pp. 354-362. 
Zhuang, Z., Wang, K., Cheng, X., Qu, X., Jiang, B., Li, Z., Luo, J., 
Shao, Z. and Duan, T. (2013). LKB1 inhibits breast cancer 
partially through repressing the Hedgehog signaling 
pathway. PLoS One, 8(7), pp. e67431. 
Zlobec, I. and Lugli, A. (2009). Invasive front of colorectal cancer: 
dynamic interface of pro-/anti-tumor factors. World J 
Gastroenterol, 15(47), pp. 5898-5906. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
298 
 
  
11. Appendices 
11.1 Summary of the morphological changes associated with decrease 
in seeding densities 
The scores in Table 3-2 were then presented as bar charts of changes at different 
densities. It was noted that cellular spreading increased in all cell lines with decrease in 
densities (Figure 11-1). Also, the spreading of all the basal-cell lines (BT20, MDA-MB-
231 and MCF10A) were more significant than that seen in all the luminal breast cancer 
cell lines. The two basal-cell lines (BT20 and MDA-MB-231) showed high cellular 
spreading even in dense cultures. All the other cell lines (MCF7, MDA-MB-361, and 
MDA-MB-453) showed less cellular spreading in the highest density. 
Both luminal breast cancer cell line (MCF7 and MDA-MB-361) and the TNBC 
cell line (MDA-MB-453) showed strong cell-cell contact morphology at the highest 
density (Figure 11-2). The basal-like/normal-like breast cancer cell line (MCF10A) 
showed tight cellular contact as seen in the luminal cell lines that correlated with 
density. The basal breast cancer cell lines (BT20 and MDA-MB-231) showed non-
linear association in response to decrease in density. Both cell lines showed increase in 
cell-cell contact at the medium density then, lost at the lower density. This pattern was 
specific to these cell lines only and was the reason the medium density was selected for 
further analysis. 
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Figure 11-1, Bar charts of qualitative score of the increase in morphological 
spreading seen at the three densities of breast cancer cell lines 
Bar chart presenting the qualitative scores of the increase in morphological spreading associated with 
decrease in seeding density. In general, all the breast cancer cell lines showed increase in cellular 
spreading with decrease in seeding density. Highlighted below in red are the subclassification of the 
breast cancer cell lines including; Luminal, HER2+ve (human EGF receptor two positive), TN (triple-
negative), NL, (normal-like), and Basal-like (BL) (basal-like). 
 
 
 
Figure 11-2, Bar charts of the cell-cell contact morphological changes seen at three 
seeding densities of breast cancer cell lines 
Bars charts presenting the qualitative scores summarising the cell-cell contact morphological changes 
associated with decreasing the seeding density. All the cell lines, except BT20 and MDA-MB-231, 
showed gradual decrease in cell-cell contact with decreasing density. The basal-cell lines (BT20 and 
MDA-MB-231) showed a specific pattern in increase in contact at the medium density. Highlighted 
below in red are the subclassification of the breast cancer cell lines including; Luminal, HER2+ve (human 
EGF receptor2 positive), TN (triple-negative), NL, (normal-like), and BL (basal-like). 
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Four cell lines showed an increase in spindle cells morphology inversely 
associated with seeding density including two luminal cell lines (MCF7 and MDA-MB-
361), the normal-like breast cancer cell line (MCF10A) and the TNBC cell line (MDA-
MB-453) (Figure 11-3). Also, both basal breast cancer cell lines (BT20 and MDA-MB-
231) showed a decrease in the spindle morphology at the medium density which then 
increased of spindle morphology at the high and low density. 
 
 
 
Figure 11-3, Bar charts of the change in spindle cells morphology seen at three 
seeding densities of breast cancer cell lines 
Bars represent the qualitative scores for the spindle morphology seen at three densities of breast cancer 
cell lines. The luminal cell lines (MCF7 and MDA-MB-361) and the triple-negative cell line (MDA-MB-
453) showed increase in spindle morphology with decreasing density. Both of the basal breast cancer cell 
lines (BT20 and MDA-MB-231) showed a dip in the spindle morphology at the medium density. 
Highlighted below in red are the subclassification of the breast cancer cell lines including; Luminal, 
HER2+ve (human EGF receptor2 positive), TN (triple-negative), NL, (normal-like), and BL (basal-like). 
 
Taken together, it can be seen that all the cell lines showed increase in the 
mesenchymal morphological features with decrease in seeding density. All cell lines 
showed increase in spindle morphology and cellular spreading with decrease in cell-cell 
contact, which are all morphological features of mesenchymal morphological change. 
The luminal cell lines (MCF7 and MDA-MB-361) and the TNBC cell line (MDA-MB-
453) showed less significant morphological mesenchymal change compared to that 
observed in all the basal breast cancer cell lines (BT20, MDA-MB-231 and MCF10A). 
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It was also noted that there was a specific morphological pattern captured in the 
medium density of some of the cell lines. As seen at the medium density of the basal-
like breast cancer cell lines (BT20 and MDA-MB-231) there was morphological 
increase in the cell-cell contact at the medium density. Also, there was decrease in the 
spindle shape at the medium density of both cell lines in the medium density. These 
observations together supported the importance of including the medium density in 
further analysis. 
11.2 Confirmation of subtype of breast cancer samples showed that all 
selected cases followed the classification specified in the pathology 
report 
 
 
 
Figure 11-4, Verification of tumour identification in samples 
Representative images of nine slides that showed verification of presence of tumour in sections. Sections 
were stained with H&E and images were captured using GT Vision (GT Vision, UK). Scale bar is added 
in the bottom right corner of the images. 
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Table 11-1: Summary table of number of cases stained and investigated for b-
catenin, E-cadherin, Gli1, Gli2 and Gli3 used and the corresponding 
clinicopathological parameters 
Numbers of sections in each of the clinicopathological parameters (A) Size, (B) Stage and (C) Grade and 
the total number of cases stained by either b-catenin, E-cadherin, Gli1, Gli2 or Gli3. 
 
Clinical criteria 
Count 
b-catenin E-cadherin Gli1 Gli2 Gli3 
Size 2cm ³ 14 11 25 12 10 2cm< 23 12 23 17 13 
Stage 
T1 13 14 23 14 11 
T2 17 7 19 11 9 
T3 2 0 3 1 1 
T4 0 0 0 0 0 
TX 5 0 3 3 2 
Grade 
1 1 1 1 1 1 
2 18 12 23 11 9 
3 18 10 24 17 13 
Total 37 23 48 29 23 
TX= stage not determined in the clinical reports 
 
Table 11-2: Numbers of sections included in the investigation and the 
corresponding histological subtype 
Summary of numbers of cases stained with each antibody (b-catenin, E-cadherin, Gli1, Gli2 and Gli3) 
and the histological subtype identified in the pathology report. DCIS= ductal carcinoma in situ, IDC= 
invasive ductal carcinoma, LCIS=lobular carcinoma in situ, ILC= invasive lobular carcinoma, NST= 
none specific type. 
 
Histological 
subtype 
Count 
b-catenin E-cadherin Gli1 Gli2 Gli3 
DCIS 1 1 2 1 0 
DCIS/IDC 15 8 12 11 7 
IDC 12 7 18 9 8 
LCIS 0 0 0 0 0 
LCIS/ILC 1 0 2 0 1 
ILC 1 1 4 1 0 
Mixed 2 1 3 0 1 
Metastatic 1 1 2 2 0 
NST 4 4 5 5 6 
Total  37 23 48 29 23 
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Table 11-3: Number of sections and the lymph node and metastasis status as 
identified in the pathology reports 
Summary table that shows the number of sections stained by either b-catenin, E-cadherin, Gli1, Gli2 or 
Gli3 and the lymph node and metastasis status as reported in the pathology report. 
 
 
Count 
b-catenin E-cadherin Gli1 Gli2 Gli3 
Lymph node 
involvement 
Positive 16 5 17 12 9 
Negative 18 14 27 13 13 
Possible 2 3 3 3 1 
Metastasis 
Yes 1 1 2 2 0 
No 35 21 45 26 23 
Possible 0 0 0 0 0 
 Total 36 (UI=1) 23 47 (UI=1) 28 (UI=1) 23 
UI= undefined in the clinical reports 
 
Table 11-4: Numbers of sections stained for investigation and the molecular 
subgroup they represent according to the pathology report and after confirmation 
Summary of the percentages (A), intensity of the immune staining (B) and IRS score (C) for E-cadherin 
in human cohort. The tables summarise the numbers and percentages of cases observed in each category 
of the scale in tumour 
 
A 
Count 
b-catenin E-cadherin Gli1 Gli2 Gli3 
ER Status Negative 23 14 34 23 14 Positive 14 9 14 6 9 
PR status Negative 29 17 39 25 18 Positive 8 6 9 4 5 
HER2 
status 
Positive 15 9 14 12 8 
Negative 22 14 34 17 15 
Molecular 
subgroup 
Luminal A 10 8 11 5 7 
Luminal B 4 1 3 1 2 
HER2 11 8 11 11 6 
TN 12 6 23 12 8 
Total 37 23 48 29 23 
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Figure 11-5, Representative immunohistochemistry images for the molecular 
classification defined by expression of prognostic markers (ER, PR and HER2) 
Samples were stained for the prognostic markers ER, PR) and HER2 (human EGF receptor 2) in order to 
verify their molecular subgroup. Images were captured at 400x magnification and scale bars were added 
to the bottom right corner. 
 
11.3 Associations between histological subtypes, molecular subgroups and 
clinicopathological parameters 
Statistical analysis was conducted on the total numbers of cases (n=48). There 
was no difference in age at diagnosis between the histological subtypes (p=-0.136, one-
way ANOVA) or molecular subgroups (p=0.574). There was no difference in tumour 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
305 
 
  
size between the histological subtype (p=0.107) or the molecular subgroup (p=0.489). 
A single case in the cohort was classified as grade 1. 
The expression of the ER prognostic marker was negatively correlated with size 
(-0.340, p=0.02), stage (-0.279, p=0.057), and grade (-0.560, p=0.000) (Table 11-5 and 
Figure 11-6). PR showed negative correlation with size (-0.247, p=0.09), stage (-0.314, 
p=0.003), and grade (-0.451, p=0.002) (Table 11-5 and Figure 11-6). The molecular 
subgroup correlated with size (0.228, p=0.094), stage (0.245, p=0.074), and grade 
(0.484, p=0.000) (Table 11-5 and Figure 11-6). Statistical analysis showed that the 
lymph node involvement correlated with stage (0.401, p=0.005) and grade (0.331, 
p=0.02) (Table 11-6 and Figure 11-7). 
 
Table 11-5: Statistical correlation between expression of prognostic markers and 
the molecular subgroup (ER, PR and HER2) with clinicopathological parameters 
(size, stage, grade and histological subtype) 
Statistical correlation was analysed using the Kendall’s Tau B test. highlighted are the comparisons that 
showed correlations and highly significant correlations were indicated in bold. 
 
 ER status PR status HER2 status Molecular subgroup 
Size 
Correlation coefficient -0.340* -0.247 -0.027 0.228 
Sig. (2-tailed) 0.02 0.09 0.854 0.094 
N 48 48 48 48 
Stage 
Correlation Coefficient -0.279 -0.314* -0.017 0.245 
Sig. (2-tailed) 0.057 0.033 0.91 0.074 
N 45 45 45 45 
Grade 
Correlation Coefficient -0.560** -0.451** -0.101 0.484** 
Sig. (2-tailed) 0 0.002 0.484 0 
N 48 48 48 48 
Histological 
subtype 
Correlation Coefficient 0.12 0.229 0.212 -0.045 
Sig. (2-tailed) 0.359 0.08 0.105 0.713 
N 48 48 48 48 
The Kendall’s TauB correlation coefficient (between -1 and +1). The statistical significance of the 
correlation is indicated as follows: *P= <0.05, **P= <0.01. 
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(A) (B)  
 
(C)  
 
Figure 11-6, Summary of statistical analysis for tumour size (A), stage (B) and 
grade (C) 
Kendall’s Tau B test was used to assess the correlations. Figure showing correlation of hormone negative 
and TN breast cancer cases with increase tumour size, stage, and grade. HER2= Human EGF receptor 2, 
TN= triple-negative. 
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Table 11-6: Statistical correlation of lymph node involvement and metastasis with 
clinicopathological parameters (size, stage, grade, histological subtype, prognostic 
markers expression and molecular subgroup) 
Statistical correlation was analysed using the Kendall’s Tau B test. highlighted are the comparisons that 
showed correlations and highly significant correlations were indicated in bold. 
 
 Lymph node 
involvement Metastasis 
Size 
Correlation coefficient 0.203 -0.198 
Sig. (2-tailed) 0.157 0.18 
N 47 47 
Stage 
Correlation Coefficient 0.401** -0.14 
Sig. (2-tailed) 0.005 0.341 
N 45 45 
Grade 
Correlation Coefficient 0.331* -0.211 
Sig. (2-tailed) 0.02 0.148 
N 47 47 
Histological 
subtype 
Correlation Coefficient -0.159 0.254 
Sig. (2-tailed) 0.22 0.055 
N 47 47 
ER status 
Correlation Coefficient -0.122 -0.137 
Sig. (2-tailed) 0.394 0.352 
N 47 47 
PR status 
Correlation Coefficient -0.182 -0.103 
Sig. (2-tailed) 0.204 0.487 
N 47 47 
HER2 status 
Correlation Coefficient -0.129 -0.105 
Sig. (2-tailed) 0.369 0.475 
N 47 47 
Molecular 
subgroup 
Correlation Coefficient 0.057 0.059 
Sig. (2-tailed) 0.674 0.67 
N 47 47 
The Kendall’s TauB correlation coefficient (between -1 and +1). The statistical significance of the 
correlation is indicated as follows: *P= <0.05, **P= <0.01. 
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Figure 11-7, Correlation between lymph node involvement of investigated breast 
cancer cases and the stage of tumour 
Kendall’s Tau B test was used to assess the correlation between lymph node involvement and the stage of 
tumour. Figure shows correlation between lymph node involvement and high stage of tumour. 
 
11.3.1 Comparing Gli3 expression in tumour centres and invasive fronts  
The percentage of Gli3 positive expressing cells showed an increase at the 
invasive front compared to the tumour centre, however, this difference did not reach 
significance (Figure 11-8-A and Table 11-7-A). The intensity of staining showed a 
significant increase at the invasive front compared to tumour centre (p-value= 0.075) 
(Figure 11-8-B and Table 11-7-B). Gli3 IRS showed that the IRS class at the invasive 
front was higher than that in the tumour centre, however this difference did not reach 
statistical significance (p-value= 0.124) (Figure 11-8-C and Table 11-7-C). 
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Figure 11-8, Gli3 expression was higher at invasive fronts in breast cancer cohort 
Figure showing comparison of Gli2 in tumour centres (to the left) compared to the invasive front (to the 
right). (A) comparison of percentage of positive cells. (B) comparison of intensity of staining. (C) 
comparison of IRS class. 
 
 
 
 
 
 
 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
310 
 
  
Table 11-7: Gli3 staining intensity showed increase at invasive front compared to 
tumour centre 
Tumour centre and invasive front frequency tables (A) for percentage of positive tumour cells, (B) 
intensity of staining, and (C) IRS class. The numbers are indicated for each score and the percentages 
were calculated from the total number of samples. Pearson Chi-square test was used to estimate the 
difference between tumour centre and invasive front. 
 
Pe
rc
en
ta
ge
 o
f p
os
iti
ve
 
tu
m
ou
r 
ce
lls
 
A Tumour centre Invasive front No. (%) No. (%) 
0 0 0 
<10 1 (4.3) 0 
10-50 7 (30.4) 0 
51-80 7 (30.4) 6 (33.3) 
>80 8 (34.8) 12 (66.7) 
Total 23 (100) 18 (100) 
Missing 0 5 (21.7) 
Total 23 (100) 23 (100) 
p-value 0.154 
 
In
te
ns
ity
 o
f s
ta
in
in
g 
 B Tumour centre  Invasive front  No. (%) No. (%) 
No colour  0 0 
Mild  11 (47.8) 2 (11.1) 
Moderate  8 (34.8) 10 (55.6) 
Intense  4 (17.4) 6 (33.3) 
Total 23 (100) 18 (100) 
Missing 0 5 (21.7) 
Total 23 (100) 23 (100) 
p-value 0.075 
 
IR
S 
cl
as
s 
C Tumour centre Invasive front  No. (%) No. (%) 
Negative 1 (4.3) 0 
Positive, weak expression 8 (34.8) 0 
Positive, mild expression 11 (47.8) 12 (66.7) 
Positive, strong expression 3 (13) 6 (33.3) 
Total 23 (100) 18 (100) 
Missing 0 5 (21.7) 
Total 23 (100) 23 (100) 
p-value 0.124 
 
11.3.2 Gli1 expression correlated with increased tumour size and hormone 
receptor negative breast cancer 
The percentage of Gli1 positive tumour cells in the tumour centre was correlated 
with an increasing of tumour size (0.288, p-value= 0.065) (Figure 11-9). The 
percentage of Gli1 positive tumour cells also increased with an increased in size.  
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Figure 11-9, Increased percentage of Gli1 positive tumour cells correlated with an 
increase in tumour size 
Figure showing comparison of percentage of tumour positive cells in correlation with tumour size (2cm ³ 
or 2cm <). Table showing numbers of cases that correspond to two groups of tumour size (2cm ³ or 
2cm<) and the corresponding percentage of positive tumour cells (0, <10, 10-50, 51-80 or >80). The 
correlation was calculated using the Kendall’s Tau B test. 
 
Nuclear localisation of Gli1 in the tumour centre and at the invasive front 
showed correlation with increasing clinical tumour stage (0.223, p-value = 0.098) 
(Figure 11-10). Increase in tumour stage correlated with more Gli1 nuclear localisation 
at invasive fronts. 
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Figure 11-10, Increased of nuclear localisation of Gli1 in the tumour centre 
correlated with tumour stage 
Figure showing correlation between increased in Gli1 nuclear localisation and increased in tumour stage 
in tumour centre. Table below the figures shows the numbers of cases, the corresponding tumour stage 
(T1, T2, T3 and T4) and the nuclear localisation of Gli1 (presented as 0, <10, 10-50, and >51). The 
correlation was calculated using the Kendall’s Tau B test. 
 
The percentage of Gli1 positive tumour cells in the tumour centre were 
correlated with the molecular subgroups of breast cancer (0.222, p-value = 0.078) 
(Figure 11-11-A). The percentage of Gli1 positivity was higher in TNBC (0.238, p-
value = 077). The nuclear localisation of Gli1 in the tumour centre showed correlation 
with subgroup (0.195, p-value = 0.091) (Figure 11-11-B). Increased nuclear localisation 
of Gli1 was higher in TNBC (0.225, p-value = 0.093) and Luminal B breast cancer 
subtype (0.28, p-value = 073). 
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Figure 11-11, The percentage of Gli1 positive tumour cells and nuclear localisation 
in tumour centre correlated with TNBC  
Figure showing an increase of the percentage of Gli1 positive tumour cells and nuclear localisation of 
Gli1 in tumour centre of TNBC. Tables below the pie charts shows the numbers of cases, the molecular 
subgroup (LumA, LumB, HER2, and TN) and the percentage of positive tumour cells for Gli1 (presented 
as 0, <10, 10-50 and >51). The correlation was calculated using the Kendall’s Tau B test. LumA = 
Luminal A, LumB = Luminal B, HER2 = Human EGF receptor 2, TNBC = Triple-negative breast cancer. 
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11.3.3 Gli2 expression correlated with lower stage, lower grade and negative 
lymph node involvement 
Gli2 staining intensity was also higher in lower grade tumours, with low 
statistical significance (-0.309, p-value = 0.077) (Figure 11-12-A). The intensity of Gli2 
staining at the invasive front increased in lower grade tumours (-0.266, p-value = 0.098) 
(Figure 11-12-B). Gli2 IRS class in the tumour centre also increased in lower grade 
tumours (-0.287) with low significance (p-value = 0.071) (Figure 11-13). In addition, 
increased Gli2 nuclear localisation was observed within lower grade tumours (-0.282, 
p-value = 0.08) (Figure 11-14). 
 
 
 
Figure 11-12, Intensity of Gli2 staining in the tumour centre and at the invasive 
front correlated negatively with tumour grade 
Figure showing increase of Gli2 staining intensity in tumour centre and at invasive front correlated with 
lower tumour grade. Table below shows the numbers of cases, tumour grade (grade1, grade2, and grade 
3) and the intensity of Gli3 staining in tumour centre and at invasive front. The correlation was calculated 
using the Kendall’s Tau B test. 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
315 
 
  
 
 
Figure 11-13, Gli2 IRS class in the tumour centre correlated with lower tumour 
grade 
Figure showing increase of Gli2 IRS class in tumour centre correlated with lower tumour grade. Table 
shows the numbers of cases, tumour grade (grade1, grade2, and grade3) and the IRS class of Gli2 
staining. The correlation was calculated using the Kendall’s Tau B test. 
 
 
 
Figure 11-14, Increased nuclear localisation of Gli2 at the invasive front correlated 
with lower tumour grade 
Figure showing increase of nuclear localisation of Gli2 at invasive front correlated with lower tumour 
grade. Table shows the numbers of cases, tumour grade (grade1, grade2 and grade3) and nuclear 
localisation of Gli2 (presented as 0, <10, 10-50, and >51). The correlation was calculated using the 
Kendall’s Tau B test. 
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Lymph node involvement correlated negatively with the percentage of Gli2 
positive expressing cells at the invasive front (-0.296, p-value = 0.06) (Figure 11-15). 
Higher Gli2 staining intensity was observed in tumours with negative lymph node 
involvement (-0.295, p-value = 0.077) (Figure 11-16). Increased nuclear localisation of 
Gli2 at the invasive front correlated with negative lymph node involvement (-0.32, p-
value = 0.067) (Figure 11-17). 
 
 
 
Figure 11-15, The percentage of Gli2 positive tumour cells at the invasive front 
correlated with negative lymph node involvement 
Figure showing increase of percentage of Gli2 positive tumour cells at invasive front correlated with 
negative lymph node. Table below shows the numbers of cases, lymph node involvement (possible, 
negative or positive) and the percentage of Gli2 positive tumour cells at invasive front. The correlation 
was calculated using the Kendall’s Tau B test. 
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Figure 11-16, Increased intensity of Gli2 staining correlated with negative lymph 
node involvement 
Figure showing increase of intensity of Gli2 staining correlated with negative lymph node involvement. 
Table below shows the numbers of cases, lymph node involvement (possible, negative and positive), and 
the intensity of Gli2 staining (no colour, mild, moderate and intense) in tumour centre. The correlation 
was calculated using the Kendall’s Tau B test. 
 
 
 
Figure 11-17, Higher Gli2 IRS class in the tumour centre correlated with lymph 
node negativity 
Figure showing higher Gli2 IRS class in tumour centre correlated with negative lymph node involvement. 
Table shows the numbers of cases, lymph node involvement (possible, negative and positive) and Gli2 
IRS class (negative, positive with weak expression, positive with mild expression and positive with 
strong expression) in tumour centre. The correlation was calculated using the Kendall’s Tau B test. 
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11.3.4 Increased Gli3 correlated with younger mean age at diagnosis and hormone 
receptor-positive breast cancer 
The percentage of Gli3 positive expressing cells in the tumour centre and at the 
invasive front correlated with a lower mean age at diagnosis (-0.302, p-value = 0.069). 
The percentage of Gli3 positivity in the tumour centre negatively correlated with 
molecular subgroup (-0.329, p-value = 0.074) (Figure 11-18). A lower percentage of 
Gli3 positive tumour cells was observed with TNBC (-0.331, p-value = 0.096). 
 
 
 
Figure 11-18, The percentage of Gli3 positive tumour cells correlated with 
hormone-positive breast cancer 
Figure showing an increase in the percentage of Gli3 positive tumour cells in correlation with hormone-
positive breast cancer. Table shows the numbers of cases, the molecular subgroup (LumA, LumB, 
HER2+ve, and TNBC) and the percentage of Gli3 positive tumour cells (presenter as 0, <10, 10-50, 51-
80, and >80). The correlation was calculated using the Kendall’s Tau B test. LumA = Luminal A, LumB 
= Luminal B, HER2 = Human EGF receptor 2, TNBC = Triple-negative breast cancer. 
 
11.3.5 Gli1 and Gli2 were co-expressed in breast cancer samples 
Table 11-8 summarises that the numbers and clinical criteria of the samples that 
were stained for all three Gli proteins. Gli1 and Gli2 were co-expressed in breast cancer 
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samples. The intensity of Gli1 staining in the tumour centre correlated with that of Gli2 
in the tumour centre (0.596, p-value = 0.064) (Figure 11-19).  
 
 
 
Figure 11-19, Correlation between Gli1 and Gli2 staining intensity in the tumour 
centre and at the invasive front 
Figure showing correlation between Gli1 and Gli2 staining intensity in tumour centre and at invasive 
front. This correlation confirms a mutual increase of Gli1 and Gli2 intensity at the invasive front and in 
the tumour centre. 
 
The increase in Gli2 staining in the tumour centre and at the invasive front was 
in parallel with increased Gli1 nuclear localisation at the invasive front (Figure 11-20). 
Increased Gli1 nuclear localisation at the invasive front was concomitant with an 
increase in proportion and intensity of Gli2 staining at the invasive front with high 
correlation coefficient at the invasive front (0.74, p-value = 0.063 and 0.745, p-value = 
0.083). 
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Figure 11-20, Nuclear localisation of Gli1 at the invasive front is correlated with 
Gli2 staining 
Figure showing an increase in Gli1 nuclear localisation in correlation with an increase of Gli2 staining in 
the tumour centre and at the invasive front. (A and B) shows correlation between the percentage of Gli2 
positive tumour cells and an increase in nuclear localisation of Gli1 at the invasive front. (C and D) 
showed correlation between Gli2 staining intensity and the increase in Gli1 localisation at the invasive 
front. (E and F) showed correlation between IRS class of Gli2 staining and the increase in nuclear 
localisation of Gli1 at the invasive front. (G and H) shows the correlation between increased nuclear 
localisation of Gli2 with increased localisation of Gli1 at the invasive front. 
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11.3.6 Expression of Gli occurs concomitantly with the expression of b-catenin in 
breast cancer samples, a marker EMT 
b-catenin expression increased at the invasive front significantly (11.3.7). The 
increase in intensity and IRS class of Gli1 staining was positively correlated with 
increased in staining intensity and IRS class of b-catenin  in serial sections(0.655, p-
value = 0.094 and 0.745, p-value = 0.083, respectively) (Figure 11-21-A and Figure 
11-21-B). The nuclear localisation of Gli1 increased concomitantly with b-catenin 
staining intensity (Figure 11-22-A) (0.745, p-value = 0.083) and IRS class (0.745, p-
value = 0.083) (Figure 11-22-B). 
 
 
 
Figure 11-21, Co-expression of Gli1 and b-catenin in breast cancer samples in 
tumour centre and at invasive front 
Figure showing an increase of Gli1 expression in parallel with b-catenin increased expression in the 
tumour centre and at the invasive front. 
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Figure 11-22, Correlation between nuclear localisation of Gli1 and b-catenin 
staining intensity and IRS class at invasive front 
Figure showing increased nuclear localisation of Gli1 in association with an increase of b-catenin 
staining intensity (A) and IRS class (B) at the invasive front. 
 
The percentage of Gli2 positivity decreased as the percentage of b-catenin 
tumour expressing cells increased in the tumour centre (-0.606, p-value = 0.085) 
(Figure 11-23). The staining intensity of Gli2 increased in the tumour centre and at the 
invasive front with increased intensity of b-catenin at the invasive front (0.739, p-value 
= 0.061 and 0.655, p-value = 0.094, respectively) (Figure 11-24-A and Figure 11-24-B). 
The IRS class of Gli2 in the tumour centre and at the invasive front correlated with IRS 
class of b-catenin at the invasive front (0.739, p-value = 0.061 and 0.655, p-value = 
0.094, respectively) (Figure 11-25-A and Figure 11-25-B). The increase in IRS class of 
b-catenin at the invasive front was associated with increased IRS class of Gli2 in the 
tumour centre and at the invasive front. 
The nuclear localisation of Gli2 in the tumour centre and the invasive front were 
associated with increased of b-catenin staining at the invasive front (Figure 11-26). 
Increased nuclear localisation of Gli2 in the tumour centre was observed to increase 
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with b-catenin intensity (0.739, p-value =0.061) (Figure 11-26-A) and IRS class 
(0.0739, p-value = 0.061) (Figure 11-26-B) at the invasive front. Gli2 nuclear 
localisation at the invasive front correlated also with intensity (0.655, p-value = 0.094) 
(Figure 11-26-C) and IRS class (0.0655, p-value = 0.094) (Figure 11-26-D) of b-catenin 
staining at the invasive front. 
 
 
 
Figure 11-23, Gli2 expression is negatively correlated with b-catenin expression in 
tumour centre 
Figure showing a decreased percentage of Gli2 expressing cells in association with an increased 
percentage of b-catenin tumour expressing cells. 
 
 
 
Figure 11-24, Increased Gli2 staining intensity in the tumour centre and invasive 
front in association with increased b-catenin staining intensity at the invasive front 
Figure showing that increased intensity of Gli2 in the tumour centre and at the invasive front correlated 
with increased staining intensity of b-catenin at the invasive front. 
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Figure 11-25, IRS class of Gli2 in the tumour centre and at the invasive front 
correlated with IRS class of b-catenin at the invasive front 
Figure showing increase Gli2 IRS class in the tumour centre and at the invasive front in parallel with an 
increase of b-catenin at the invasive front. 
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Figure 11-26, Gli2 nuclear localisation in the tumour centre and at the invasive 
front were associated with increased b-catenin at the invasive front 
Figure showing that the nuclear localisation of Gli2 in the tumour centre (A and B) and at the invasive 
front (C and D) correlated with b-catenin staining intensity (A and C) and IRS class (B and D). 
 
Gli3 staining intensity (Figure 11-27-A) and IRS class (Figure 11-27-B) in the 
tumour centre correlated negatively with the percentage of b-catenin expressing tumour 
cells at the invasive front. Gli3 staining intensity was lower in the tumour centre of 
samples that had high expression of b-catenin at the invasive front (-0.653, p-value = 
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0.094). IRS class of Gli3 staining also showed a decrease with in samples that had a 
high percentage of positive tumour cells at the invasive front (-0.653, p-value = 0.094). 
Percentage of Gli3 positivity in the tumour centre decreased with increase nuclear 
localisation of b-catenin in the tumour centre (-0.601, p-value = 0.08) (Figure 11-28). 
 
 
 
Figure 11-27, Gli3 staining intensity and IRS class in tumour centre correlate 
negatively with the percentage of b-catenin staining at the invasive front 
Figure showing a decrease of Gli3 staining intensity and IRS class in tumour centre correlated with an 
increase of percentage of b-catenin positive tumour cells. 
 
 
 
Figure 11-28, Decreased percentage of Gli3 positive tumour cells in the tumour 
centre correlate with increased b-catenin nuclear score in the tumour centre 
Figure showing that increased nuclear localisation of b-catenin in the tumour centre correlated with lower 
percentage of Gli3 positive tumour cells in the tumour centre. 
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Table 11-8: Numbers and clinical criteria of breast cancer samples used for cross 
comparing Gli1, Gli2, Gli3, b-catenin and E-cadherin 
Tables showing the number of breast cancer samples that were stained by Gli1, Gli2, Gli3, b-catenin and 
E-cadherin. The table also summarise the clinical parameters and the numbers of cases that correspond to 
each parameter. DCIS = Ductal carcinoma in situ, IDC = Invasive ductal carcinoma, NST = None 
specific type, HER2 = Human EGF receptor 2, ER, PR = progesterone receptor. 
 
 Number % 
Tumour size 
2cm ³ 1 11.1 
2cm < 8 88.9 
Stage 
T1 4 44.4 
T2 5 55.6 
Grade 
Grade 1 1 11.1 
Grade 2 2 22.2 
Grade 3 6 66.7 
Histological Subtype 
DCIS/IDC 4 44.4 
IDC 4 44.4 
NST 1 11.1 
ER status 
Negative 7 77.8 
Positive 2 22.2 
PR status 
Negative 8 88.9 
Positive 1 11.1 
HER2 status 
Positive 4 44.4 
Negative 5 55.6 
Molecular subgroup 
Luminal A 2 22.2 
HER2 4 44.4 
Triple-negative 3 33.3 
Lymph node involvement 
Positive 3 33.3 
Negative 5 55.6 
Possible 1 11.1 
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Table 11-9: Table showing the correlation of Gli1 expression with Age, tumour 
size, stage, grade, histological subtype, molecular subgroup and prognostic 
receptor status 
Tables showing the correlation between the pathological parameters (age, tumour size, stage, grade, 
histological subtype, molecular subgroup, prognostic receptor status) with the (percentage of positivity, 
intensity of immune reaction, IRS class and nuclear score) of Gli1 in tumour centres and at the invasive 
fronts. DCIS = Ductal carcinoma in situ, IDC = Invasive ductal carcinoma, NST = None specific type, 
HER2 = Human EGF receptor 2, ER, PR = progesterone receptor. Highlighted in bold are the parameters 
that showed significance and close to significant correlation values.  
 
 
Tumour centre Invasive front Nuclear score 
% Intensity IRS Class % Intensity 
IRS 
Class 
Tumour 
centre 
Invasive 
front 
Age 
Correlation 
Coefficient 0.043 -0.09 -0.007 0.14 0.064 0.126 0.168 0.066 
Sig. (2-tailed) 0.698 0.417 0.948 0.282 0.622 0.33 0.13 0.608 
N 48 48 48 37 37 37 48 37 
Tumour 
size 
Correlation 
Coefficient 0.187 0.22 0.192 0.288 0.229 .311* .295* .367* 
Sig. (2-tailed) 0.164 0.1 0.152 0.065 0.146 0.046 0.027 0.018 
N 48 48 48 37 37 37 48 37 
Tumour 
stage 
Correlation 
Coefficient 0.093 0.135 0.168 0.212 0.08 0.231 0.223 .317* 
Sig. (2-tailed) 0.498 0.318 0.212 0.187 0.617 0.146 0.098 0.043 
N 45 45 45 34 34 34 45 34 
Tumour 
grade 
Correlation 
Coefficient 0.027 -0.063 0.027 0.055 -0.061 -0.043 0.048 0.042 
Sig. (2-tailed) 0.837 0.638 0.84 0.727 0.7 0.781 0.717 0.785 
N 48 48 48 37 37 37 48 37 
Histological 
subtype 
Correlation 
Coefficient -0.067 0.004 0.014 0.114 0.064 -0.037 0.005 0.042 
Sig. (2-tailed) 0.582 0.977 0.908 0.419 0.65 0.791 0.969 0.762 
N 48 48 48 37 37 37 48 37 
ER status 
Correlation 
Coefficient -0.162 0.234 0.078 0.024 0.194 0.104 -0.081 -0.092 
Sig. (2-tailed) 0.228 0.081 0.562 0.877 0.218 0.506 0.546 0.55 
N 48 48 48 37 37 37 48 37 
PR status 
Correlation 
Coefficient -0.111 0.158 0.026 -0.035 0.15 0.014 -0.074 -0.084 
Sig. (2-tailed) 0.407 0.24 0.847 0.822 0.339 0.929 0.582 0.587 
N 48 48 48 37 37 37 48 37 
HER2 
status 
Correlation 
Coefficient 0.114 -0.024 0.002 0.014 -0.159 -0.125 0.09 0.103 
Sig. (2-tailed) 0.399 0.859 0.991 0.928 0.313 0.422 0.5 0.506 
N 48 48 48 37 37 37 48 37 
Molecular 
subgroup 
Correlation 
Coefficient 0.222 -0.186 0.006 0.025 -0.172 -0.045 0.195 0.108 
Sig. (2-tailed) 0.078 0.137 0.96 0.862 0.244 0.756 0.119 0.455 
N 48 48 48 37 37 37 48 37 
Lymph 
node 
involvement 
Correlation 
Coefficient -0.073 0.044 0.023 0.033 0.07 -0.071 0.073 -0.169 
Sig. (2-tailed) 0.582 0.741 0.861 0.828 0.649 0.645 0.582 0.265 
N 47 47 47 36 36 36 47 36 
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Tumour centre Invasive front Nuclear score 
% Intensity IRS Class. % Intensity 
IRS 
Class. 
Tumour 
centre 
Invasive 
front 
DUCTAL 
Correlation 
Coefficient 0.192 0.014 0.04 -0.044 -0.028 0.067 0.034 -0.174 
Sig. (2-tailed) 0.153 0.918 0.767 0.781 0.861 0.669 0.802 0.261 
N 48 48 48 37 37 37 48 37 
LOBULAR 
Correlation 
Coefficient -0.004 -0.103 -0.1 0.038 -0.066 -0.007 0.111 .311* 
Sig. (2-tailed) 0.974 0.443 0.455 0.808 0.677 0.962 0.407 0.044 
N 48 48 48 37 37 37 48 37 
DCIS 
Correlation 
Coefficient -0.097 0.024 -0.011 -0.182 -0.086 -0.009 -0.049 0.046 
Sig. (2-tailed) 0.469 0.859 0.934 0.246 0.584 0.955 0.714 0.765 
N 48 48 48 37 37 37 48 37 
IDC 
Correlation 
Coefficient 0.263 0.004 0.067 -0.032 -0.073 0.013 0.055 -0.227 
Sig. (2-tailed) 0.05 0.973 0.617 0.837 0.641 0.933 0.681 0.142 
N 48 48 48 37 37 37 48 37 
LCIS 
Correlation 
Coefficient -0.118 -0.091 -0.13 0.126 -0.152 -0.101 0.036 0.109 
Sig. (2-tailed) 0.38 0.499 0.333 0.419 0.335 0.516 0.788 0.479 
N 48 48 48 37 37 37 48 37 
ILC 
Correlation 
Coefficient -0.004 -0.103 -0.1 0.038 -0.066 -0.007 0.111 .311* 
Sig. (2-tailed) 0.974 0.443 0.455 0.808 0.677 0.962 0.407 0.044 
N 48 48 48 37 37 37 48 37 
LUMA 
Correlation 
Coefficient -0.16 0.157 -0.038 -0.035 0.043 -0.086 -0.17 -0.044 
Sig. (2-tailed) 0.235 0.242 0.778 0.822 0.785 0.58 0.206 0.778 
N 48 48 48 37 37 37 48 37 
LUMB 
Correlation 
Coefficient -0.027 0.168 0.211 0.086 0.246 0.28 0.143 -0.086 
Sig. (2-tailed) 0.839 0.212 0.115 0.584 0.117 0.073 0.287 0.577 
N 48 48 48 37 37 37 48 37 
HER2 
Correlation 
Coefficient -0.107 -0.071 -0.123 -0.073 0.013 -0.046 -0.18 -0.057 
Sig. (2-tailed) 0.426 0.598 0.357 0.643 0.935 0.766 0.179 0.712 
N 48 48 48 37 37 37 48 37 
TNBC 
Correlation 
Coefficient 0.238 -0.154 0.033 0.039 -0.177 -0.051 0.225 0.127 
Sig. (2-tailed) 0.077 0.252 0.805 0.803 0.26 0.743 0.093 0.413 
N 48 48 48 37 37 37 48 37 
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Table 11-10: Table showing the correlation of Gli2 expression with Age, tumour 
size, stage, grade, histological subtype, molecular subgroup and prognostic 
receptor status 
Tables showing the correlation between the pathological parameters (age, tumour size, stage, grade, 
histological subtype, molecular subgroup, prognostic receptor status) with the (percentage of positivity, 
intensity of immune reaction, IRS class and nuclear score) of Gli2 in tumour centres and at the invasive 
fronts. DCIS = Ductal carcinoma in situ, IDC = Invasive ductal carcinoma, NST = None specific type, 
HER2 = Human EGF receptor 2, ER, PR = progesterone receptor. Highlighted in bold are the parameters 
that showed significance and close to significant correlation values.  
 
 
Tumour centre Invasive front Nuclear score 
% Intensity IRS Class % Intensity 
IRS 
Class 
Tumour 
centre 
Invasive 
front 
Age 
Correlation 
Coefficient -0.132 0.044 0.003 0.003 -0.032 -0.042 -0.006 0.058 
Sig. (2-tailed) 0.37 0.763 0.984 0.982 0.83 0.78 0.968 0.702 
N 29 29 29 29 29 29 29 29 
Tumour 
size 
Correlation 
Coefficient -.348* -0.138 -0.239 -0.201 -0.146 -0.183 -0.165 -0.077 
Sig. (2-tailed) 0.05 0.437 0.18 0.268 0.421 0.313 0.356 0.673 
N 29 29 29 29 29 29 29 29 
Tumour 
stage 
Correlation 
Coefficient -.480** -0.136 -0.216 -0.232 -0.145 -0.178 -0.184 -0.292 
Sig. (2-tailed) 0.009 0.462 0.251 0.219 0.44 0.344 0.324 0.125 
N 26 26 26 26 26 26 26 26 
Tumour 
grade 
Correlation 
Coefficient -0.269 -0.309 -0.287 0.009 -0.266 -0.25 -.383* -0.282 
Sig. (2-tailed) 0.124 0.077 0.102 0.958 0.136 0.162 0.03 0.118 
N 29 29 29 29 29 29 29 29 
Histological 
subtype 
Correlation 
Coefficient 0.31 0.154 0.241 .330* 0.164 0.21 0.132 0.162 
Sig. (2-tailed) 0.057 0.344 0.14 0.048 0.323 0.206 0.422 0.334 
N 29 29 29 29 29 29 29 29 
ER status 
Correlation 
Coefficient 0.119 0.213 0.187 -0.105 0.122 0.112 0.247 0.199 
Sig. (2-tailed) 0.503 0.229 0.295 0.564 0.501 0.539 0.167 0.275 
N 29 29 29 29 29 29 29 29 
PR status 
Correlation 
Coefficient 0.067 0.167 0.146 -0.082 -0.013 -0.026 0.193 0.096 
Sig. (2-tailed) 0.707 0.346 0.412 0.651 0.943 0.885 0.279 0.598 
N 29 29 29 29 29 29 29 29 
HER2 
status 
Correlation 
Coefficient 0.093 .401* 0.329 0.154 0.191 0.174 .368* 0.27 
Sig. (2-tailed) 0.598 0.024 0.065 0.399 0.291 0.337 0.039 0.14 
N 29 29 29 29 29 29 29 29 
Molecular 
subgroup 
Correlation 
Coefficient -0.069 0.04 0.007 0.14 -0.043 -0.047 -0.011 -0.083 
Sig. (2-tailed) 0.678 0.813 0.965 0.412 0.8 0.782 0.948 0.629 
N 29 29 29 29 29 29 29 29 
Lymph 
node 
involvement 
Correlation 
Coefficient .419* 0.295 0.321 0.296 0.193 0.252 0.207 0.32 
Sig. (2-tailed) 0.016 0.091 0.068 0.097 0.276 0.156 0.238 0.074 
N 28 28 28 28 28 28 28 28 
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Tumour centre Invasive front Nuclear score 
% Intensity IRS Class. % Intensity 
IRS 
Class. 
Tumour 
centre 
Invasive 
front 
DUCTAL 
Correlation 
Coefficient -.416* -0.023 -0.151 -.423* -0.171 -0.222 -0.033 -0.149 
Sig. (2-tailed) 0.019 0.897 0.398 0.02 0.346 0.221 0.855 0.416 
N 29 29 29 29 29 29 29 29 
LOBULAR 
Correlation 
Coefficient . . . . . . . . 
Sig. (2-tailed) . . . . . . . . 
N 29 29 29 29 29 29 29 29 
DCIS 
Correlation 
Coefficient -0.17 -0.167 -0.226 -0.278 -0.137 -0.174 -0.114 -0.145 
Sig. (2-tailed) 0.338 0.346 0.204 0.126 0.451 0.337 0.523 0.429 
N 29 29 29 29 29 29 29 29 
IDC 
Correlation 
Coefficient -0.33 0.071 -0.045 -.460* -0.223 -0.273 0.068 -0.195 
Sig. (2-tailed) 0.063 0.688 0.799 0.012 0.218 0.132 0.705 0.286 
N 29 29 29 29 29 29 29 29 
LCIS 
Correlation 
Coefficient . . . . . . . . 
Sig. (2-tailed) . . . . . . . . 
N 29 29 29 29 29 29 29 29 
ILC 
Correlation 
Coefficient 0.172 0.203 0.207 0.129 0.148 0.149 0.217 0.13 
Sig. (2-tailed) 0.333 0.252 0.245 0.477 0.416 0.414 0.225 0.476 
N 29 29 29 29 29 29 29 29 
LUMA 
Correlation 
Coefficient 0.144 0.251 0.234 -0.013 0.208 0.203 0.281 0.314 
Sig. (2-tailed) 0.417 0.158 0.19 0.945 0.251 0.263 0.116 0.085 
N 29 29 29 29 29 29 29 29 
LUMB 
Correlation 
Coefficient -0.034 -0.045 -0.069 -0.207 -0.16 -0.173 -0.034 -0.208 
Sig. (2-tailed) 0.846 0.799 0.698 0.255 0.378 0.34 0.848 0.255 
N 29 29 29 29 29 29 29 29 
HER2 
Correlation 
Coefficient -0.082 -.390* -0.308 -0.078 -0.134 -0.112 -.361* -0.196 
Sig. (2-tailed) 0.644 0.028 0.084 0.669 0.459 0.539 0.044 0.284 
N 29 29 29 29 29 29 29 29 
TNBC 
Correlation 
Coefficient -0.017 0.209 0.149 0.163 0.032 0.018 0.152 0.029 
Sig. (2-tailed) 0.924 0.239 0.402 0.37 0.86 0.92 0.394 0.874 
N 29 29 29 29 29 29 29 29 
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Table 11-11: Table showing the correlation of Gli3 expression with Age, tumour 
size, stage, grade, histological subtype, molecular subgroup and prognostic 
receptor status 
Tables showing the correlation between the pathological parameters (age, tumour size, stage, grade, 
histological subtype, molecular subgroup, prognostic receptor status) with the (percentage of positivity, 
intensity of immune reaction, IRS class and nuclear score) of Gli3 in tumour centres and at the invasive 
fronts. DCIS = Ductal carcinoma in situ, IDC = Invasive ductal carcinoma, NST = None specific type, 
HER2 = Human EGF receptor 2, ER, PR = progesterone receptor. Highlighted in bold are the parameters 
that showed significance and close to significant correlation values.  
 
 
Tumour centre Invasive front Nuclear score 
% Intensity IRS Class % Intensity 
IRS 
Class 
Tumour 
centre 
Invasive 
front 
Age 
Correlation 
Coefficient -0.302 0.167 0.005 -.495* 0.067 0.057 -0.08 -0.079 
Sig. (2-tailed) 0.069 0.325 0.977 0.015 0.731 0.779 0.629 0.699 
N 23 23 23 18 18 18 23 16 
Tumour 
size 
Correlation 
Coefficient -0.162 0.219 0.075 -0.081 -0.095 -0.161 0.039 -0.084 
Sig. (2-tailed) 0.415 0.28 0.711 0.74 0.684 0.506 0.842 0.729 
N 23 23 23 18 18 18 23 16 
Tumour 
stage 
Correlation 
Coefficient 0 0.174 0.201 0 0 0 -0.09 -0.188 
Sig. (2-tailed) 1 0.406 0.331 1 1 1 0.658 0.438 
N 21 21 21 17 17 17 21 15 
Tumour 
grade 
Correlation 
Coefficient -0.069 0.119 0.053 0.038 0.034 -0.038 0.006 0.038 
Sig. (2-tailed) 0.724 0.55 0.791 0.873 0.883 0.873 0.974 0.87 
N 23 23 23 18 18 18 23 16 
Histological 
subtype 
Correlation 
Coefficient 0.269 0 0.118 0.089 .502* .512* .391* .671** 
Sig. (2-tailed) 0.143 1 0.525 0.693 0.021 0.023 0.032 0.003 
N 23 23 23 18 18 18 23 16 
ER status 
Correlation 
Coefficient .402* -0.007 0.207 0.081 0.095 0.161 0.093 0.068 
Sig. (2-tailed) 0.043 0.973 0.305 0.74 0.684 0.506 0.637 0.778 
N 23 23 23 18 18 18 23 16 
PR status 
Correlation 
Coefficient .468* 0.074 0.204 0.316 0.062 0 0.284 0.19 
Sig. (2-tailed) 0.019 0.715 0.312 0.192 0.79 1 0.151 0.431 
N 23 23 23 18 18 18 23 16 
HER2 
status 
Correlation 
Coefficient -0.121 -0.299 -0.304 -0.322 -0.048 0.081 -0.061 0.204 
Sig. (2-tailed) 0.541 0.14 0.132 0.184 0.839 0.74 0.756 0.398 
N 23 23 23 18 18 18 23 16 
Molecular 
subgroup 
Correlation 
Coefficient -0.329 -0.091 -0.226 -0.12 -0.212 -0.272 -0.202 -0.112 
Sig. (2-tailed) 0.074 0.628 0.226 0.592 0.325 0.223 0.27 0.615 
N 23 23 23 18 18 18 23 16 
Lymph 
node 
involvement 
Correlation 
Coefficient -0.025 -0.159 -0.184 -0.025 -0.235 -0.19 0.044 -0.104 
Sig. (2-tailed) 0.898 0.425 0.353 0.915 0.304 0.424 0.819 0.659 
N 23 23 23 18 18 18 23 16 
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Tumour centre Invasive front Nuclear score 
% Intensity IRS Class. % Intensity 
IRS 
Class. 
Tumour 
centre 
Invasive 
front 
DUCTAL 
Correlation 
Coefficient -0.209 -0.078 -0.17 0 -.688** -.750** -.403* -.585* 
Sig. (2-tailed) 0.292 0.699 0.4 1 0.003 0.002 0.042 0.015 
N 23 23 23 18 18 18 23 16 
LOBULAR 
Correlation 
Coefficient 0 0.117 0.099 -0.343 0.303 0.343 -0.096 -0.028 
Sig. (2-tailed) 1 0.566 0.623 0.157 0.194 0.157 0.629 0.908 
N 23 23 23 18 18 18 23 16 
DCIS 
Correlation 
Coefficient -0.279 0.118 -0.007 -0.088 -0.207 -0.175 -0.219 -.567* 
Sig. (2-tailed) 0.16 0.561 0.971 0.718 0.376 0.47 0.268 0.019 
N 23 23 23 18 18 18 23 16 
IDC 
Correlation 
Coefficient -0.209 -0.078 -0.17 0 -.688** -.750** -.403* -.585* 
Sig. (2-tailed) 0.292 0.699 0.4 1 0.003 0.002 0.042 0.015 
N 23 23 23 18 18 18 23 16 
LCIS 
Correlation 
Coefficient 0 0.117 0.099 -0.343 0.303 0.343 -0.096 -0.028 
Sig. (2-tailed) 1 0.566 0.623 0.157 0.194 0.157 0.629 0.908 
N 23 23 23 18 18 18 23 16 
ILC 
Correlation 
Coefficient 0 0.117 0.099 -0.343 0.303 0.343 -0.096 -0.028 
Sig. (2-tailed) 1 0.566 0.623 0.157 0.194 0.157 0.629 0.908 
N 23 23 23 18 18 18 23 16 
LUMA 
Correlation 
Coefficient 0.217 -0.059 0.029 -0.088 0.207 0.351 0.184 0.247 
Sig. (2-tailed) 0.276 0.771 0.885 0.718 0.376 0.148 0.353 0.305 
N 23 23 23 18 18 18 23 16 
LUMB 
Correlation 
Coefficient 0.342 0.084 0.31 0.25 -0.147 -0.25 -0.138 -0.245 
Sig. (2-tailed) 0.085 0.678 0.123 0.303 0.528 0.303 0.484 0.31 
N 23 23 23 18 18 18 23 16 
HER2 
Correlation 
Coefficient -0.088 0.271 0.13 0.175 0.155 0.088 0.155 -0.044 
Sig. (2-tailed) 0.658 0.183 0.518 0.47 0.506 0.718 0.432 0.856 
N 23 23 23 18 18 18 23 16 
TNBC 
Correlation 
Coefficient -0.331 -0.242 -0.332 -0.25 -0.246 -0.25 -0.239 -0.031 
Sig. (2-tailed) 0.096 0.233 0.099 0.303 0.293 0.303 0.227 0.897 
N 23 23 23 18 18 18 23 16 
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Table 11-12: Table showing the correlation between Gli and Gli2 
Tables showing the correlation between with the (percentage of positivity, intensity of immune reaction, 
IRS class and nuclear score) of Gli1 and Gli2 in tumour centres and at the invasive fronts.  
 
 
Gli2 
Tumour centre Invasive front Nuclear score 
% Intensity IRS Class % Intensity IRS Class Tumour centre 
Invasive 
front 
G
li1
 
Tu
m
ou
r c
en
tre
 
% 
Correlation 
Coefficient -0.138 -0.432 -0.432 -0.073 -0.227 -0.271 -0.332 -0.253 
Sig. (2-tailed) 0.648 0.175 0.175 0.814 0.469 0.389 0.293 0.451 
N 9 9 9 9 9 9 9 8 
Intensity 
Correlation 
Coefficient 0.5 0.596 0.596 0.491 0.393 0.602 0.301 0.476 
Sig. (2-tailed) 0.102 0.064 0.064 0.118 0.217 0.059 0.346 0.161 
N 9 9 9 9 9 9 9 8 
IRS Class 
Correlation 
Coefficient .715* 0.497 0.497 .755* 0.55 .762* 0.215 0.582 
Sig. (2-tailed) 0.019 0.123 0.123 0.016 0.084 0.017 0.501 0.087 
N 9 9 9 9 9 9 9 8 
In
va
siv
e 
fro
nt
 
% 
Correlation 
Coefficient 0.167 -0.405 -0.405 0.273 0 0 -0.405 0 
Sig. (2-tailed) 0.671 0.343 0.343 0.503 1 1 0.343 1 
N 6 6 6 6 6 6 6 6 
Intensity 
Correlation 
Coefficient 0.418 0.674 0.674 0.545 0.804 0.804 0.674 .818* 
Sig. (2-tailed) 0.289 0.114 0.114 0.181 0.051 0.051 0.114 0.045 
N 6 6 6 6 6 6 6 6 
IRS Class 
Correlation 
Coefficient 0.74 0.745 0.745 0.804 1.000* 1.000* 0.745 0.704 
Sig. (2-tailed) 0.063 0.083 0.083 0.051 . . 0.083 0.087 
N 6 6 6 6 0 6 6 6 
N
uc
le
ar
 sc
or
e  Tumour 
centre 
Correlation 
Coefficient 0.379 0 0 0.546 0 0.232 -0.249 0.253 
Sig. (2-tailed) 0.209 1 1 0.078 1 0.46 0.43 0.451 
N 9 9 9 9 9 9 9 8 
Invasive 
front 
Correlation 
Coefficient 0.74 0.745 0.745 0.804 1.000* 1.000* 0.745 0.704 
Sig. (2-tailed) 0.063 0.083 0.083 0.051 . . 0.083 0.087 
N 6 6 6 6 6 6 6 6 
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Table 11-13: Table showing the correlation of Gli1 and Gli3 
Tables showing the correlation between with the (percentage of positivity, intensity of immune reaction, 
IRS class and nuclear score) of Gli1 and Gli3 in tumour centres and at the invasive fronts.  
 
 
Gli3 
Tumour centre Invasive front Nuclear score 
% Intensity IRS Class % Intensity IRS Class Tumour centre 
Invasive 
front 
G
li1
 
Tu
m
ou
r c
en
tre
 
% 
Correlation 
Coefficient -0.182 -0.455 -0.455 -0.408 0.102 . -0.291 0 
Sig. (2-tailed) 0.557 0.148 0.148 0.29 0.791 . 0.347 1 
N 9 9 9 7 7 7 9 6 
Intensity 
Correlation 
Coefficient -0.038 0.354 0.354 0.297 0 . 0.377 0.087 
Sig. (2-tailed) 0.904 0.267 0.267 0.432 1 . 0.229 0.827 
N 9 9 9 7 7 7 9 6 
IRS Class 
Correlation 
Coefficient -0.34 -0.118 -0.118 -0.198 -0.198 . 0.189 -0.087 
Sig. (2-tailed) 0.279 0.711 0.711 0.6 0.6 . 0.547 0.827 
N 9 9 9 7 7 7 9 6 
In
va
siv
e 
fro
nt
 
% 
Correlation 
Coefficient -0.364 -.905* -.905* -0.405 . . -0.545 0 
Sig. (2-tailed) 0.372 0.034 0.034 0.343 . . 0.181 1 
N 6 6 6 6 6 6 6 5 
Intensity 
Correlation 
Coefficient 0 0.201 0.201 0.135 . . 0.545 0.617 
Sig. (2-tailed) 1 0.637 0.637 0.752 . . 0.181 0.197 
N 6 6 6 6 6 6 6 5 
IRS Class 
Correlation 
Coefficient -0.402 0 0 0 . . 0.302 0 
Sig. (2-tailed) 0.328 1 1 1 . . 0.463 1 
N 6 6 6 6 6 6 6 5 
N
uc
le
ar
 sc
or
e  Tumour 
centre 
Correlation 
Coefficient -0.546 -0.379 -0.379 -0.297 0.198 . 0.109 0.261 
Sig. (2-tailed) 0.078 0.228 0.228 0.432 0.6 . 0.724 0.511 
N 9 9 9 7 7 7 9 6 
Invasive 
front 
Correlation 
Coefficient -0.402 0 0 0 . . 0.302 0 
Sig. (2-tailed) 0.328 1 1 1 . . 0.463 1 
N 6 6 6 6 6 6 6 5 
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Table 11-14: Table showing the correlation of Gli1 and b-catenin 
Tables showing the correlation between with the (percentage of positivity, intensity of immune reaction, 
IRS class and nuclear score) of Gli1 and b-catenin in tumour centres and at the invasive fronts.  
 
 
b-catenin 
Tumour centre Invasive front Nuclear score 
% Intensity IRS Class % Intensity IRS Class Tumour centre 
Invasive 
front 
G
li1
 
Tu
m
ou
r c
en
tre
 
% 
Correlation 
Coefficient 0.215 . . 0.537 -0.396 -0.396 -0.048 -0.519 
Sig. (2-tailed) 0.536 . . 0.155 0.295 0.295 0.886 0.153 
N 8 8 8 7 7 7 8 7 
Intensity 
Correlation 
Coefficient -0.296 . . -0.507 0.655 0.655 0.316 0.571 
Sig. (2-tailed) 0.414 . . 0.195 0.094 0.094 0.365 0.128 
N 8 8 8 7 7 7 8 7 
IRS Class 
Correlation 
Coefficient -0.165 . . 0.077 0.594 0.594 0.391 0.194 
Sig. (2-tailed) 0.638 . . 0.839 0.116 0.116 0.247 0.592 
N 8 8 8 7 7 7 8 7 
In
va
siv
e 
fro
nt
 
% 
Correlation 
Coefficient 0.107 . . 0.539 -0.405 -0.405 -0.201 -0.64 
Sig. (2-tailed) 0.803 . . 0.206 0.343 0.343 0.637 0.134 
N 6 6 6 6 6 6 6 6 
Intensity 
Correlation 
Coefficient 0.213 . . 0.135 0.674 0.674 0.201 0.64 
Sig. (2-tailed) 0.617 . . 0.752 0.114 0.114 0.637 0.134 
N 6 6 6 6 6 6 6 6 
IRS Class 
Correlation 
Coefficient 0 . . 0 0.745 0.745 0.556 0.589 
Sig. (2-tailed) 1 . . 1 0.083 0.083 0.197 0.171 
N 6 6 6 6 6 6 6 6 
N
uc
le
ar
 sc
or
e Tumour 
centre 
Correlation 
Coefficient 0.054 . . 0.447 0.481 0.481 0.622 0.378 
Sig. (2-tailed) 0.877 . . 0.232 0.199 0.199 0.063 0.294 
N 8 8 8 7 7 7 8 7 
Invasive 
front 
Correlation 
Coefficient 0 . . 0 0.745 0.745 0.556 0.589 
Sig. (2-tailed) 1 . . 1 0.083 0.083 0.197 0.171 
N 6 6 6 6 6 6 6 6 
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Table 11-15: Table showing the correlation of Gli1 and E-cadherin 
Tables showing the correlation between with the (percentage of positivity, intensity of immune reaction, 
IRS class and nuclear score) of Gli1 and E-cadherin in tumour centres and at the invasive fronts.  
 
 
E-cadherin 
Tumour centre Invasive front Nuclear score 
% Intensity IRS Class % Intensity IRS Class Tumour centre 
Invasive 
front 
G
li1
 
Tu
m
ou
r c
en
tre
 
% 
Correlation 
Coefficient 0.405 -0.215 -0.054 -0.096 -0.473 -0.473 0.405 -0.215 
Sig. (2-tailed) 0.228 0.536 0.877 0.775 0.174 0.174 0.228 0.536 
N 8 8 8 8 8 8 8 8 
Intensity 
Correlation 
Coefficient -0.278 -0.118 -0.118 0.211 0.434 0.434 -0.278 -0.118 
Sig. (2-tailed) 0.426 0.744 0.744 0.546 0.232 0.232 0.426 0.744 
N 8 8 8 8 8 8 8 8 
IRS Class 
Correlation 
Coefficient 0.556 -0.474 -0.059 0.211 -0.173 -0.173 0.556 -0.474 
Sig. (2-tailed) 0.111 0.191 0.87 0.546 0.633 0.633 0.111 0.191 
N 8 8 8 8 8 8 8 8 
In
va
siv
e 
fro
nt
 
% 
Correlation 
Coefficient 0.625 -0.53 . 0.267 0 0 0.625 -0.53 
Sig. (2-tailed) 0.167 0.264 . 0.557 1 1 0.167 0.264 
N 5 5 5 5 5 5 5 5 
Intensity 
Correlation 
Coefficient 0 0.612 . 0.617 0.408 0.408 0 0.612 
Sig. (2-tailed) 1 0.221 . 0.197 0.414 0.414 1 0.221 
N 5 5 5 5 5 5 5 5 
IRS Class 
Correlation 
Coefficient 0.53 -0.25 . 0.756 0.25 0.25 0.53 -0.25 
Sig. (2-tailed) 0.264 0.617 . 0.114 0.617 0.617 0.264 0.617 
N 5 5 5 5 5 5 5 5 
N
uc
le
ar
 sc
or
e  Tumour 
centre 
Correlation 
Coefficient 0 -0.431 -.700* -0.383 -0.315 -0.315 0 -0.431 
Sig. (2-tailed) 1 0.216 0.044 0.253 0.365 0.365 1 0.216 
N 8 8 8 8 8 8 8 8 
Invasive 
front 
Correlation 
Coefficient 0.53 -0.25 . 0.756 0.25 0.25 0.53 -0.25 
Sig. (2-tailed) 0.264 0.617 . 0.114 0.617 0.617 0.264 0.617 
N 5 5 5 5 5 5 5 5 
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Table 11-16: Table showing the correlation of Gli2 and Gli3 
Tables showing the correlation between with the (percentage of positivity, intensity of immune reaction, 
IRS class and nuclear score) of Gli2 and Gli3 in tumour centres and at the invasive fronts.  
 
 
Gli3 
Tumour centre Invasive front Nuclear score 
% Intensity IRS Class % Intensity IRS Class Tumour centre 
Invasive 
front 
G
li2
 
Tu
m
ou
r c
en
tre
 
% 
Correlation 
Coefficient -0.364 -0.038 -0.038 -0.481 -0.096 . 0.109 -0.167 
Sig. (2-tailed) 0.24 0.904 0.904 0.199 0.797 . 0.724 0.672 
N 9 9 9 7 7 7 9 6 
Intensity 
Correlation 
Coefficient 0.203 0.632 0.632 -0.167 -0.167 . 0.608 . 
Sig. (2-tailed) 0.535 0.056 0.056 0.683 0.683 . 0.063 . 
N 9 9 9 7 7 7 9 6 
IRS Class 
Correlation 
Coefficient 0.203 0.632 0.632 -0.167 -0.167 . 0.608 . 
Sig. (2-tailed) 0.535 0.056 0.056 0.683 0.683 . 0.063 . 
N 9 9 9 7 7 7 9 6 
In
va
siv
e 
fro
nt
 
% 
Correlation 
Coefficient -0.308 0 0 -0.546 0.109 . 0.308 0.204 
Sig. (2-tailed) 0.333 1 1 0.163 0.78 . 0.333 0.623 
N 9 9 9 7 7 7 9 6 
Intensity 
Correlation 
Coefficient 0.04 0.167 0.167 0.109 -0.546 . 0.04 -0.408 
Sig. (2-tailed) 0.901 0.611 0.611 0.78 0.163 . 0.901 0.325 
N 9 9 9 7 7 7 9 6 
IRS Class 
Correlation 
Coefficient -0.164 0.085 0.085 0.109 -0.546 . 0.123 -0.408 
Sig. (2-tailed) 0.613 0.795 0.795 0.78 0.163 . 0.704 0.325 
N 9 9 9 7 7 7 9 6 
N
uc
le
ar
 sc
or
e  Tumour 
centre 
Correlation 
Coefficient 0.395 0.639 0.639 -0.167 -0.167 . 0.439 . 
Sig. (2-tailed) 0.223 0.052 0.052 0.683 0.683 . 0.176 . 
N 9 9 9 7 7 7 9 6 
Invasive 
front 
Correlation 
Coefficient -0.054 0 0 -0.327 -0.327 . 0.212 0.204 
Sig. (2-tailed) 0.875 1 1 0.403 0.403 . 0.539 0.623 
N 8 8 8 7 7 7 8 6 
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Table 11-17: Table showing the correlation of Gli2 and b-catenin  
Tables showing the correlation between with the (percentage of positivity, intensity of immune reaction, 
IRS class and nuclear score) of Gli2 and b-catenin in tumour centres and at the invasive fronts.  
 
 
b-catenin  
Tumour centre Invasive front Nuclear score 
% Intensity IRS Class % Intensity IRS Class Tumour centre 
Invasive 
front 
G
li2
 
Tu
m
ou
r c
en
tre
 
% 
Correlation 
Coefficient -0.606 . . -0.307 0.594 0.594 0.196 -0.065 
Sig. (2-tailed) 0.085 . . 0.417 0.116 0.116 0.563 0.858 
N 8 8 8 7 7 7 8 7 
Intensity 
Correlation 
Coefficient -0.501 . . -0.572 0.739 0.739 0 0.161 
Sig. (2-tailed) 0.172 . . 0.147 0.061 0.061 1 0.67 
N 8 8 8 7 7 7 8 7 
IRS Class 
Correlation 
Coefficient -0.501 . . -0.572 0.739 0.739 0 0.161 
Sig. (2-tailed) 0.172 . . 0.147 0.061 0.061 1 0.67 
N 8 8 8 7 7 7 8 7 
In
va
siv
e 
fro
nt
 
% 
Correlation 
Coefficient -0.507 . . -0.163 0.632 0.632 0.3 -0.069 
Sig. (2-tailed) 0.156 . . 0.676 0.105 0.105 0.382 0.854 
N 8 8 8 7 7 7 8 0 
Intensity 
Correlation 
Coefficient -0.059 . . -0.338 0.655 0.655 -0.105 0.286 
Sig. (2-tailed) 0.87 . . 0.388 0.094 0.094 0.763 0.447 
N 8 8 8 7 7 7 8 7 
IRS Class 
Correlation 
Coefficient -0.25 . . -0.338 0.655 0.655 0.223 0.286 
Sig. (2-tailed) 0.491 . . 0.388 0.094 0.094 0.524 0.447 
N 8 8 8 7 7 7 8 7 
N
uc
le
ar
 sc
or
e Tumour 
centre 
Correlation 
Coefficient -0.25 . . -0.572 0.739 0.739 -0.334 0.161 
Sig. (2-tailed) 0.491 . . 0.147 0.061 0.061 0.34 0.67 
N 8 8 8 7 7 7 8 7 
Invasive 
front 
Correlation 
Coefficient -0.231 . . 0 0.655 0.655 -0.231 0.071 
Sig. (2-tailed) 0.554 . . 1 0.094 0.094 0.554 0.849 
N 7 7 7 7 7 7 7 7 
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Table 11-18: Table showing the correlation of Gli2 and E-cadherin   
Tables showing the correlation between with the (percentage of positivity, intensity of immune reaction, 
IRS class and nuclear score) of Gli2 and E-cadherin in tumour centres and at the invasive fronts.  
 
 
E-cadherin   
Tumour centre Invasive front Nuclear score 
% Intensity IRS Class % Intensity IRS Class Tumour centre 
Invasive 
front 
G
li2
 
Tu
m
ou
r c
en
tre
 
% 
Correlation 
Coefficient 0.106 -0.563 0 0.35 0.412 0.412 0.106 -0.563 
Sig. (2-tailed) 0.759 0.115 1 0.307 0.248 0.248 0.759 0.115 
N 8 8 8 8 8 8 8 8 
Intensity 
Correlation 
Coefficient 0.275 -0.293 0.488 0.347 0.143 0.143 0.275 -0.293 
Sig. (2-tailed) 0.45 0.439 0.197 0.339 0.705 0.705 0.45 0.439 
N 8 8 8 8 8 8 8 8 
IRS Class 
Correlation 
Coefficient 0.275 -0.293 0.488 0.347 0.143 0.143 0.275 -0.293 
Sig. (2-tailed) 0.45 0.439 0.197 0.339 0.705 0.705 0.45 0.439 
N 8 8 8 8 8 8 8 8 
In
va
siv
e 
fro
nt
 
% 
Correlation 
Coefficient 0.056 -0.652 -0.237 0.105 0.173 0.173 0.056 -0.652 
Sig. (2-tailed) 0.874 0.072 0.514 0.763 0.633 0.633 0.874 0.072 
N 8 8 8 8 8 8 8 8 
Intensity 
Correlation 
Coefficient .728* 0.258 .775* .918* 0.378 0.378 .728* 0.258 
Sig. (2-tailed) 0.046 0.495 0.04 0.011 0.317 0.317 0.046 0.495 
N 8 8 8 8 8 8 8 8 
IRS Class 
Correlation 
Coefficient 0.564 -0.067 0.467 0.711 0.293 0.293 0.564 -0.067 
Sig. (2-tailed) 0.121 0.86 0.217 0.05 0.439 0.439 0.121 0.86 
N 8 8 8 8 8 8 8 8 
N
uc
le
ar
 sc
or
e  Tumour 
centre 
Correlation 
Coefficient 0.42 0.149 .745* 0.53 0.218 0.218 0.42 0.149 
Sig. (2-tailed) 0.248 0.693 0.049 0.144 0.564 0.564 0.248 0.693 
N 8 8 8 8 8 8 8 8 
Invasive 
front 
Correlation 
Coefficient 0.169 0.4 0.4 0.653 0.645 0.645 0.169 0.4 
Sig. (2-tailed) 0.666 0.327 0.327 0.094 0.114 0.114 0.666 0.327 
N 7 7 7 7 7 7 7 7 
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Table 11-19: Table showing the correlation of Gli3 and b-catenin  
Tables showing the correlation between with the (percentage of positivity, intensity of immune reaction, 
IRS class and nuclear score) of Gli2 and b-catenin in tumour centres and at the invasive fronts.  
 
 
b-catenin 
Tumour centre Invasive front Nuclear score 
% Intensity IRS Class % Intensity IRS Class Tumour centre 
Invasive 
front 
G
li3
 
Tu
m
ou
r c
en
tre
 
% 
Correlation 
Coefficient 0.282 . . -0.079 -0.102 -0.102 -0.601 0 
Sig. (2-tailed) 0.43 . . 0.838 0.791 0.791 0.08 1 
N 8 8 8 7 7 7 8 7 
Intensity 
Correlation 
Coefficient -0.237 . . -0.653 0.422 0.422 -0.105 0.276 
Sig. (2-tailed) 0.514 . . 0.094 0.28 0.28 0.763 0.461 
N 8 8 8 7 7 7 8 7 
IRS Class 
Correlation 
Coefficient -0.237 . . -0.653 0.422 0.422 -0.105 0.276 
Sig. (2-tailed) 0.514 . . 0.094 0.28 0.28 0.763 0.461 
N 8 8 8 7 7 7 8 7 
In
va
siv
e 
fro
nt
 
% 
Correlation 
Coefficient 0.632 . . -0.2 -0.2 -0.2 0.447 0.632 
Sig. (2-tailed) 0.157 . . 0.655 0.655 0.655 0.317 0.157 
N 6 6 6 6 6 6 6 6 
Intensity 
Correlation 
Coefficient . . . . . . . . 
Sig. (2-tailed) . . . . . . . . 
N 6 6 6 6 6 6 6 6 
IRS Class 
Correlation 
Coefficient . . . . . . . . 
Sig. (2-tailed) . . . . . . . . 
N 6 6 6 6 6 6 6 6 
N
uc
le
ar
 sc
or
e Tumour 
centre 
Correlation 
Coefficient -0.059 . . -0.163 0.632 0.632 0.105 0.414 
Sig. (2-tailed) 0.87 . . 0.676 0.105 0.105 0.763 0.269 
N 8 8 8 7 7 7 8 7 
Invasive 
front 
Correlation 
Coefficient 0.617 . . 0.756 . . -0.617 0 
Sig. (2-tailed) 0.197 . . 0.114 . . 0.197 1 
N 5 5 5 5 5 5 5 5 
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Table 11-20: Table showing the correlation of Gli3 and E-cadherin   
Tables showing the correlation between with the (percentage of positivity, intensity of immune reaction, 
IRS class and nuclear score) of Gli2 and E-cadherin in tumour centres and at the invasive fronts.  
 
 
E-cadherin  
Tumour centre Invasive front Nuclear score 
% Intensity IRS Class % Intensity IRS Class Tumour centre 
Invasive 
front 
G
li3
 
Tu
m
ou
r c
en
tre
 
% 
Correlation 
Coefficient 0.111 0.355 0.355 0.053 -0.087 -0.087 0.111 0.355 
Sig. (2-tailed) 0.75 0.327 0.327 0.88 0.811 0.811 0.75 0.327 
N 8 8 8 8 8 8 8 8 
Intensity 
Correlation 
Coefficient -0.056 -0.059 0.237 -0.105 -0.173 -0.173 -0.056 -0.059 
Sig. (2-tailed) 0.874 0.87 0.514 0.763 0.633 0.633 0.874 0.87 
N 8 8 8 8 8 8 8 8 
IRS Class 
Correlation 
Coefficient -0.056 -0.059 0.237 -0.105 -0.173 -0.173 -0.056 -0.059 
Sig. (2-tailed) 0.874 0.87 0.514 0.763 0.633 0.633 0.874 0.87 
N 8 8 8 8 8 8 8 8 
In
va
siv
e 
fro
nt
 
% 
Correlation 
Coefficient 0.135 0.316 0.2 0.135 -0.2 -0.2 0.135 0.316 
Sig. (2-tailed) 0.752 0.48 0.655 0.752 0.655 0.655 0.752 0.48 
N 6 6 6 6 6 6 6 6 
Intensity 
Correlation 
Coefficient -0.405 -0.632 -1.000* -0.539 -0.2 -0.2 -0.405 -0.632 
Sig. (2-tailed) 0.343 0.157 . 0.206 0.655 0.655 0.343 0.157 
N 6 6 6 6 6 6 6 6 
IRS Class 
Correlation 
Coefficient . . . . . . . . 
Sig. (2-tailed) . . . . . . . . 
N 6 6 6 6 6 6 6 6 
N
uc
le
ar
 sc
or
e  Tumour 
centre 
Correlation 
Coefficient -0.111 -0.237 -0.237 -0.421 -0.434 -0.434 -0.111 -0.237 
Sig. (2-tailed) 0.75 0.514 0.514 0.227 0.232 0.232 0.75 0.514 
N 8 8 8 8 8 8 8 8 
Invasive 
front 
Correlation 
Coefficient -0.261 0 -0.645 -0.348 -0.129 -0.129 -0.261 0 
Sig. (2-tailed) 0.511 1 0.12 0.381 0.756 0.756 0.511 1 
N 6 6 6 6 6 6 6 6 
 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
343 
 
  
 
 
Figure 11-29, Representation of percentage of Gli3 positive tumour cells and the 
intensity of immune reaction in breast cancer sections   
Representative sections stained for Gli3 by IHC. Images were captured by Leica microscope in 400x 
magnification. (A) the percentage of Gli3 positive tumour cells. (B) the intensity of the staining. Scale 
bars were added to the bottom right corner of each image. (¨) was used to indicate area of positivity in 
images. 
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Figure 11-30, Gli3 expression was higher in invasive fronts of breast cancer 
samples   
Representative IHC images of the same breast cancer sample showing higher Gli2 in the invasive front 
(B) compared to the tumour centre (A). Images were captured using three different magnifications (100X, 
200X and 400X) by the Leica microscope. (¨) was used to indicate area of positivity in images. 
 
11.3.7 b-catenin and E-cadherin expression is higher in invasive front compared 
to tumour centre  
Expression of b-catenin and E-cadherin were compared in tumour centres and 
invasive fronts of breast cancer cases. The percentage of positive cells and intensity of 
staining of b-catenin was assessed according to the scores presented in Figure 11-31. 
Out of 37 cases stained with b-catenin, invasive front was not identifiable in two (5.4%) 
of cases (Table 11-21-A).  
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Out of 37 cases, 23 (62.2%) showed b-catenin positivity in more than 80% of 
tumour cells in the tumour centres compared to 29 (66.6%) invasive fronts (Table 
11-21-A and Figure 11-32-A). 28 (75.7%) tumour centres showed intense b-catenin 
staining compared to 34 (82.9%) invasive fronts (Table 11-21-B and Figure 11-32-B). 
26 (70.3%) cases had the highest IRS scores for b-catenin staining in tumour centres 
compared to 28 (80%) in the invasive front (Table 11-21-C and -Figure 11-32-C). This 
was confirmed by looking at breast cancer cases as seen in the representative images 
(Figure 11-33). The percentage of positive expressing cells and IRS classes of b-catenin 
were correlated in tumour centre and invasive front (0.477** and 0.293, respectively).  
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Figure 11-31, Representation of percentage of b-catenin positive tumour cells and 
the intensity of immune reaction in breast cancer sections   
Representative sections stained for b-catenin by IHC. Images were captured by Leica microscope in 400x 
magnification. (A) the percentage of b-catenin positive tumour cells. (B) the intensity of the staining. 
Scale bars were added to the bottom right corner of each image. (¨) was used to indicate area of 
positivity in images. 
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Table 11-21: Frequency tables for percentage of positive cells, intensity of staining, 
and IRS class of the sections included in the analysis of b-catenin in breast cancer 
cohort 
Tumour centre and invasive front frequency tables (A) for percentage of positive tumour cells, (B) 
intensity of staining, and (C) IRS class. The numbers are indicated for each score and the percentages 
were calculated from the total number of samples. Kendell’s tau B test was used to assess the correlations 
with in each parameter in the tumour centre and invasive front. 
 
Pe
rc
en
ta
ge
 o
f p
os
iti
ve
 
tu
m
ou
r 
ce
lls
 
A Tumour centre Invasive front No. (%) No. (%) 
0 0 0 
<10 1 (2.7) 0 
10-50 2 (5.4) 2 (5.7) 
51-80 11 (29.7) 9 (25.7) 
>80 23 (62.2) 24 (66.6) 
Total 37 (100) 35 (100) 
Missing 0 2 (5.4) 
Total 37 (100) 37 (100) 
TauB 0.477* 
 
In
te
ns
ity
 o
f s
ta
in
in
g 
 B Tumour Centre  Invasive front  No. (%) No. (%) 
No colour  0 0 
Mild reaction 1 (2.7) 1 (2.9) 
Moderate reaction 8 (21.6) 5 (14.3) 
Intense reaction 28 (75.7) 29 (82.9) 
Total 37 (100 35 (100) 
Missing 0 2 (5.4) 
Total 37 (100) 37 (100) 
TauB - 
 
IR
S 
cl
as
s 
C Tumour Centre Invasive front  No. (%) No. (%) 
Negative 0 0 
Positive, weak expression 1 (2.7) 0 
Positive, mild expression 10 (27) 7 (20) 
Positive, strong expression 26 (70.3) 28 (80) 
Total 37 (100) 35 (100) 
Missing 0 2 (5.4) 
Total 37 (100) 37 (100) 
TauB 0.293 
The Kendall’s TauB correlation coefficient (between -1 and +1). The statistical significance of the 
correlation is indicated as follows: *P= <0.05, **P= <0.01. 
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Figure 11-32, b-catenin expression was higher in invasive fronts in breast cancer 
cohort   
Figure showing comparison of b-catenin in tumour centres (to the left) compared to the invasive front (to 
the right). (A) comparison of percentage of positive cells. (B) comparison of intensity of staining. (C) 
comparison of IRS class.  
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Figure 11-33, b-catenin expression was higher in invasive fronts of breast cancer 
samples   
Representative IHC images of the same breast cancer sample showing higher b-catenin in the invasive 
front (B) compared to the tumour centre (A). Images were captured using three different magnifications 
(100X, 200X and 400X) by the Leica microscope.  
 
Two cases (5.4%) showed negative nuclear staining of b-catenin in tumour 
centres compared to none of the cases in the invasive front (Table 11-22). In tumour 
centre, b-catenin nuclear positivity was higher than 50% in 13 (35.1%) cases compared 
to 15 (42.9%) cases in the invasive front (Figure 11-34). The nuclear localisation of b-
catenin in tumour cells was correlated in tumour centres and invasive fronts (0.463**). 
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Table 11-22: Frequency tables of b-catenin nuclear localisation in breast cancer 
cases showing increased nuclear expression of b-catenin in tumour invasive front  
Tables showing nuclear expression of b-catenin in cells in tumour centre and invasive front. The numbers 
are indicated for each score and the percentages were calculated from the total number of samples. 
Kendell’s tau B test was used to assess the correlations with in each parameter in the tumour centre and 
invasive front. 
 
 Nuclear expression of b-catenin 
A Tumour Centre  Invasive Front  
 No. (%) No. (%) 
No nuclear expression 2 (5.4) 0 
 <10% of tumour cells 9 (24.3) 5 (14.3) 
10% - 50% of tumour cells 13 (35.1) 15 (42.9) 
≥51% of tumour cells  13 (35.1) 15 (42.9) 
Total included 37 (100) 35 (100) 
Missing 0 2 (5.4) 
Total 37 (100) 37(100) 
TauB 0.463** 
The Kendall’s TauB correlation coefficient (between -1 and +1). The statistical significance of the 
correlation is indicated as follows: *P= <0.05, **P= <0.01. 
 
 
 
Figure 11-34, b-catenin expression was higher in invasive fronts in breast cancer 
cohort   
Figure showing comparison of b-catenin in tumour centres (to the left) compared to the invasive front (to 
the right).  
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Figure 11-35, Nuclear expression of b-catenin in tumour cells is higher in invasive 
front of breast cancer   
Representative IHC images of the same breast cancer sample showing increased nuclear localisation of b-
catenin in tumour cells in the invasive front (to right) compared to the tumour centre (to left). Images 
were captured using three different magnifications (100X, 400X and 600X) by the Leica microscope.  
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The percentage of positive cells and intensity of E-cadherin staining were 
assessed according to the scores presented in Figure 11-36. Invasive fronts were 
identifiable in all cases stained for E-cadherin (23) (Table 11-23-A).  
Out of 23 cases, 14 (60.9%) cases showed E-cadherin positivity in more than 
80% of tumour cells in the tumour centres compared to 16 (69.6%) invasive fronts 
(Table 11-23-A and Figure 11-37-A). 14 (60.9%) tumour centres showed intense E-
cadherin staining compared to 19 (82.6%) invasive fronts (Table 0-1-B and Figure 
11-37-B). 13 (56.5%) cases had the highest IRS scores of E-cadherin in tumour centres 
compared to 19 (82.6%) in the invasive front (Table 0-1-C and Figure 11-37-C). This 
was confirmed by looking at breast cancer cases as seen in the representative images 
(Figure 11-38). The percentage of positive expressing cells, staining intensity and IRS 
classes were correlated in tumour centre and invasive front (0.466*, 0.406* and 0.513*, 
respectively).  
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Figure 11-36, Representation of percentage of E-cadherin positive tumour cells 
and the intensity of immune reaction in breast cancer sections   
Representative sections stained for E-cadherin by IHC. Images were captured by Leica microscope in 
400x magnification. (A) the percentage of E-cadherin positive tumour cells. (B) the intensity of the 
staining. Scale bars were added to the bottom right corner of each image. (¨) was used to indicate area of 
positivity in images. 
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Table 11-23: Frequency tables for percentage of positive cells, intensity of staining, 
and IRS class of the sections included in the analysis of E-cadherin in breast 
cancer cohort 
Tumour centre and invasive front frequency tables (A) for percentage of positive tumour cells, (B) 
intensity of staining, and (C) IRS class. The numbers are indicated for each score and the percentages 
were calculated from the total number of samples. Kendell’s tau B test was used to assess the correlations 
with in each parameter in the tumour centre and invasive front. 
 
Pe
rc
en
ta
ge
 o
f 
po
sit
iv
e 
tu
m
ou
r 
ce
lls
 
A Tumour centre Invasive front No. (%) No. (%) 
0 0 0 
<10 0 1 (4.3) 
10-50 3 (13) 1 (4.3) 
51-80 6 (26.1) 5 (21.7) 
>80 14 (60.9) 16 (69.6) 
Total 23 (100) 23 (100) 
TauB 0.466* 
 
In
te
ns
ity
 o
f 
st
ai
ni
ng
  
B Tumour Centre  Invasive front  No. (%) No. (%) 
No colour  0 0 
Mild reaction 1 (4.3) 2 (8.7) 
Moderate reaction 8 (34.8) 2 (8.7) 
Intense reaction 14 (60.9) 19 (82.6) 
Total 23 (100) 23 (100) 
TauB 0.406* 
 
IR
S 
cl
as
s 
C Tumour Centre Invasive front  
No. (%) No. (%) 
Negative 0 1 (4.3) 
Positive, weak expression 0 0 
Positive, mild expression 10 (43.5) 3 (13) 
Positive, strong expression 13 (56.5) 19 (82.6) 
Total 23 (100) 23 (100) 
TauB 0.513* 
The Kendall’s TauB correlation coefficient (between -1 and +1). The statistical significance of the 
correlation is indicated as follows: *P= <0.05, **P= <0.01. 
 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
355 
 
  
 
 
Figure 11-37, E-cadherin expression was higher in invasive fronts in breast cancer 
cohort   
Figure showing comparison of E-cadherin in tumour centres (to the left) compared to the invasive front 
(to the right). (A) comparison of percentage of positive cells. (B) comparison of intensity of staining. (C) 
comparison of IRS class.  
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Figure 11-38, E-cadherin expression was higher in invasive fronts of breast cancer 
samples   
Representative IHC images of the same breast cancer sample showing higher E-cadherin in the invasive 
front (B) compared to the tumour centre (A). Images were captured using three different magnifications 
(100X, 200X and 400X) by the Leica microscope.  
 
11.3.8 Alteration in localisation and level of Gli1 in breast cancer cells following 
treatment with cyclopamine or LDE225 
Alteration of Gli1 and b-catenin localisation in the cell lines was evaluated to 
determine whether localisation changed following treatment with cyclopamine or 
LDE225. The morphology of MCF7 and MDA-MB-231 was observed under a phase 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
357 
 
  
contrast microscope in both cell lines and did not change following treatment with 1µM 
and 10µM cyclopamine or LDE225. 
Gli1 protein was highly visible in cytoplasm and nucleus of MCF7 cells with b-
catenin showing localisation in regions area of cell-cell contact. Following 1µM and 
10µM cyclopamine treatment, Gli1 was visibly reduced with less nuclear localisation in 
MCF7 cells. b-catenin localisation in MCF7 cells was not visibly changed following 
1µM and 10µM cyclopamine. Nuclear localisation of Gli1 protein reduced following 
1µM and 10µM of LDE225 treatment in MCF7. The cytoplasmic localisation was 
notably reduced following the highest concentration of LDE225. 
b-catenin protein was visible in the cytoplasm and in areas of cell-cell contact of 
MDA-MB-231 in both the vehicle control and following 1µM and 10µM treatment 
with cyclopamine or LDE225. There was an increase in cell-cell contact localisation of 
b-catenin at the highest concentration of either treatment. Gli1 protein was highly 
expressed in the cytoplasm and nucleus of MDA-MB-231. The Gli1 protein visibly 
decreased in the cytoplasm and nucleus of cells following either treatment. 
11.3.9 Hedgehog inhibition regulates the expression of Gli1 in both MCF7 and 
MDA-MB-231 
Gli1 is the active form of Gli, upon activation of Hh pathway, this protein 
translocates to the nucleus where it acts as a transcription factor (Ruiz i Altaba et al., 
2007) (Figure 0-7). Therefore positivity (the percentage of Gli1 positive cells) and 
(level of expression (MFI)) were evaluated following pathway inhibition with either 
cyclopamine or LDE225 using flow cytometry and compared against the vehicle 
control. 
In MCF7 cells, Gli1 positivity showed a 10% increase compared to the vehicle 
control following 1µM, 5µM and 10µM cyclopamine treatment (p-value<0.0001). MFI 
(level of Gli1 expression) showed a 40% increase in level compared to that of the 
vehicle control following cyclopamine treatment at all concentrations (p-value<0.0001). 
Gli1 positivity following LDE225 treatment increased by 12% (p-value<0.0001) and 
8% (p-value<0.0001) at 1µM and 5µM, respectively, while decreasing at 10µM 
treatment by 5% (p-value<0.0001). The level of Gli1 expression (MFI) in MCF7 
increased following LDE225 treatment at 1µM by 40% (p-value<0.0001) and at 5µM 
by 30% (p-value<0.0001) . 
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Treatment of MDA-MB-231 with 1µM cyclopamine or LDE225 increased Gli1 
positivity by 5% (p-value<0.0001) and 2%, respectively. Gli1 positivity in MDA-MB-
231 increased by 2% (p-value<0.01) at 5µM and 10µM treatment with cyclopamine. 
The positivity of Gli1 decreased by 3% (p-value<0.05). Gli1 level of expression (MFI) 
increased following cyclopamine treatment at 1µM, 5µM and 10µM by 78% (p-
value<0.0001), 17% (p-value<0.0001) and 8% (p-value<0.001). MFI (level of Gli1 
expression) of MDA-MB-231 increased following 1µM and 5µM LDE225 treatment by 
17% (p-value<0.01), 13% (p-value<0.05). 
 
 
 
Figure 11-39, Increase of Gli1 positivity (percentage positive cells) of MCF7 
following cyclopamine or LDE225 treatment. 
Presentation of percentage of Gli1 protein expression in MCF7 following treatment with either 
cyclopamine or LDE225 at 1µM, 5µM and 10µM. Percentage of positive cells were estimated using flow 
cytometry, and K562 cell line was used as positive control for Gli1 protein expression. Bars present the 
percentage of Gli1 positive cells and MFI of Gli1 following treatment with cyclopamine (A and B) or 
LDE225 (D and E). Results displayed as bars of MFI ± S.D. Overlap histograms of the Gli1 protein in 
MCF7 cells, comparing (unstained cells, vehicle control, 1µM, 5µM, and 10µM) of cyclopamine (C) or 
LDE225 treatment (F). This figure is representative of n=3 experiments in triplicate. Statistical analysis 
was conducted, and significant difference between samples was indicated by **** p-value<0.0001. 
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Figure 11-40, Increase of Gli1 positivity in MDA-MB-231 cells following 
cyclopamine or LDE225 treatment. 
Presentation of percentage of Gli1 protein expression in MDA-MB-231 following treatment with either 
cyclopamine or LDE225 at 1µM, 5µM and 10µM. Percentage of positive cells were estimated using flow 
cytometry, and K562 cell line was used as positive control for Gli1 protein expression. Bars present the 
percentage of Gli1 positive cells and MFI of Gli1 following treatment with cyclopamine (A and B) or 
LDE225 (D and E). Results displayed as bars of MFI ± S.D. Overlap histograms of the Gli1 protein in 
MDA-MB-231 cells, comparing (unstained cells, vehicle control, 1µM, 5µM, and 10µM) of cyclopamine 
(C) or LDE225 treatment (F). This figure is representative of n=3 experiments in triplicate. Statistical 
analysis was conducted, and significant difference between samples was indicated by * p-value<0.05, ** 
p-value<0.01, *** p-value<0.001 and **** p-value<0.0001. 
 
11.3.10Alteration of Gli2 expression following treatment with cyclopamine or 
LDE225. 
Positivity of Gli2 (percentage of positive cells) and level of expression (MFI) 
were evaluated using flow cytometry. Those parameters were evaluated in the cells 
following pathway inhibition with either cyclopamine or LDE225 and compared 
against the vehicle control. Gli2 has been shown to have two forms with opposing 
actions (activator and repressor) depending on post-transcriptional modification (Figure 
0-8) (Ruiz i Altaba et al., 2007). 
Gli2 positivity (percentage of positive cells) and MFI (level of Gli2 expression) 
in MCF7 cells decreased following cyclopamine or LDE225. The positivity of Gli2 
decreased following 10µM cyclopamine treatment by 5% (p-value<0.001). Level of 
Gli2 expression in MCF7 cells decreased by 17% (p-value<0.0001) at 1µM and 
decreased by 40% (p-value<0.0001) at 5µM of LDE225 treatment. The overlay 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
360 
 
  
histogram of MCF7 cells after cyclopamine treatment showed that there were two 
populations of positive cells, one showing a higher expression level (MFI) than the 
other. The overlay histogram of vehicle control, 1µM and 5µM LDE225 showed that 
there were two populations of positively expressing cells, one having a higher level of 
expression than the other. 
Gli2 positivity in MDA-MB-231 decreased by less than 2% following 1µM and 
5µM cyclopamine and following 10µM cyclopamine treatment which did not reach 
statistical significance in all comparisons. MFI (level of Gli2 expression) showed a 
sharp decrease following 1µM and 10µM cyclopamine treatment (p-value0.01 and p-
value<0.001 respectively) summarised in Error! Reference source not found.-B. MFI 
increased following 5µM treatment in MDA-MB-231 cells to reach a level similar to 
that in the vehicle control. MFI showed a dropped to half the level of vehicle control 
following 1µM LDE225 treatment (p-value<0.0001). MFI increased following 5µM to 
reach a level similar to the vehicle control (p-value<0.0001). Following 10µM 
treatment by LDE225, MFI of MDA-MB-231 cells doubled compared to the level seen 
in vehicle control (p-value<0.0001). 
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Figure 11-41, Reduction of Gli2 in a dose-dependent manner following treatment 
with cyclopamine or LDE225 
Presentation of percentage of Gli2 protein expression in MCF7 following treatment with either 
cyclopamine or LDE225 at 1µM, 5µM and 10µM. Percentage of positive cells was estimated using flow 
cytometry, and K562 cell line was used as a positive control for Gli2 protein expression. Bars present the 
percentage of Gli2 positive cells and MFI of Gli2 following treatment with cyclopamine (A and B) or 
LDE225 (D and E). Results displayed as bars of MFI ± S.D. Overlap histograms of the Gli2 protein in 
MCF7 cells, comparing (unstained cells, vehicle control, 1µM, 5µM, and 10µM) of cyclopamine 
treatment (C) and LDE225 treatment (F). This figure is representative of n=3 experiments in triplicate. 
Statistical analysis was conducted, and significant difference between samples was indicated by ** p-
value<0.01, *** p-value<0.001 and **** p-value<0.0001. 
 
 
 
 
 
 
 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
362 
 
  
 
 
Figure 11-42, Alteration in Gli2 level of expression in MDA-MB-231 cells following 
treatment with cyclopamine or LDE225. 
Presentation of percentage of Gli2 protein expression in MDA-MB-231 following treatment with either 
cyclopamine or LDE225 at 1µM, 5µM and 10µM. Percentage of positive cells were estimated using flow 
cytometry, and K562 cell line was used as positive control for Gli2 protein expression. Bars present the 
percentage of Gli2 positive cells and MFI of Gli2 following treatment with cyclopamine (A and B) or 
LDE225 (D and E). Results displayed as bars of MFI ± S.D. Overlap histograms of the Gli2 protein in 
MDA-MB-231 cells, comparing (unstained cells, vehicle control, 1µM, 5µM, and 10µM) of cyclopamine 
(C) or LDE225 treatment (F). This figure is representative of n=3 experiments in triplicate. Statistical 
analysis was conducted, and significant difference between samples was indicated by ** p-value<0.01, 
*** p-value<0.001 and **** p-value<0.0001. 
 
11.3.11Alteration of Gli3 expression following cyclopamine or LDE225 treatment 
of breast cancer cell lines 
Gli3 is the repressor form of the Gli proteins (Figure 0-8) (Ruiz i Altaba et al., 
2007), therefore, assessing changes in Gli3 expression was essential for determining the 
effect of inhibiting the Hh signalling pathway using cyclopamine or LDE225. The 
expression of Gli3 was evaluated in the cells using flow cytometry to estimate the 
percentage of positive cells (positivity) and MFI (level of expression). 
Gli3 positivity of MCF7 decreased significantly following 1µM and 10µM 
cyclopamine by 13% (p-value<0.01) and by 16% (p-value<0.0001). The level of Gli3 
expression (MFI) decreased by 12% (p-value<0.01) at 1µM and by 20% (p-
value<0.001) 5µM treatment with cyclopamine. The histograms of 5µM and 10µM 
cyclopamine or LDE225 treatments showed that there was a separate population of low 
Gli3 expressing cells that was not distinct in vehicle or 1µM treatment.  
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Figure 11-43, Dose-dependent decrease of Gli3 in MCF7 cells following either 
cyclopamine or LDE225 treatment. 
Presentation of percentage of Gli3 protein expression in MCF7 following treatment with either 
cyclopamine or LDE225 at 1µM, 5µM and 10µM. Percentage of positive cells were estimated using flow 
cytometry, and K562 cell line was used as positive control for Gli3 protein expression. Bars present the 
percentage of Gli3 positive cells and MFI of Gli3 following treatment with cyclopamine (A and B) or 
LDE225 (D and E). Results displayed as bars of MFI ± S.D. Overlap histograms of the Gli3 protein in 
MCF7 cells, comparing (unstained cells, vehicle control, 1µM, 5µM, and 10µM) of cyclopamine 
treatment (C) and LDE225 treatment (F). This figure is representative of n=3 experiments in triplicate. 
Statistical analysis was conducted, and significant difference between samples was indicated by * p-
value<0.05, ** p-value<0.01, and **** p-value<0.0001. 
 
In MDA-MB-231, Gli3 positivity dropped following 1µM treatment with 
cyclopamine by 6% (p-value<0.0001). Gli3 positivity was higher than the vehicle 
control following 5µM and 10µM cyclopamine treatment without statistical 
significance. MFI (level of Gli3 expression) in MDA-MB-231 cells decreased by 30% 
following 1µM cyclopamine (p-value<0.0001). MFI of Gli3 in MDA-MB-231 
following 5µM and 10µM treatment was greater than the vehicle control with statistical 
significance between the vehicle control and 5µM treatment (p-value 0.001). Gli3 
positivity increased following 1µM and 5µM treatment with LDE225 in MDA-MB-231 
cells by 1% without reaching statistical significance. The positivity of Gli3 decreased 
following treatment with LDE225 at the highest concentration compared to vehicle 
control, but without significance. MFI increased following 1µM and 5µM LDE225 
treatment in MDA-MB-231 cells by 17% (p-value<0.01) and 13% (p-value<0.05), 
respectively compared to the vehicle control. 
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Figure 11-44, Alteration of Gli3 positivity and MFI of MDA-MB-231 cells 
following treatment with either cyclopamine or LDE225. 
Percentage of positive cells were estimated using flow cytometry, and K562 cell line was used as positive 
control for Gli3 protein expression. Bars present the percentage of Gli3 positive cells and MFI of Gli3 
following treatment with cyclopamine (A and B) or LDE225 (D and E). Results displayed as bars of MFI 
± S.D. Overlap histograms of the Gli3 protein in MDA-MB-231 cells, comparing (unstained cells, 
vehicle control, 1µM, 5µM, and 10µM) of cyclopamine (C) or LDE225 treatment (F). This figure is 
representative of n=3 experiments in triplicate. Statistical analysis was conducted, and significant 
difference between samples was indicated by * p-value<0.05, ** p-value<0.01, *** p-value<0.001 and 
**** p-value<0.0001. 
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Figure 11-45, Morphology of MCF7 cells and visual alteration of Gli1 and b-
catenin localisation following treatment with cyclopamine or LDE225. 
Visual presentation of MCF7 following treatment for 48 hours with either cyclopamine or LDE225 at 
1µM or 10µM compared to vehicle control. Phase contrast images of MCF7 cells captured under 400x 
magnification using black and white camera of a Leica phase contrast microscope (A and B). 
Immunofluorescence Z stacked images of MCF7 cells captured under confocal microscope at 630x 
magnification. MCF7 cells were double stained for b-catenin (Red) and Gli1 (green) and visualised by 
fluorescence labelled secondary antibodies Alexa Fluor® (488 and 594). DAPI was used to stain nucleus 
of cells (Blue). Yellow arrows were used to highlight localisation of the protein in nucleus of cells and 
light blue arrows were used to highlight cytoplasmic localisation of protein. Visual localisation of b-
catenin and Gli1 proteins in MCF7 cells treated with cyclopamine (C) or LDE225 (D). This figure is a 
representative of three biological repeats with similar observations. 
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Figure 11-46, Morphology of MDA-MB-231 cells and visual alteration of Gli1 and 
b-catenin localisation following treatment with cyclopamine or LDE225. 
Visual presentation of MDA-MB-231 following treatment for 48 hours with either cyclopamine or 
LDE225 at 1µM or 10µM compared to vehicle control. Phase contrast images of MDA-MB-231 cells 
captured under 400x magnification using black and white camera of a Leica phase contrast microscope 
(A and B). Immunofluorescence Z stacked images of MDA-MB-231 cells captured under confocal 
microscope at 630x magnification. MDA-MB-231 cells were double stained for b-catenin (Red) and Gli1 
(green) and visualised by fluorescence labelled secondary antibodies Alexa Fluor® (488 and 594). DAPI 
was used to stain nucleus of cells (Blue). Yellow arrows were used to highlight localisation of the protein 
in nucleus of cells and light blue arrows were used to highlight cytoplasmic localisation of protein. Visual 
localisation of b-catenin and Gli1 proteins in MDA-MB-231 cells treated with cyclopamine (C) or 
LDE225 (D). This figure is a representative of three biological repeats with similar observations. 
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11.3.12Alteration of nuclear localisation of Gli2 and Gli3 in MCF7 and MDA-MB-
231 following treatment with Hh inhibitors 
Gli2 and Gli3 were visually observed under a confocal microscope (following 
immunocytochemistry) to determine whether Hh inhibition with 1µM or 10µM of 
either cyclopamine or LDE225 affects the localisation of both proteins. Gli2 protein 
was cytoplasmic in MCF7 and no clear nuclear localisation of the protein was noted in 
the vehicle control. No changes in the level nor the localisation of Gli2 were observed 
in MCF7 following cyclopamine treatment with 1µM or 10µM in MCF7 were 
observed. The cytoplasmic localisation of Gli2 was visibly reduced in cells at 1µM and 
10µM of LDE225 whereas conversely, the nuclear localisation increased. 
The localisation of b-catenin in MCF7 cells was cytoplasmic and at area of cell-
cell contact. It was observed that the level of expression of b-catenin protein was 
visibly reduced following treatment with cyclopamine or LDE225 in MCF7 cells. Gli3 
protein was both cytoplasmic and in the nucleus of MCF7 cells. Following inhibition 
with cyclopamine, the cytoplasmic Gli3 reduced with a concomitant increase in nuclear 
localisation, especially at 10µM cyclopamine or LDE225. Gli3 was reduced in MCF7 
cells following inhibition with LDE225 and the nuclear localisation increased at the 
highest dose compared to the vehicle control. Cytoplasmic Gli3 in MCF7 cells was 
reduced following LDE225 in parallel with increased nuclear localisation in a dose-
dependent manner. 
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Figure 11-47, Alteration of Gli2, Gli3 and b-catenin localisation in MCF7 cells 
following treatment with cyclopamine or LDE225. 
Immunofluorescence Z stacked images of MCF7 cells captured under confocal microscope at 630x 
magnification. MCF7 cells were double stained for Gli2 or b-catenin (Red) and Gli3 (green) and 
visualised by fluorescence labelled secondary antibodies Alexa Fluor® (488 and 594). DAPI was used to 
stain nucleus of cells (Blue). Yellow arrows were used to highlight localisation of the protein in nucleus 
of cells. Light blue arrows were used to highlight cytoplasmic localisation of protein. Visual localisation 
of Gli2 in MCF7 cells treated with cyclopamine (A) or LDE225 (B). Localisation of b-catenin (Red) and 
Gli3 (Green) in MCF7 cells following treatment with cyclopamine (C) or LDE225 (D) at 1 and 10µM 
compared to the vehicle control. This figure is a representative of three biological repeats with similar 
observations. 
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Gli2 localisation in MDA-MB-231 cells was both nuclear and cytoplasmic. Gli2 
was visibly reduced in the cytoplasm and nucleus of MDA-MB-231 cells following 
cyclopamine treatment with no clear difference in localisation of protein at both 1µM 
and 10µM. Following LDE225 treatment of MDA-MB-231 cells, cytoplasmic 
localisation of Gli2was notably reduced. The localisation of b-catenin in MDA-MB-231 
cells was at the border of cells in the vehicle control. The expression of b-catenin in 
MDA-MB-231 cells increased with concentration of cyclopamine and showed cell-cell 
contact localisation. 
The expression of Gli3 in MDA-MB-231 cells was cytoplasmic without visible 
nuclear localisation. The nuclear localisation of Gli3 increased following cyclopamine 
treatment, and no difference was observed following treatment at both concentrations. 
Gli3 cytoplasmic localisation was reduced following treatment without clear difference 
between treatments at both concentrations of cyclopamine. Cytoplasmic localisation of 
Gli3 was reduced following LDE225 treatment in MDA-MB-231 with a notable 
reduction in nuclear protein following treatment at 10 µM. 
In MCF7 cells, the expression of E-cadherin was strong with notable 
cytoplasmic and membrane localisation in the vehicle control. E-cadherin expression in 
MDA-MB-231 cells was cytoplasmic showing punctate deposits of protein without 
clear membrane localisation in the vehicle control. Following cyclopamine treatment of 
MCF7, membrane localisation of E-cadherin increased without visible changes in the 
level of protein. E-cadherin localisation was not visually changed in MDA-MB-231 
following cyclopamine treatment. In MCF7 cells, localisation of E-cadherin was not 
visually altered following LDE225 treatment. In the MDA-MB-231 cell line, E-
cadherin protein level increased without cell-cell contact localisation. 
 
 
 
 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
370 
 
  
 
 
Figure 11-48, Changes in localisation of Gli2, Gli3 and b-catenin proteins in MDA-
MB-231 cells following treatment with cyclopamine or LDE225. 
Immunofluorescence Z stacked images of MDA-MB-231 cells captured under confocal microscope at 
630x magnification. MDA-MB-231 cells were double stained for Gli2 or b-catenin (Red) and Gli3 
(green) and visualised by fluorescence labelled secondary antibodies Alexa Fluor® (488 and 594). DAPI 
was used to stain nucleus of cells (Blue). Yellow arrows were used to highlight localisation of the protein 
in nucleus of cells. Light blue arrows were used to highlight cytoplasmic localisation of protein. Visual 
localisation of Gli2 in MDA-MB-231 cells treated with cyclopamine (A) or LDE225 (B). Localisation of 
b-catenin (Red) and Gli3 (Green) in MDA-MB-231 cells following treatment with cyclopamine (C) or 
LDE225 (D) at 1 and 10µM compared to the vehicle control. This figure is a representative of three 
biological repeats with similar observations. 
 
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
371 
 
  
 
 
Figure 11-49, Alteration of Gli3 and E-cadherin localisation in MCF7 and MDA-
MB-231 cells following treatment with cyclopamine or LDE225. 
Immunofluorescence Z stacked images of MCF7 (A and B) and MDA-MB-231 (C and D) captured under 
confocal microscope at 630x magnifications. MCF7 and MDA-MB-231 cells were double stained for E-
cadherin (Red) and Gli3 (green) and visualised by fluorescence labelled secondary antibodies Alexa 
Fluor® (488 and 594). DAPI was used to stain nucleus of cells (Blue). Yellow arrows were used to 
highlight localisation of protein in nucleus of cells. Light blue arrows were used to highlight cytoplasmic 
localisation of protein. Visual localisation of Gli3 (Green) and E-cadherin (Red) in MCF7 and cells 
treated with cyclopamine (A) or LDE225 (B) at 1 and 10µM compared to the vehicle control. localisation 
of E-catenin (Red) and Gli3 (Green) in MDA-MB-231 cells following treatment with cyclopamine (C) or 
LDE225 (D) at 1 and 10µM compared to the vehicle control. This figure is a representative of three 
biological repeats with similar observations. 
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The alteration in level of expression of Gli1, Gli2 and Gli3 in MCF7 and MDA-
MB-231 cell lines following treatment with cyclopamine or LDE225 were summarised 
in Table 11-24, the nuclear and cytoplasmic localisation of the proteins as seen by 
confocal microscopy are also summarised in Table 11-25 and Table 11-26. 
 
Table 11-24: Gli1 expression increased in MCF7 and MDA-MB-231 concurrent 
with decreased Gli2 and Gli3 expression as seen by flow cytometry following 
treatment with Hh inhibitors. 
This table summarises changes in Gli proteins expression following treatment with cyclopamine or 
LDE225 at 1µM, 5µM and 10µM. Arrows indicate the change of expression compared to the vehicle 
control. 
 
 1 µM cyclopamine 
5 µM 
cyclopamine 
10 µM 
cyclopamine 
1 µM 
LDE225 
5 µM 
LDE225 
10 µM 
LDE225 
Gli1 
MCF7 ­­­ ­­­ ­­­ ­­ ­­ ­ 
MDA-MB-231 ­­ ­ ­ ­ - ¯ 
Gli2 
MCF7 - ¯ - ¯ - ¯¯ 
MDA-MB-231 ¯ - ¯¯ ¯¯ ¯ ­ 
Gli3 
MCF7 ¯¯ - ¯¯ - - ¯ 
MDA-MB-231 ¯¯ ­ - ­ - - 
 
Table 11-25: Decreased nuclear Gli1 with increased nuclear Gli3 following 
treatment with cyclopamine or LDE225. 
This table summarises the effect of inhibiting Hh signalling on nuclear localisation of Gli1, Gli2, and 
Gli3 after treatment with cyclopamine or LDE225 at 1µM and 10µM for 48hours as seen by confocal 
microscopy. Arrows indicate qualitative observation of expression compared to the vehicle control. 
 
 Treatment 1 µM cyclopamine 
10 µM 
cyclopamine 
1 µM 
LDE225 
10 µM 
LDE225 
Gli1 
MCF7 ¯ ¯ ¯ ¯¯¯ 
MDA-MB-231 ¯ ¯ ¯¯ ¯¯ 
Gli2 
MCF7 ­ ­ ­­ ­­ 
MDA-MB-231 ¯¯ ¯ - - 
Gli3 
MCF7 ­ ­­ - ­ 
MDA-MB-231 ­­­ ­­­ ­­­ ­ 
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Table 11-26: Decrease of cytoplasmic localisation of Gli1, Gli2 and Gli3 in MCF7 
and MDA-MB-231 cells following inhibition of Hh signalling. 
This table summarises the effect of cyclopamine or LDE225 treatment on cytoplasmic localisation of 
Gli1, Gli2 and Gli3 at 1µM and 10µM as seen by confocal microscopy. Arrows indicate observation of 
expression compared to the vehicle control. 
 
 Treatment 1 µM cyclopamine 
10 µM 
cyclopamine 
1 µM 
LDE225 
10 µM 
LDE225 
Gli1 
MCF7 ¯ ¯ ¯ ¯¯¯ 
MDA-MB-231 ¯ ¯ 
¯¯¯ ¯¯¯ 
Gli2 
MCF7 
- - ¯¯ ¯¯ 
MDA-MB-231 
¯¯¯ ¯¯¯ ¯¯ ¯¯ 
Gli3 
MCF7 
- - 
¯ ¯¯ 
MDA-MB-231 ¯ ¯¯ 
¯¯ ¯¯ 
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12.2.1 poster presentation 
1) Investigation of the Process of Epithelial Mesenchymal Transition in Triple 
Negative and Basal Like Breast Cancer. In CRIB Annual Meeting 10th January 2014  
2) The investigation of epithelial mesenchymal transition in triple negative and 
basal like breast cancer. In CRIB Annual Meeting 16th January 2015 
3) Investigation of new tissue biomarkers for triple negative breast cancer. In the 
postgraduate conference. 27th June 2014.  
4) The investigation of Epithelial Mesenchymal Transition in Triple Negative 
Breast Cancer and Basal Like Breast Cancer. In the Centre for Research in Biosciences 
(CRIB) Annual Meeting. At 16th of January 2015 
5) The investigation of epithelial mesenchymal transition in triple negative and 
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6) The investigation of epithelial mesenchymal transition in triple negative and 
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7) The investigation of the regulation of the process of epithelial mesenchymal 
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8) The Investigation of the Regulation of the process of Epithelial Mesenchymal 
Transition in Triple Negative and Basal like Breast Cancer. In the NCRI Cancer 
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cells. At the UK Breast Cancer Research Symposium. At 22nd and 23rd of July 2016  
The Potential Role of the Hedgehog Signalling Pathway in the Regulation of Epithelial-Mesenchymal Transition in Breast Cancer	May	30,	2018	
 
  
375 
 
  
10) The Role of Hedgehog Signalling Pathway in the Regulation of Epithelial 
Mesenchymal Transition (EMT) in Breast Cancer. In The Centre for Research in 
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